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Abstract 
Structural Determinants for Reversible β-lactamase Inhibition 
Kyle DeFrees 
 
Antibiotic resistance is one the largest health concerns of the modern era, 
threatening decades of progress in antibacterial research and development. β-lactams, 
the first line of defense against most Gram positive and negative pathogens, are 
increasingly ineffective in clinical settings, driven in large part by the proliferation of β-
lactamases, enzymes which degrade β-lactams. While these proteins have evolved 
over millions of years with hundreds of known variants, clinical selection has led to the 
proliferation of extended spectrum β-lactamases and carbapenems like CTX-M and 
KPC-2, respectively. Previous generation β-lactamase inhibitors such as clavulanic acid 
and sulbactam are ineffective against these enzymes, creating a pressing need for new 
inhibitor development. 
While the recent discovery and approval of covalent-reversible avibactam and 
vaborbactam have shown great promise in bridging this gap, further clinical selection 
will likely drive new enzymes and mutations resistant to these agents, such as the 
spread of metallo-lactamases, or mutations within the KPC-2 family. Given the paucity 
of information around non-covalent β-lactamase inhibition, we sought to further 
characterize the specific interactions of a potent, non-covalent CTX-M inhibitor, 
revealing the importance of amide-π stacking against the β3 backbone (Chapter 2). 
Building off of this work, we also discovered new non-covalent scaffolds for the 
inhibition of KPC-2 (Chapters 3 and 4). Our work revealed how the improved 
 vii 
hydrophobicity and conformational flexibility of carbapenemases such as KPC-2 can be 
exploited for building non-covalent affinity, supporting future efforts towards combating 
emerging resistance. These structure-guided efforts are also being supported by 
unbiased fragment screening (Chapter 5), which aims to bridge the inhibition gap 
between enzyme classes, with the overall goal of developing a non-covalent scaffold 
with broader β-lactamase activity. 
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Chapter 1 
β-lactamases and Non-covalent Inhibitor Discovery 
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β-lactams and β-lactamases: 
β-lactam antibiotics have been a staple in the modern antibacterial arsenal since 
penicillin’s mass production in 1940, treating otherwise incurable bacterial infections. β-
lactams target penicillin-binding proteins (PBPs), the enzyme class responsible for 
assembling peptidoglycan. Traditional “Class A” PBPs are two domain enzymes; the N-
terminal transglycosylase domain stitches together MurNAc and GlcNAc, whereas the 
C-terminal transpeptidase domain recognizes the D-Ala-D-Ala stem peptide and 
attaches it to a coupling partner (Figure 1-1).1 The nucleophilic residue of the coupling 
partner varies per organism, but is often the amine of glycine (typically from a 
pentaglycine linker), lysine, or a diaminopimelate (DAP) group.1 As PBPs are essential 
for bacterial growth and replication, isolated transglycosylase (Class B) and 
transpeptidase (Class C) domains also exist; these variants allow for precise 
localization and modification of the peptidoglycan to fit the organisms needs. 1 
 
 
Figure 1-1. Schematic of peptidoglycan formation. Adapted from reference 2. 
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β-lactam antibiotics target the transpeptidase domain of Class A and C PBPs; the 
lactam-acid motif mimics the D-Ala-D-Ala substrate, and upon nucleophilic attack, 
results in a stable acyl intermediate, thus inhibiting the enzyme (Figure 1-2). This 
process is not bactericidal alone, but peptidoglycan is constantly being remodeled to 
accommodate growth and reproduction, so inhibition eventually results in a 
peptidoglycan-deficient organism (L-form), which is susceptible to oxidative stress or 
osmotic shock in certain environments.3, 4  
 
 
Figure 1-2. β-lactams mimic native substrate D-Ala-D-Ala. 
 
Given the importance of the transpeptidase domain, bacteria have developed a 
number of mechanisms to overcome β-lactam antibiotics. The first, and perhaps most 
worrying, is modification of PBPs. Overproduction can often compensate for natively 
resistant organisms, but mutations yielding decreased affinity for β-lactams have also 
been observed.5-7 Some of these mutants are also capable of slowly hydrolyzing the 
stable acyl-PBP complex, resulting in deactivated antibiotic and unbound PBP.6, 7 
Further modifications of the donor and acceptor stem peptides have also been 
observed; these modifications vary by organism, and are often associated with 
increased resistance to β-lactams, presumably by promoting the production and use of 
PBPs that carry intrinsic resistance due to the aforementioned modifications.5-7 Aside 
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from PBP modification, bacteria also posses strong homeostatic control as a part of 
nutrient acquisition and xenobiotic repulsion; porin and importer loss can therefore 
provide total resistance, though modulation is often detrimental to overall fitness.8 Active 
repulsion via ATP-binding cassette (ABC) exporters typically provide moderate 
resistance; β-lactams only need to reach the periplasm in Gram negatives however, so 
exporter overexpression is best suited for organisms with intrinsically impermeable 
outer membranes.8 Given these limitations, the most common resistance mechanism 
across all organisms is β-lactamase expression, an enzyme class that deactivates β-
lactams. Like PBPs, these enzymes will recognize a lactam substrate and form an acyl 
intermediate, except β-lactamases have an activated tetrahedral intermediate that is 
primed for subsequent hydrolysis, thus destroying the antibiotic (Figure 1-3). β-
lactamase production is capable of providing complete resistance without any fitness 
detriment, and thus is the preferred resistance mechanism among most Gram positive 
and negative bacteria. 
 
 
Figure 1-3. β-lactamases deactivate β-lactams via hydrolysis. Hydrolysis occurs via 
ordered, nucleophilic water. 
 
β-lactamase evolution has taken place over millions of years; there are over 1400 
known β-lactamases, with more being discovered every year.9-11 Broadly, these 
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enzymes can be classified by structural homology into four distinct classes: A-D.9-11 
Class A β-lactamases are canonical serine hydrolases that evolved from PBPs with 
discreet structural modifications, such as the introduction of a loop to block stem peptide 
binding. Typical members include variants like CTX-M, KPC, TEM, and SHV; there are 
many known point mutants for these enzymes. Class B enzymes are di-Zn hydrolases, 
and are entirely structurally unrelated to PBPs and the other β-lactamase classes. While 
the evolutionary history for these enzymes remains murky, it is thought that many 
evolved from tRNAses, some of which already poses weak β-lactamase activity.12 
Typical members of this class include IMP, VIM, and NDM. Class C enzymes also 
evolved from PBPs, but have a mutated acid-binding motif, and are typically under 
chromosomal control (most β-lactamases are now on mobile plasmids, but originated as 
chromosomal proteins, such as the Class A KPC from Klebsiella). Typical members of 
this family include AmpC, CMY, and ACT. Class D enzymes are also related to PBPs, 
but these have an open stem-peptide binding channel and use a carboxylated lysine as 
a general base. This class is comprised of the OXA enzymes, which have many known 
point mutants. 
Given the importance of β-lactamases towards clinical resistance, significant effort 
has been made to inhibit these enzymes, and thus restore β-lactam activity. The first 
approved β-lactamase inhibitor is a β-lactam itself, clavulanic acid, which presents a 
secondary electrophile upon lactam scission. While limited in substrate scope (Figure 
1-4), this compound inhibited the clinically relevant β-lactamases of the time, SHV and 
TEM. Shortly thereafter another β-lactam based inhibitor was approved for use, 
sulbactam, which improved the spectrum of inhibition within Class A enzymes. While 
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these two inhibitors are still used in combination therapies today, the clinical expression 
of β-lactamases has expanded over the resulting decades, creating an antibiotic 
resistance crisis.11 Recent developments in the field, which occurred during the duration 
of this research, resulted in two additional β-lactamase inhibitors, avibactam and 
vaborbactam. Avibactam, approved in 2015, is a cyclic-N-sulfated urea (Figure 1-4) that 
acts as a covalent reversible inhibitor; this inhibitor type has an improved spectrum of 
inhibition, hitting almost all Class A and C enzymes, and some Class D enzymes. 
Vaborbactam, which is a cyclic boronic acid, was approved in 2017; this covalent 
molecule has a similar spectrum of inhibition to avibactam (Figure 1-4). 
 
 
Figure 1-4. All approved β-lactamase inhibitors are covalent substrates. Avibactam 
(2015) and vaborbactam (2017) have greatly improved inhibition profiles. 
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While these two classes have revolutionized clinical outcomes with their improved 
spectrum of inhibition, many future challenges remain. To start, neither scaffold has 
Class B activity, particularly against NDM or VIM enzymes, which are increasingly 
prevalent in clinical isolates. While a variant of vaborbactam might have useful activity 
against some Class B enzymes,13 all of the approved β-lactamase inhibitors are 
covalent, and primarily rely on Kinact for potent inhibition. Kiapp is modest, typically in the 
µM range,14, 15 and the covalent mechanisms employed are incompatible with Class B 
enzymes, as the nucleophile is an ordered, bridging water. Both compound classes also 
struggle with Class D inhibition, particularly with Kiapp – some OXA variants are 
completely resistant to both scaffolds.15, 16 Avibactam also has a scaffold-specific 
liability, as the N-sulfate required for activity is hydrolytically labile. Some β-lactamases 
such as KPC have been observed to catalyze this desulfation, inactivating avibactam.14, 
17 Importantly, this behavior has not been evolutionarily selected for, suggesting a 
potential mechanism for future avibactam-type resistance. Avibactam and vaborbactam 
are also covalent reversible, so they are susceptible to improved deacylation rates. 
Evolutionary selection has guided β-lactamases towards being “good enough,” but 
further pressure may result in more efficient enzymes that are better at hydrolyzing both 
β-lactam substrates and future covalent inhibitors. 
Taken together, there is an outstanding need for improved Ki across enzyme 
classes, but a lack of concerted knowledge about implementation. Many companies and 
researchers have tried to build non-covalent scaffolds over the preceding decades, but 
as evidenced by the approved inhibitors, were not successful. The challenges 
presented by β-lactamases are primarily two-fold: 1) the active site is particularly solvent 
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exposed (Figure 1-5); substrate β-lactams are polar, and recognition is primarily via H-
bonds, and 2) broader spectrum enzymes (i.e. can hydrolyze a larger diversity of β-
lactams) are more conformationally dynamic, sometimes at the expense of key residues 
used for building non-covalent affinity.18, 19 While challenging to address, it is important 
to note that there is a high degree of structural conservation, with similar substrate 
envelopes across diverse enzymes. Notably, hydrolyzed substrates are weak non-
covalent inhibitors themselves, with Ki in the µM range for many enzymes (see Chapter 
3 for more discussion). Given the substrate homology, it therefore appears feasible to 
build non-covalent affinity across multiple distinct enzymes. To that end, this project 
aimed to better understand the molecular requirements for reversible inhibition, and to 
discover novel chemical matter with improved Ki against multiple enzyme classes. 
 
 
Figure 1-5. Apo CTX-M-9. Active site residues shown as sticks (PDB: 2P74). 
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Non-covalent Inhibitor Discovery: 
Our lab, in collaboration with Prof. Yu Chen at University of South Florida, previously 
sought to generate the first non-covalent inhibitors of a model Class A enzyme, CTX-M. 
CTX-M is an extended spectrum β-lactamase whose substrate scope includes 
penicillins and later generation cephalosporins, and as such, was a prime target for 
discovery due to a versatile substrate envelope and clinical significance. Inhibitor 
discovery for this enzyme first began as a Docking fragment screen,20 resulting in high 
mM fragments with similar chemotypes, such as a tetrazole, which binds the acid-
binding motif, as well as a fluoro-aryl, which appeared to pack against the β3 strand 
(Figure 1-6). These efforts were supported by crystallography, and through a series of 
SAR-by-purchase resulted in low mM fragments presenting both aryl and tetrazole 
motifs. Further structure-based optimization resulted in a 21 µM aryl-F compound, as 
well as a 1.3 µM benzimidazole. Combining the two motifs as a CF3-benzimidazole 
resulted in 1, a 90 nM inhibitor of CTX-M-9.21 
 
 
Figure 1-6. Fragment based lead discovery of compound 1. Ki calculated from a 
biochemical IC50 (nitrocefin substrate) using Ki = IC50/(1 + [S]/Km). 
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High-resolution crystallography of 1 with CTX-M-9 (0.89 Å) supported the previous 
analog structures (Figure 1-7); the tetrazole sits nicely in the Thr235/Ser237/Ser130 
acid-binding motif, and the amide carbonyl hydrogen bonds with Asn132 and Asn104. 
The CF3-benzimidazole packs against the β3 strand and hydrogen bonds with Asp240 – 
the H seems to be localized on the benzimidazole – whereas the CF3 anchors in the 
hydrophobic Pro167 sub pocket. Compound 1 also restored cefotaxime activity in CTX-
M expressing clinical isolates,22 representing the first utility of a potent, non-covalent 
inhibitor of a β-lactamase. Overall, this fragment based approach resulted in a > 10,000 
fold increase in affinity with only ~ 40 compounds synthesized, suggesting that this 
process could be expanded to other target enzymes in the future. 
 
 
Figure 1-7. Compound 1 in complex with CTX-M-9 at 0.89 Å. 2Fo-Fc (blue) and Fo-Fc 
(red) contoured to 1.5 σ and 2.5 σ, respectively (PDB: 4UA7). Black dashes denote 
hydrogen bonds. 
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Exploring Molecular Interactions with CTX-M: 
Given the labs previous success with compound 1, the focus of this project was to 
understand the nuances of CTX-M inhibition and apply it towards inhibition other β-
lactamases. The structure-based design process resulting in compound 1 incorporated 
a tetrazole to engage the acid-binding motif, and only tested three anionic isosteres in 
the aryl-CF3 progenitor series (Figure 1-8). We sought to explore whether the tetrazole 
was required for potent inhibition, and attempted replacement with non-anionic azoles, 
H-bond donor/acceptor groups, and acids. Surprisingly, none of these analogs were 
very active, and even the free acid, of which a tetrazole is a bioisostere, was nearly 
inactive. These results suggested that the charge and π character of the tetrazole was 
important; neither acid nor azole was sufficient alone. It was observed that the tetrazole 
forms a π stacking interaction with the amide of the β3 strand Gly236; this is actually 
one of two such stacking interactions by 1, as the benzimidazole also packs against the 
amide of the β3 strand Gly238 (Figure 1-9). These interactions appeared to be very 
important for the observed CTX-M affinity, and resulted in the probing of heteroarene 
amide-π interactions, as discussed more thoroughly in Chapter 2. 
 
 12 
 
Figure 1-8. Most tetrazole replacements were entirely inactive. Ki calculated from a 
biochemical IC50 (nitrocefin substrate) using Ki = IC50/(1 + [S]/Km). 
 
 
Figure 1-9. Amide-π interactions of compound 1. Yellow dashed lines denote 
putative π-interactions; both were slightly offset and spaced by 3.3-3.5 Å. (PDB: 4UA7) 
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While the tetrazole was the best heterocycle tested in our amide-π study, the activity 
of 1 may also be bolstered by an observed low-barrier hydrogen bond (LBHB), which is 
a special type of short, strong hydrogen bond where the pKa of the donor and acceptor 
atoms are equal, resulting in a bond where the hydrogen is equally shared and more 
covalent in character.23 These bonds are much stronger than normal hydrogen bonds, 
with an estimated ΔH of formation of 15-20 kcal/mol.23 Compound 1 is important for the 
observed bond; the tetrazole hydrogen bonds to Ser130, which hydrogen bonds to 
Lys73, which has the observed LBHB with Ser70 (Figure 1-10).24 The aryl ring is also 
likely important, as the hydration state changes from the apo structure, with waters 1 
and 4 supporting H-bonding partner Ser70. Importantly, the observed hydrogen density 
is equidistant from both atoms, with a total bond length of 2.53 Å, in line with predicted 
LBHBs.23 While there is a fair amount of debate about the role of LBHBs in protein 
structure and function, recent NMR work supports our crystallographic observations, 
suggesting that it is a true LBHB. It therefore seems likely that the observed LBHB is 
stabilizing the bound form of 1. 
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Figure 1-10. The tetrazole of 1 stabilizes a low barrier hydrogen bond in CTX-M. 
(A) The tetrazole engages in a hydrogen-bonding network involving Lys73 and Ser70. 
(B) Apo (top) and 1 (bottom) bound CTX-M at 0.79 Å and 0.89 Å, respectively. 2Fo−Fc 
maps (blue) are contoured at 1.5 σ. The positive Fo−Fc peaks (red, 2 σ) indicate the 
positions of hydrogen atoms. Note the differences in hydration and the Lys73—Ser70 
LBHB. Adapted from reference 24. 
 
 
Translation to KPC-2 Inhibition: 
The previous work revealed the importance of the tetrazole and amide-π interactions 
towards potent, non-covalent CTX-M inhibition. When tested against other similar 
enzymes, like the Class A TEM-1 or SHV-2, compound 1 quickly lost activity (Table 1-
1). The previous acid analogs also showed a similar trend, with no detectable TEM-1 
activity, and a similar (though not as severe) drop in SHV-2 activity, with a noticeable 
penalty for tetrazole replacement. Surprisingly, the Class A carbapenemase KPC-2 
showed the least preference for acid-type, with no drop in activity on tetrazole 
Lys73
Ser70Ser130
Apo
Bound
0.79 Å
0.89 Å
A B
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replacement. Curious, we were able to obtain a structure of the sulfonic acid analog 
bound to KPC-2 (Figure 1-11), which revealed an unexpected binding orientation – the 
sulfonic acid pointed into the acid binding motif, but the CF3-benzimidazole sat near the 
Tyr105 hydrophobic shelf. This positioning is clearly suboptimal, and mirrored additional 
KPC-2 structures obtained for other analogs within the original aryl series (not shown). 
 
Table 1-1. KPC-2 activity is unaffected by tetrazole replacement. 
 
Ki calculated from a biochemical IC50 (nitrocefin substrate) using Ki = IC50/(1 + [S]/Km). 
 
CTX-M-14    
Ki (μM)
TEM-1           
Ki (μM)
SHV-2           
Ki (μM)
KPC-2           
Ki (μM)
0.089 > 1700 27 182
1500 > 2000 200 232
889 > 2000 149 184
450 > 7000 180 160
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Figure 1-11. Sulfonic acid analog of 1 in complex with KPC-2. Orange dashes 
denote hydrogen bonds. Note the suboptimal CF3-benzimidazole orientation. 
 
KPC-2 is of particular interest due to its ability to hydrolyze nearly all β-lactams, 
especially carbapenems, one the most efficacious β-lactam classes for serious Gram-
negative infections. Given the clinical significance, we wanted to transition CTX-M 
specific scaffold 1 into a potent KPC-2 inhibitor. Looking at the superimposition of KPC-
2 onto the CTX-M complex of 1 (Figure 1-12), there are several key enzyme 
differences. For one, while the acid-binding motif is still intact, there is a S237T 
mutation, and further down the β3 strand, a twist enforced by a structural disulfide. We 
hypothesized that steric occlusion caused by this twist gave the unfavorable binding 
pose observed for the sulfonic acid analog. At the “bottom” of the active site, we lose a 
hydrogen bond with the amide via a N104P mutation, but the hydrophobic sub-pocket is 
retained with P167L. Given these changes, we felt that it was possible to retain 
favorable interactions while avoiding steric clash with the β3 strand, so we synthesized 
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~ 80 analogs roughly falling into four categories (Figure 1-13): 1) aryl replacements, 
with an emphasis on smaller heterocycles near the amide linkage, 2) different aryl meta 
substitutions – a ring twist would putatively accommodate the β3 strand, 3) sulfonamide 
analogs, in order to provide sp3 flexibility and optimal Asn interactions, and 4) truncated 
fusions, to reduce total interactions near the β3 twist. Unfortunately, all of these analogs 
failed to significantly improve KPC-2 activity, and led us to believe that the aryl tetrazole 
scaffold was not well suited for inhibiting other β-lactamases. These observations 
directly lead to the scaffold discovery and optimization efforts of Chapters 3 and 4, 
which are focused primarily on KPC-2, as well as the fragment discovery efforts of 
Chapter 5, which aim to discover broad-spectrum scaffolds against diverse β-
lactamases. 
 
 
Figure 1-12. Compound 1 complex with CTX-M-9 superimposed onto an apo KPC-
2 structure. CTX-M (white and yellow, PDB code 4UA7); apo KPC-2 (green, PDB code 
5UL8). Apo KPC-2 structure has a bound sulfate in the acid-binding motif. 
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Figure 1-13. Synthesized analogs of the original aryl scaffold. ~ 80 total analogs 
were synthesized to improve KPC-2 activity; none were successful in improving Ki. 
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Chapter 2 
An Empirical Study of Amide–Heteroarene π-stacking Interactions Using 
Reversible Inhibitors of a Bacterial Serine Hydrolase 
 
Kyle DeFrees, M. Trent Kemp, Xochina ElHilali-Pollard, Xiujun Zhang, Ahmed 
Mohamed, Yu Chen, and Adam R. Renslo 
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Abstract:  
Compared to aryl–aryl π-stacking interactions, the analogous stacking of 
heteroarenes on amide π systems is less well understood and vastly underutilized in 
structure-based drug design. Recent theoretical studies have delineated the important 
geometric coordinates of the interaction, some of which have been confirmed with 
synthetic model systems based on Rebek imides. Unfortunately, a broadly useful and 
tractable protein–ligand model system of this interaction has remained elusive. Here we 
employed a known inhibitor scaffold to study π-stacking of diverse heteroarene 
substituents on the amide face of Gly238 in the cephalosporinases CTX-M-14 and CTX-
M-27. Biochemical inhibition constants (Ki) and biophysical binding constants (Kd) were 
determined for nineteen new analogues against both enzymes, while multiple high-
resolution co-crystal structures revealed remarkably consistent placement of the probe 
heteroarene on Gly238. The data presented support the predicted importance of 
opposing dipoles in amide–heteroarene interactions and should be useful for evaluating 
other theoretical predictions concerning these interactions.  
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Introduction: 
Mining of large crystallographic data sets has revealed the importance of non-
canonical intermolecular interactions in protein structure and also in protein–ligand 
binding.1-4 One of these is the ability of protein backbone amides to participate in 
stacking interactions with their π surfaces. First noted in the stacking of aromatic side 
chains on backbone amides,1 the importance of the interaction in protein–ligand binding 
is becoming increasingly apparent. An important example is found in the S1 pocket of 
the serine protease factor Xa (fXa), which is lined by an amide backbone π surface that 
can engage heterocycles in the P1 side chain of fXa inhibitors.5, 6 In a recent 
computational study, Sherrill and co-workers concluded that the well-known affinity of 
chloroarene P1 moieties for the S1 pocket is better understood in terms of π stacking 
with the backbone amides than by a Cl–π interaction with Tyr228.  
Recent computational studies by Imai,7 Diederich,8 and Wheeler9 have sought to 
define the optimal geometries and distances for amide–heteroarene interaction, using 
formamide7 or N-methylacetamide8, 9 (NMAC) as a model amide (Figure 2-1). In 
general these studies have suggested a preference for offset stacking in which the 
dipole moments or local electric field of the amide and heteroarene are roughly opposed 
(i.e. α ∼ 180°, Figure 2-1). Wheeler showed, however, that intermolecular N–H3C 
interactions could override the preference for opposed dipoles in some cases. 
Wheeler’s model9 therefore introduces additional molecular descriptors to better capture 
these local effects and has most recently10 been extended to stacking on the π surface 
of Arg–Asp salt bridges.  
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Figure 2-1. Coordinate system employed in computational studies of amide–
heteroarene interactions. Dipole moment vectors for the pyridyl ring (red arrow) and 
amide (blue arrow) are shown, using the physics convention with arrowhead 
electropositive. 
 
Rebek introduced the use of cleft-like imides derived from Kemp’s triacid11 to model 
a variety of molecular phenomena, from the stacking and H-bonding of adenine bases 
to abiotic self-replicating systems.12, 13 Recently, Diederich14 described an elegant 
application of this platform to interrogate amide–heteroarene π-stacking interactions. 
This system comprises a Rebek imide host and cognate 2,6-di(isobutyramido)pyridine 
guest that associate in non-polar solvents with their respective para substituents held in 
close proximity for interaction (Figure 2-2). Using double-mutant analyses to isolate 
incremental Gibbs free energies (ΔΔG) for the interacting distal substituents, this study 
confirmed the favourable effects of N-methyl carboxamide stacking on several different 
heteroarenes and confirmed N–Me amides as preferred stacking partners compared to 
phenyl, ethyl, or thiomethyl groups.  
 
Figure 2-2. A Rebek imide host bound through complementary hydrogen bonding 
to its cognate guest, placing pendant substituents (blue) in close proximity. 
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Factor Xa and its known ligands (Figure 2-3) would appear to be excellent models 
to study amide–heteroarene interactions in a more pharmacologically relevant context. 
A strong cation–π interaction in the S4 pocket along with a Cl–π interaction in S1 places 
an oxazole ring ∼ 3.8 Å from the amide surface of Gln192, well placed for an amide–
heteroarene interaction. However, a liability of this scaffold is the fact that the 
heteroarene ring being probed also serves as a linker to the P1 side chain. As noted by 
Diederich,6 replacement of 2,4-oxazole with related heteroarenes such as isoxazole or 
2,5-oxazole significantly alters the angular relationship between the tricyclic core and 
the terminal chlorothiophene, an effect that is likely to overwhelm and confound any 
attempt to isolate and study the amide–heteroarene interaction within this system.  
 
Figure 2-3. Factor Xa inhibitor (left) and its interaction with Gln192 in the complex 
crystal structure (PDB: 2Y5G). 
 
A more recent study by the same group15 employed reversible-covalent inhibitors of 
the cysteine protease cathepsin L in which the terminus of the P3 side chain was 
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altered with diverse heteroarenes expected to interact with an amide π surface lining the 
S3 pocket. With a terminal heteroarene, this system avoids the problem of variable 
angles of departing bonds in different heteroarenes. However, study of the cathepsin 
inhibitors revealed a different complication – the targeted amides of Gly67 and Gly68 in 
the S3 pockets are arranged with opposite dipole orientations. Thus, while the expected 
preference of heteroarenes over simple arenes was confirmed, flexibility in the ligand’s 
P3 side chain allowed interaction with the amide π surface of either Gly67 or Gly68, 
rendering the effects of relative dipole–dipole angles impossible to discern.  
Here we propose the serine hydrolase CTX-M, an extended-spectrum β-lactamase, 
as an improved model system for study of amide–heteroarene π-stacking under 
physiological conditions. The utility of this system hinges on a non-covalent, reversible 
inhibitor scaffold previously described by our laboratories,16, 17 and exemplified by 1 
(Figure 2-4). Extensive crystallographic characterization of 1 and its congeners has 
revealed a highly conserved binding mode enforced by multiple polar and hydrophobic 
interactions in the active site of CTX-M enzymes. These interactions include H-bonding 
and stacking of the tetrazole ring with the β-3 strand, H-bonding with Asn132 and 
Asn104, and a hydrophobic interaction between the trifluoromethyl group and Pro167 
(ESI, Figure 2-11). Most relevant to the current study is Gly238 of the β-3 strand, which 
presents a π surface ideally positioned for stacking with probe heterocycles (i.e., R) in 
analogues such as 2–20 (Figure 2-4). 
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Figure 2-4. Known CTX-M inhibitor 1 and new analogues 2–20 described herein. 
 
Herein we describe the synthesis of 2–20 and the determination of Ki and Kd values 
for all analogues against CTX-M-14 and CTX-M-27. High-resolution complex crystal 
structures of select analogues confirmed the expected binding mode, which places the 
heteroarene substituent ∼ 3.7–3.9 Å from Gly238. The activity and binding data are 
interpreted in terms of suggested8, 9 ‘rules-of-thumb’ governing the interaction. We find 
these rules to be useful for predicting affinities in congeneric series, but caution that 
more rigorous computational analysis will be required to understand the subtleties of 
this interaction.  
 
Results and Discussion: 
The heteroarenes employed in analogues 2–20 were selected to encompass the 
majority of ring systems examined in earlier computational studies, and included 
regioisomeric pyridine, pyrimidine, furan, and thiophene analogues, as well as nitrogen 
heterocycles of increasing N-atom count (Figure 2-5). The phenyl analogue 2 was 
prepared as a control and comparator. The synthesis of 2–20 involved the late-stage 
coupling of the relevant benzoic acid intermediates with commercial 3-(1H-tetrazol-5-
yl)aniline using HATU. Benzoic acids for 2–13 and 15 were synthesized via Suzuki 
coupling of heterocyclic boronic acids or bromides with tert-butyl 3-bromo-5-
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(trifluoromethyl) benzoate or 3-bromo-5-(trifluoromethyl)benzoic acid, followed by 
cleavage of the t-butyl ester (when required). Benzoic acid intermediates for the 
preparation of analogues 14 and 16 were prepared via Ullman/Goldberg coupling, while 
compound 17 was obtained by reaction of tert-butyl 3-bromo-5-(trifluoro- 
methyl)benzoate with imidazole in the presence of CuI and Pd(OAc)2.18 Benzoic acid 
intermediates used for the preparation of compounds 18–20 were obtained via 
cycloaddition or cyclization reactions of the corresponding azide, amine, or nitrile, 
respectively. All final analogues were purified by HPLC before evaluation. Full synthetic 
details and characterization of all analogues are provided in the ESI. 
 
Figure 2-5. Structure of CTX-M inhibitors 2–20 bearing diverse heteroaryl 
substituents R. Blue spheres denote atom of attachment. Red arrows depict direction 
and magnitude of calculated dipole moments of corresponding methyl-substituted 
heteroarenes using B3LYP/6-31G** with PBF solvation (10.64ε). 
 
To determine whether the pendant heteroarenes in 2–20 are properly positioned to 
stack on Gly238 in the β-3 strand, the structures of representative analogues were 
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solved in complex with both CTX-M-14 and CTX-M-27. These CTX-M isoforms differ 
only by the presence of Asp (CTX-M-14) or Gly (CTX-M-27) at position 240 of the β-3 
strand, directly adjacent to the site of amide–heteroarene interaction with Gly238 (there 
is no residue 239 in the CTX-M sequence due to numbering conventions in Class A β-
lactamases). Ligands 3, 14, and 20 were solved in complex with CTX-M-14 to 
resolutions of 1.4 Å, 1.4 Å, and 1.25 Å, respectively. These structures revealed a highly 
conserved binding orientation that is exactly analogous to that of 1, with the pendant 
heteroarene involved in an apparent stacking interaction with Gly238, as posited 
(Figure 2-6 and ESI Figure 2-12). In all three structures, the side chain of Asp240 
swings away from the terminal heteroarene ring towards solvent to accommodate the 
stacking interaction.  
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Figure 2-6. Complex structures of analogues 3 (PDB: 6OOK; top), 14 (PDB: 6OOJ; 
middle) and 20 (PDB: 6OOF; bottom) bound to CTX-M-14 at 1.4 Å, 1.4 Å, and 1.25 
Å resolution. Unbiased Fo–Fc densities are shown at 3σ. Stacking distances are 
indicated, as measured from centroid of the heteroarene to the amide nitrogen atom. 
 
It is notable that compound 20 binds in the canonical fashion when one considers 
that an unfavourable charge–charge interaction might have been expected between the 
tetrazol-5-yl ring and Asp240. Consistent with this, analogue 20 was both the weakest 
inhibitor of CTX-M-14, and the most potent inhibitor of CTX-M-27, Gly240 replacing 
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Asp240 in the latter enzyme, thereby removing the putative charge–charge interaction 
(Table 2-1). Thus, a likely unfavourable interaction with Gly240 in CTX-M-14 is 
insufficient to produce a distinct binding mode for 20, thus suggesting that the remaining 
analogues in the series bind similarly.  
High resolution (1.5 Å and 1.25 Å) structures were also solved of compounds 14 and 
20 in complex with CTX-M-27 and revealed the expected binding mode and 
engagement of Gly238 (Figure 2-7). Amide–heteroarene stacking distances in the five 
new complex structures were measured from the centre of electron density of the 
heteroarene ring to the midpoint of the amide nitrogen atom and varied between 3.7–3.9 
Å, values that are consistent with those expected for an amide–heteroarene π-stacking 
interaction.  
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Figure 2-7. Complex structures of analogues 14 (PDB: 6OOH; top) and 20 (PDB: 
6OOE; bottom) bound to CTX-M-27 at 1.5 Å and 1.25 Å. Unbiased Fo–Fc densities 
are shown at 3σ. Stacking distances are indicated, as measured from centroid of the 
heteroarene to the amide nitrogen atom.  
 
Compounds 2–20 were tested in 11-point dose response, in technical triplicate, for 
inhibition of both CTX-M-14 and CTX-M-27 using a nitrocefin substrate assay (Table 2-
1). The inhibition curves for all replicates are provided as ESI and speak to the precision 
of the measured Ki values. Consistent with the movement of Asp240 noted in the X-ray 
structures, analogues 2–20 returned Ki values that were ca. 5–10-fold weaker for CTX-
M-14 than for CTX-M-27, the latter requiring no analogous movement of residue 240 to 
accommodate ligand binding (Figure 2-6 and 2-7). Similar isoform potency shifts 
across the analogue series provides additional evidence for a conserved binding mode.  
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Table 2-1. Ki and Kd values for heterocycles 2–20 with CTX-M-14 and CTX-M-27.  
 
a Mean ± SEM of three replicates. Calculated from IC50 using Ki = IC50/(1 + [S]/Km). Km 
values were measured for each replicate. b Mean ± SEM of four replicates. SPR 
generated Kd values were measured at binding equilibrium. c Mean ± SEM of two 
replicates. SPR generated Kd values were measured at binding equilibrium. d Calculated 
from ΔΔG = −RTln(Ki,N/Ki,2) at 298 K, where N represents the compound to which 
reference compound 2 is being compared. Positive values indicate improved affinity. e 
Same as d, except Kd values were used relative to compound 2. Positive values 
indicate improved affinity. f Not determined due to solubility limits. g Mean ± SEM of four 
replicates.  
 
Compared to phenyl congener 2, the heteroarene-bearing compounds 3–20 exhibited 
Ki values that were improved by ∼ 3–6-fold (analogue 20 being an exception, for the 
reasons noted above). This was the expected result, and is consistent with the 
predictions of the computational studies that enhanced dipole–dipole and local 
electrostatic interaction favour heteroarenes as stacking partners over simple arenes. 
The magnitude of the potency shift was modest but statistically significant given the high 
precision of the Ki determinations. The compressed range of Ki values would be 
consistent with the expected weak nature of the amide–heteroarene interaction, and 
might further imply relatively small differences in desolvation energies across the 
congeneric series. If correct, this would be notable, given that previous model systems 
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have exploited more hydrophobic binding pockets, in part to mitigate confounding 
desolvation effects.  
To probe the binding affinities of 2–20 for CTX-M, we determined Kd values against 
both proteins by surface plasmon resonance (SPR) spectroscopy, employing the same 
avi-tagged proteins used for the Ki determinations. Standard error in the mean values 
(SEM) revealed the high precision of the Kd determinations, similar to the Ki data. We 
found the Kd values in absolute terms to be remarkably close to the biochemical Ki 
values for the majority of analogues, whereas some compounds like 3, 6, 7, 9 and 10 
showed modest ∼2–3-fold differences between Kd and Ki. In fact, only compound 20 
exhibited Kd values that were more than 3-fold different from Ki against both proteins. 
Limited solubility of phenyl comparator 2 did not allow a Kd determination vs. CTX-M-14, 
while the Kd value of 2 vs. CTX-M-27 was ∼ 4-fold weaker than the respective Ki. 
Overall, the biochemical and biophysical evaluation of 2–20 vs. CTX-M-14 and CTX-M-
27 provided a robust data set for analyses of amide–heteroarene interactions. We used 
the CTX-M-27 Ki and Kd values to calculate ΔΔGKi and ΔΔGKd values for analogues 3–
20 in reference to comparator 2 (Table 2-1).  
Taken together, the earlier computational studies of Diederich and Wheeler predict 
that stronger amide–heteroarene π-stacking interactions should be expected when one 
or more of the following conditions are met: 
(1) An antiparallel orientation of amide and heteroarene dipole moment vectors.  
(2) A greater magnitude of the dipole moment(s). 
(3) The heteroarene is more electron-deficient. 
(4) Heteroarene ring nitrogens can participate in N⋯H–C interactions with the 
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proximal amide function. 
We considered whether these simple ‘rules-of-thumb’, as might be applied by a 
practiced medicinal chemist, could be used to predict rank-order differences in the 
measured Ki and Kd values for 2–20. In performing this analysis, we assume that 
differences in ΔΔG values arise from the relative strength of the corresponding amide–
heteroarene interaction, and ignore differences in desolvation penalties between 
analogues (though admittedly these may be important in certain cases). To eliminate 
the confounding effects of Asp240 and its interaction with the various heteroarenes, we 
limit the analysis to the data generated for CTX-M-27. 
In computational studies of amide–heteroarene stacking the dipole interaction angle 
α (Figure 2-1) is varied systematically so as to identify the optimal value. In the present 
case, the binding mode of 2–20 in CTX-M places strict geometric constraints on the 
orientation of Gly238 and the interacting heteroarene, producing relative sub-optimal α 
values in many cases. Unsurprisingly then, calculated dipole magnitude alone was a 
poor predictor of experimental ΔΔGKi and ΔΔGKd values (Figure 2-8). Discerning the 
effects of α on ΔΔG instead requires consideration of computed dipole magnitude and 
direction in the context of the established crystallographic binding mode. 
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Figure 2-8. Computed dipole moments (µ) vs. (A) ΔΔGKi and (B) ΔΔGKd for 2–20. 
Dipole moments calculated from the corresponding methyl derivatives using B3LYP/6-
31G** with PBF solvation (10.64ε).  
 
First, we considered regioisomeric series of pyridine (3–5) and pyrimidine (5–8) 
congeners, which are presented below in their predicted orientation relative to amide 
Gly238 when bound in CTX-M (Figure 2-9 and 2-10). Among these six analogues, the 
2-pyridyl (3) and 2-pyrimidyl (6) heteroarenes are arranged with opposed dipole 
moments relative to the Gly238 amide, while 4–5 and 7–8 have less favourable dipole–
dipole orientations. In fact, the expected α values for 3 and 6 when bound to CTX-M are 
quite close to the optimal values of 105° (for 3) and 176° (for 6) reported by Wheeler for 
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3–8 were more compressed and while the same rank-order trend holds for pyrimidines 
6–8, the Ki values of 3–5 are very similar or within experimental error. Nevertheless, it 
was striking that rank-order binding affinities (Kd) of analogues 3–8 could be correctly 
predicted solely on the basis of the amide–heteroarene interaction. 
 
 
Figure 2-9. Relative orientation of Gly238 and heteroarene substituent R in 
analogues 3–5. Calculated dipole moments are shown in red; amide dipole in blue as 
reported by Diederich.15 
 
 
Figure 2-10. Relative orientation of Gly238 and heteroarene substituent R for 
analogues 6–8. 
 
The predicted8 beneficial effect of additional ring nitrogen atoms was also reflected 
in the superior Kd values of pyrimidines 6–8 as compared to their corresponding 
pyridine regioisomers 3–5. The 3–5-fold differences in Kd across the two series are 
admittedly modest and one might be wary of overinterpreting these differences. On the 
other hand, a medicinal chemist applying a qualitative dipole–dipole analysis 
prospectively would have judged correctly which analogues to prioritize for synthesis 
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and evaluation, and so such rules-of-thumb appear useful as applied to a rigid ligand 
scaffold and well behaved ligand–protein binding interaction such as that explored here.  
In contrast to 6–8, the regioisomeric forms of the thiophene (9–10) and furan (11–
12) analogues exhibited practically identical Ki and Kd values (Table 2-1). This finding is 
consistent with the similar magnitude and direction of dipole moments for these 
regioisomers (Figure 2-5). Also the Ki and Kd values of 11–12 were superior to 9–10 
across all four data sets, consistent with a stronger amide-stacking interaction for the 
more electron-deficient furans as compared to thiophenes. The data for the remaining 
heterocyclic analogues 13–20 were not interpretable in terms of the rules of thumb 
applied. The presence of N–H donors in many of these analogues (13, 15, and 17) likely 
make polar interactions and desolvation penalties more significant, and these effects 
may overwhelm the more subtle contributions of dipole–dipole and local electrostatic 
interactions. A more rigorous analysis involving computed descriptions of local 
electrostatics and surface polarizability will likely be required to understand and make 
accurate predictions across a broader range of heterocycle–amide interactions present 
in 13–20. The exceptional binding affinity of tetrazole analogue 20 is however consistent 
with the predictions of Wheeler9 regarding tetrazole–amide interaction.  
Finally, it is worth noting that analogues bearing axially unsymmetrical heteroarenes 
will have two distinct rotameric states capable of stacking on Gly238. The present 
crystal structures of 3 and 14 are of insufficient resolution to identify a preferred 
rotamer, but such analysis may be possible in the future, given that sub-Å resolution 
structures of 1 have been solved in which unambiguous heteroatom assignments are 
possible (ESI, Figure 2-11).19 The identification of a preferred rotameric state in this 
 39 
way would enable a more refined understanding of how α values and other factors 
impact binding affinity in this model system.  
 
Conclusions: 
Herein we present a new model system to study amide–heteroarene π-stacking in a 
pharmacologically relevant context. The bacterial hydrolase CTX-M-27 and inhibitor 
scaffold represented by 2–20 offer several advantages over previously employed model 
systems. These include: (1) a reversible and non-covalent ligand scaffold into which 
diverse heteroarenes can be incorporated in a terminal position, (2) a highly predictable 
and conserved binding mode that places the probe heterocycle unambiguously in 
contact with Gly238, and (3) a protein system that is highly amenable to X-ray 
crystallographic studies at high and ultra-high resolutions. The activity and binding data 
described herein appear to significantly report on the relative strength of amide–
heteroarene stacking interactions between analogues, providing the first example where 
easily applied rules-of-thumb were used successfully to explain experimental binding 
affinity data, at least for congeneric series of analogues. In closing, we note that 
computational studies of the heteroarene-amide interaction present in this new model 
system should be facilitated by the geometric constraints imposed by the binding mode 
of 2–20 in CTX-M. It is our hope that a combination of theoretical and empirical study of 
this model system will produce new insights into the factors governing this 
intermolecular interaction.  
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Experimental: 
Synthesis and characterization 
The syntheses and characterization of new compounds 2–20 are described in the 
ESI. All compounds tested were judged to be of >95% purity as assessed by a Waters 
Micromass ZQ 4000 equipped with Waters 2795 Separation Module, Waters 2996 
Photodiode Array Detector (254 nm), and Waters 2424 ELS detector. Separations were 
carried out with an XBridge BEH C18, 3.5 µm, 4.6 × 20 mm column, at ambient 
temperature (unregulated) using a mobile phase of water–methanol containing a 
constant 0.05% formic acid.  
 
Protein expression and purification 
All enzymes from this study were expressed using the BL21 (DE3) cell line. Cells 
were grown on LB agar plates supplemented with 50 µg mL-1 kanamycin from cell 
stocks stored at −80 °C. Single colonies were used to inoculate 50 mL of LB broth with 
50 mg mL-1 kanamycin and grown at 37 °C overnight. From the overnight culture, 10 mL 
of cells were used to inoculate 1 L of 2 × YT broth for untagged and avitagged CTX-M-
14 and CTX-M-27. The cells were grown at 37 °C until an OD600 of 0.5 to 0.8 was 
reached at 600 nm. Overexpression of protein was induced with the addition of 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) at 20 °C for 24 hours, and the cells were 
harvested with centrifugation at 5000 RPM for 15 minutes at 4 °C. 
For the untagged CTX-M-14 and CTX-M-27 cell pellets were resuspended in 50 mM 
MES pH 8.0 with 2 mM EDTA, while AviTag CTX-M-14 and CTX-M-27 were 
resuspended in 20 mM Tris pH 8.0, 300 mM NaCl, 10% glycerol with 10 mM imidazole. 
Cells were lysed with sonication and cellular components separated via 
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ultracentrifugation at 45000 RPM for 1 hour. Untagged enzymes were loaded onto a CM 
sepharose column and eluted with an increasing NaCl gradient. The AviTag CTX-M was 
loaded onto a HisTrap affinity column and eluted with an increasing imidazole gradient. 
All enzymes were additionally purified using a size exclusion HiLoad 16/60 Superdex 75 
column. Final protein purity was evaluated with SDS-Page to be at or greater than 95%.  
 
β-lactamase inhibition assays 
The hydrolytic activity of CTX-M-14 and CTX-M-27 was determined using the β-
lactamase substrate nitrocefin in a reaction buffer containing 100 mM Tris pH 7.0, 20 
mM NaCl, 0.02% Triton X-100, and 5% DMSO. Nitrocefin hydrolysis was monitored via 
absorbance (486 nm) using a FlexStation 3 microplate reader at 37 °C. The nitrocefin 
concentration was 50 µM for all inhibition assays. Compounds were tested for IC50 in 
11-point dose response up to 2.5 mM and 500 µM for CTX-M-14 and CTX-M-27, 
respectively (as solubility allowed). The protein was added last to initiate the reaction; 
the final protein concentration was 0.1 nM for both enzymes. All compounds were 
tested as technical triplicates with three independent replicates. IC50 values were 
converted to Ki using Ki = IC50/(1 + [S]/Km). The Km of nitrocefin was measured for each 
replicate: 50–64 µM for CTX-M-14, and 14–22 µM for CTX-M-27 (data in ESI). 
Nitrocefin was purchased from Sigma-Aldrich.  
 
SPR binding assays 
Compound Kd values were measured on a Biacore 4000 at 25 °C. Avi-CTX-M-14 
and Avi-CTX-M-27 were immobilized on a Series S CM5 chip with EDC/NHS coupled 
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Neutravidin using 10 mM HEPES pH 7.5, 150 mM NaCl, 0.05% Tween 20, and 250 µM 
TCEP-HCl. Protein immobilization levels varied between 3340–6166 RU and 4104–
6634 RU for CTX-M-14 and CTX-M-27, respectively. Running buffer consisted of 10 
mM HEPES pH 7.5, 150 mM NaCl, 0.05% Tween 20, 250 µM TCEP-HCl, and 5% 
DMSO. Compounds were flowed for 90 s on and 120 s off, with a 50% DMSO needle 
wash between injections. Compounds were tested in 10-point dose response with two 
internal blanks up to 500 µM and 50 µM for CTX-M-14 and CTX-M-27, respectively (as 
solubility allowed). Sensogram data was reference subtracted, solvent corrected, and 
blank subtracted; Kd values were measured at equilibrium binding between 65–85 s. All 
compounds were tested in quadruplicate for CTX-M-14 and in duplicate for CTX-M-27. 
Representative sensograms and Kd fits can be viewed in the ESI.  
 
Crystallization and structure determination 
All enzyme crystals were grown using the hanging drop approach, where both CTX-
M-14 and CTX-M-27 protein stocks used were at 20 mg mL-1. Equal parts well solution 
of 1 M potassium phosphate pH 7.9 were mixed with protein and incubated at 20 °C. 
Complex structures were generated by soaking 5–10 mM ligand concentrations with 
protein crystals for 6–12 hours in 1 M potassium phosphate pH 7.9 or 1.44 M sodium 
citrate prior to cryoprotecting with 30% (wt/vol) sucrose supplemented crystal mother 
liquor. Crystal diffraction data sets were collected at the beamlines 22-ID, 22-BM, and 
19-BM at Argonne National Lab Advanced Photon Source (APS). The data sets were 
indexed, integrated and scaled using the program HKL2000. Initial models were 
obtained via molecular replacement with the program Phaser in the Phenix suite. 
Refinement was carried out using phenix.refine, and ligand restraint files were 
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generated with the program elBOW. The mFo-DFc and 2mFo-DFc maps were generated 
with the program phenix.mtz2map program for all structures. PDB codes for deposited 
structures are provided below.  
CTX-M-14 with compound 3: 6OOK  
CTX-M-14 with compound 14: 6OOJ  
CTX-M-27 with compound 14: 6OOH  
CTX-M-14 with compound 20: 6OOF  
CTX-M-27 with compound 20: 6OOE  
 
Dipole calculations 
Dipole moments were calculated with Jaguar in Maestro using the corresponding 
methyl derivatives, as done by Diederich in previous studies. Structures were first 
optimized using B3LYP/ 6-31G**, then dipoles were calculated using B3LYP/6-31G** 
with PBF solvation (10.64ε). This dielectric was chosen as a surrogate for the local 
binding environment in CTX-M, which is moderately solvent exposed. Dipoles were also 
calculated for water (80.37ε) and CHCl3 (4.806ε), which had little effect on the 
magnitude and no effect on the relative rank order of dipole strength (ESI, Figure 2-12). 
Model type also held no effect; M06-2X/6-31G** and B3LYP-D3/6-31G** with PBF 
solvation (10.64ε) was the same as B3LYP/6-31G**, and gas phase B3LYP/6-31G** 
was the same as LMP2/6-31G** (ESI, Figure 2-12). These results suggest that the 
reported dipole magnitude and rank order are accurate.  
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Electronic Supporting Information 
Supplementary Figures 
 
Figure 2-11. Compound 1 in complex with CTX-M-14 at 0.89Å. 2Fo-Fc (blue): 1.5 σ; 
Fo-Fc (red): 2.5 σ (H-omit). Compound previously reported in references 16 and 17 in 
the main text; PDB: 4UA7. 
 
 
Figure 2-12. Comparison of calculated dipoles between solvents and models. A) 
B3LYP/6-31G**, PBF: DCE (10.65 ε) vs. PBF: H2O (blue, 80.37 ε) and PBF: CHCl3 (red, 
4.806 ε). B) B3LYP/6-31G**, PBF: DCE vs. M06-2X/6-31G**, PBF: DCE (blue) and 
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B3LYP-D3/6-31G**, PBF: DCE (red). C) B3LYP/6-31G**, gas phase vs. LMP2/6-31G**, 
gas phase. 
 
 
Figure 2-13. Front (A) and top (B) view of compound 14 with CTX-M-14. C) 
Superimposed top view of 3, 14, and 20 with CTX-M-14. 
 
Biochemical Data 
Each curve is a replicate generated from a technical triplicate. Compounds were 
tested up to 2.5 mM or 500 uM for CTX-M-14 and CTX-M-27, respectively (as solubility 
allowed). 
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CTX-M-27 Biochemical Data: 
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SPR Data 
Compounds were tested in 10-point dose response with two internal blanks up to 
500 uM and 50 µM for CTX-M-14 and CTX-M-27, respectively (as solubility allowed). All 
compounds were tested in quadruplicate for CTX-M-14 and in duplicate for CTX-M-27. 
Kd was measured at equilibrium binding between 65-85s. 
 
Representative sensograms for CTX-M-14: 
 
-1 0 1 2 3
0
20
40
60
80
100
120
Compound 17 - CTX-M-27
log(Compound 17) (µM)
Pe
rc
en
t A
ct
iv
ity
-1 0 1 2 3
0
20
40
60
80
100
120
Compound 18 - CTX-M-27
log(Compound 18) (µM)
Pe
rc
en
t A
ct
iv
ity
-1 0 1 2 3
0
20
40
60
80
100
120
Compound 19 - CTX-M-27
log(Compound 19) (µM)
Pe
rc
en
t A
ct
iv
ity
-1 0 1 2 3
0
20
40
60
80
100
120
Compound 20 - CTX-M-27
log(Compound 20) (µM)
Pe
rc
en
t A
ct
iv
ity
-1 0 1 2 3
0
200
400
600
800
log(Compound 3) (µM)
R
es
po
ns
e 
(R
U
)
Compound 3 - CTX-M-14
 53 
 
 
 
 
-1 0 1 2 3
0
100
200
300
400
log(Compound 4) (µM)
R
es
po
ns
e 
(R
U
)
Compound 4 - CTX-M-14
-1 0 1 2 3
0
100
200
300
400
log(Compound 5) (µM)
R
es
po
ns
e 
(R
U
)
Compound 5 - CTX-M-14
-1 0 1 2 3
0
200
400
600
800
log(Compound 6) (µM)
R
es
po
ns
e 
(R
U
)
Compound 6 - CTX-M-14
-1 0 1 2 3
0
100
200
300
400
log(Compound 7) (µM)
R
es
po
ns
e 
(R
U
)
Compound 7 - CTX-M-14
 54 
 
 
 
 
-1 0 1 2 3
0
50
100
150
200
log(Compound 8) (µM)
R
es
po
ns
e 
(R
U
)
Compound 8 - CTX-M-14
-1 0 1 2 3
0
100
200
300
400
log(Compound 9) (µM)
R
es
po
ns
e 
(R
U
)
Compound 9 - CTX-M-14
-1 0 1 2 3
0
100
200
300
400
log(Compound 10) (µM)
R
es
po
ns
e 
(R
U
)
Compound 10 - CTX-M-14
-1 0 1 2 3
0
100
200
300
400
log(Compound 11) (µM)
R
es
po
ns
e 
(R
U
)
Compound 11 - CTX-M-14
 55 
 
 
 
 
-1 0 1 2 3
0
100
200
300
400
log(Compound 12) (µM)
R
es
po
ns
e 
(R
U
)
Compound 12 - CTX-M-14
-1 0 1 2 3
0
100
200
300
400
log(Compound 13) (µM)
R
es
po
ns
e 
(R
U
)
Compound 13 - CTX-M-14
-1 0 1 2 3
0
100
200
300
400
log(Compound 14) (µM)
R
es
po
ns
e 
(R
U
)
Compound 14 - CTX-M-14
-1 0 1 2 3
0
50
100
150
200
log(Compound 15) (µM)
R
es
po
ns
e 
(R
U
)
Compound 15 - CTX-M-14
 56 
 
 
 
 
-1 0 1 2 3
0
50
100
150
200
log(Compound 16) (µM)
R
es
po
ns
e 
(R
U
)
Compound 16 - CTX-M-14
-1 0 1 2 3
0
100
200
300
400
log(Compound 17) (µM)
R
es
po
ns
e 
(R
U
)
Compound 17 - CTX-M-14
-1 0 1 2 3
0
100
200
300
400
log(Compound 18) (µM)
R
es
po
ns
e 
(R
U
)
Compound 18 - CTX-M-14
-1 0 1 2 3
0
50
100
150
200
log(Compound 19) (µM)
R
es
po
ns
e 
(R
U
)
Compound 19 - CTX-M-14
 57 
 
 
Representative sensograms for CTX-M-27: 
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Crystallographic Data 
Table 2-2. X-ray data collection and refinement statistics. 
 
 
 
Dipole Calculations 
Dipoles were calculated with a methyl at the point of attachment; structures were 
optimized with B3LYP/6-31G** prior to dipole calculation. 
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B3LYP/6-31G**; PBF: DCE (10.65 ε) 
 
 
B3LYP/6-31G**; PBF: H2O (80.37 ε) 
 
 
B3LYP/6-31G**; PBF: CHCl3 (4.806 ε) 
 
 
Compound Gas Phase Energy Solution Phase Energy Solvation Energy       
(kcal/mol)
HOMO LUMO QM Dipole 
(D)
QM Dipole X 
(D)
QM Dipole Y 
(D)
QM Dipole Z 
(D)
2 -271.578488 -271.58247 -2.499131 -0.240232 -0.002133 0.463176 -0.285068 -0.36506 0
3 -287.616296 -287.624158 -4.932937 -0.25393 -0.026293 2.651741 2.623243 -0.387716 0
4 -287.613682 -287.621816 -5.104312 -0.253439 -0.024655 3.309159 1.229136 3.072419 0
5 -287.614708 -287.623465 -5.495336 -0.262352 -0.024947 3.727299 -1.913623 -3.198563 0
6 -303.655234 -303.666316 -6.954164 -0.257676 -0.04309 2.377625 1.099734 2.108005 0
7 -303.655009 -303.666395 -7.145241 -0.262914 -0.043459 3.493428 1.07138 3.325084 0
8 -303.651512 -303.662934 -7.167572 -0.262527 -0.045594 3.844931 -1.995047 3.286835 0
9 -592.330722 -592.335014 -2.693378 -0.227616 -0.010871 1.034642 0.665349 -0.792335 -0.000768
10 -592.329452 -592.333807 -2.732275 -0.230464 -0.012426 1.363993 -0.104598 -1.359976 0.000603
11 -269.353086 -269.357967 -3.062408 -0.217858 0.016877 0.763495 0.425025 -0.634254 0.00001
12 -269.347484 -269.352356 -3.057625 -0.221196 0.014465 1.244542 -0.097378 -1.240726 0.000847
13 -249.495923 -249.504932 -5.653324 -0.20191 0.04379 2.321089 -0.426593 2.28155 0.001166
14 -265.522355 -265.532677 -6.4773 -0.244642 0.015965 3.266098 1.68403 -2.798471 -0.000869
15 -265.529696 -265.542853 -8.256297 -0.246401 0.017209 2.701276 2.409078 1.22198 0.000098
16 -265.535403 -265.549161 -8.632925 -0.228099 0.025706 5.520107 -1.256347 -5.375237 0.000983
17 -265.548463 -265.563967 -9.728804 -0.221107 0.031191 5.083593 -4.764769 1.771959 0.007474
18 -281.544963 -281.560477 -9.735667 -0.264789 -0.01048 6.360991 2.105532 -6.002412 0.000069
19 -297.573052 -297.591624 -11.654125 -0.304945 -0.026451 7.815559 0.845976 7.769638 0
20 -297.583578 -297.6046 -13.191199 -0.300764 -0.023761 7.766349 7.333139 2.557586 0
Compound Gas Phase Energy Solution Phase Energy Solvation Energy       
(kcal/mol)
HOMO LUMO QM Dipole 
(D)
QM Dipole X 
(D)
QM Dipole Y 
(D)
QM Dipole Z 
(D)
2 -271.578452 -271.581714 -2.046934 -0.239484 -0.00143 0.44862 -0.278004 -0.3521 0
3 -287.616222 -287.622584 -3.991815 -0.253299 -0.025335 2.414631 2.385242 -0.375586 0
4 -287.613617 -287.620324 -4.208525 -0.252981 -0.023801 3.133705 1.137203 2.920082 0
5 -287.614634 -287.621834 -4.518118 -0.261632 -0.023975 3.516843 -1.807647 -3.016719 0
6 -303.655093 -303.664322 -5.791053 -0.255578 -0.042322 2.231569 1.033354 1.977898 0
7 -303.654888 -303.66437 -5.949808 -0.260599 -0.042648 3.289413 0.981849 3.13946 0
8 -303.651395 -303.66086 -5.939002 -0.260244 -0.044793 3.621407 -1.879782 3.095321 0
9 -592.330647 -592.334221 -2.242323 -0.226654 -0.009866 0.963784 0.588012 -0.763624 -0.000018
10 -592.329344 -592.33299 -2.288027 -0.229424 -0.011389 1.291218 -0.092571 -1.287895 -0.000954
11 -269.353019 -269.357124 -2.575602 -0.217087 0.017587 0.715456 0.400727 -0.592702 -0.000246
12 -269.34739 -269.352191 -3.01288 -0.220349 0.014368 1.218788 -0.088761 -1.215551 0.000546
13 -249.495807 -249.503211 -4.646594 -0.200576 0.044627 2.186178 -0.391365 2.150862 0.001224
14 -265.522241 -265.530827 -5.387862 -0.24328 0.017347 3.06943 1.536605 -2.657112 -0.000978
15 -265.529418 -265.540434 -6.912604 -0.244663 0.018496 2.559449 2.267994 1.186162 0.000329
16 -265.535249 -265.546636 -7.145288 -0.226629 0.026859 5.250173 -1.205787 -5.109833 0.000633
17 -265.548258 -265.560962 -7.971984 -0.219736 0.031883 4.76464 -4.462819 1.668834 0.005931
18 -281.544782 -281.557569 -8.023798 -0.263267 -0.008382 6.019743 -1.947741 5.695929 0
19 -297.572866 -297.588371 -9.729789 -0.301057 -0.024633 7.474376 0.847945 7.426122 0
20 -297.5832 -297.600634 -10.939654 -0.299287 -0.022213 7.383831 6.948783 2.497072 0
Compound Gas Phase Energy Solution Phase Energy Solvation Energy       
(kcal/mol)
HOMO LUMO QM Dipole 
(D)
QM Dipole X 
(D)
QM Dipole Y 
(D)
QM Dipole Z 
(D)
2 -271.578452 -271.578534 -0.051712 -0.240829 -0.002739 0.48856 -0.300036 -0.385577 0
3 -287.616222 -287.621639 -3.399163 -0.255681 -0.028817 2.842759 2.809459 -0.43384 0
4 -287.613617 -287.619234 -3.524996 -0.254987 -0.027062 3.534241 1.29068 3.290138 0
5 -287.614634 -287.620832 -3.889164 -0.264011 -0.027126 3.974551 -2.03931 -3.41149 0
6 -303.655093 -303.663985 -5.579627 -0.264041 -0.047122 2.44517 1.136897 2.164791 0
7 -303.654888 -303.6647 -6.156897 -0.269557 -0.047199 3.755247 1.174285 3.566922 0
8 -303.651395 -303.661228 -6.170466 -0.268779 -0.049059 4.092602 -2.135383 3.491351 0
9 -592.330647 -592.331157 -0.320023 -0.228298 -0.011627 1.044568 0.645105 -0.82156 0.000932
10 -592.329344 -592.329858 -0.322362 -0.231187 -0.013194 1.379518 -0.09718 -1.376091 0.000775
11 -269.353019 -269.352458 0.352449 -0.218771 0.015738 0.802421 0.467163 -0.65241 -0.000225
12 -269.34739 -269.346688 0.440413 -0.222276 0.013178 1.296883 -0.091947 -1.293619 0.000312
13 -249.495807 -249.501927 -3.840296 -0.20204 0.043967 2.403203 -0.434937 2.363516 0.002206
14 -265.522241 -265.53082 -5.383658 -0.247448 0.012345 3.484909 1.927776 -2.903146 -0.003404
15 -265.529418 -265.541846 -7.798577 -0.248477 0.014121 2.880142 2.612758 1.211904 -0.001133
16 -265.535249 -265.547646 -7.779101 -0.230055 0.023664 5.787087 -1.285639 -5.642474 -0.0005
17 -265.548258 -265.563499 -9.564275 -0.222501 0.02984 5.398173 -5.038694 1.936953 0.006607
18 -281.544782 -281.559717 -9.371439 -0.270039 -0.016725 6.79725 -2.322442 6.388182 0
19 -297.572866 -297.591159 -11.479392 -0.314829 -0.033862 8.279873 0.906028 8.230153 0
20 -297.5832 -297.606237 -14.455879 -0.306172 -0.02977 8.366223 7.912965 2.716371 0
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M06-2X/6-31G**; PBF: DCE (10.65 ε) 
 
 
B3LYP-D3/6-31G**; PBF: DCE (10.65 ε) 
 
 
B3LYP/6-31G**; gas phase 
 
 
Compound Gas Phase Energy Solution Phase Energy Solvation Energy       
(kcal/mol)
HOMO LUMO QM Dipole 
(D)
QM Dipole X 
(D)
QM Dipole Y 
(D)
QM Dipole Z 
(D)
2 -271.442768 -271.447608 -3.036903 -0.292104 0.032375 0.432983 -0.270257 -0.338284 0
3 -287.479704 -287.488451 -5.488838 -0.305341 0.010172 2.693945 2.669744 -0.36029 0
4 -287.477151 -287.486049 -5.58377 -0.304821 0.01217 3.325684 1.266235 3.075195 0
5 -287.478142 -287.487715 -6.007428 -0.314898 0.01127 3.731682 -1.914788 -3.202973 0
6 -303.518445 -303.53042 -7.514676 -0.323877 -0.004964 2.452971 1.138653 2.17268 0
7 -303.518217 -303.530406 -7.648937 -0.328906 -0.005923 3.513279 1.11233 3.332544 0
8 -303.514755 -303.52687 -7.602285 -0.326966 -0.00753 3.852266 -1.998159 3.293526 0
9 -592.199498 -592.204572 -3.184479 -0.279741 0.025431 1.006035 0.654288 -0.764208 -0.000739
10 -592.198112 -592.203298 -3.254658 -0.282648 0.024006 1.307978 -0.098133 -1.304291 0.000691
11 -269.231198 -269.236944 -3.605648 -0.269791 0.058325 0.764255 0.447519 -0.619527 -0.000053
12 -269.2255 -269.23125 -3.607936 -0.273627 0.056013 1.236591 -0.08754 -1.233488 0.000887
13 -249.377746 -249.387944 -6.399138 -0.253976 0.085194 2.3648 -0.424663 2.326358 0.001263
14 -265.402102 -265.413447 -7.119553 -0.298399 0.059076 3.327758 1.717168 -2.850492 -0.000942
15 -265.408965 -265.423429 -9.076523 -0.300771 0.05996 2.770402 2.474451 1.245879 0.000179
16 -265.41715 -265.432012 -9.326421 -0.281143 0.069265 5.606389 -1.283138 -5.457578 0.000982
17 -265.430052 -265.44682 -10.521879 -0.273885 0.074125 5.149403 -4.821765 1.807453 0.007536
18 -281.422654 -281.438995 -10.25389 -0.318599 0.03554 6.463688 -2.120071 6.106108 0
19 -297.449575 -297.468754 -12.035135 -0.370799 0.022432 7.914928 0.869632 7.867009 0
20 -297.459801 -297.481551 -13.648337 -0.357342 0.025114 7.833508 7.413467 2.530681 0
Compound Gas Phase Energy Solution Phase Energy Solvation Energy       
(kcal/mol)
HOMO LUMO QM Dipole 
(D)
QM Dipole X 
(D)
QM Dipole Y 
(D)
QM Dipole Z 
(D)
2 -271.586283 -271.590317 -2.531579 -0.240484 -0.002368 0.460872 -0.28335 -0.363478 0
3 -287.623258 -287.631235 -5.005546 -0.254 -0.026448 2.653929 2.625399 -0.3881 0
4 -287.620856 -287.629059 -5.147537 -0.253428 -0.024674 3.301769 1.224918 3.066147 0
5 -287.621888 -287.630728 -5.547271 -0.262344 -0.024969 3.720652 -1.909846 -3.193077 0
6 -303.661245 -303.672505 -7.065548 -0.258114 -0.043193 2.378039 1.099844 2.108415 0
7 -303.661277 -303.672723 -7.182538 -0.262396 -0.043493 3.47384 1.062114 3.307488 0
8 -303.657945 -303.669523 -7.26515 -0.262922 -0.045637 3.845258 -1.995072 3.287202 0
9 -592.336615 -592.34097 -2.732324 -0.227609 -0.010826 1.009217 0.638246 -0.781768 -0.000738
10 -592.335265 -592.339726 -2.799249 -0.230406 -0.012386 1.364935 -0.105954 -1.360816 0.000601
11 -269.358227 -269.363164 -3.097821 -0.217786 0.016959 0.750408 0.414392 -0.625612 -0.000029
12 -269.352698 -269.357654 -3.109574 -0.221117 0.01455 1.227594 -0.098625 -1.223626 0.000815
13 -249.50171 -249.51078 -5.69162 -0.201869 0.043741 2.279418 -0.414338 2.241443 0.001174
14 -265.527471 -265.537828 -6.499675 -0.244664 0.016147 3.249848 1.667978 -2.78915 -0.00086
15 -265.534464 -265.547799 -8.367494 -0.246286 0.017235 2.65305 2.361626 1.208883 0.000157
16 -265.540644 -265.554512 -8.702104 -0.228082 0.02573 5.498556 -1.254802 -5.353465 0.000953
17 -265.553358 -265.568995 -9.812129 -0.221088 0.031158 5.05346 -4.737936 1.757659 0.007338
18 -281.549329 -281.565063 -9.872712 -0.264785 -0.010604 6.364264 -2.109336 6.004544 0
19 -297.576723 -297.595385 -11.71033 -0.304661 -0.026359 7.787776 0.847453 7.74153 0
20 -297.586912 -297.608356 -13.456348 -0.300768 -0.023764 7.777045 7.344791 2.556654 0
Compound Gas Phase Energy Solution Phase Energy Solvation Energy       
(kcal/mol)
HOMO LUMO QM Dipole 
(D)
QM Dipole X 
(D)
QM Dipole Y 
(D)
QM Dipole Z 
(D)
2 -271.578452 -271.590317 -2.531579 -0.235541 0.002387 0.350155 -0.216006 -0.27559 0
3 -287.616222 -287.631235 -5.005546 -0.247809 -0.020994 1.803148 1.779325 -0.292143 0
4 -287.613617 -287.629059 -5.147537 -0.248305 -0.01909 2.369615 0.837358 2.216733 0
5 -287.614634 -287.630728 -5.547271 -0.249441 -0.019466 2.678329 -1.376729 -2.297404 0
6 -303.655093 -303.672505 -7.065548 -0.24486 -0.038586 1.636696 0.765002 1.446909 0
7 -303.654888 -303.672723 -7.182538 -0.249001 -0.038582 2.516365 0.699957 2.417055 0
8 -303.651395 -303.669523 -7.26515 -0.248332 -0.040486 2.78933 -1.449873 2.382904 0
9 -592.330647 -592.34097 -2.732324 -0.222568 -0.005639 0.74899 0.421677 -0.619011 -0.000133
10 -592.329344 -592.339726 -2.799249 -0.225458 -0.00733 0.970368 -0.084307 -0.966698 -0.000455
11 -269.353019 -269.363164 -3.097821 -0.213146 0.021886 0.566741 0.305094 -0.477612 -0.000307
12 -269.34739 -269.357654 -3.109574 -0.217191 0.018931 0.94826 -0.079153 -0.944951 0.000181
13 -249.495807 -249.51078 -5.69162 -0.195236 0.04802 1.744903 -0.29823 1.719228 0.001119
14 -265.522241 -265.537828 -6.499675 -0.236191 0.023951 2.379334 1.07995 -2.120126 -0.000401
15 -265.529418 -265.547799 -8.367494 -0.236305 0.023972 1.942908 1.694168 0.951151 0.000847
16 -265.535249 -265.554512 -8.702104 -0.220244 0.031237 4.134794 -0.965472 -4.020495 0.00027
17 -265.548258 -265.568995 -9.812129 -0.214502 0.034837 3.62858 -3.40388 1.257053 0.0031
18 -281.544782 -281.565063 -9.872712 -0.256426 -0.000158 4.703161 -1.40877 4.487214 0
19 -297.572866 -297.595385 -11.71033 -0.282679 -0.01712 5.932309 0.747572 5.885017 0
20 -297.5832 -297.608356 -13.456348 -0.283974 -0.015807 5.78498 5.413476 2.039676 0
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LMP2/6-31G**; gas phase 
 
 
Synthetic Procedures 
General Procedures: Reactions were magnetically stirred. Air and/or moisture 
sensitive reactions were carried out under an argon atmosphere in oven-dried 
glassware using anhydrous solvents from commercial suppliers. Air and/or moisture 
sensitive reagents were transferred via syringe or cannula and were introduced into 
reaction vessels through rubber septa. All anhydrous solvents used were purchased 
from Sigma-Aldrich and used without further purification. Solvents to be employed in 
flash column chromatography and reaction work-up procedures were purchased from 
either Sigma-Aldrich or Fisher Scientific. All other reagents were obtained commercially 
and used without further purification, unless otherwise stated. Reactions were 
monitored using LCMS and thin layer chromatography (TLC) performed on 0.25-mm 
EMD pre-coated glass-backed silica gel 60 F-254 plates. Compounds were visualized 
under UV light or through staining with permanganate, bromocresol green, or magic, 
when appropriate. Reaction products and chromatography fractions were concentrated 
Compound Gas Phase Energy Solution Phase Energy Solvation Energy       
(kcal/mol)
HOMO LUMO QM Dipole 
(D)
QM Dipole X 
(D)
QM Dipole Y 
(D)
QM Dipole Z 
(D)
2 -270.660593 -271.590317 -2.531579 -0.316801 0.143843 0.460872 -0.28335 -0.363478 0
3 -286.67968 -287.631235 -5.005546 -0.331147 0.122068 2.653929 2.625399 -0.3881 0
4 -286.678839 -287.629059 -5.147537 -0.330547 0.125119 3.301769 1.224918 3.066147 0
5 -286.679482 -287.630728 -5.547271 -0.340129 0.124353 3.720652 -1.909846 -3.193077 0
6 -302.704589 -303.672505 -7.065548 -0.360591 0.108706 2.378039 1.099844 2.108415 0
7 -302.702124 -303.672723 -7.182538 -0.366447 0.107929 3.47384 1.062114 3.307488 0
8 -302.70012 -303.669523 -7.26515 -0.35725 0.1059 3.845258 -1.995072 3.287202 0
9 -591.120704 -592.34097 -2.732324 -0.311406 0.132776 1.009217 0.638246 -0.781768 -0.000738
10 -591.119356 -592.339726 -2.799249 -0.315113 0.129543 1.364935 -0.105954 -1.360816 0.000601
11 -268.511014 -269.363164 -3.097821 -0.301147 0.170253 0.750408 0.414392 -0.625612 -0.000029
12 -268.505703 -269.357654 -3.109574 -0.30605 0.166146 1.227594 -0.098625 -1.223626 0.000815
13 -248.684136 -249.51078 -5.69162 -0.281473 0.195672 2.279418 -0.414338 2.241443 0.001174
14 -264.696015 -265.537828 -6.499675 -0.332034 0.173594 3.249848 1.667978 -2.78915 -0.00086
15 -264.702661 -265.547799 -8.367494 -0.333524 0.172465 2.65305 2.361626 1.208883 0.000157
16 -264.708941 -265.554512 -8.702104 -0.308957 0.183902 5.498556 -1.254802 -5.353465 0.000953
17 -264.721616 -265.568995 -9.812129 -0.303034 0.187446 5.05346 -4.737936 1.757659 0.007338
18 -280.703001 -281.565063 -9.872712 -0.350306 0.152408 6.364264 -2.109336 6.004544 0
19 -296.715009 -297.595385 -11.71033 -0.40561 0.14152 7.787776 0.847453 7.74153 0
20 -296.724616 -297.608356 -13.456348 -0.39568 0.142856 7.777045 7.344791 2.556654 0
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by rotary evaporation at 30-35 °C at 20 Torr, then Hi-Vac at 0.5 Torr overnight, unless 
otherwise indicated. 
 
Instrumentation: NMR spectra were recorded on a Bruker AvanceIII HD 400 MHz 
spectrometer (with 5 mm BBFO Z-gradient Smart Probe) calibrated to CH(D)Cl3 as an 
internal reference (7.26 and 77.00 ppm for 1H and 13C NMR spectra, respectively). Data 
for 1H NMR spectra are reported in terms of chemical shift (δ, ppm), multiplicity, 
coupling constant (Hz), and integration. Data for 13C NMR spectra are reported in terms 
of chemical shift (δ, ppm), with multiplicity and coupling constants in the case of C–F 
coupling. The following abbreviations are used to denote the multiplicities: s = singlet; d 
= doublet; dd = doublet of doublets; dt = doublet of triplets; dq = doublet of quartets; ddd 
= doublet of doublet of doublets; t = triplet; td = triplet of doublets; tt = triplet of triplets; q 
= quartet; qd = quartet of doublets; quin = quintet; sex = sextet; m = multiplet. LCMS 
and compound purity were determined using a Waters Micromass ZQ 4000, equipped 
with a Waters 2795 Separation Module, Waters 2996 Photodiode Array Detector, and a 
Waters 2424 ELSD. Separations were carried out with an XBridge BEH C18, 5µm, 4.6 x 
20 mm column, at ambient temperature (unregulated), using a mobile phase of water-
methanol containing a constant 0.1% formic acid. HPLC was performed on a Waters 
2535 Separation Module with a Waters 2998 Photodiode Array Detector. Separations 
were carried out with an XBridge BEH C18, 5µm, 19 x 50 mm column, at ambient 
temperature (unregulated), using a mobile phase of water-methanol containing a 
constant 0.05% formic acid. Column chromatography was carried out using a Biotage 
SP1 flash chromatography system with silica gel cartridges from Silicycle. 
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General Procedure A: A 20 mL vial is charged with the appropriate carboxylic acid (1.0 
equiv.), commercially available 3-(1H-tetrazol-5-yl)aniline (1.1 equiv.), DMF, N,N-
diisopropylethylamine (2.1 equiv.), and HATU (1.1 equiv.). The reaction mixture is 
stirred for 18h or until judged complete by LCMS. The crude reaction mixture is directly 
purified by reverse phase HPLC (water/MeOH/0.05% formic acid) to afford the desired 
product. 
 
General Procedure B: A 20 mL vial is charged with the appropriate carboxylic acid (1.0 
equiv.), DMF, and N,N-diisopropylethylamine (1.0 equiv.). HATU (1.05 equiv.) is then 
added, and the reaction mixture is allowed to stir for 20 minutes. Commercially available 
3-(1H-tetrazol-5-yl)aniline (1.1 equiv.) and N,N-diisopropylethylamine (1.1 equiv.) are 
subsequently added, and the reaction is stirred at room temperature for 24 h or until 
judged complete by LCMS. The crude reaction mixture is directly purified by reverse 
phase HPLC (water/MeOH/0.05% formic acid) to afford the desired product. 
 
General Procedure C: A 20 mL vial is charged with the appropriate t-butyl ester (1.0 
equiv.), fitted with a septa, and purged with Ar. The vial is then charged with dry 4M HCl 
in dioxanes (4 mL), and the reaction is stirred at room temperature for 18-72h or until 
judged complete by LCMS. The reaction mixture is then concentrated and dried under 
hivac overnight, affording the desired semi-crude product. 
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General Procedure D: A 3 mL vial with cap is purged with Ar and charged with the 
appropriate halide (1.0 equiv), bis(pinacoloto)diboron (1.1 equiv.), potassium acetate 
(2.0 equiv.), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride 
dichloromethane complex (0.02 equiv.), and dry tetrahydrofuran (1 mL). The reaction 
mixture is purged with Ar, sealed, and heated at 80 °C for 18h. The reaction mixture is 
then cooled to rt and charged with a solution of potassium carbonate (2.0 equiv.) in 
water (620 uL), the second halide (1.2 equiv.), and 1,1'-
bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.02 
equiv.). The reaction mixture is purged with Ar, sealed, and vigorously stirred at 80 °C 
for 18h. The crude reaction mixture is then transferred to a sep funnel with ~ 75 mL 
EtOAc and ~10 mL water. ~ 50 mL sat. NaHCO3 is added, the layers separated, and 
the organic layer further washed with ~ 40 mL water and brine. The organic layer is 
dried over MgSO4, concentrated, and purified on a silica column with EtOAc:hexanes to 
afford the desired product. 
 
General Procedure E: S1 (1 equiv.) and an aqueous K2CO3 solution (1M, 1.25 equiv.) 
were added to 0.5 mL of 1,4 dioxane. Argon was bubbled through the resulting solution 
to remove oxygen before the boronic acid (1.2 equiv.) and 1,1'-
bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.05 
equiv.) were added. The reaction was then warmed to 80 °C and stirred until complete 
by LCMS (18–24h). The reaction mixture was allowed to cool to r.t., diluted with MeOH, 
and filtered through celite. The filtrate was concentrated and purified as noted. 
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General Procedure F: Aryl t-butyl ester (1 equiv.) was suspended in 1:1 TFA/CH2Cl2 
and stirred until complete by either TLC or LCMS (3-18 h). Solvent was removed in 
vacuo and the resulting crude acid was used without further purification. The newly 
generated acid (1.0 equiv.), triethylamine (3.0 equiv.), and 3-(1H-tetrazol-5-yl)aniline 
(1.2 equiv.) were suspended in 0.5 mL DMF and placed under argon. HATU (1.5 equiv.) 
was added and the reaction was stirred until complete by LCMS (18-24h). The reaction 
was then diluted with DMF and purified by reverse phase HPLC (water/MeOH/0.05% 
formic acid) to afford the desired product. 
 
 
 
tert-butyl 3-bromo-5-(trifluoromethyl)benzoate (S1). Commercially available 3-
bromo-5-trifluoromethylbenzoic acid (5.000 g, 18.6 mmol, 1.0 equiv) was dissolved in 
dry dichloromethane (50 ml). N,N-dimethylformamide (400 ul, 5.2 mmol, 0.3 equiv) was 
added; oxalyl chloride (2.000 ml, 23.3 mmol, 1.3 equiv.) was subsequently added 
dropwise. The reaction mixture was allowed to stir at rt for 4h. The solvent was then 
removed under reduced pressure, and the residue was azeotroped with toluene twice. 
The remaining residue was diluted with dry tetrahydrofuran (65 mL) and cooled to 0 °C. 
Lithium tert-butoxide (2.976 g, 37.2 mmol, 2.0 equiv) was added in bulk to the reaction 
mixture; the reaction mixture was allowed to slowly warm to rt over 18h. ~ 100 mL water 
was then added, and the reaction mixture was extracted with 2 x 100 mL EtOAc. The 
organics were washed with ~ 50 mL 0.1 N HCl, water, and brine, then dried over 
MgSO4. Purified on a silica column with 0-5% EtOAc:hexanes. S1 (4.589, 76%) 
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obtained as a colorless, crystalline solid. 1H NMR (400 MHz, CDCl3) δ = 8.30 (s, 1H), 
8.18 (s, 1H), 7.93 (s, 1H), 1.63 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 163.01, 135.72, 
134.67, 132.49 (q, J = 33.5 Hz), 132.00 (q, J = 3.7 Hz), 125.02 (q, J = 3.7 Hz), 122.71, 
122.83 (q, J = 272.9 Hz), 82.78, 28.08; 19F NMR (376 MHz, CDCl3) δ = -62.89 (s, 3F); 
did not ionize by ESI. 
 
 
 
tert-butyl 5-(trifluoromethyl)-[1,1'-biphenyl]-3-carboxylate (S2). S1 was reacted with 
commercially available phenylboronic acid according to general procedure E. Crude 
product was filtered through a silica gel plug; the plug was washed with hexanes and 
the product eluted with ethyl acetate. S2 (46 mg, 65%) obtained as a colorless liquid. 1H 
NMR (400 MHz, CDCl3) δ = 8.42 (s, 1H), 8.24, (s, 1H), 8.01 (s, 1H), 7.64 - 7.67 (m, 2H), 
7.50 - 7.54 (m, 2H), 7.43 - 7.47 (m, 1 H), 1.67 (s, 9H); did not ionize by ESI. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-5-(trifluoromethyl)-[1,1'-biphenyl]-3-carboxamide (2). 
S2 (46.0 mg, 0.173 mmol, 1.0 equiv) was reacted according to general procedure F. 2 
(28.8 mg, 50% over two steps) was obtained as a white solid. 1H NMR (400 MHz, 
acetone-d6) δ = 10.16 (br s, 1H), 8.69 (s, 1H), 8.61 (s, 1H), 8.35 (s, 1H), 8.19 (s, 1H), 
8.07 (br d, J = 8.04 Hz, 1H), 7.93 (br d, J = 7.67 Hz, 1H), 7.86 (br d, J = 7.43 Hz, 2H), 
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7.54 - 7.65 (m, 3H), 7.46 - 7.53 (m, 1H); 13C NMR (100 MHz, acetone-d6) δ = 164.22, 
156.83, 142.57, 139.97, 138.60, 136.75, 131.07 (q, J = 32.28 Hz), 129.79, 129.69, 
129.19, 128.59, 127.29, 126.21 - 126.47 (m), 125.84, 123.18 - 123.40 (m), 122.60, 
118.78; 19F NMR (376 MHz, acetone-d6) δ = -63.03 (s, 3F); HRMS (ESI) calculated for 
C21H13F3N5O [M - H]- m/z 408.1078, found 408.1070. 
 
 
 
tert-butyl 3-(pyridin-2-yl)-5-(trifluoromethyl)benzoate (S3). S1 (65.0 mg, 0.20 mmol, 
1 equiv) was reacted with commercially available 2-bromopyridine according to general 
procedure D, except 5 mol% catalyst was used. Instead of a workup, the reaction 
mixture was allowed to cool to room temperature, diluted with MeOH, and filtered 
through celite. The filtrate was concentrated and purified via silica gel with 
EtOAc:hexanes. S3 (18.0 mg, 26%) obtained as a clear liquid. 1H NMR (400 MHz, 
CDCl3) δ = 8.72 - 8.80 (m, 2H), 8.50 - 8.55 (m, 1H), 8.29 (s, 1H), 7.83 - 7.89 (m, 2H), 
7.31 - 7.38 (m, 1H), 1.66 (s, 9H); LRMS (ESI) calculated for C17H17F3NO2 [M + H]+ m/z 
324.11, found 324.02. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(pyridin-2-yl)-5-(trifluoromethyl)benzamide (3). S3 
(18.0 mg, 0.056 mmol, 1.0 equiv) was reacted according to general procedure F. 3 
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(16.4 mg, 78% over two steps) obtained as a white solid. 1H NMR (400 MHz, acetone-
d6) δ = 10.31 (br s, 1H), 9.05 (s, 1H), 8.77 (dd, J = 4.75, 0.73 Hz, 1H), 8.75 (s, 1H), 8.71 
(s, 1H), 8.44 (s, 1H), 8.26 (d, J = 7.91 Hz, 1H), 8.17 (br d, J = 8.16 Hz, 1H), 7.95 - 8.01 
(m, 2H), 7.57 (t, J = 7.97 Hz, 1H), 7.46 (ddd, J = 7.52, 4.78, 0.73 Hz, 1H); 13C NMR (100 
MHz, acetone-d6) δ = 164.09, 154.21, 149.91, 140.80, 139.95, 137.42, 136.69, 130.93 
(d, J = 32.28 Hz), 129.62, 129.10, 126.11 (br d, J = 3.67 Hz), 124.78 (br d, J = 3.67 Hz), 
123.59, 122.52, 122.07, 120.87, 118.94; 19F NMR (376 MHz, acetone-d6) δ = -63.12 (s, 
3F); HRMS (ESI) calculated for C20H12F3N6O [M - H]- m/z 409.1030, found 409.1022. 
 
 
 
tert-butyl 3-(pyridin-3-yl)-5-(trifluoromethyl)benzoate (S4). S1 was reacted with 
commercially available pyridin-3-ylboronic acid according to general procedure E. Crude 
product was purified via silica gel with EtOAc:hexanes. S4 (26 mg, 40%) obtained as a 
colorless liquid. 1H NMR (400 MHz, CDCl3) δ = 8.89 - 8.94 (m, 1H), 8.70 (br d, J = 4.14 
Hz, 1H), 8.40 (s, 1H), 8.28 (s, 1H), 7.99 (s, 1H), 7.93 - 7.97 (m, 1H), 7.46 (dd, J = 7.91, 
4.87 Hz, 1H), 1.66 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 164.03, 149.56, 148.20, 
139.04, 134.60, 133.86, 131.86 (q, J = 30.08 Hz), 131.26, 127.35 - 127.54 (m), 125.62 - 
125.95 (m), 123.82, 82.49, 28.14; 19F NMR (376 MHz, CDCl3) δ = -62.68 (s, 3F); LRMS 
(ESI) calculated for C17H17F3NO2 [M + H]+ m/z 324.11, found 324.02. 
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N-(3-(1H-tetrazol-5-yl)phenyl)-3-(pyridin-3-yl)-5-(trifluoromethyl)benzamide (4). S4 
(34 mg, 0.105 mmol, 1.0 equiv) was reacted according to general procedure F. 4 (25 
mg, 58% over two steps) obtained as a white solid. 1H NMR (400 MHz, pyridine-d5) δ = 
11.72 (s, 1H), 9.27 (br s, 1H), 9.07 - 9.22 (m, 3H), 9.04 (br s, 1H), 8.76 (br d, J = 4.75 
Hz, 1H), 8.70 (s, 2H), 8.64 (s, 1H), 8.21 (br dd, J = 6.15, 1.03 Hz, 2H), 8.12 (s, 1H), 7.85 
(br dd, J = 7.85, 1.28 Hz, 1H), 7.33 (br dd, J = 7.85, 4.81 Hz, 1H); 13C NMR (100 MHz, 
pyridine-d5) δ = 165.24, 149.76, 148.58, 140.59, 139.35, 137.59, 134.48, 134.16, 
131.07 (d, J = 32.28 Hz), 130.48, 129.99, 127.61, 126.56 (br d, J = 3.67 Hz), 124.48 (br 
d, J = 4.40 Hz), 123.82, 123.13, 122.85, 119.87; 19F NMR (376 MHz, pyridine-d5) δ = -
62.03 (s, 3F); HRMS (ESI) calculated for C20H12F3N6O [M - H]- m/z 409.1030, found 
409.1023. 
 
 
 
tert-butyl 3-(pyridin-4-yl)-5-(trifluoromethyl)benzoate (S5). S1 was reacted with 
commercially available pyridin-4-ylboronic acid according to general procedure E. Crude 
product was purified via HPLC using water/MeOH/0.05% formic acid. S5 (34 mg, 54%) 
obtained as a white powder. 1H NMR (400 MHz, CDCl3) δ = 8.79 (br s, 2H), 8.45 (s, 
1H), 8.31 (s, 1H), 8.04 (s, 1H), 7.59 (br s, 2H), 1.66 (s, 9H); 13C NMR (100 MHz, CDCl3) 
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δ = 163.90, 150.61, 146.09, 139.42, 133.95, 131.92 (d, J = 33.01 Hz), 131.15, 127.35 
(br d, J = 3.67 Hz), 126.61 (q, J = 3.67 Hz), 82.60, 28.14; 19F NMR (376 MHz, CDCl3) δ 
= -62.70 (s, 3F); LRMS (ESI) calculated for C17H17F3NO2 [M + H]+ m/z 324.11, found 
324.09. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(pyridin-4-yl)-5-(trifluoromethyl)benzamide (5). S5 
(19.4 mg, 0.060 mmol, 1.0 equiv) was reacted according to general procedure F. 5 (19 
mg, 77% over two steps) obtained as a white solid. 1H NMR (400 MHz, pyridine-d5) δ = 
11.74 (s, 1H), 9.26 (br d, J = 1.46 Hz, 1H), 8.77 - 8.83 (m, 2H), 8.70 (s, 3H), 8.66 (s, 
1H), 8.17 - 8.23 (m, 2H), 8.15 (s, 1H), 7.56 - 7.61 (m, 1H), 7.46 - 7.52 (m, 2H); 13C NMR 
(100 MHz, pyridine-d5) δ = 165.10, 150.80, 145.43, 140.57, 139.53, 137.64, 131.12 (d, J 
= 33.01 Hz), 130.42, 130.03, 127.47, 126.53 (br d, J = 3.67 Hz), 125.17 - 125.70 (m), 
123.16, 121.69, 119.87; 19F NMR (376 MHz, pyridine-d5) δ = -62.07 (s, 3F); HRMS 
(ESI) calculated for C20H12F3N6O [M - H]- m/z 409.1030, found 409.1023. 
 
 
 
tert-butyl 3-(pyrimidin-2-yl)-5-(trifluoromethyl)benzoate (S6). S1 (100 mg, 0.308 
mmol, 1.0 equiv) was reacted with commercially available 2-bromopyrimidine according 
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to general procedure D. S6 (75.2 mg, 75%) obtained as a white solid. 1H NMR (400 
MHz, CDCl3) δ = 9.23 (br s, 1H), 8.90 (br s, 1H), 8.86 (d, J = 4.9 Hz, 2H), 8.35 (s, 1H), 
7.28 (t, J = 4.9 Hz, 1H), 1.69 - 1.63 (m, 9H); 13C NMR (100 MHz, CDCl3) δ = 164.23, 
162.64, 157.44, 138.87, 133.48, 132.12, 131.33 (q, J = 33.0 Hz), 128.58 (q, J = 3.7 Hz), 
128.13 (q, J = 4.2 Hz), 123.77 (q, J = 272.9 Hz), 120.03, 82.17, 28.14; 19F NMR (376 
MHz, CDCl3) δ = -62.66 (s, 3F); LRMS (ESI) calculated for C16H16F3N2O2 [M + H]+ m/z 
325.11, found 324.94. 
 
 
 
3-(pyrimidin-2-yl)-5-(trifluoromethyl)benzoic acid (S7). S6 (75.2 mg, 0.232 mmol, 1.0 
equiv) was reacted according to general procedure C (24h). Semi-crude S7 (65.6 mg, 
106%) obtained as a white solid. 1H NMR (400 MHz, CD3OD, drops CDCl3) δ = 9.20 (br 
s, 1H), 8.90 (d, J = 4.9 Hz, 2H), 8.83 (br s, 1H), 8.34 (br s, 1H), 7.46 (t, J = 5.0 Hz, 1H); 
13C NMR (100 MHz, CD3OD, drops CDCl3) δ = 166.42, 161.55, 157.62, 138.31, 132.48, 
132.26, 131.21 (q, J = 33.0 Hz), 128.38 (q, J = 3.7 Hz), 128.11 (q, J = 3.7 Hz), 120.49, 
123.67 (q, J = 272.2 Hz); 19F NMR (376 MHz, CD3OD, drops CDCl3) δ = -63.99 (s, 3F); 
LRMS (ESI) calculated for C12H6F3N2O2 [M - H]- m/z 267.05, found  267.06. 
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N-(3-(1H-tetrazol-5-yl)phenyl)-3-(pyrimidin-2-yl)-5-(trifluoromethyl)benzamide (6). 
S7 (65.6 mg, 0.245 mmol, 1.0 equiv) was reacted with 3-(1H-tetrazol-5-yl)aniline in 3 
mL DMF according to general procedure B. 6 (65.4 mg, 65%) obtained as a white solid. 
1H NMR (400 MHz, CD3OD, drops CDCl3) δ = 9.18 (br s, 1H), 8.84 (d, J = 4.9 Hz, 2H), 
8.83 (br s, 1H), 8.35 (t, J = 1.7 Hz, 1H), 8.32 (br s, 1H), 7.91 (br dd, J = 1.2, 8.3 Hz, 1H), 
7.74 (br d, J = 7.8 Hz, 1H), 7.50 (t, J = 7.9 Hz, 1H), 7.36 (t, J = 4.9 Hz, 1H); 13C NMR 
(100 MHz, CD3OD, drops CDCl3) δ = 166.65, 163.18, 158.59, 157.50, 140.31, 139.95, 
137.21, 132.38 (q, J = 30.1 Hz), 131.34, 130.75, 128.59 (d, J = 3.7 Hz), 127.37 (q, J = 
3.7 Hz), 126.03, 124.49, 124.01, 124.72 (q, J = 272.2 Hz), 121.38, 120.32; 19F NMR 
(376 MHz, CD3OD, drops CDCl3) δ = -63.57 (s, 3F); HRMS (ESI) calculated for 
C19H11F3N7O [M - H]- m/z 410.0983, found 410.0974. 
 
 
 
tert-butyl 3-(pyrimidin-4-yl)-5-(trifluoromethyl)benzoate (S8). S1 (100 mg, 0.308 
mmol, 1.0 equiv) was reacted with commercially available 4-chloropyrimidine 
hydrochloride according to general procedure D, except potassium carbonate (136 mg, 
0.984 mmol, 3.2 equiv) and water (992 ul) were used in the second step. S8 (84.5 mg, 
85%) obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ = 9.31 (br d, J = 1.4 Hz, 
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1H), 8.84 (d, J = 5.4 Hz, 1H), 8.80 (br s, 1H), 8.57 (br s, 1H), 8.33 (br s, 1H), 7.81 (dd, J 
= 1.5, 5.4 Hz, 1H), 1.63 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 163.71, 161.41, 
159.24, 158.03, 137.67, 133.77, 131.82 (q, J = 33.0 Hz), 130.86, 128.32 (q, J = 3.9 Hz), 
127.56 (q, J = 3.7 Hz), 123.43 (q, J = 272.9 Hz), 117.03, 82.53, 28.03; 19F NMR (376 
MHz, CDCl3) δ = -62.78 (s, 3F); LRMS (ESI) calculated for C16H16F3N2O2 [M + H]+ m/z 
325.11, found 325.01. 
 
 
 
3-(pyrimidin-4-yl)-5-(trifluoromethyl)benzoic acid hydrochloride (S9). S8 (84.5 mg, 
0.261 mmol, 1.0 equiv) was reacted according to general procedure C (24h). Semi-
crude S9 (80.8 mg, 102%) obtained as a white solid. 1H NMR (400 MHz, CD3OD) δ = 
9.60 (br s, 1H), 9.20 (d, J = 6.1 Hz, 1H), 9.16 (br s, 1H), 8.86 (br s, 1H), 8.67 (dd, J = 
1.0, 6.1 Hz, 1H), 8.50 (br s, 1H); 13C NMR (100 MHz, CD3OD) δ = 166.81, 165.56, 
153.72, 152.18, 136.13, 133.41, 132.52, 131.91 (q, J = 33.0 Hz), 129.89 (q, J = 4.2 Hz), 
128.70 (q, J = 3.9 Hz), 123.43 (q, J = 272.2 Hz), 118.72; 19F NMR (376 MHz, CD3OD) δ 
= -64.35 (s, 3F); LRMS (ESI) calculated for C12H6F3N2O2 [M - H]- m/z 267.05, found 
267.06. 
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N-(3-(1H-tetrazol-5-yl)phenyl)-3-(pyrimidin-4-yl)-5-(trifluoromethyl)benzamide (7). 
S9 (80.8 mg, 0.265 mmol, 1.0 equiv) was reacted with 3-(1H-tetrazol-5-yl)aniline in 3 
mL DMF according to general procedure B, except 2 equiv N,N-diisopropylethylamine 
(93 uL) was used in the first step. 7 (68.8 mg, 63%) obtained as a white solid. 1H NMR 
(400 MHz, DMSO-d6) δ = 10.84 (s, 1H), 9.36 (d, J = 1.0 Hz, 1H), 9.07 (br s, 1H), 9.00 
(d, J = 5.4 Hz, 1H), 8.73 (s, 1H), 8.58 (s, 1H), 8.50 (s, 1H), 8.37 (dd, J = 1.2, 5.4 Hz, 
1H), 8.03 (dd, J = 1.1, 8.2 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.63 (t, J = 8.0 Hz, 1H); 13C 
NMR (100 MHz, DMSO-d6) δ = 163.76, 160.33, 158.90, 158.70, 155.77, 139.63, 
137.60, 136.49, 130.21, 129.90, 130.22 (q, J = 33.0 Hz), 126.70 (br q, J = 3.7 Hz), 
126.40 (br q, J = 3.7 Hz), 124.93, 122.96, 122.48, 123.72 (q, J = 272.9 Hz), 118.91, 
117.95; 19F NMR (376 MHz, DMSO-d6) δ = -61.16 (s, 3F); HRMS (ESI) calculated for 
C19H11F3N7O [M - H]- m/z 410.0983, found 410.0975. 
 
 
 
tert-butyl 3-(pyrimidin-5-yl)-5-(trifluoromethyl)benzoate (S10). S1 (100 mg, 0.308 
mmol, 1.0 equiv) was reacted with commercially available 5-bromopyrimidine according 
to general procedure D. S10 (74.3 mg, 75%) obtained as a white solid. 1H NMR (400 
MHz, CDCl3) δ = 9.26 (s, 1H), 9.00 (s, 2H), 8.37 (br s, 1H), 8.30 (br s, 1H), 7.96 (br s, 
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1H), 1.61 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 163.55, 158.37, 154.96, 135.53, 
134.21, 132.40, 132.16 (q, J = 33.0 Hz), 131.06, 127.18 (q, J = 3.7 Hz), 126.53 (q, J = 
4.2 Hz), 123.32 (q, J = 272.9 Hz), 82.67, 28.02; 19F NMR (376 MHz, CDCl3) δ = -62.77 
(s, 3F); LRMS (ESI) calculated for C16H16F3N2O2 [M + H]+ m/z 325.11, found 325.09. 
 
 
 
3-(pyrimidin-5-yl)-5-(trifluoromethyl)benzoic acid hydrochloride (S11). S10 (74.3 
mg, 0.229 mmol, 1.0 equiv) was reacted according to general procedure C (48h). Semi-
crude S11 (70.1 mg, 100%) obtained as a white solid. 1H NMR (400 MHz, CD3OD, 
drops CDCl3) δ = 9.36 (s, 1H), 9.28 (s, 2H), 8.56 (s, 1H), 8.19 (s, 1H), 7.98 (s, 1H); 19F 
NMR (376 MHz, CD3OD, drops CDCl3) δ = -63.56 (s, 3F); LRMS (ESI) calculated for 
C12H6F3N2O2 [M - H]- m/z 267.05, found 266.99. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(pyrimidin-5-yl)-5-(trifluoromethyl)benzamide (8). 
S11 (70.1 mg, 0.230 mmol, 1.0 equiv) was reacted with 3-(1H-tetrazol-5-yl)aniline in 2.5 
mL DMF according to general procedure B, except 2 eq N,N-diisopropylethylamine 
(80.2 uL) was used in the first step. 8 (16.5 mg, 17%) obtained as a white solid. 1H NMR 
(400 MHz, CD3OD/CD3CN/CDCl3) δ = 10.60 (s, 1H), 10.55 (br s, 2H), 9.91 (br s, 1H), 
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9.88 - 9.84 (m, 1H), 9.75 (br s, 1H), 9.61 (br s, 1H), 9.29 (br d, J = 8.3 Hz, 1H), 9.17 (br 
d, J = 7.8 Hz, 1H), 8.99 - 8.92 (m, 1H); 13C NMR (100 MHz, CD3OD/CD3CN/CDCl3) δ = 
166.15, 159.15, 157.98, 156.69, 140.71, 138.28, 137.25, 133.85, 133.01 (q, J = 33.0 
Hz), 131.22, 128.23 (br q, J = 3.7 Hz), 126.86, 126.21 (br q, J = 4.4 Hz), 124.51, 
124.33, 120.54; 19F NMR (376 MHz, CD3OD/CD3CN/CDCl3) δ = -62.05 (s, 3F); HRMS 
(ESI) calculated for C19H11F3N7O [M - H]- m/z 410.0983, found 410.0976.  
 
 
 
tert-butyl 3-(thiophen-2-yl)-5-(trifluoromethyl)benzoate (S12). A 3 mL vial with cap 
was purged with Ar and charged with S1 (100 mg, 0.308 mmol, 1.0 equiv), thiophene-2-
boronic acid (98 mg, 0.769 mmol, 2.5 equiv), cesium carbonate (251 mg, 0.769 mmol, 
2.5 equiv), tetrakis(triphenylphosphine)palladium(0) (21 mg, 0.018 mmol, 0.06 equiv), 
and dry 1,2-dimethoxyethane (2.5 mL). The reaction mixture was purged again, sealed, 
and heated at 80 °C for 18h. The crude reaction mixture was transferred to a sep funnel 
with ~ 75 mL EtOAc and ~ 5 mL water. ~ 50 mL sat. NaHCO3 was added, the layers 
separated, and the organic layer washed with ~ 50 mL water and brine. The EtOAc was 
dried over MgSO4 and concentrated. Purified on a silica column with 0-15% 
EtOAc:hexanes. S12 (70.7 mg, 70%) obtained as a glassy solid. 1H NMR (400 MHz, 
CDCl3) δ = 8.39 (br s, 1H), 8.13 (br s, 1H), 7.97 (br s, 1H), 7.43 (dd, J = 1.0, 3.7 Hz, 
1H), 7.38 (dd, J = 1.2, 5.1 Hz, 1H), 7.13 (dd, J = 3.7, 5.1 Hz, 1H), 1.66 (s, 9H); 13C NMR 
(100 MHz, CDCl3) δ = 164.09, 141.67, 135.55, 133.55, 131.51 (q, J = 33.0 Hz), 129.71, 
128.33, 126.35, 125.88 (q, J = 3.7 Hz), 124.68, 124.71 (q, J = 3.7 Hz), 123.61 (q, J = 
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272.9 Hz), 82.23, 28.08; 19F NMR (376 MHz, CDCl3) δ = -62.77 (s, 3F); did not ionize by 
ESI. 
 
 
 
3-(thiophen-2-yl)-5-(trifluoromethyl)benzoic acid (S13). S12 (70.7 mg, 0.215 mmol, 
1.0 equiv) was reacted according to general procedure C (48h). Semi-crude S13 (59.6 
mg, 102%) obtained as a white solid. 1H NMR (400 MHz, CD3OD) δ = 8.36 (s, 1H), 8.09 
(s, 1H), 7.99 (br s, 1H), 7.48 (dd, J = 1.2, 3.7 Hz, 1H), 7.45 (dd, J = 1.0, 5.1 Hz, 1H), 
7.10 (dd, J = 3.7, 5.1 Hz, 1H); 13C NMR (100 MHz, CD3OD) δ = 166.29, 140.95, 135.90, 
132.61, 131.32 (q, J = 33.0 Hz), 129.42, 128.23, 126.35, 125.29 (q, J = 3.7 Hz), 124.82, 
124.23 (q, J = 3.7 Hz), 123.66 (q, J = 271.7 Hz); 19F NMR (376 MHz, CD3OD) δ = -
64.35 (s, 3F); LRMS (ESI) calculated for C12H6F3O2S [M - H]- m/z 271.01, found 270.93. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(thiophen-2-yl)-5-(trifluoromethyl)benzamide (9). 
S13 (59.6 mg, 0.219 mmol, 1.0 equiv) was reacted with 3-(1H-tetrazol-5-yl)aniline in 2.5 
mL DMF according to general procedure B. 9 (60.9 mg, 67%) obtained as a white solid. 
1H NMR (400 MHz, DMSO-d6) δ = 10.77 (s, 1H), 8.57 (t, J = 1.7 Hz, 1H), 8.50 (s, 1H), 
8.24 (s, 1H), 8.18 (s, 1H), 8.01 (dd, J = 1.2, 8.3 Hz, 1H), 7.83 (dd, J = 1.0, 3.7 Hz, 1H), 
7.80 (d, J = 7.8 Hz, 1H), 7.71 (dd, J = 1.1, 5.0 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 7.23 (dd, 
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J = 3.7, 4.9 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) δ = 163.83, 156.04, 140.62, 
139.56, 136.45, 135.31, 130.25 (d, J = 32.3 Hz), 129.73, 128.81, 128.34, 127.60, 
126.11, 125.34, 124.40 (br d, J = 4.4 Hz), 122.95 (d, J = 4.4 Hz), 122.78, 122.40, 
123.69 (d, J = 272.9 Hz), 118.91; 19F NMR (376 MHz, DMSO-d6) δ = -61.16 (s, 3F); 
HRMS (ESI) calculated for C19H11F3N5OS [M - H]- m/z 414.0642, found 414.0634. 
 
 
 
tert-butyl 3-(thiophen-3-yl)-5-(trifluoromethyl)benzoate (S14). A 3 mL vial with cap 
was purged with Ar and charged with S1 (100 mg, 0.308 mmol, 1.0 equiv), thiophene-3-
boronic acid (98 mg, 0.769 mmol, 2.5 equiv), cesium carbonate (251 mg, 0.769 mmol, 
2.5 equiv), tetrakis(triphenylphosphine)palladium(0) (21 mg, 0.018 mmol, 0.06 equiv), 
and dry 1,2-dimethoxyethane (2.5 mL). The reaction mixture was purged again, sealed, 
and heated at 80 °C for 18h. The crude reaction mixture was transferred to a sep funnel 
with ~ 75 mL EtOAc and ~ 5 mL water. ~ 50 mL sat. NaHCO3 was added, the layers 
separated, and the organic layer washed with ~ 50 mL water and brine. The EtOAc was 
dried over MgSO4 and concentrated under reduced pressure. Purified on a silica 
column with 0-15% EtOAc:hexanes. S14 (90.1 mg, 89%) obtained as a glassy solid. 1H 
NMR (400 MHz, CDCl3) δ = 8.39 (br s, 1H), 8.16 (br s, 1H), 7.98 (br s, 1H), 7.59 (dd, J = 
1.8, 2.6 Hz, 1H), 7.45 (d, J = 1.2 Hz, 1H), 7.44 (s, 1H), 1.66 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ = 164.28, 139.96, 136.83, 133.40, 131.36 (q, J = 32.5 Hz), 130.35, 127.03, 
126.55 (q, J = 3.7 Hz), 125.96, 124.56 (q, J = 3.7 Hz), 123.73 (q, J = 272.9 Hz), 122.02, 
82.11, 28.09; 19F NMR (376 MHz, CDCl3) δ = -62.67 (s, 3F); did not ionize by ESI. 
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3-(thiophen-3-yl)-5-(trifluoromethyl)benzoic acid (S15). S14 (90.1 mg, 0.274 mmol, 
1.0 equiv) was reacted according to general procedure C (48h). Semi-crude S15 (79.3 
mg, 106%) obtained as a white solid. 1H NMR (400 MHz, CD3OD) δ = 8.41 (t, J = 1.3 
Hz, 1H), 8.12 - 8.10 (m, 1H), 8.05 - 8.02 (m, 1H), 7.74 (dd, J = 1.5, 2.9 Hz, 1H), 7.50 - 
7.48 (m, 1H), 7.46 - 7.43 (m, 1H); 13C NMR (100 MHz, CD3OD) δ = 168.34, 141.13, 
138.91, 134.07, 132.87 (q, J = 33.0 Hz), 131.90, 128.59, 127.96 (q, J = 3.7 Hz), 127.14, 
125.78 (q, J = 4.2 Hz), 123.89, 125.54 (q, J = 271.7 Hz); 19F NMR (376 MHz, CD3OD) δ 
= -64.16 (s, 3F); LRMS (ESI) calculated for C12H6F3O2S [M - H]- m/z 271.01, found 
270.93. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(thiophen-3-yl)-5-(trifluoromethyl)benzamide (10). 
S15 (79.3 mg, 0.291 mmol, 1.0 equiv) was reacted with 3-(1H-tetrazol-5-yl)aniline in 2.5 
mL DMF according to general procedure B. 10 (97.3 mg, 80%) obtained as a white 
solid. 1H NMR (400 MHz, DMSO-d6) δ = 10.74 (s, 1H), 8.61 (s, 1H), 8.58 (t, J = 1.7 Hz, 
1H), 8.28 (s, 1H), 8.23 (dd, J = 1.3, 2.8 Hz, 1H), 8.21 (s, 1H), 8.04 - 8.00 (m, 1H), 7.83 - 
7.78 (m, 2H), 7.76 - 7.72 (m, 1H), 7.62 (t, J = 8.0 Hz, 1H); 13C NMR (100 MHz, DMSO-
d6) δ = 164.16, 155.92, 139.64, 139.15, 136.56, 136.23, 130.10 (q, J = 31.5 Hz), 
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129.77, 129.00, 127.73, 126.33, 125.36 (d, J = 3.2 Hz), 125.10, 123.49, 122.85, 122.71 
(d, J = 3.7 Hz), 123.86 (d, J = 272.9 Hz), 122.37, 118.88; 19F NMR (376 MHz, DMSO-
d6) δ = -60.21 (s, 3F); HRMS (ESI) calculated for C19H11F3N5OS [M - H]- m/z 414.0642, 
found 414.0635. 
 
 
 
tert-butyl 3-(furan-2-yl)-5-(trifluoromethyl)benzoate (S16). S1 was reacted with 
commercially available furan-2-ylboronic acid according to general procedure E. Crude 
product was filtered through a silica gel plug; the plug was washed with hexanes and 
the product was eluted with CH2Cl2. S16 (31 mg, 50%) obtained as a colorless liquid. 1H 
NMR (400 MHz, CDCl3) δ = 8.41 - 8.46 (m, 1H), 8.29 (s, 1H), 8.02 (s, 1H), 7.65 (dd, J = 
5.66, 3.35 Hz, 1H), 7.48 (dd, J = 5.78, 3.23 Hz, 1H), 1.67 (s, 9H); did not ionize by ESI. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(furan-2-yl)-5-(trifluoromethyl)benzamide (11). S16 
(28.3 mg, 0.091 mmol, 1.0 equiv) was reacted according to general procedure F. 11 (21 
mg, 58% over two steps) obtained as a white solid. 1H NMR (400 MHz, pyridine-d5) δ = 
11.71 (br s, 1H), 10.56 (br s, 2H), 9.24 (br s, 1H), 8.35 (br s, 1H), 8.08 - 8.21 (m, 3H), 
7.66 (br s, 1H), 6.96 (br d, J = 1.83 Hz, 1H), 6.54 (br s, 1H); 13C NMR (100 MHz, 
pyridine-d5) δ = 166.77, 153.04, 145.23, 142.14, 138.84, 133.62, 132.38 (br d, J = 31.54 
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Hz), 131.53, 128.61, 128.12, 124.25, 121.40, 113.94, 109.59; 19F NMR (376 MHz, 
pyridine-d5) δ = -62.3 (s, 3F); HRMS (ESI) calculated for C19H11F3N5O2 [M - H]- m/z 
398.0870, found  398.0865. 
 
 
 
tert-butyl 3-(furan-3-yl)-5-(trifluoromethyl)benzoate (S17). S1 was reacted with 
commercially available furan-3-ylboronic acid according to general procedure E. Crude 
product was purified via silica gel with hexanes:CH2Cl2. S17 (50.3 mg, 77%) obtained 
as a colorless liquid. 1H NMR (400 MHz, CDCl3) δ = 8.27 - 8.29 (m, 1H), 8.12 (s, 1H), 
7.86 (d, J = 0.85 Hz, 2H), 7.54 (t, J = 1.70 Hz, 1H), 6.78 (dd, J = 1.70, 0.73 Hz, 1H), 
1.65 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 164.31, 144.28, 139.47, 133.73, 133.43, 
131.42 (q, J = 32.52 Hz), 129.78, 125.73 - 126.14 (m), 124.79, 124.49 (q, J = 3.67 Hz), 
108.56, 82.19, 28.11; 19F NMR (376 MHz, CDCl3) δ = -62.79 (s, 3F); did not ionize by 
ESI. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(furan-3-yl)-5-(trifluoromethyl)benzamide (12). S17 
(30.5 mg, 0.098 mmol, 1.0 equiv) was reacted according to general procedure F. 12 (39 
mg, 50% over two steps) obtained as a white solid. 1H NMR (400 MHz, pyridine-d5) δ = 
11.82 - 12.21 (m, 2H), 11.65 - 11.75 (m, 1H), 9.22 - 9.33 (m, 1H), 8.59 - 8.69 (m, 1H), 
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8.37 - 8.46 (m, 1H), 8.10 - 8.32 (m, 4H), 7.70 - 7.80 (m, 1H), 7.15 - 7.35 (m, 2H), 6.92 - 
7.03 (m, 1H); 13C NMR (100 MHz, pyridine-d5) δ = 165.47, 144.69, 140.66, 137.37, 
134.23, 131.04, 130.72, 130.02, 129.17, 128.91, 128.42, 127.11, 125.54 (br d, J = 3.67 
Hz), 125.13 (br d, J = 3.67 Hz), 124.93, 119.86, 108.79; 19F NMR (376 MHz, pyridine-
d5) δ = -62.17 (s, 3F); HRMS (ESI) calculated for C19H11F3N5O2 [M - H]- m/z 398.0870, 
found 398.0863. 
 
 
 
3-(trifluoromethyl)-5-(1-(triisopropylsilyl)-1H-pyrrol-3-yl)benzoic acid (S18). 
Commercially available 3-bromo-5-(trifluoromethyl)benzoic acid (54 mg, 0.20 mmol, 1 
equiv) was reacted with commercially available (1-(triisopropylsilyl)-1H-pyrrol-3-
yl)boronic acid according to general procedure E. Crude product was loaded onto a plug 
of C18-silica; the plug was washed with water and the product eluted with MeOH. Crude 
S18 was used without further purification. LRMS (ESI) calculated for C21H27F3NO2Si [M 
- H]- m/z 410.18, found 410.2. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(1H-pyrrol-3-yl)-5-(trifluoromethyl)benzamide (13). 
Crude S18 was taken up in 1.0 mL of a 1M tetrabutylammonium fluoride solution in 
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THF. The reaction was stirred until complete by TLC (ca. 2 hr), then concentrated. The 
resulting crude 3-(1H-pyrrol-3-yl)-5-(trifluoromethyl)benzoic acid was reacted according 
to general procedure F. 13 (12 mg, 15% over three steps) obtained as a white solid. 1H 
NMR (400 MHz, pyridine-d5) δ = 12.17 - 12.39 (m, 1H), 11.57 - 11.72 (m, 1H), 9.23 (br 
s, 1H), 8.14 - 8.42 (m, 5H), 6.75 - 6.91 (m, 2H); 19F NMR (376 MHz, pyridine-d5) δ = -
62.11 (s, 3F); HRMS (ESI) calculated for C19H12F3N6O [M - H]- m/z 397.1030, found 
397.1023. 
 
 
 
3-(1H-pyrazol-1-yl)-5-(trifluoromethyl)benzoic acid (S19). Commercially available 3-
bromo-5-(trifluoromethyl)benzoic acid (54 mg, 0.20 mmol, 1 equiv), K2CO3 (155 mg, 1.1 
mmol, 5.6 equiv), and N,N-dimethylglycine hydrochloride (45 mg, 0.3 mmol, 1.6 equiv) 
were suspended in 0.5 mL of dry DMSO. Argon was bubbled through the resulting 
solution to remove oxygen before copper(I) iodide (30 mg, 0.2 mmol, 0.8 equiv) and 
pyrazole (18 mg, 0.3 mmol, 1.3 equiv) were added to the reaction mixture. The reaction 
was then warmed to 100 °C and stirred for 18h. The reaction mixture was allowed to 
cool to room temperature, diluted with MeOH, and filtered through celite. Crude S19 
was used without further purification. LRMS (ESI) calculated for C11H6F3N2O2 [M - H]- 
m/z 255.05, found 254.97. 
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N-(3-(1H-tetrazol-5-yl)phenyl)-3-(1H-pyrazol-1-yl)-5-(trifluoromethyl)benzamide 
(14). Crude S19 was reacted according to general procedure F. 14 (17 mg, 21% over 
two steps) obtained as a white solid. 1H NMR (400 MHz, pyridine-d5) δ = 11.76 (br d, J = 
13.15 Hz, 1H), 9.23 (br d, J = 12.90 Hz, 1H), 8.91 (br d, J = 13.27 Hz, 1H), 8.50 - 8.57 
(m, 1H), 8.27 - 8.45 (m, 3H), 8.09 - 8.24 (m, 3H), 7.91 (br d, J = 13.76 Hz, 1H), 6.57 (br 
d, J = 12.66 Hz, 1H); 13C NMR (100 MHz, pyridine-d5) δ = 164.87, 142.05, 140.95, 
140.51, 138.19, 131.34 (d, J = 33.01 Hz), 130.00, 127.86, 127.38, 123.20, 121.84 - 
122.04 (m), 121.49, 119.91, 117.97 (d, J = 2.93 Hz), 108.81; 19F NMR (376 MHz, 
pyridine-d5) δ = -62.33 (s, 3F); HRMS (ESI) calculated for C18H11F3N7O [M - H]- m/z 
398.0983, found 398.0976. 
 
 
 
3-(1H-pyrazol-3-yl)-5-(trifluoromethyl)benzoic acid (S20). Commercially available 3-
bromo-5-(trifluoromethyl)benzoic acid (54 mg, 0.20 mmol, 1 equiv) was reacted with 
commercially available (1H-pyrazol-3-yl)boronic acid according to general procedure E. 
Crude product was loaded onto a plug of C18-silica; the plug was washed with water 
and the product eluted with MeOH. Crude S20 was used without further purification. 
LRMS (ESI) calculated for C11H6F3N2O2 [M - H]- m/z 255.05, found 254.97. 
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N-(3-(1H-tetrazol-5-yl)phenyl)-3-(1H-pyrazol-5-yl)-5-(trifluoromethyl)benzamide 
(15). Crude S20 was reacted according to general procedure F. 15 (1.4 mg, 1.8% over 
two steps) obtained as a white solid. 1H NMR (400 MHz, acetone-d6) δ = 8.63 (br d, J = 
15.22 Hz, 2H), 8.33 (br s, 2H), 8.18 (s, 2H), 8.07 - 8.12 (m, 1H), 7.94 (br d, J = 7.79 Hz, 
1H), 7.58 (t, J = 7.97 Hz, 1H); 19F NMR (376 MHz, acetone-d6) δ = -63.14 (s, 3F); 
HRMS (ESI) calculated for C18H11F3N7O [M - H]- m/z 398.0983, found 398.0977. 
 
 
 
tert-butyl 3-(1H-imidazol-1-yl)-5-(trifluoromethyl)benzoate (S21). A 3 mL vial with 
cap was purged with Ar and charged with S1 (100 mg, 0.308 mmol, 1.0 equiv), 
imidazole (27 mg, 0.400 mmol, 1.3 equiv), potassium carbonate (238 mg, 1.72 mmol, 
5.6 equiv), copper(I) iodide (47 mg, 0.246 mmol, 0.8 equiv), and N,N-dimethylglycine 
hydrochloride (69 mg, 0.492 mmol, 1.6 equiv). The vial was purged with Ar; dry dimethyl 
sulfoxide (1.5 ml) was then added, and the vial was sealed and heated at 120 °C for 
18h. The crude reaction mixture was transferred to a sep funnel with ~ 75 mL EtOAc 
and ~10 mL water. ~ 50 mL sat. NaHCO3 was added, the layers separated, and the 
organic layer washed with ~ 40 mL water and brine. The organic layer was dried over 
MgSO4 and concentrated under reduced pressure. Purified on a silica column with 0-
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60% EtOAc:hexanes. S21 (34.7 mg, 36%) obtained as a white solid. 1H NMR (400 
MHz, CDCl3) δ = 8.20 (s, 1H), 8.19 (br d, J = 1.9 Hz, 1H), 7.94 (s, 1H), 7.79 (br s, 1H), 
7.36 (t, J = 1.3 Hz, 1H), 7.26 (br s, 1H), 1.63 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 
163.08, 137.94, 135.47, 135.02, 132.70 (q, J = 33.5 Hz), 131.30, 125.16, 124.85 (q, J = 
3.7 Hz), 121.51 (q, J = 3.7 Hz), 122.97 (q, J = 272.9 Hz), 117.97, 83.02, 28.02; 19F NMR 
(376 MHz, CDCl3) δ = -62.84 (s, 3F); LRMS (ESI) calculated for C15H16F3N2O2 [M + H]+ 
m/z 313.11, found 313.01. 
 
 
 
3-(1H-imidazol-1-yl)-5-(trifluoromethyl)benzoic acid hydrochloride (S22). S21 (34.7 
mg, 0.111 mmol, 1.0 equiv) was reacted according to general procedure C (24h). Semi-
crude S22 (33.8 mg, 104%) obtained as a white solid. 1H NMR (400 MHz, CD3OD) δ = 
9.70 (s, 1H), 8.62 (s, 1H), 8.46 (s, 1H), 8.41 (s, 1H), 8.25 (s, 1H), 7.84 (br s, 1H); 13C 
NMR (100 MHz, CD3OD) δ = 164.90, 136.16, 135.26, 134.52, 132.63 (q, J = 34.2 Hz), 
127.16 (q, J = 3.7 Hz), 127.04, 123.63 (q, J = 3.7 Hz), 122.98 (d, J = 272.2 Hz), 121.59, 
120.90; 19F NMR (376 MHz, CD3OD) δ = -64.15 (s, 3F); LRMS (ESI) calculated for 
C11H6F3N2O2 [M - H]- m/z 255.05, found 255.06. 
 
 
 
 
CF3
HO
O
N
N
HCl
 91 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide 
(16). S22 (33.8 mg, 0.115 mmol, 1.0 equiv) was reacted with 3-(1H-tetrazol-5-yl)aniline 
in 2 mL DMF according to general procedure B, except 2 eq N,N-diisopropylethylamine 
(40 uL) was used in the first step. 16 (30.2 mg, 66%) obtained as a white solid. 1H NMR 
(400 MHz, DMSO-d6) δ = 10.77 (s, 1H), 8.55 (s, 3H), 8.32 (s, 1H), 8.26 (s, 1H), 8.03 (s, 
1H), 8.00 (dd, J = 1.2, 8.3 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 
7.20 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = 163.91, 156.70, 139.94, 138.21, 
137.84, 136.59 (br s), 131.36 (d, J = 32.3 Hz), 130.83, 130.31, 126.17, 123.83, 123.03, 
122.96, 122.93 - 122.78 (m), 123.91 (d, J = 272.9 Hz), 120.46 - 120.30 (m), 119.25, 
118.77; 19F NMR (376 MHz, DMSO-d6) δ = -61.02 (s, 3F); HRMS (ESI) calculated for 
C18H11F3N7O [M - H]- m/z 398.0983, found 398.0976. 
 
 
 
3-(1H-imidazol-2-yl)-5-(trifluoromethyl)benzoic acid (S23). A 3 mL vial with 
cap/septa was purged with Ar and charged with imidazole (22 mg, 0.323 mmol, 1.0 
equiv), palladium(II) acetate (4 mg, 0.016 mmol, 0.05 equiv), copper(I) iodide (123 mg, 
0.646 mmol, 2.0 equiv), and S1 (210 mg, 0.646 mmol, 2.0 equiv). The vial was purged 
with Ar and charged with 1.62 mL degassed DMF (Ar bubbling for 30 min). The vial was 
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sealed and heated at 140 °C for 48h. After cooling to rt, the reaction mixture was filtered 
through a nylon 0.2 um syringe filter and purified by reverse phase HPLC 
(water/MeOH/0.05% formic acid) to afford the desired product. S23 (15.9 mg, 19%) 
obtained as a light blue solid. 1H NMR (400 MHz, CD3OD, drops CDCl3) δ = 8.80 (br s, 
1H), 8.40 (br s, 1H), 8.27 (br s, 1H), 7.33 (br s, 2H); 19F NMR (376 MHz, CD3OD, drops 
CDCl3) δ = -64.29 (s, 3F); LRMS (ESI) calculated for C11H6F3N2O2 [M - H]- m/z 255.05, 
found 255.11. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(1H-imidazol-2-yl)-5-(trifluoromethyl)benzamide 
(17). S23 (15.9 mg, 0.062 mmol, 1.0 equiv) was reacted with 3-(1H-tetrazol-5-yl)aniline 
in 2.5 mL DMF according to general procedure A, except 3 eq N,N-
diisopropylethylamine (32 uL) was used. 17 (14.1 mg, 57%) obtained as a white solid. 
1H NMR (400 MHz, DMSO-d6) δ = 10.73 (br s, 1H), 8.85 (br s, 1H), 8.48 (br s, 2H), 8.29 
(s, 1H), 7.92 (br d, J = 7.8 Hz, 1H), 7.82 (br s, 1H), 7.48 (br s, 1H), 7.27 (br s, 2H); 19F 
NMR (376 MHz, DMSO-d6) δ = -61.20 (s, 3F); HRMS (ESI) calculated for C18H11F3N7O 
[M - H]- m/z 398.0983, found 398.0979. 
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tert-butyl 3-azido-5-(trifluoromethyl)benzoate (S24). A 3 mL vial with cap was purged 
with Ar and charged with S1 (125 mg, 0.384 mmol, 1.0 equiv), sodium azide (50 mg, 
0.769 mmol, 2.0 equiv), copper(I) iodide (7.3 mg, 0.038 mmol, 0.1 equiv), sodium 
ascorbate (3.8 mg, 0.019 mmol, 0.05 equiv), and N,N'-dimethyethylenediamine (6.2 ul, 
0.058 mmol, 0.15 equiv). Ethanol (1.28 ml) and water (550 ul) were then added; the vial 
was purged with Ar, sealed, and heated at 80 °C for 3h. The crude reaction mixture was 
then transferred to a sep funnel with ~ 75 mL EtOAc and ~ 30 mL water. The aqueous 
layer was basified by the addition of ~ 20 mL sat. NaHCO3; the layers were separated, 
and the organic layer was further extracted with ~ 50 mL water and brine. The organic 
layer was dried over MgSO4 and concentrated to an oil. Purified on a silica column with 
0-10% EtOAc:hexanes. Product containing fractions were combined and carefully 
rotovapped. (Note: Product is moderately volatile) S24 (93.7 mg, 85%) obtained as a 
light yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.98 (s, 1H), 7.83 (br s, 1H), 7.38 (br s, 
1H), 1.62 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 163.44, 141.48, 134.72, 132.49 (q, J 
= 33.5 Hz), 122.83, 122.47 (q, J = 4.2 Hz), 119.51 (q, J = 3.7 Hz), 123.15 (q, J = 272.9 
Hz), 82.62, 28.04; 19F NMR (376 MHz, CDCl3) δ = -63.00 (s, 3F); did not ionize by ESI. 
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tert-butyl 3-(trifluoromethyl)-5-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)benzoate 
(S25). A 3 mL vial was charged with S24 (93.7 mg, 0.326 mmol, 1.0 equiv), 
ethynyltrimethylsilane (1.153 mL, 8.16 mmol, 25.0 equiv), copper(I) Iodide (186 mg, 
0.979 mmol, 3.0 equiv), and N,N-diisopropylethylamine (511 ul, 2.94 mmol, 9.0 equiv). 
1.76 mL dry THF was then added, and the vial was sealed and heated at 80 °C 
overnight. The crude reaction mixture was filtered, and the filtrand was washed with ~ 
50 mL cold THF. The filtrate was concentrated under reduced pressure, affording crude 
S25 (168.4 mg, 134%) as a light brown solid. LRMS (ESI) calculated for 
C17H22F3N3O2Si [M + H]+ m/z 386.14, found 386.01. 
 
 
 
3-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzoic acid (S26). Crude S25 (168.4 mg) 
was reacted according to general procedure C (32h), except after the t-butyl was 
removed by LCMS, 4 mL water was added, and the reaction mixture was heated at 40 
°C for an additional 16h. The reaction mixture was then transferred to a sep funnel with 
~ 75 mL EtOAc and ~ 30 mL water. The aqueous layer was basified by the addition of ~ 
30 mL sat. NaHCO3; the layers were separated, and the aqueous layer was acidified to 
pH 1 with concentrated HCl. The aqueous layer was further extracted with 3 x 50 mL 
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EtOAc. The new organic layers were combined, dried over MgSO4, and concentrated. 
Semi-crude S26 (36.8 mg, 44% over two steps) obtained as a white solid. 1H NMR (400 
MHz, CD3OD, drops CDCl3) δ = 8.73 (s, 1H), 8.70 (s, 1H), 8.42 (s, 1H), 8.33 (s, 1H), 
7.93 (s, 1H); 13C NMR (100 MHz, CD3OD, drops CDCl3) δ = 166.89, 139.35, 137.41, 
133.91 (q, J = 33.7 Hz), 127.38 (q, J = 3.7 Hz), 125.87, 124.68, 124.19, 122.31 (q, J = 
3.7 Hz), 124.69 (q, J = 272.2 Hz); 19F NMR (376 MHz, CD3OD, drops CDCl3) δ = -64.16 
(s, 3F); LRMS (ESI) calculated for C10H5F3N3O2 [M - H]- m/z 256.04, found 256.05. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzamide 
(18). S26 (36.8 mg, 0.143 mmol, 1.0 equiv) was reacted with 3-(1H-tetrazol-5-yl)aniline 
in 2.5 mL DMF according to general procedure B. 18 (28.0 mg, 49%) obtained as a 
white solid. 1H NMR (400 MHz, DMSO-d6, drops EtOAc) δ = 10.85 (s, 1H), 9.12 (s, 1H), 
8.88 (s, 1H), 8.53 (s, 2H), 8.45 (s, 1H), 8.08 (s, 1H), 7.97 (br d, J = 7.5 Hz, 1H), 7.81 (br 
s, 1H), 7.56 (br t, J = 6.6 Hz, 1H); 13C NMR (100 MHz, DMSO-d6, drops EtOAc) δ = 
163.03, 156.04, 139.26, 137.48, 137.39, 134.92, 130.81 (q, J = 33.8 Hz), 129.55, 
127.54 (br), 124.10 (br d, J = 2.9 Hz), 123.92, 123.28, 122.42 (br d, J = 2.9 Hz), 123.34 
(d, J = 272.9 Hz), 121.76, 119.63 (br d, J = 2.2 Hz), 118.71 (br); 19F NMR (376 MHz, 
DMSO-d6, drops EtOAc) δ = -61.14 (s, 3F); HRMS (ESI) calculated for C17H10F3N8O [M 
- H]- m/z 399.0935, found 399.0928. 
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tert-butyl 3-amino-5-(trifluoromethyl)benzoate (S27). S1 (250 mg, 0.769 mmol, 1.0 
equiv), copper(I) iodide (29 mg, 0.154 mmol, 0.2 equiv), potassium carbonate (319 mg, 
2.31 mmol, 3.0 equiv), and trans-4-hydroxy-L-proline (40 mg, 0.308 mmol, 0.4 equiv) 
were added to a teflon screw capped vial. dimethyl sulfoxide (3 mL) and 30.0% 
ammonium hydroxide (1.500 ml, 13.5 mmol, 17.6 equiv) were added, and the reaction 
mixture was sealed and heated at 70 °C for 18h (Note: The solution began to degass 
upon addition of NH4OH – seal the vessel quickly). The reaction mixture was transferred 
to a sep funnel with ~ 75 mL water and ~ 40 mL EtOAc. The layers were separated, and 
the aqueous layer was further extracted with 2 x 40 mL EtOAc. The organic layers were 
combined, dried over MgSO4, and concentrated to give colorless oil. Purified on a silica 
column with 0-15% EtOAc:hexanes. S27 (46.5 mg, 23%) obtained as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ = 7.58 (s, 1H), 7.44 (s, 1H), 7.02 (s, 1H), 1.59 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ = 164.68, 146.90, 133.83, 131.69 (q, J = 32.3 Hz), 123.78 (q, 
J = 272.2 Hz), 118.53, 115.87 (q, J = 4.4 Hz), 114.68 (q, J = 4.2 Hz), 81.69, 28.07; 19F 
NMR (376 MHz, CDCl3) δ = -62.97 (s, 3F); LRMS (ESI) calculated for C12H15F3NO2 [M + 
H]+ m/z 262.10, found 261.97. 
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tert-butyl 3-(1H-tetrazol-1-yl)-5-(trifluoromethyl)benzoate (S28). A 3 mL vial was 
charged with S27 (46.5 mg, 0.178 mmol, 1.0 equiv). The vial was backfilled with Ar and 
charged with triethyl orthoformate (148 ul, 0.890 mmol, 5.0 equiv), sodium azide (58 
mg, 0.890 mmol, 5.0 equiv), and glacial acetic acid (1 mL). The reaction mixture was 
sealed and heated at 100 °C for 3h, then transferred to a sep funnel with ~ 75 mL water 
and ~ 40 mL EtOAc. The layers were separated, and the aqueous layer was further 
extracted with 2 x 40 mL EtOAc. The organic layers were combined, dried over MgSO4, 
and concentrated to give colorless oil. Purified on silica gel with 0-15% EtOAc:hexanes. 
S28 (33.4 mg, 60%) obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ = 9.22 (s, 
1H), 8.49 (br s, 1H), 8.37 (s, 1H), 8.23 (s, 1H), 1.64 (s, 9H); 13C NMR (100 MHz, CDCl3) 
δ = 162.49, 140.57, 135.48, 134.38, 133.21 (q, J = 34.0 Hz), 127.35 (q, J = 3.7 Hz), 
124.74, 121.66 (q, J = 3.7 Hz), 122.66 (q, J = 273.4 Hz), 83.61, 28.01; 19F NMR (376 
MHz, CDCl3) δ = -62.92 (s, 3F); LRMS (ESI) calculated for C13H14F3N4O2 [M + H]+ m/z 
315.10, found 315.06. 
 
 
 
3-(1H-tetrazol-1-yl)-5-(trifluoromethyl)benzoic acid (S29). S28 (33.4 mg, 0.106 
mmol, 1.0 equiv) was reacted according to general procedure C (48h). Semi-crude S29 
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(30.0 mg, 109%) obtained as an off-white solid. 1H NMR (400 MHz, CD3OD) δ = 9.98 (s, 
1H), 8.74 (s, 1H), 8.48 (s, 1H), 8.40 (s, 1H); 13C NMR (100 MHz, CD3OD) δ = 166.54, 
143.46, 136.67, 135.85, 133.96 (q, J = 34.2 Hz), 128.10 (q, J = 3.7 Hz), 126.66, 123.14 
(q, J = 3.2 Hz), 124.59 (q, J = 272.2 Hz); 19F NMR (376 MHz, CD3OD) δ = -64.39 (s, 
3F); LRMS (ESI) calculated for C9H4F3N4O2 [M - H]- m/z 257.04, found  257.04. 
 
 
 
N-(3-(1H-tetrazol-5-yl)phenyl)-3-(1H-tetrazol-1-yl)-5-(trifluoromethyl)benzamide 
(19). S29 (30.0 mg, 0.116 mmol, 1.0 equiv) was reacted with 3-(1H-tetrazol-5-yl)aniline 
in 2 mL DMF according to general procedure B. 21 (22.1 mg, 47%) obtained as a white 
solid. 1H NMR (400 MHz, CD3OD, drops CD3CN) δ = 9.52 (s, 1H), 8.53 (s, 1H), 8.34 (s, 
1H), 8.29 (s, 1H), 8.23 (s, 1H), 7.75 (dd, J = 1.2, 8.0 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 
7.43 (t, J = 8.0 Hz, 1H); 13C NMR (100 MHz, CD3OD, drops CD3CN) δ = 164.82, 157.96, 
143.39, 140.43, 139.27, 136.29, 133.36 (q, J = 33.7 Hz), 131.17, 127.04, 126.57 (q, J = 
3.4 Hz), 125.43, 124.35, 124.24, 124.52 (d, J = 272.2 Hz), 122.40 (q, J = 3.7 Hz), 
120.32; 19F NMR (CD3OD, drops CD3CN) δ = -62.20 (s, 3F); HRMS (ESI) calculated for 
C16H9F3N9O [M - H]- m/z 400.0888, found 400.0881. 
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3-(1H-tetrazol-5-yl)-5-(trifluoromethyl)benzoic acid (S30). A 15 mL sealed tube was 
backfilled with argon and charged with commercially available 3-cyano-5-
(trifluoromethyl)benzoic acid (100 mg, 0.465 mmol, 1.0 equiv), sodium azide (91 mg, 
1.40 mmol, 3.0 equiv), and ammonium chloride (81 mg, 1.63 mmol, 3.5 equiv). 4 mL 
DMF was then used to wash the walls/seal area; the tube was flushed with Ar, sealed, 
and stirred at 100 °C for 18h. The crude reaction mixture was transferred to a sep 
funnel with ~ 75 mL H2O and EtOAc, and the aqueous layer was adjusted to pH 1 with 
conc. HCl. The layers were separated, and the aqueous layer was further extracted with 
2 x 30 mL EtOAc. The organics were combined, dried over MgSO4, and concentrated, 
giving brown oil. Dried on hivac overnight. The remaining residue was rotovaped with 2 
x 10 mL portions of toluene and dried under hivac again, yielding semi-crude S30 
(129.7 mg, 108%) as a brown solid. 1H NMR (400 MHz, CD3OD) δ = 8.80 (s, 1H), 8.46 
(s, 1H), 8.30 (s, 1H); 13C NMR (100 MHz, CD3OD) δ = 167.01, 158.00, 134.66, 133.11 
(q, J = 33.0 Hz), 132.41, 129.29 (br d, J = 3.7 Hz), 128.49 (br d, J = 3.7 Hz), 128.33, 
124.83 (q, J = 272.2 Hz); 19F NMR (376 MHz, CD3OD) δ = -64.41 (s, 3F); LRMS (ESI) 
calculated for C9H4F3N4O2 [M - H]- m/z 257.04, found 257.04. 
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N-(3-(1H-tetrazol-5-yl)phenyl)-3-(1H-tetrazol-5-yl)-5-(trifluoromethyl)benzamide 
(20). S30 (130 mg, 0.502 mmol, 1.0 equiv) was reacted with 3-(1H-tetrazol-5-yl)aniline 
in 3 mL DMF according to general procedure A. 22 (122.7 mg, 61%) obtained as a light 
tan solid. 1H NMR (400 MHz, CD3OD) δ = 8.82 (s, 1H), 8.45 (br s, 1H), 8.44 (t, J = 1.8 
Hz, 1H), 8.35 (s, 1H), 7.82 (dt, J = 8.2, 1.0 Hz, 1H), 7.72 - 7.67 (m, 1H), 7.48 (t, J = 7.9 
Hz, 1H); 13C NMR (100 MHz, CD3OD) δ = 166.17, 158.70, 157.72, 140.86, 138.41, 
133.14 (q, J = 33.0 Hz), 131.12, 131.01, 128.91, 127.75 - 127.47 (m), 126.25, 124.87, 
124.34, 125.02 (d, J = 272.2 Hz), 120.71; 19F NMR (376 MHz, CD3OD) δ = -64.25 (s, 
3F); HRMS (ESI) calculated for C16H9F3N9O [M - H]- m/z 400.0888, found 400.0882. 
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HRMS Spectra 
Compound 2: 
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Chapter 3 
Active-Site Druggability of Carbapenemases and  
Broad-Spectrum Inhibitor Discovery 
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Abstract: 
Serine and metallo-carbapenemases are a serious health concern due to their 
capability to hydrolyze nearly all β-lactam antibiotics. However, the molecular basis for 
their unique broad-spectrum substrate profile is poorly understood, particularly for 
serine carbapenemases, such as KPC-2. Using substrates and newly identified small 
molecules, we compared the ligand binding properties of KPC-2 with 
the noncarbapenemase CTX-M-14, both of which are Class A β- lactamases with highly 
similar active sites. Notably, compared to CTX-M-14, KPC-2 was more potently inhibited 
by hydrolyzed β-lactam products (product inhibition), as well as by a series of novel 
tetrazole-based inhibitors selected from molecular docking against CTX-M-14. Together 
with complex crystal structures, these data suggest that the KPC-2 active site has an 
enhanced ability to form favorable interactions with substrates and small molecule 
ligands due to its increased hydrophobicity and flexibility. Such properties are even 
more pronounced in metallo-carbapenemases, such as NDM-1, which was also 
inhibited by some of the novel tetrazole compounds, including one displaying 
comparable low µM affinities against both KPC-2 and NDM-1. Our results suggest that 
carbapenemase activity confers an evolutionary advantage on producers via a broad β-
lactam substrate scope but also a mechanistic Achilles’ heel that can be exploited for 
new inhibitor discovery. The complex structures demonstrate, for the first time, how 
noncovalent inhibitors can be engineered to simultaneously target both serine and 
metallo-carbapenemases. Despite the relatively modest activity of the current 
compounds, these studies also demonstrate that hydrolyzed products and tetrazole-
 113 
based chemotypes can provide valuable starting points for broad-spectrum inhibitor 
discovery against carbapenemases. 
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Introduction: 
β-lactam compounds, such as penicillins, are the most widely used antibiotics due to 
their effective inhibition of transpeptidases during bacterial cell wall synthesis.1-3 β-
lactamases catalyze β-lactam hydrolysis and are the primary mediators of bacterial 
resistance to these antibiotics in Gram negative bacteria.4, 5 There are four β-lactamase 
families; classes A, C, and D use a catalytic serine to form an acyl-enzyme complex 
during catalysis, whereas Class B are metalloenzymes that rely on Zn(II) ions to 
mediate the hydrolysis reaction without a covalent intermediate.6, 7 
Although extended-spectrum β-lactam antibiotics (e.g., ceftazidime) and 
carbapenems (e.g., imipenem) initially resisted hydrolysis by β-lactamases, new β-
lactamase activity has evolved against these antibiotics.8-10 Most notably, the past 
decade has seen the rise of carbapenemases able to deactivate carbapenems, often 
regarded as antibiotics of a last resort.11-15 Even more alarming is that many of these 
enzymes also function as extended-spectrum β-lactamases (ESBLs) and hydrolyze 
nearly all other β-lactam antibiotics. Among them, KPC-216-19 (Class A) and NDM-120, 21 
(Class B) enzymes cause the most serious health concerns.  
Despite the biomedical importance of KPC-2, the molecular basis of its 
carbapenemase activity is not well understood, particularly with regard to its ability to 
bind to a wide range of β-lactam substrates. The KPC-2 active site is highly similar to 
other Class A enzymes, such as CTX-M-14, a common ESBL that lacks 
carbapenemase activity.22-24 We have recently determined two complex structures of 
KPC-2 bound by hydrolyzed β-lactam products, the first such complexes obtained with a 
wild-type (WT) serine β-lactamase.23 Previous studies have suggested that the newly 
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generated carboxylate group in the product may cause unfavorable steric and 
electrostatic interactions in the active site, leading to the release of the product.25 The 
KPC-2 product complexes illustrate the differences between KPC-2 and 
noncarbapenemases, such as CTX-M-14, including a more open and hydrophobic 
active site in KPC-2. Such features are also observed in NDM-1, which harbors a 
relatively flat substrate binding pocket with a large number of hydrophobic residues.26, 27 
In this study, we investigate how these unique binding site features manifest 
themselves in carbapenemases’ interactions with small molecules, especially how these 
properties may translate into their broad substrate profile and the prospects for inhibitor 
discovery. Although the use of a β-lactamase inhibitor in conjunction with a β-lactam 
antibiotic is a well-established strategy to counter resistance, including the recent 
success of broad spectrum cyclic boronate compounds,28-31 developing cross-class β-
lactamase inhibitors active against both serine and metallo-carbapenemases remains 
extremely challenging because of their fundamentally different catalytic mechanisms 
and three-dimensional structures.28, 32, 33 Our results, particularly crystal structures of 
novel compounds bound noncovalently by KPC-2 and NDM-1, provide valuable insights 
for drug discovery efforts against these clinically important enzymes. 
 
Results and Discussion: 
Product inhibition of noncarbapenemase vs carbapenemase 
Our recent determination of two KPC-2 product complex crystal structures, together 
with previous NDM-1 product complexes,26, 34, 35 suggest that hydrolyzed β-lactam 
products can potentially serve as inhibitors of carbapenemases. In comparison, 
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previous attempts to obtain product complexes with other WT serine β-lactamase 
crystals were unsuccessful, partially for reasons described above. To quantify the 
difference in interactions with the product, we tested two hydrolyzed products, penicillin 
1 (penicillin G) and cephalosporin 2 (cephalothin), against the noncarbapenemase CTX- 
M-14, as well as the carbapenemases KPC-2 and NDM-1 (Table 3-1). Interestingly, 
both products inhibited KPC-2 much more potently than CTX-M-14, despite the highly 
similar active sites of the two Class A β-lactamases. Hydrolyzed penicillin G did not 
show any inhibition of CTX-M-14 at the highest concentration tested in our assays (10 
mM), although previous studies showed that hydrolyzed penicillins inhibited other 
narrow-spectrum β-lactamases with a Ki ∼ 40 mM.36 In comparison, the hydrolyzed 
penicillin G was found to be a high-µM inhibitor of both KPC-2 and NDM-1. Even more 
impressively, hydrolyzed cephalothin inhibited KPC-2 and NDM-1 with apparent Ki 
values of 1.96 and 63.5 µM, respectively, while showing only mM affinity for CTX-M-14. 
These results demonstrate that the hydrolyzed β-lactams studied interact more 
favorably with carbapenemases as compared to otherwise similar noncarbapenemases.  
 
Table 3-1. Inhibition by Hydrolyzed β-Lactam Products  
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Binding of novel small molecule ligands by CTX-M-14 and KPC-2 
We have previously used a structure-based fragment-screening approach to identify 
the first nM non-covalent serine β-lactamase inhibitors using a tetrazole-based scaffold, 
targeting CTX-M.37, 38 We found that the tetrazole ring displays high shape and 
electrostatic complementarity with an active site pocket that binds to the substrate 
C3(4)-carboxylate group in CTX-M. On the basis of the conservation of this site in Class 
A β-lactamases, we hypothesized that tetrazole-bearing compounds may inhibit KPC-2 
as well. We virtually screened a series of tetrazole-containing fragments and lead-sized 
compounds against CTX-M-14, followed by biochemical evaluation against CTX-M-14, 
KPC-2, and NDM-1. Among the active inhibitors identified, every one demonstrated 
enhanced activity against KPC-2 compared to CTX-M-14, by approximately 5-fold or 
more (Table 3-2).  
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Table 3-2. Inhibition by Tetrazole-Based Compoundsa 
 
a All compounds were obtained from commercial sources, except 7s* and 8*, which 
were synthesized. Compounds 8 and 8* are racemates. 
 
To illustrate the structural basis of this difference, we determined the crystal 
structures of two compounds in complex with CTX-M-14 and KPC-2, which, for the first 
time, demonstrated that the tetrazole moiety can indeed bind to the C3(4)-carboxylate 
binding site in other Class A β- lactamases besides CTX-M (Figure 3-1). Compound 3 
showed a nearly identical binding mode for both proteins (Figure 3-1A, B). The 
tetrazole moiety is nestled in a conserved subpocket consisting of three polar residues 
 
 Structure CTX-M14 (µM) 
KPC-2 
(µM) 
NDM-1 
(µM) 
3 
 
4200 ± 300 386 ± 33 No     inhibition 
4 
 
No     
inhibition 123 ± 37 
No     
inhibition 
5 
 
1780 ± 320 288 ± 27 No     inhibition 
6 
 
2540 ± 410 195 ± 44 No     inhibition 
7 
 
1850 ± 640 239 ± 23 56 ± 8 
7s* 
 
637 ± 123 44 ± 6 62 ± 9 
8 
 
No      
inhibition 231 ± 6 376 ± 22 
8* 
 
No     
inhibition 315 ± 19 290 ± 13 
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and a Gly. It stacks on top of the relatively flat peptide backbone surrounding Gly236 
and forms three hydrogen bonds with Ser130, Thr235, and Ser/Thr237 in CTX-M-
14/KPC-2. Compound 3 also establishes a hydrogen bond with Asn132 in both proteins. 
However, the distal dichlorobenzene ring engages in more nonpolar interactions with 
Pro104, Trp105, and Leu167 in KPC-2, in comparison to Asn104 and Tyr105 in CTX-M-
14.  
 
 
Figure 3-1. Complex crystal structure of compounds 3 and 6 with CTX-M-14 and 
KPC-2. (A) Compound 3 with CTX-M-14. (B) Compound 3 with KPC-2. (C) Compound 6 
with CTX-M-14. (D) Compound 6 with KPC-2. The simulated annealing composite Fo−Fc 
omit map (gray) are contoured at 2.5 σ and 2 σ for the CTX-M-14 (1.4 Å resolutions) 
and KPC-2 structures (1.7−2.2 Å resolutions), respectively. Black-dashed lines depict 
hydrogen bonds. 
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Compound 6 adopted slightly different poses in the two Class A β-lactamases 
(Figure 3-1C, D). In CTX-M-14, the tricyclic ring system flips up to interact with Ser237 
and the protein backbone between Ser237 and Gly238 at the end of the β3 strand; in 
KPC-2, it stacks on top of Trp105 while forming additional nonpolar interactions with 
Leu167. The more extensive nonpolar interactions of both 3 and 6 in KPC-2 explain the 
approximately 10 fold higher binding affinity. 
 
Dual inhibition of serine and metallo-carbapenemases 
The majority of the newly identified tetrazole compounds did not inhibit NDM-1. This 
result is unsurprising, considering that Class A and B β-lactamases have drastically 
different catalytic mechanisms and three-dimensional structures, and that the 
compounds were originally selected for CTX-M-14. However, two compounds, 7 and 8, 
were active against both KPC-2 and NDM-1, despite exhibiting little to no activity 
against CTX-M-14 (Table 3-2). In particular, compound 7 showed Ki values of 239 µM 
for KPC-2 and 56 µM for NDM-1. Unexpectedly, the X-ray complex crystal structures of 
7 clearly revealed the bound ligand to be a regioisomer of the purported structure (7s) 
provided by the commercial compound supplier (Figure 3-2). In KPC-2, the tetrazole 
moiety binds in the same pocket as the other complex structures. The carbonyl group is 
positioned in the oxyanion hole, formed by the backbone groups of Ser70 and Thr237, 
and establishes a hydrogen bond with Thr237N. The two benzene rings have nonpolar 
contacts with Pro104, Leu167, and Asn170. In NDM-1, the tetrazole group forms 
hydrogen bonds with Lys211Nζ and Asn220N and also interacts with one of the zinc 
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ions. This is the same subpocket bound by the substrate C3(4)-carboxylate group in 
previous NDM-1 product complex structures.26, 34, 35 Meanwhile, the amide linker points 
its oxygen toward the zinc ion, with a distance of 2.5 Å, suggesting weak interactions. In 
addition, the distal ring system forms extensive nonpolar interactions with Leu65, 
Met67, Val73, and Trp93. 
 
 
Figure 3-2. Complex crystal structure of compound 7 with KPC-2 (A) and NDM-1 
(B). The simulated annealing composite Fo−Fc omit map (gray) contoured at 2.0 σ for 
KPC-2 (1.86 Å resolution) and 2.5 σ for NDM-1 (1.15 Å resolution). Black-dashed lines 
depict hydrogen bonds or coordination with metal ions. 
 
We subsequently synthesized compound 7s, and the regioisomeric form purported 
to comprise the original commercial sample. Compared with 7, analog 7s displayed 
similar activity for NDM-1 but better affinity for KPC-2, resulting in comparable Ki’s for 
both proteins (44 and 62 µM for KPC-2 and NDM-1, respectively) and similar ligand 
efficiency values (0.24 and 0.23 kcal/mol per heavy atom (relative binding free 
energy/HA)). The crystal structure of 7s with KPC-2 clearly shows that the amide 
carbonyl group is positioned outside the oxyanion hole, different from 7 (ESI, Figure 3-
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4). The densities for the two benzene rings are significantly weaker, likely due to 
potential alternative conformations. Overall, one of the rings is oriented downward to 
interact with Pro104, Trp105, and Leu167; whereas the other one points upward to form 
contacts with the Thr237 side chain. It appears that the aryl rings of both 7 and 7s can 
establish a large number of nonpolar interactions with the protein, yet 7s is 5-fold more 
potent than 7. We hypothesize this could be due to the displacement of the structural 
water in the oxyanion hole by 7, which can be energetically costly due to the three 
favorable hydrogen bond interactions the water forms with Ser70 and Thr237. In 
comparison, compound 7 establishes only one hydrogen bond with Thr237N through its 
carbonyl oxygen, while slightly displacing the carbonyl group of Thr237 due to some 
unfavorable interactions involving the bridging five-membered ring (Figure 3-2). 
Compound 8 also showed comparable activities for both serine and metallo-β-
lactamases (Table 3-2). To further probe the shared binding hot spots of serine and 
metallo-carbapenemases, we synthesized a small series of compound 8 analogs, 
including deconstructed fragments (10, 13, and 14) that may serve as a better starting 
point for future lead optimization (Table 3-3). The results further demonstrate that he 
amido-tetrazole scaffold could provide a novel chemotype active against two structurally 
different, yet functionally related enzymes. As expected, the majority of these 
compounds did not display better activities than compound 8. Interestingly, compound 
13 exhibited higher activity against NDM-1 than 8, even though it lacks one of the aryl 
side chains. This observation suggests that the backbone of 8 is suboptimal in its ability 
to enable both aryl groups to interact with protein. In addition, some of the new analogs, 
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particularly 11−13, are less potent against KPC-2 than NDM-1, underscoring the 
structural differences between these two enzymes.  
 
Table 3-3. Inhibition by Analogs of Compound 8a  
 
a Compounds 9, 11, and 12 are racemates.  
 
Complex crystal structures were determined for 9, a close analog of 8, with KPC-2 
and NDM-1, showing how this inhibitor is accommodated in the active sites of the two 
proteins (Figure 3-3). Although 9 was synthesized as a racemate, the R stereoisomer 
appears to fit the electron density the best in both KPC-2 and NDM-1. Despite the 
significant structural difference between these enzymes, side chains in 9 are seen to 
 
 Structure CTX-M-14 (µM) 
KPC-2 
(µM) 
NDM-1 
(µM) 
9 
 
No      
inhibition 479 ± 41 477 ± 40 
10 
 
No      
inhibition 1070 ± 160 2140  ± 70 
11 
 
No      
inhibition 1570 ± 70 203.5 ± 29 
12 
 
No      
inhibition 2000 ± 50 310 ± 19 
13 
 
No      
inhibition 
No      
inhibition 91.5 ± 3.53 
14 
 
No      
inhibition 2370 ± 650 353 ± 3.53 
N
H
O H
N
NN
N
N
H
N
H
O H
N
NN
N
N
H
N
H
O
S
NN
N
N
H
O
N
H
O
S
NN
N
N
H
O O
N
H
O
S
NN
N
N
H
N
H
O
S
NN
N
N
H
O O
 124 
interact favorably with residues of both proteins. The amido-tetrazole moiety is 
anchored similarly to that of compound 7 in both KPC-2 and NDM-1, although the amide 
linker is placed outside the oxyanion hole of KPC-2, resembling compound 7s. The 
electron densities for the side chains are relatively weak. There appears to be 
alternative conformations due to the rotation of the amide linker, although it is not 
possible to model them accurately at the current resolutions. Overall the α-phenyl side 
chain forms nonpolar contacts with Leu167/Asn170 in KPC-2 and Leu65/Trp93 in NDM-
1. The aniline side chain establishes less contact with both proteins; it is within van der 
Waals contact distance with selected atoms of Thr237/Gly239 of KPC-2, and 
Val73/Asn220 of NDM-1. We have also determined several other crystal structures, 
including 8 (ESI, Figure 3-5), 10, 12, and 13. The amido-tetrazole groups of these 
structures adopted similar binding modes to 9, but the densities for the side chains were 
also relatively weak for most of these compounds, again suggesting that the aryl rings 
cannot form optimal protein contacts when displayed from this scaffold backbone. 
 
 
Figure 3-3. Complex crystal structure of compound 9 with KPC-2 and NDM-1. (A) 
KPC-2, (B) NDM-1. The simulated annealing composite Fo−Fc omit map (gray) 
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contoured at 2.5 σ (1.42 Å resolution) for KPC-2 and 2σ (1.65 Å resolution) for NDM-1. 
Black dashed lines depict hydrogen bonds or coordination with metal ions. 
 
Active site druggability in carbapenemase function and inhibition  
Carbapenemases, such as KPC-2 and NDM- 1, can hydrolyze nearly all β-lactam 
compounds. Our results, particularly those comparing KPC-2 and CTX-M-14, suggest 
that carbapenemases’ broad substrate spectrum correlates with their active sites’ 
enhanced druggability, i.e., ability to interact favorably with small molecules. The active 
sites of CTX-M-14 and KPC-2 are similar, with nearly identical main chain 
configurations, except at the end of the β3 strand (G238/D240 in CTX-M-14 and 
C238/G239/V240 in KPC-2; note, that residue 239 is missing in CTX-M-14 due to 
numbering conventions) caused by the Cys69-Cys238 disulfide bond in KPC-2. The 
most significant side chain differences between the active sites of CTX-M-14 and KPC-2 
include N104P, Y105W, and P167L substitutions. These substitutions increase the 
hydrophobicity of the active site, while also making the binding pocket slightly more 
open, particularly surrounding Pro104 in KPC-2. Similarly, in NDM-1, there are a large 
number of hydrophobic residues, and the active site is relatively flat compared with 
serine β-lactamases.26, 27 In addition, in previous structures, Trp105 has demonstrated 
considerable side chain flexibility in KPC-2 compared with the equivalent Tyr105 of 
CTX-M-14, possibly allowing KPC-2 to adapt to different ligands.23 This plasticity is even 
more evident in NDM-1 with the movement of the Met67-Phe70 loop.21, 26, 34, 35 The 
increased hydrophobicity, flexibility, and openness of the active sites enables the 
carbapenemases to accommodate a wide range of β-lactams potentially also with 
enhanced binding affinities. Whereas this broad-spectrum substrate profile confers 
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evolutionary advantage in bacterial resistance, the enhanced active site druggability 
makes carbapenemases susceptible to novel inhibitor binding, exposing a key 
weakness of these enzymes. 
Tetrazole-based inhibitors have previously been identified against either serine38, 39 
or metallo-β-lactamases,40, 41 highlighting the utility of the tetrazole moiety as an anchor 
for inhibitor binding in these enzymes. In particular, the placement of the tetrazole 
moiety in our NDM-1 complex structures, determined at pH 3.85, is nearly identical to 
that in a previous complex structure of a different tetrazole inhibitor and the Bacteroides 
fragilis metallo-β-lactamase (PDB, 1A8T),36 determined at pH 6.6. These observations 
suggest that the low pH used for our NDM-1 complex crystals did not affect the binding 
of the titratable tetrazole group to the protein, most likely because the pKa of the 
tetrazole group is perturbed by the interactions with the positively charged Zn ions and 
Lys211. Furthermore, to our knowledge, these inhibitors represent the first tetrazole-
based dual-activity compounds active against both serine and metallo-β-lactamases. 
They are also the only cross-class inhibitors showing the same mode of action against 
these enzymes. Previous inhibitors, including the cyclobutanone analogs of β-lactam 
antibiotics,42, 43 cyclic boronates,31, 44 alkylboronates,45 and the recently discovered 
bisphosphonate compounds,46 appear to serve as noncovalent inhibitors for the metallo 
enzymes but deactivate serine β-lactamases mostly through a covalent mechanism. In 
addition, despite the success of cyclic boronate inhibitors, cross-class inhibitor 
development has remained challenging, with most inhibitor discovery efforts focusing on 
either serine47−55 or metallo β-lactamases.56−64 
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Our biochemical and structural data demonstrate the functional similarities between 
these two groups of enzymes, and indicate that other tetrazole-based compounds can 
potentially be developed as high affinity dual-activity inhibitors. Admittedly, the 
potencies of the unoptimized compounds described herein are relatively modest and 
are not presented as drug leads per se. Nevertheless, specific analogs, such as 7s, 
exhibit reasonable ligand efficiency values (∼ 0.24 kcal/mol per HA) against both KPC-2 
and NDM-1, and thus represent useful starting points for cross-class inhibitor discovery. 
Moreover, the complex crystal structures presented herein demonstrate how an amido-
tetrazole can occupy the substrate C3(4)-carboxylate binding subsite in both KPC-2 and 
NDM-1 and furthermore reveal additional binding hot spots in the active site. This 
structural information should be broadly useful to studies of lead discovery and 
optimization for these important drug targets. 
The inhibition of KPC-2 and NDM-1 by hydrolyzed β-lactam products, especially 
hydrolyzed cephalosporins, suggests the possibility of using these scaffolds in 
designing carbapenemase inhibitors. Our recent structure of CTX-M-14 with a penilloate 
product, where the newly generated carboxylate group is eliminated through a 
decarboxylation process, also demonstrates the broad potential of these compounds as 
β-lactamase inhibitors, similar to previous studies on Bacillus cereus β-lactamase.36,65 
Inhibition by a product fragment of tazobactam was observed for GES-2 Class A 
carbapenemase as well, although its distinct structure and binding mode represents a 
special case.66 Interestingly, hydrolyzed piperacillin products have also been shown to 
inhibit Pseudomonas aeruginosa PBP3, a member of the penicillin-binding protein 
(PBP) family, highlighting the potential value of β-lactam products in novel antibiotic 
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discovery, and the active site features shared between PBPs and serine β-
lactamases.67  
 
Conclusion: 
The biochemical and structural data in this study have illustrated unique ligand 
binding properties of carbapenemases that can be exploited in novel antibiotic 
development. Increased druggability may be characteristic of the active site not only for 
carbapenemases but also for other enzymes with broad-spectrum substrate profiles. In 
addition to hydrolyzed β-lactam products, the amido-tetrazole scaffold described here 
provides new chemotypes for further inhibitor discovery, targeting both serine and 
metallo-carbapenemases, in efforts to counter antibiotic resistance, particularly in 
bacteria coproducing both of these enzymes. 
 
Material and Methods: 
Construct design 
CTX-M-14 and KPC-2 were cloned as previously described.23, 37 The NDM-1 gene 
sequence (residues 42−270) was cloned into the pET-GST expression vector with an N-
terminal 6X His-tag and thrombin cleavage site. The NDM-1 construct was transformed 
into NEB 5-alpha competent E. coli and plated onto an LB agar plate containing 50 
µg/mL kanamycin. Single colonies were grown overnight at 37 °C in LB media 
containing 50 µg/mL kanamycin. A mini-prep kit was used to isolate plasmid DNA, and 
the nucleotide sequence of the NDM-1 construct was verified. 
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Protein expression and purification 
BL21(DE3) competent E. coli cells were transformed and used for protein 
expression for CTX-M-14, KPC-2, and NDM-1. CTX-M-14 and KPC-2 were expressed 
and purified as previously described.23, 37 For NDM-1, BL21(DE3) cells were inoculated 
into 50 mL of LB media containing 50 µg/mL of kanamycin and grown overnight at 37 
°C. For large scale production, 1 L of 2xYT media containing 50 µg/mL of kanamycin 
was inoculated with 10 mL of the overnight starter culture and grown at 37 °C with 
shaking until the OD600 reached 0.6−0.8. To initiate protein expression, isopropyl β-D-
1-thiogalactopyranoside (IPTG) was added to 0.5 mM, and protein expression was 
continued at 20 °C for 22 h. The cell pellet was prepared by centrifugation at 4000g for 
20 min at 4 °C. The cell pellet was resuspended in 35 mL of buffer A (20 mM HEPES 
pH 8.0, 500 mM NaCl, 10% (v/v) glycerol, 20 mM imidazole, 50 µM ZnSO4) with a 
protease inhibitor cocktail tablet (Roche). Cells were lysed through sonication, and the 
cell lysate was centrifuged at 45000 rpm for 1 h. The supernatant was filtered and 
loaded onto a His-trap nickel affinity column (GE healthcare Life Sciences, USA) 
previously equilibrated with buffer A. After the sample was loaded, the column was 
washed with five column volumes of the same buffer, and a linear gradient of increasing 
imidazole was used to elute the protein. Fractions containing NDM-1, based on SDS-
PAGE, were pooled, and exchanged with buffer containing 20 mM Tris-HCl pH 8.0, 150 
mM NaCl, 10% (v/v) glycerol. The 6X His-tag was cleaved at 20 °C using thrombin at an 
1:100 ratio (thrombin:NDM-1). After overnight cleavage, samples were again run 
through a His-trap nickel affinity column, and the flow through containing untagged 
NDM-1 was collected. The samples were then concentrated and prepared for a final gel 
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filtration column run. Before loading the sample, a Superdex 75 16/60 gel filtration 
column (GE healthcare Life Sciences, USA) was equilibrated with 20 mM HEPES pH 
8.0, 100 mM NaCl, and 100 µM ZnSO4. The concentration of the protein was measured 
through absorbance at 280 nm using an extinction coefficient of 27 960 M−1 cm−1. SDS-
PAGE analysis indicated that the protein was more than 95% pure. Protein fractions 
were pooled together and concentrated to 20 mg/mL. Protein samples were aliquoted, 
flash frozen with liquid nitrogen, and stored at −80 °C. 
 
Virtual screening 
A database of commercially available tetrazole-containing compounds was 
downloaded from ZINC68 and docked to the active site of an in-house structure of CTX-
M-14 using DOCK 3.669,70 and procedures described previously.38 The 1000 top 
ranking compounds were manually examined. Those showing the best complementarity 
with the protein and chemical diversity were selected and purchased.  
 
Hydrolyzed products 
Hydrolyzed penicillin G (1) was purchased from Sigma-Aldrich. Hydrolyzed 
cephalothin (2) was prepared as follows. Commercially available cephalothin (37.1 mg, 
0.094 mmol, 1.0 equiv.) was dissolved in water (47 uL) in a 1.5 mL epi tube, followed by 
dropwise addition of an aqueous 1 M sodium hydroxide solution (94 uL, 0.094 mmol, 
1.0 equiv.). The tube was lightly vortexed for 2 min, allowed to sit for 15 min, and then 
cooled to 0 °C with an ice bucket. A cooled 1 M solution of HCl (188 uL, 0.188, 2.0 
equiv.) was then added dropwise, and the resulting precipitate was filtered and washed 
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with 2 mL of 1 M HCl and 2 mL of cold water. The resulting tan powder was dried under 
hivac, affording 2 (8.5 mg, 26%) as a light tan solid. LCMS of the solid indicated a 
single, broad peak. LRMS (ESI) (m/z): [M + H]+ calculated for C14H15N2O5S2, 355.04; 
found, 355.03. 
 
Novel inhibitors 
Commercially available tetrazole compounds were purchased and purified before 
testing, except for 5 and 6, due to the low quantity. Compound synthesis is described in 
the ESI.  
 
β-lactamase inhibition assays 
The hydrolytic activity of CTX-M-14 and KPC-2 was determined using the β- 
lactamase substrate nitrocefin in a reaction buffer containing 100 mM Tris pH 7.0 and 
0.01% (v/v) Triton X-100. Nitrocefin hydrolysis was monitored using a Biotek Synergy 
Mx monochromator-based multimode microplate reader at a 486 nm wavelength. For 
CTX-M-14 and KPC-2 inhibition assays, the nitrocefin concentration used was 40 and 
10 µM, respectively. The Km of nitrocefin for CTX-M-14 is 22 µM, and for KPC-2, it is 10 
µM. For NDM-1, nitrocefin was used as a substrate in a reaction buffer consisting of 50 
mM HEPES pH 7.2, 50 µM ZnSO4, 0.01% (v/v) Triton X-100, and 1 µg/mL bovine serum 
albumin (BSA). The Km of nitrocefin for NDM- 1 is 3 µM, and the nitrocefin 
concentration used in the reaction was 10 µM. Compounds were used for IC50 
measurements up to 10 mM based on their solubility in DMSO. The final protein 
concentration used in the reaction for CTX-M-14, KPC-2, and NDM-1 was 0.3, 1, and 2 
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nM, respectively. The protein was added last to initiate the reaction. The experiments 
were performed in triplicates, and the results were averaged. 
 
Crystallization and structure determination 
CTX-M-14 was crystallized as previously described.37 Briefly; a 10 mg/ mL solution 
of CTX-M-14 was used to grow crystals in 1.0 M potassium phosphate dibasic pH 8.3. 
CTX-M-14 complex crystals were prepared via being soaked in 1.44 M sodium citrate 
and 5−10 mM inhibitors for 1−24 h based on crystal stability. KPC-2 was crystallized as 
previously described.23 Briefly, 10−20 mg/mL of KPC-2 was used to grow crystals in 2 M 
(NH4)2SO4 and 5% (v/v) ethanol. KPC-2 complex crystals were prepared via being 
soaked in 1.44 M sodium citrate and 10 mM inhibitors for 40 min. A 10 mg/mL solution 
of NDM-1 was used to grow crystals in 0.05 M potassium phosphate monobasic, 0.01 M 
calcium chloride, and 25% (w/v) PEG8000. Complex NDM-1 crystals were prepared via 
being soaked in 0.05 M sodium acetate pH 3.85, 25% (w/v) PEG8000, and 10 mM 
inhibitors. Diffraction data were collected at the beamlines 22-ID-D and 23-ID-D of the 
Advanced Photon Source (APS), Argonne National Laboratory (ANL), and beamline 
8.3.1 at the Advanced Light Source (ALS), Lawrence Berkeley National Laboratory 
(LBNL). Data indexing, integration, and scaling were performed using HKL-2000,71 
iMOSFLM,72 and SCALA73 of the CCP4 suite.74 Phasing was performed using molecular 
replacement (PDB accession code, 1YLT for CTX-M-14; 3C5A for KPC-2; and 4TZF for 
NDM-1) with the program phaser75 of the PHENIX suite.76 Structure refinement was 
performed using phenix.refine77 of the PHENIX suite, and model building was performed 
using WinCoot.78 The eLBOW program79 of the PHENIX suite was used to generate 
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ligand restraints. The quality of the model was assessed by MolProbity.80 The 
composite omit map program81 of the PHENIX suite was used to generate composite 
simulated annealing mFo−DFc omit maps. Protein structure figures were generated 
using PyMOL (Schrödinger, LLC). 
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Electronic Supporting Information: 
Crystallographic Data 
Table 3-4. Crystallographic data collection and refinement statistics.  
 
 149 
 
* Data was collected from a single crystal for each structure. Values in parenthesis are 
for the highest-resolution shell. 
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Supplementary Figures 
 
Figure 3-4. Complex crystal structure of compound 7s with KPC-2. The simulated 
annealing composite Fo – Fc omit map (gray) contoured at 1.5 σ for compound 7s with 
KPC-2. Black dashed lines depict hydrogen bonds. 
 
 
 
Figure 3-5. Complex crystal structure of compound 8 with KPC-2 and NDM-1. The 
simulated annealing composite Fo –Fc omit map (gray) contoured at 2.0 σ for both KPC-
2 (A) and NDM-1 (B). Black dashed lines depict hydrogen bonds or coordination with 
metal ions.  
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Synthetic Procedures 
General Procedures: Reactions were magnetically stirred unless otherwise indicated. 
Air and/or moisture sensitive reactions were carried out under an argon atmosphere in 
oven-dried glassware using anhydrous solvents from commercial suppliers. Air and/or 
moisture sensitive reagents were transferred via syringe or cannula and were 
introduced into reaction vessels through rubber septa. All anhydrous solvents used 
were purchased from Sigma-Aldrich and used without further purification. Solvents to be 
employed in flash column chromatography and reaction work-up procedures were 
purchased from either Sigma-Aldrich or Fisher Scientific. All other reagents were 
obtained commercially and used without further purification, unless otherwise stated. 
Reactions were monitored using LCMS and thin layer chromatography (TLC) performed 
on 0.25-mm EMD pre-coated glass-backed silica gel 60 F-254 plates. Compounds were 
visualized under UV light or through staining with permanganate. Reaction product 
solutions and chromatography fractions were concentrated by rotary evaporation at 30 
°C at 20 Torr, then Hi-Vac at 0.5 Torr overnight, unless otherwise indicated. 
 
Instrumentation: NMR spectra were recorded on a Bruker AvanceIII HD 400 MHz 
spectrometer (with 5 mm BBFO Z-gradient Smart Probe) calibrated to CH(D)Cl3 as an 
internal reference (7.26 and 77.00 ppm for 1H and 13C NMR spectra, respectively). Data 
for 1H NMR spectra are reported in terms of chemical shift (δ, ppm), multiplicity, 
coupling constant (Hz), and integration. Data for 13C NMR spectra are reported in terms 
of chemical shift (δ, ppm). The following abbreviations are used to denote the 
multiplicities: s = singlet; d = doublet; dd = doublet of doublets; dt = doublet of triplets; 
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dq = doublet of quartets; ddd = doublet of doublet of doublets; t = triplet; td = triplet of 
doublets; tt = triplet of triplets; q = quartet; qd = quartet of doublets; quin = quintet; sex = 
sextet; m = multiplet. LCMS and compound purity were determined using a Waters 
Micromass ZQ 4000, equipped with a Waters 2795 Separation Module, Waters 2996 
Photodiode Array Detector, and a Waters 2424 ELSD. Separations were carried out 
with an XBridge BEH C18, 5µm, 4.6 x 20 mm column, at ambient temperature 
(unregulated) using a mobile phase of water-methanol containing a constant 0.1% 
formic acid. HPLC was performed on a Waters 2535 Separation Module with a Waters 
2998 Photodiode Array Detector. Separations were carried out with an XBridge BEH 
C18, 5µm, 19 x 50 mm column, at ambient temperature (unregulated) using a mobile 
phase of water-methanol containing a constant 0.05% formic acid. 
  
General Procedure A: A vial is charged with the appropriate carboxylic acid (1.0 
equiv), DMF, and N,N′-diisopropylethylamine (1.0 equiv). HATU (1.05 equiv) is then 
added, and the reaction mixture is allowed to stir for 10 minutes. 5-aminotetrazole 
monohydrate (1.1 equiv) and N,N′-diisopropylethylamine (1.1 equiv) are subsequently 
added, and the reaction is stirred at room temperature for 24 h or until judged complete 
by LCMS. The crude reaction mixture is directly purified by reverse phase HPLC 
(water/MeOH/0.05% formic acid) to afford the desired product. 
 
General Procedure B: An oven-dried flask is charged with the appropriate carboxylic 
acid (1.0 equiv), CH2Cl2 (305 equiv), and DMF (20 drops). Oxalyl chloride (1.1 equiv) is 
subsequently added dropwise, and the reaction is stirred at room temperature for 3 h. 
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Separately, 5-aminotetrazole monohydrate (2.0 equiv) is suspended in CH2Cl2 (305 
equiv) and N,N′-diisopropylethylamine (3.0 equiv) in an oven-dried flask. The 
aforementioned oxalyl chloride solution is then added dropwise to this solution, followed 
by a 2.0 mL CH2Cl2 rinse of the parent flask. The reaction suspension is stirred at room 
temperature for 24 h or until judged complete by LCMS. The reaction mixture is 
concentrated under reduced pressure, taken up in DMF, and purified by reverse phase 
HPLC (water/MeOH/0.05% formic acid) to afford the desired product. 
 
 
 
1,3-Diphenyl-N-(1H-tetrazol-5-yl)-1H-pyrazole-5-carboxamide (7s*). Commercially 
available 2,5-diphenyl-2H-pyrazole-3-carboxylic acid (50 mg, 0.189 mmol, 1.0 equiv) 
was reacted with 5-aminotetrazole monohydrate in DMF (1.0 mL) according to general 
procedure A to afford 7s* (25.0 mg, 40%) as a white solid. 1H NMR (400 MHz, DMSO-
d6) δ = 12.27 (br s, 1H), 7.72 - 7.11 (m, 11H); 13C NMR (100 MHz, DMSO-d6) δ = 
160.45, 145.25, 145.17, 139.57, 129.70, 129.47, 129.31, 129.21, 129.17, 126.08, 
109.26; LRMS (ESI) calculated for C17H14N7O [M + H]+ m/z 332.11, found 332.08. 
 
 
 
2-Phenyl-2-(phenylthio)-N-(1H-tetrazol-5-yl)acetamide (8*). Commercially available 
2-phenyl-2-(phenylsulfanyl)acetic acid (100 mg, 0.409 mmol, 1.0 equiv) was reacted 
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with 5-aminotetrazole monohydrate according to general procedure B to afford 8* (70 
mg, 55%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 8.20 (s, 0.2H), 7.56 (br d, 
J = 6.8 Hz, 2H), 7.47 - 7.19 (m, 8H), 5.50 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = 
168.61, 151.34, 136.35, 134.18, 131.19, 129.69, 129.17, 128.86, 128.01, 55.58; LRMS 
(ESI) calculated for C15H14N5OS [M + H]+ m/z 312.08, found 312.02. 
 
 
 
2-Phenyl-2-(phenylamino)-N-(1H-tetrazol-5-yl)acetamide (9). Commercially available 
anilino(phenyl)acetic acid (50 mg, 0.220 mmol, 1.0 eq) was reacted with 5-
aminotetrazole monohydrate in DMF (2.5 mL) according to general procedure A to 
afford 9 (12.6 mg, 20%) as a white solid. 1H NMR (400 MHz, CD3OD) δ = 7.59 (br s, 
2H), 7.49 - 7.28 (m, 3H), 7.13 (br t, J = 7.3 Hz, 2H), 6.82 - 6.63 (m, 3H), 5.22 (br s, 1H); 
13C NMR (100 MHz, CD3OD) δ = 171.73, 161.72, 146.78, 137.62, 128.73, 128.56, 
128.18, 127.39, 118.00, 113.44, 62.46; LRMS (ESI) calculated for C15H15N6O [M + H]+ 
m/z 295.12, found 294.88. 
 
 
 
2-(Phenylamino)-N-(1H-tetrazol-5-yl)acetamide (10). Commercially available phenyl 
glycine (50 mg, 0.331 mmol, 1.0 equiv) was reacted with 5-aminotetrazole monohydrate 
in DMF (2.5 mL) according to general procedure A to afford 10 (7.1 mg, 10%). 1H NMR 
(400 MHz, CD3OD, drops DMSO-d6) δ = 8.27 (s, 0.2H), 7.18 (br t, J = 7.5 Hz, 2H), 6.76 
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- 6.65 (m, 3H), 4.06 (s, 2H); LRMS (ESI) calculated for C9H11N6O [M + H]+ m/z 219.09, 
found 218.97. 
 
 
 
2-Phenyl-2-(phenylsulfinyl)acetic acid (S1). Commercially available 2-phenyl-2-
(phenylsulfanyl)acetic acid (150 mg, 0.614 mmol, 1.0 equiv) was dissolved in MeOH 
(4.0 mL) in a glass vial. A solution of potassium monopersulfate (217 mg, 1.3 mmol, 2.1 
equiv) in H2O (1.0 mL) was then added dropwise, followed by a H2O (0.5 mL) rinse of 
the vessel. The reaction suspension was stirred at room temperature for 2 h, and then 
concentrated under reduced pressure. The residue was suspended with ~ 3 mL cold 
water, filtered, washed with cold H2O and hexanes, and dried under vacuum overnight. 
Semi-crude S1 (155.2 mg) was used without further purification. LRMS (ESI) calculated 
for C14H13O3S [M + H]+ m/z 261.05, found 260.87. 
 
 
 
2-Phenyl-2-(phenylsulfinyl)-N-(1H-tetrazol-5-yl)acetamide (11). S1 (97 mg, 0.374 
mmol, 1.0 equiv) was reacted with 5-aminotetrazole monohydrate in DMF (2.5 mL) 
according to general procedure A to afford 11 (8.5 mg, 7%) as a white solid. Note: 
While the diastereomers are separable by HPLC, they interconvert on a day’s 
timescale; the diastereomeric mixture was tested in the biochemical assay. 1H NMR 
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(400 MHz, CD3OD, drops DMSO-d6)) δ = 8.45 (br s, 1H), 7.79 - 7.67 (m, 0.5H), 7.66 - 
7.05 (m, 9.5H), 5.06 (br s, 0.5H), 4.99 (br s, 0.5H); LRMS (ESI) calculated for 
C15H14N5O2S [M + H]+ m/z 328.08, found 327.83. 
 
 
 
2-Phenyl-2-(phenylsulfonyl)acetic acid (S2). Commercially available 2-phenyl-2-
(phenylsulfanyl)acetic acid (150 mg, 0.614 mmol, 1.0 equiv) was dissolved in MeOH 
(5.0 mL) in a glass vial. A solution of potassium monopersulfate (867 mg, 5.16 mmol, 
8.4 equiv) in H2O (4.0 mL) was then added dropwise at room temperature. The reaction 
suspension was stirred for 72 h, and then concentrated under reduced pressure. The 
slurry was suspended with ~ 10 mL cold water, filtered, washed with 3 x 10 mL cold 
H2O and 10 mL hexanes, and dried under vacuum overnight. Semi-crude S2 (146.1 mg) 
was used without further purification. Note: This intermediate was prone to 
spontaneous decarboxylation while in solution; appeared to be bench stable when dry. 
1H NMR (400 MHz, CD3OD) δ = 7.72 - 7.64 (m, 3H), 7.54 - 7.47 (m, 2H), 7.43 - 7.36 (m, 
3H), 7.34 - 7.28 (m, 2H), 5.39 (s, 1H); 13C NMR (100 MHz, CD3OD) δ = 166.28, 137.06, 
133.91, 130.21, 129.37, 129.15, 128.65, 128.43, 128.07, 74.39. 
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2-Phenyl-2-(phenylsulfonyl)-N-(1H-tetrazol-5-yl)acetamide (12). S2 (30 mg, 0.109 
mmol, 1.0 equiv) was reacted with 5-aminotetrazole monohydrate according to general 
procedure B, but with 5 mL CH2Cl2 (718 equiv) in each vessel. 12 (19.4 mg, 52%) 
obtained as a white solid. 1H NMR (400 MHz, CD3OD) δ = 8.33 (s, 0.4H), 7.71 - 7.64 
(m, 3H), 7.54 - 7.45 (m, 4H), 7.39 (t, J = 7.3 Hz, 1H), 7.35 - 7.27 (m, 2H); 13C NMR (100 
MHz, CD3OD) δ = 162.63, 154.56, 136.78, 134.10, 130.29, 129.44, 129.31, 128.54, 
128.39, 128.08, 100.00; LRMS (ESI) calculated for C15H14N5O3S [M + H]+ m/z 344.07, 
found 343.86. 
 
 
 
2-(Phenylthio)-N-(1H-tetrazol-5-yl)acetamide (13). Commercially available 2-
(phenylthio)acetic acid (100 mg, 0.499 mmol, 1.0 eq) was reacted with 5-aminotetrazole 
monohydrate in DMF (2.5 mL) according to general procedure A to afford 13 (18.0 mg, 
13%). 1H NMR (400 MHz, DMSO-d6) δ = 8.16 (s, 0.3H), 7.41 (d, J = 7.5 Hz, 2H), 7.33 
(br t, J = 7.5 Hz, 2H), 7.21 (t, J = 7.3 Hz, 1H), 3.95 (s, 2H); 13C NMR (100 MHz, DMSO-
d6) δ = 167.69, 163.61, 135.92, 129.53, 128.69, 126.65, 36.82; LRMS (ESI) calculated 
for C9H10N5OS [M + H]+ m/z 236.05, found 235.82. 
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2-(Phenylsulfonyl)-N-(1H-tetrazol-5-yl)acetamide (14). Commercially available 2-
(phenylsulfonyl)acetic acid (40 mg, 0.200 mmol, 1.0 equiv) was reacted with 5-
aminotetrazole monohydrate according to general procedure B, but with 5 mL CH2Cl2 
(390 equiv) in each vessel. 14 (12.2 mg, 23%) obtained as a white solid. 1H NMR (400 
MHz, DMSO-d6) δ = 8.15 (s, 0.5H), 7.92 (d, J = 7.5 Hz, 2H), 7.76 (t, J = 7.3 Hz, 1H), 
7.66 (t, J = 7.7 Hz, 2H), 4.58 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ = 163.59, 
160.11, 139.71, 134.57, 129.75, 128.53, 61.37; LRMS (ESI) calculated for C9H10N5O3S 
[M + H]+ m/z 268.04, found 267.78. 
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Chapter 4 
Targeting the Conserved Hydrophobic Shelf for Carbapenemase KPC-2 
 
Kyle DeFrees, Afroza Akhtar, Xiujun Zhang, Derek Nichols, Erica Cambeis,  
Yu Chen, and Adam R. Renslo 
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Identification of New Inhibitor Chemotypes: 
We have previously used structure-based fragment screening to identify the first nM 
non-covalent serine β-lactamase inhibitors, resulting in compound 1, an 85 nM inhibitor 
of CTX-M.1 We found that the tetrazole of 1 displays high shape and electrostatic 
complementarity with the active site pocket that binds to the β-lactam C3(4)-carboxylate 
group. Given this sites conservation across Class A β-lactamases, we hypothesized that 
permutations of the tetrazole scaffold may be well suited to inhibit the carbapenemase 
KPC-2. As seen in the superimposition of KPC-2 with the CTX-M complex of 1 (Figure 
4-1), KPC-2 harbors several important structural differences. While the C3(4)-
carboxylate binding site is well conserved with a S237T mutation, G238C and a 
structural disulfide results in a twisted β3 strand, putting G239 in direct steric clash with 
the benzimidazole of 1. While the hydrophobic sub pocket near the CF3 is conserved 
with P167L, a key hydrogen bond to the amide is lost with a N104P mutation. Notably, 
the Tyr105 hydrophobic shelf, which remains untargeted by the original scaffold, is 
maintained as Trp105 in KPC-2. Based off of these similarities, we hypothesized that 
analogs targeting this conserved shelf may be able to inhibit both CTX-M and KPC-2. 
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Figure 4-1. Compound 1 complex with CTX-M-9 superimposed onto an apo KPC-2 
structure. CTX-M: white and yellow, PDB code 4UA7; KPC-2: green, PDB code 5UL8. 
 
In order to better meet the steric requirements of the twisted β3 strand, we 
synthesized a panel of indane-type analogs with a simple aryl component (Table 4-1). 
Using a nitrocefin biochemical assay, we found that 3-fluoro-aryl syn diastereomer 2 
displayed modest CTX-M activity, but no detectable KPC-2 activity. Gratifyingly, syn 
CF3 analog 3 improved CTX-M activity 5-fold, in line with the original SAR for CTX-M, 
and displayed detectable KPC-2 activity. As expected, anti diastereomer 4 displayed no 
observable activity for either enzyme. Crystallography with the more soluble 2 revealed 
the expected binding mode with CTX-M (Figure 4-2A); the indane is well positioned 
over the Tyr105 surface, with the aryl-amide portion binding in the same orientation as 
the original scaffold. Surprisingly, soaks of 2 with KPC-2 revealed an suboptimal binding 
orientation with the unexpected enantiomer of the syn diastereomer (Figure 4-2B); 
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instead of binding down the pocket, the indane scaffold sat over the Trp105 shelf and 
out into solvent. While this result could be attributed to the weak affinity of 2 towards 
KPC-2, we thought steric clash with G239 was driving the suboptimal binding mode, 
and sought to allow more aryl flexibility by synthesizing the sp3 sulfonamides 5 and 6. 
Syn 5 did not improve KPC-2 activity over amide 3, and anti 6 retained similar activity to 
5, suggesting that the indane scaffold was binding in an unproductive manner across all 
analogs. 
 
Table 4-1. Biochemical activities of indanes 2-6.a 
 
a Relative stereochemistry indicated as the syn or anti diastereomers. b Calculated from 
IC50 using Ki = IC50/(1 + [S]/Km). Km values were measured the day of the experiment. 
IC50 values were fit from a technical triplicate with a SE < 1.1 µM. c Compound also 
displayed partial inhibition, see ESI for curves. 
 
   
CTX-M-14 
Kib (μM) 
KPC-2   
Kib (μM) 
2 
 
176 > 800 
3 
 
37 386 
4 
 
> 1500 > 800 
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> 1500 ~ 270c 
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> 1500 ~ 460c 
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Figure 4-2. Crystal structures reveal binding mode of indane 2 to CTX-M-9 and 
KPC-2. (A) CTX-M-9. (B) KPC-2. Water molecules are shown as red hashes. Yellow 
dashes represent putative hydrogen bonds. 
 
Given these results, it appeared larger changes were required for optimal KPC-2 
inhibition. We hypothesized that pulling the amide in by one atom, to form an indoline, 
would help alleviate potential steric clashes with the β3 twist. Docking of indoline 7 
appeared to give putative binding modes where the indoline stacked against the G239 
twist (ESI, Figure 4-6), so analogs 7 and 8 were synthesized. These analogs showed 
no detectable CTX-M activity, and like the indane, had minimal differences between 
A
B
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amide 7 and sulfonamide 8 (Table 4-2). Crystallography of 7 with KPC-2 revealed a 
similar binding mode to 2 (Figure 4-3A); the aryl-CF3 stacked over Trp105 and out of 
the active site. When compared to the indane bound CTX-M (Figure 4-2A), the 
tetrazole of 7 appeared to bind at a slight angle, which may be a result of the preferred 
threonine conformation in KPC-2. With this angle in mind, we also docked amide-
spaced tetrazole 9 (Figure 4-3B), which packed nicely against the β3 twist, with 
additional H-bonding to Asp132 and hydrophobic interactions with Leu167. Biochemical 
testing of 9 and sulfonamide 10 revealed similar inhibition patterns however, with no 
detectable CTX-M activity, and no major differences in KPC-2 activity (Table 4-2). 
Docking with the more flexible tetrahydroisoquinoline 11 was uninspiring (ESI, Figure 4-
6), and while amide 11 and sulfonamide 12 showed the best KPC-2 activity, the lack of 
difference between the sp2 amide and sp3 sulfonamide suggested unproductive binding 
modes. 
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Table 4-2. Biochemical activities of analogs 7-12.a 
 
a All compounds are racemates. b Calculated from IC50 using Ki = IC50/(1 + [S]/Km). Km 
values were measured the day of the experiment. IC50 values were fit from a technical 
triplicate with a SE < 1.1 µM. c Compound also displayed partial inhibition, see ESI for 
curves. 
 
   
CTX-M-14    
Kib (μM) 
KPC-2           
Kib (μM) 
7 
 
> 1500 912 
8 
 
> 1500 530b 
9 
 
> 1500 710 
10 
 
~ 1500 ~ 350 
11 
 
1300 348 
12 
 
> 1500 249 
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Figure 4-3. Crystal structure of indoline 7 with KPC-2; docking pose of indoline 9 
with KPC-2. (A) Compound 7 bound to KPC-2. (B) Selected docking pose of compound 
9 with KPC-2. Water molecules are shown as red dashes. Yellow dashed lines 
represent putative hydrogen bonds. 
 
Attempts to gain structural insight into these analogs were unsuccessful, but the 
putative docking pose of 9 suggested an opportunity to build interactions towards the 
conserved hydrophobic shelf, so a few α-modified amido-tetrazole indolines were 
synthesized (Table 4-3). While smaller modifications like methyl 13 or phenyl 14 were 
not expected to fully reach the shelf, benzyl 15 began to pick up moderate KPC-2 
A
B
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activity. Surprisingly, NHBoc 16, which was originally intended as a synthetic 
intermediate for further derivatization, showed the best activity with a 51 µM Ki against 
KPC-2, while amine 17 had no detectable activity. While our hypothesis was based on 
the putative pose of 9, we were able to get a structure of 16 in complex with KPC-2, 
which revealed an unexpected binding mode (Figure 4-4). Instead of stacking over the 
Trp105 hydrophobic shelf, the NHBoc bound down the channel, pointing a carbonyl 
towards the oxyanion hole with a hydrogen bond to ordered water, and the tert-butyl 
packed over Leu167. The aryl-CF3 surprisingly displaced the Trp105 shelf, packing over 
Pro107 and forcing the Trp into an alternate conformation where it engaged in a 
hydrophobic and π-offset interaction with the indoline core. 
 
Table 4-3. Biochemical activities of analogs 13-17.a 
 
 
 
CTX-M-14    
Kib (μM) 
KPC-2           
Kib (μM) 
9 H > 1500 710 
13 Me > 850 ~ 750 
14 Ph > 1500 634 
15 Bn > 1500 166 
16 NHBoc > 750 51 
17 NH2 > 1500 > 800 
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a All compounds are racemates. b Calculated from IC50 using Ki = IC50/(1 + [S]/Km). Km 
values were measured the day of the experiment. IC50 values were fit from a technical 
triplicate with a SE < 1.1 µM. 
 
 
Figure 4-4. Crystal structure reveals the binding mode of indoline 16 to KPC-2. 
Top and side views. Water molecules are shown as red hashes. Yellow dashed lines 
represent putative hydrogen bonds. 
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Exploring KPC-2 Specific Interactions: 
Given the activity and binding mode of 16, we sought to further probe the role of the 
NHBoc by making a small series of derivatives (Table 4-4). Changing from the tightly 
packed t-butyl of 16 to the more open benzyl of 18 resulted in a 3-fold reduction in 
activity. Surprisingly, changing from a t-butyl carbamate to the t-butyl-urea of 19 or 
benzyl-urea of 20 was not well tolerated, and building further down the channel with 
cumyl 21 or gemdimethyl pyrazole 22 were not sufficient to compensate for the 
disfavored urea. The analogous carbamates of 21 and 22 could not be synthesized due 
to synthetic instability, with the carbamate preferring to engage in elimination. Changing 
to the butyric amide 23 was better tolerated with a 3-fold loss in activity, which was 
similar to the t-butyl sulfamate 24. Given the bias towards carbamates, a few 
oxazolidinones were also synthesized to see if conformational restriction would offer 
any additional benefit. Unfortunately, gem-dimethyl oxazolidinone 25 was not tolerated, 
and phenyl analog 26 had a 4-fold reduction in activity, with analogs 27 and 28 showing 
no detectable activity. These results suggest that the carbamate is uniquely suited for 
binding at the G239 twist; modification disturbs the t-butyl anchoring on Leu167, which 
in turn destabilizes the Trp105 stack. 
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Table 4-4. Biochemical activities of indoline analogs 18-28.a 
 
a All compounds are racemates at the indoline stereocenter. b Calculated from IC50 
using Ki = IC50/(1 + [S]/Km). Km values were measured the day of the experiment. IC50 
values were fit from a technical triplicate with a SE < 1.1 µM. 
 
Since initial attempts to replace or modify the t-butyl carbamate were not successful, 
we instead sought to explore the aryl-CF3 and indoline core. Complete replacements via 
hydrophobic amino acid and amino acid-like amido-tetrazoles 29-34 were not tolerated 
(Table 4-5), and modification to the analogous tetrahydroisoquinolines 35 and 36 were 
also not tolerated, suggesting that the indoline core has important specific interactions. 
A series of truncations were devised to look at the contributions of individual 
components (Table 4-6). Notably, removing the sp2 amide of 16 to give benzylic 37 
 
 
CTX-M-14    
Kib (μM) 
KPC-2           
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KPC-2           
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> 750 51 23 
 
> 300 136 
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> 1500 174 24 
 
> 450 161 
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> 600 > 400 25 
 
> 600 > 400 
20 
 
> 600 > 400 26 
 
> 600 188 
21 
 
> 600 > 400 27 
 
> 600 > 400 
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> 600 > 400 28 
 
> 750 > 400 
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accounts for a > 10 fold decrease in activity (tested to solubility limits). Removing the 
CF3 (38) accounts for a 4-fold decrease in activity, where introducing a pyridine (39) or 
pyrimidine (40), which should improve rotation around the amide, resulted in a further 3-
fold loss in activity (12-fold from parent). Analogs with a 2-thiophene (41) or 2-pyrrole 
(42) were equivalent to the phenyl 38, along with benzyl carbamate 43. Further 
truncations to the acetyl (44) or amine (45) gave a 12-fold loss in activity, roughly 
equivalent to the pyridine or pyrimidine analogs. Taken together, these results suggest 
that significant interaction energy is coming from the stabilization of the sp2 amide 
interacting with the offset Trp105 shelf (Figure 4-4), with the aryl-CF3 serving as a 
hydrophobic “lever arm” to stabilize the overall bound complex. 
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Table 4-5. Biochemical activities of analogs 29-36.a 
 
a All compounds are racemates (as applicable). b Calculated from IC50 using Ki = IC50/(1 
+ [S]/Km). Km values were measured the day of the experiment. IC50 values were fit from 
a technical triplicate with a SE < 1.1 µM. 
 
 
 
 
 
CTX-M-14    
Kib (μM) 
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> 1500 > 800 
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> 1500 > 800 
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> 1500 > 800 
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> 1500 > 800 
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> 750 > 400 
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> 1500 > 800 
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> 1500 713 
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> 1500 > 800 
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Table 4-6. Biochemical activities of analogs 37-45.a 
 
a All compounds are racemates. b Calculated from IC50 using Ki = IC50/(1 + [S]/Km). Km 
values were measured the day of the experiment. IC50 values were fit from a technical 
triplicate with a SE < 1.1 µM. 
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> 750 51 
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> 1500 180 
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> 750 150 
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> 1500 253 
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While Trp105 displacement onto Pro104 has been observed in various KPC-2 
crystal structures, the binding mode observed for 16 is extremely KPC-2 specific; such 
conformers are not observed in CTX-M since Tyr105 cannot displace onto Asp104. 
Additionally, the ligand efficiency for the aryl-CF3 indoline core is quite poor, so small 
amino acid-like compounds were synthesized to recapitulate Tyr105 interactions, while 
also providing improved side chain flexibility (Table 4-7). Tryptophan derivative 46 had 
no detectable KPC-2 activity, but hydroxybenzoxazole 47 was equivalent to the 
previous indoline truncations. Introducing a hydrogen bond donor in 
hydroxybenzimidazole 48  gave a Ki equivalent to the des-CF3 analog 38. Moving from 
hydroxybenzimidazole to oxindole 49 gave further improvement (124 μM), with 49 being 
only 2.5-fold worse than parent indoline 16. The smaller hydroxypyridine 50 had no 
detectable activity, whereas quinolone 51 and directly linked quinolone 52 had fringe 
activity. Given these results, it seems the carbonyl and hydrogen bond donating abilities 
of 48 and 49 are both preferred over either interaction alone (46 and 47). This smaller 
scaffold, though still relatively weak, has improved ligand efficiency over indoline 16, 
and represents a tractable starting point for further inhibitor discovery. 
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Table 4-7. Biochemical activities of analogs 46-52.a 
 
a All compounds are racemates. b Calculated from IC50 using Ki = IC50/(1 + [S]/Km). Km 
values were measured the day of the experiment. IC50 values were fit from a technical 
triplicate with a SE < 1.1 µM. 
 
Prospects for Broad-Spectrum Inhibitor Discovery: 
While the pursuit of KPC-2 activity resulted in the loss of detectable CTX-M activity, 
both starting indane 2 and indoline 16 occupy similar envelope space (Figure 4-5), with 
the primary point of envelope divergence being the displacement of the hydrophobic 
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shelf in KPC-2. The more flexible oxindole 49 should better accommodate the rigid shelf 
requirements of CTX-M, but likely shows no detectable CTX-M activity due to the 
suboptimal t-butyl carbamate. Our previous work with aryl scaffold 1 showed the 
importance of the aryl-CF3 and the benzimidazole packing interactions against the β3 
strand; further derivatization of the flexible carbamate in line with original SAR should 
allow for improved CTX-M activity. Furthermore, the small panel of heterocycles tested 
in Table 4-7 was by no means exhaustive; depending on the binding mode of 49 with 
KPC-2, additional interactions may be gained through further heterocycle optimization. 
 
 
Figure 4-5. Compound 2 complex with CTX-M-9 superimposed onto the 
compound 16 complex with KPC-2. CTX-M-9: teal and green; KPC-2: yellow and 
white. 
 
Though structurally divergent from the Class A CTX-M and KPC-2, we also tested 
our compounds against the metallo-β-lactamase NDM-1 (ESI, Tables 4-8 and 4-9). The 
larger indoline analogs in Table 4-4 showed no detectable NDM-1 inhibition, at times 
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even showing paradoxical activation. While the size and shape of these molecules were 
likely to preclude binding, previous work by our labs has highlighted the potential for 
amido-tetrazoles to act as inhibitors of NDM-1,2 primarily through hydrophobicity and 
chelation-driven interactions. The smaller amino acid-like analogs in Table 4-5 and 
Table 4-7 showed some traces of activity, but the NDM-1 active site seems to prefer 
aryl hydrophobicity to aliphatic or polar interactions. While cross-class inhibition appears 
tenable, further work on the amido-tetrazole scaffold would be required for improved 
NDM-1 inhibition. 
We also tested our compounds against the distinct Class D serine-β-lactamase 
OXA-48 (ESI, Table 4-10). OXA-48 has a number of key differences from KPC-2 (ESI, 
Figure 4-7); the acid-binding motif loses a Thr for a Phe, and the resulting β3 strand, 
though twisted, is very different from the Gly238 orientation in KPC-2. Perhaps most 
importantly, the hydrophobic shelf is also perturbed, with an Ile stacking over the 
targeted Trp. Unsurprisingly, none of our compounds showed detectable activity against 
OXA-48. It should be noted that many of the currently approved BLIs, such as 
avibactam, struggle with Kiapp against OXA enzymes;3, 4 building activity against this 
enzyme class would require significant work, as the SAR around non-covalent affinity is 
largely unknown. 
 
Conclusion: 
The biochemical and structural data herein have illustrated how the unique ligand 
binding properties of KPC-2 can be exploited to build non-covalent affinity, and how 
such data could be used to link potent, non-covalent ESBL scaffolds to carbapenemase 
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activity. The amido-tetrazole scaffolds described here provide further chemotypes for 
new inhibitor discovery, laying the groundwork for future work targeting both serine and 
metallo-carbapenemases. The discovery of such multi-mode inhibitors is an important 
area in the fight against future antibiotic resistance. 
 
Materials and Methods: 
Synthesis and Characterization 
The syntheses and characterization of new compounds 2–52 are described in the 
ESI. All compounds tested were judged to be of > 95% purity as assessed by NMR and 
a Waters Micromass ZQ 4000 equipped with Waters 2795 Separation Module, Waters 
2996 Photodiode Array Detector (254 nm), and Waters 2424 ELS detector. Separations 
were carried out with an XBridge BEH C18, 3.5 µm, 4.6 × 20 mm column, at ambient 
temperature (unregulated) using a mobile phase of water–methanol containing a 
constant 0.05% formic acid. 
 
β-lactamase Inhibition Assays 
The hydrolytic activity of CTX-M-14 and KPC-2 was determined using the β-
lactamase substrate nitrocefin in a reaction buffer containing 100 mM Tris pH 7.0, 20 
mM NaCl, 0.02% Triton X-100, and 5% DMSO; NDM-1 used a reaction buffer 
containing 100 mM HEPES pH 7.5, 150 mM NaCl, 50 µM ZnCl2, 0.01% Triton X-100, 
and 5% DMSO; OXA-48 used a reaction buffer containing 100 mM Tris-H2SO4 pH 7.0, 
50 mM NaHCO3, 0.01% Triton X-100, and 5% DMSO. Nitrocefin hydrolysis was 
monitored via absorbance (486 nm) using a FlexStation 3 microplate reader at 37 °C. 
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The nitrocefin concentration was 50 µM for all inhibition assays. Compounds were 
tested for IC50 in an 11-point dose response up to 2.5 mM as solubility allowed. For 
CTX-M-14 the protein was added last to initiate the reaction; the final protein 
concentration was 0.1 nM. For KPC-2, NDM-1, and OXA-48 the protein was added to 
compound and allowed to incubate for 30 m at 37 °C before addition of nitrocefin; the 
final protein concentration was 0.3 nM, 3 nM, and 0.1 nM, respectively. All compounds 
were tested as technical triplicates. IC50 values were converted to Ki using Ki = IC50/(1 + 
[S]/Km). The Km of nitrocefin was measured each day of testing: 40 - 107 µM for CTX-M-
14, 8 - 27 µM for KPC-2, 4 – 6 µM for NDM-1, and 185 – 214 µM for OXA-48. All data is 
presented in the ESI. Nitrocefin was purchased from Sigma-Aldrich. 
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Electronic Supporting Information: 
Supplementary Figures 
 
Figure 4-6. Selected docking poses of compounds 7 (A) and 11 (B) with KPC-2. 
Putative hydrogen bonds denoted by yellow dashes. Both enantiomers were docked. 
 
 
 
Figure 4-7. Compound 16 complex with KPC-2 superimposed onto a structure of 
apo OXA-48. With (A) and without (B) 16. KPC-2: yellow and green; OXA-48: white 
(PDB code 4S2P). Red hashes denote water. 
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Supplementary Tables 
Table 4-8. NDM-1 activities of indoline analogs 16, 18-28.a 
 
a All compounds are racemates at the indoline stereocenter. b Calculated from IC50 
using Ki = IC50/(1 + [S]/Km). Km values were measured the day of the experiment. IC50 
values were fit from a technical triplicate. c Displayed paradoxical activation – see 
curves below. 
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Table 4-9. NDM-1 activities of amido-tetrazole analogs 29-34, 44, and 46-52.a 
 
a All compounds are racemates (when applicable). b Calculated from IC50 using Ki = 
IC50/(1 + [S]/Km). Km values were measured the day of the experiment. IC50 values were 
fit from a technical triplicate. c Displayed paradoxical activation – see curves below. 
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Table 4-10. OXA-48 activities of various amido-tetrazole analogs.a 
 
a All compounds are racemates (when applicable). b Calculated from IC50 using Ki = 
IC50/(1 + [S]/Km). Km values were measured the day of the experiment. IC50 values were 
fit from a technical triplicate. 
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> 1000 21 
 
> 850 
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Biochemical Data 
Each curve is generated from a technical triplicate. Top compound concentrations 
ranged from 500 µM to 2.5 mM, as solubility allowed. 
 
Km Measurements – CTX-M-14: 
 
 
 
Km Measurements – KPC-2: 
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Km Measurements – NDM-1: 
 
 
Km Measurements – OXA-48: 
 
 
CTX-M-14 Biochemical Data: 
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KPC-2 Biochemical Data: 
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NDM-1 Biochemical Data: 
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OXA-48 Biochemical Data: 
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Synthetic Procedures 
General Procedures: Reactions were magnetically stirred. Air and/or moisture 
sensitive reactions were carried out under an argon atmosphere in oven-dried 
glassware using anhydrous solvents from commercial suppliers. Air and/or moisture 
sensitive reagents were transferred via syringe or cannula and were introduced into 
reaction vessels through rubber septa. All anhydrous solvents used were purchased 
from Sigma-Aldrich and used without further purification. Solvents to be employed in 
flash column chromatography and reaction work-up procedures were purchased from 
either Sigma-Aldrich or Fisher Scientific. All other reagents were obtained commercially 
and used without further purification, unless otherwise stated. Reactions were 
monitored using LCMS and thin layer chromatography (TLC) performed on 0.25-mm 
EMD pre-coated glass-backed silica gel 60 F-254 plates. Compounds were visualized 
under UV light or through staining with permanganate, ninhydrin, bromocresol green, or 
magic, when appropriate. Reaction products and chromatography fractions were 
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concentrated by rotary evaporation at 25-35 °C at 20 Torr, then hivac at 0.5 Torr 
overnight, unless otherwise indicated. 
 
Instrumentation: NMR spectra were recorded on a Bruker AvanceIII HD 400 MHz 
spectrometer (with 5 mm BBFO Z-gradient Smart Probe) calibrated to CH(D)Cl3 as an 
internal reference (7.26 and 77.00 ppm for 1H and 13C NMR spectra, respectively). Data 
for 1H NMR spectra are reported in terms of chemical shift (δ, ppm), multiplicity, 
coupling constant (Hz), and integration. Data for 13C NMR spectra are reported in terms 
of chemical shift (δ, ppm), with multiplicity and coupling constants in the case of C–F 
coupling. The following abbreviations are used to denote the multiplicities: s = singlet; d 
= doublet; dd = doublet of doublets; dt = doublet of triplets; dq = doublet of quartets; ddd 
= doublet of doublet of doublets; t = triplet; td = triplet of doublets; tt = triplet of triplets; q 
= quartet; qd = quartet of doublets; quin = quintet; sex = sextet; m = multiplet. LCMS 
and compound purity were determined using a Waters Micromass ZQ 4000, equipped 
with a Waters 2795 Separation Module, Waters 2996 Photodiode Array Detector, and a 
Waters 2424 ELSD. Separations were carried out with an XBridge BEH C18, 5µm, 4.6 x 
20 mm column, at ambient temperature (unregulated), using a mobile phase of water-
methanol containing a constant 0.1% formic acid. HPLC was performed on a Waters 
2535 Separation Module with a Waters 2998 Photodiode Array Detector. Separations 
were carried out with an XBridge BEH C18, 5µm, 19 x 50 mm column, at ambient 
temperature (unregulated), using a mobile phase of water-methanol containing a 
constant 0.05% formic acid. Column chromatography was carried out using a Biotage 
SP1 flash chromatography system with silica gel cartridges from Silicycle. 
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General Procedure A: A round bottom is charged with the appropriate amine (1.0 
equiv.), solvent, and N,N-diisopropylethylamine (3.1 equiv.). The acyl- or sulfonyl 
chloride (1.1 equiv.) is then added dropwise, and the reaction mixture is stirred for 14h 
or until judged complete by LCMS. The crude reaction mixture is then transferred to a 
sep funnel with ~ 75 mL EtOAc and ~ 10 mL water. ~ 50 mL sat. NaHCO3 is added, the 
layers separated, and the organic layer further washed with ~ 40 mL water and brine. 
The organic layer is dried over MgSO4, concentrated, and purified on a silica column 
with EtOAc:hexanes to afford the desired product. 
  
General Procedure B: The appropriate methyl ester (1.0 equiv.) is suspended or 
dissolved in methanol, after which a 1M aqueous solution of lithium hydroxide is slowly 
added dropwise. The reaction mixture is stirred for 14h or until judged complete by 
LCMS; additional lithium hydroxide is added portion-wise as necessary. Once complete, 
the reaction mixture is transferred to a sep funnel with water, the aqueous pH adjusted 
to 1 with conc. HCl, and the aqueous layer extracted with three portions of EtOAc. The 
organics are combined, dried over MgSO4, and concentrated under reduced pressure. 
Semi-crude product is taken forward as-is. 
 
General Procedure C: An oven-dried flask is charged with the appropriate carboxylic 
acid (1.0 equiv.), dichloromethane, and DMF (drops). Oxalyl chloride (1.1 equiv.) is 
subsequently added dropwise, and the reaction is stirred at room temperature for 3 h. 
Separately, 5-aminotetrazole monohydrate (2.0 equiv) is suspended in dichloromethane 
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and N,N′-diisopropylethylamine (3.0 equiv.) in an oven-dried flask. The aforementioned 
oxalyl chloride solution is then added dropwise to this solution, followed by a 
dichloromethane rinse of the parent flask. The reaction suspension is stirred at room 
temperature for 24 h or until judged complete by LCMS, then concentrated under 
reduced pressure, taken up in DMF, and purified by reverse phase HPLC 
(water/MeOH/0.05% formic acid) to afford the desired product. 
  
General Procedure D: A 20 mL vial is charged with the appropriate carboxylic acid (1.0 
equiv.), DMF, and N,N-diisopropylethylamine (1.0 equiv.). HATU (1.05 equiv) is then 
added, and the reaction mixture is allowed to stir for 10m-1h. Commercially available 
amine (1.1 equiv.) and N,N-diisopropylethylamine (1.1 equiv.) are subsequently added, 
and the reaction is stirred at room temperature for 18h or until judged complete by 
LCMS. The crude reaction mixture is directly purified by reverse phase HPLC 
(water/MeOH/0.05% formic acid) to afford the desired product. 
 
General Procedure E: A 20 mL vial is charged with the appropriate Boc protected 
amine (1.0 equiv.), fitted with a septa, and purged with Ar. The vial is then charged with 
dry 4M HCl in dioxanes, and the reaction is stirred at room temperature for 18-72h or 
until judged complete by LCMS. The reaction mixture is then concentrated and dried 
under hivac overnight, affording the desired semi-crude product as the HCl salt. 
 
General Procedure F: A dried round bottom is charged with the appropriate methyl 
ester (1.0 equiv.) and dry tetrahydrofuran. After cooling to -78 °C, 1M LHMDS in 
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tetrahydrofuran is added dropwise (1.0 equiv). Separately, 2,4,6-triisopropylbenzene 
sulfonyl azide (1.3 equiv.) is dissolved in dry tetrahydrofuran, then cooled to -78 °C. 
After 45m-1h of enolization, the azide solution is cannulated over at -78 °C. Once 
addition is complete, the reaction is allowed to stir for 2 minutes, at which point glacial 
acetic acid is added (4.6 equiv.) – the reaction mixture is then immediately warmed to 
r.t. and allowed to stir overnight. The crude reaction mixture is then transferred to a sep. 
funnel with EtOAc and washed with sat. NaHCO3 and brine. The organic layer is dried 
over MgSO4, concentrated, and purified on a silica column with EtOAc:hexanes to 
afford the desired product. 
 
General Procedure G: A 3-mL vial is charged with amine (1.0 equiv.), dry 
dichloromethane (1.5 mL), and N,N-diisopropylethylamine (1.0 equiv.). The reaction vial 
is cooled to 0 °C and 4-nitrophenylchloroformate (1.1 equiv.) is added (Note: works best 
as bulk-solid addition); stirred at 0 °C for 30m. A solution of partner amine (1.1 equiv.) in 
dry dichloromethane (1 mL) is then added to the reaction, followed by N,N-
diisopropylethylamine (1.2 equiv.). The reaction is allowed to slowly warm to r.t. 
overnight, after which it is transferred to a sep. funnel with ~ 75 mL dichloromethane 
and washed with 3 x 50 mL 1M Na2CO3 (or until yellow coloration ceases). The organic 
layer is washed with an additional 40 mL 0.1N HCl and brine, dried over MgSO4, 
concentrated, and purified on a silica column with EtOAc:hexanes to afford the desired 
product. 
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General Procedure H: A 20 mL vial is charged with the appropriate carboxylic acid (1.0 
equiv), DMF, commercially available 5-aminotetrazole monohydrate (1.1 equiv), and 
N,N-diisopropylethylamine (2.1 equiv). HATU (1.1 equiv) is then added, and the reaction 
mixture is stirred for 18h or until judged complete by LCMS. The crude reaction mixture 
is directly purified by reverse phase HPLC (water/MeOH/0.05% formic acid) to afford 
the desired product. 
 
 
 
methyl 3-(hydroxyimino)-2,3-dihydro-1H-indene-1-carboxylate (S1). Commercially 
available 3-oxo-1-indancarboxylic acid (5.000 g, 28.4 mmol, 1.0 equiv.) was dissolved in 
dry methanol (50 mL). Sulfuric acid (62 uL, 1.1 mmol, 0.04 equiv.) was then added, and 
the reaction mixture was refluxed at 100 °C for 13h. The crude reaction mixture was 
then concentrated to dryness and transferred to a sep funnel with ~ 75 mL EtOAc. The 
organic layer was washed with ~ 50 mL sat. NaHCO3, water, and brine; the combined 
aqueous layers were washed with an additional ~ 50 mL EtOAc. The organics were 
combined, dried over MgSO4, and concentrated to dryness, yielding a yellow-orange oil. 
The oil was dissolved in ethanol (40 mL); hydroxylamine hydrochloride (2.367 g, 34.1 
mmol, 1.2 equiv.) and sodium acetate (4.657 g, 56.8 mmol, 2.0 equiv.) were 
subsequently added, followed by water (40 mL) and ethanol (40 mL) (rinsed walls). 
Stirred for 4h. The reaction mixture was concentrated to remove the ethanol and 
transferred to a sep funnel with ~ 150 mL EtOAc. The organic layer was washed with 2 
x 50 mL water and 50 mL brine; dried over MgSO4 and concentrated to dryness. S1 
O
O
N
OH
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(5.56 g, 96%) obtained as fluffy tan solid. 1H NMR (400 MHz, CDCl3) δ = 8.88 (br s, 1H), 
7.71 (d, J = 7.1 Hz, 1H), 7.58 - 7.52 (m, 1H), 7.44 - 7.33 (m, 2H), 4.23 (dd, J = 3.9, 8.8 
Hz, 1H), 3.78 (s, 3H), 3.44 (dd, J = 4.1, 19.0 Hz, 1H), 3.27 - 3.18 (m, 1H); 13C NMR (100 
MHz, CDCl3) δ = 172.72, 161.49, 144.62, 135.75, 130.74, 128.53, 125.77, 121.70, 
52.52, 46.17, 29.65; LRMS (ESI) calculated for C11H12NO3 [M + H]+ m/z 206.08, found 
206.03.  
 
 
 
methyl 3-amino-2,3-dihydro-1H-indene-1-carboxylate acetate (S2). S1 (5.547 g, 
27.0 mmol, 1.0 equiv.) was dissolved in 200 mL 20% acetic acid in ethanol (slow to 
dissolve). The mixture was hydrogenated for 42h using an “H-Cube” flow hydrogenator 
with a 10% Pd/C cartridge; 1 mL/min, 30 bar H2, 45 °C, loop configuration. The reaction 
mixture was then concentrated to dryness and dried under hivac for 3d. Crude acetate 
S2 (9.780 g, 144%) obtained as a thick, colorless oil (Note: free base is unstable; will 
spontaneously polymerize at 0 °C). 1H NMR (400 MHz, CD3OD) δ = 7.59 - 7.47 (m, 2H), 
7.44 - 7.38 (m, 2H), 4.77 (dd, J = 5.1, 7.8 Hz, 1H), 4.20 (dd, J = 5.6, 8.0 Hz, 1H), 3.80 
(s, 3H), 2.80 (td, J = 8.0, 14.1 Hz, 1H), 2.46 - 2.38 (m, 1H), 1.93 (s, 3H); 13C NMR (100 
MHz, CD3OD) δ = 178.74, 175.54, 142.58, 140.69, 131.12, 129.97, 126.62, 126.13, 
55.76, 53.28, 49.44, 35.27, 23.19; LRMS (ESI) calculated for C11H14NO2 [M + H]+ m/z 
192.10, found 192.07. 
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methyl (syn)-3-(3-fluorobenzamido)-2,3-dihydro-1H-indene-1-carboxylate (S3). 
Crude S2 (500 mg, 1.64 mmol, 1.0 equiv.) was suspended in dry dichloromethane (10 
mL). 3-fluorobenzoyl chloride (300 uL, 2.46 mmol, 1.5 equiv.), N,N-
diisopropylethylamine (630 uL, 3.61 mmol, 2.2 equiv.), and N,N-dimethylaminopyridine 
(1 flake) were then added, and the reaction was stirred for 14h. The crude reaction 
mixture was transferred to a sep funnel with additional dichloromethane and washed 
with ~ 50 mL NH4Cl, sat. NaHCO3, and brine. The organic layer was dried over MgSO4, 
concentrated under reduced pressure, and purified on a silica column with 20% 
EtOAc:hexanes. Syn and anti diastereomers were separable; syn S3 obtained as a tan 
solid (170 mg, 33%). 1H NMR (400 MHz, CDCl3) δ = 7.55 - 7.49 (m, 2H), 7.46 - 7.30 (m, 
5H), 7.21 (ddt, J = 1.1, 2.6, 8.3 Hz, 1H), 6.33 (br d, J = 8.4 Hz, 1H), 5.89 (q, J = 7.7 Hz, 
1H), 4.22 (dd, J = 3.8, 8.6 Hz, 1H), 3.73 (s, 3H), 3.05 (ddd, J = 4.0, 7.8, 13.6 Hz, 1H), 
2.21 (ddd, J = 6.4, 8.7, 13.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ = 173.39, 165.88, 
162.75 (d, J = 248.0 Hz), 143.04, 140.33, 136.57 (d, J = 6.9 Hz), 130.26 (d, J = 7.6 Hz), 
128.73, 128.56, 125.36, 124.54, 122.35 (d, J = 3.1 Hz), 118.62 (d, J = 21.4 Hz), 114.43 
(d, J = 22.9 Hz), 54.57, 52.32, 48.34, 37.30. 
 
 
 
(syn)-3-(3-fluorobenzamido)-2,3-dihydro-1H-indene-1-carboxamide (S4). Syn S3 
(72 mg, 0.23 mmol, 1.0 equiv.) was taken in 3:2:1 tetrahydrofuran:methanol:water (2 
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mL). Solid lithium hydroxide was added (21 mg, 0.89 mmol, 4.0 equiv.), and the reaction 
was stirred for 1.5h. The solvent was then removed under reduced pressure, diluted 
with water, transferred to a sep funnel, and washed with 2 x ~ 50 mL EtOAc. The 
aqueous layer was adjusted to pH 1 and extracted with 3 x ~ 50 mL EtOAc; the 
extraction was dried over MgSO4 and concentrated to give a white solid. The 
intermediate acid was taken up in acetone (2 mL); di-tert-butyl dicarbonate (65.3 mg, 
0.299 mmol, 1.3 equiv.), pyridine (3 uL, 0.38 mmol, 1.65 equiv.), and ammonium 
bicarbonate (23.6 mg, 0.299 mmol, 1.3 equiv.) were then added. The reaction was 
stirred for 12h at which point it was poured into 5% HCl and extracted with 3 x ~ 50 mL 
EtOAc. Dried over MgSO4 and concentrated, yielding semi-crude syn S4 as a white 
solid (28 mg, 41%). 1H NMR (400 MHz, CDCl3) δ = 7.59 - 7.40 (m, 4H), 7.39 - 7.23 (m, 
3H), 7.21 - 7.07 (m, 1H), 5.74 (dt, J = 2.3, 8.3 Hz, 1H), 4.13 - 4.08 (m, 1H), 2.71 (td, J = 
8.1, 14.2 Hz, 1H), 2.33 (td, J = 2.6, 14.1 Hz, 1H). 
 
 
 
N-((syn)-3-cyano-2,3-dihydro-1H-inden-1-yl)-3-fluorobenzamide (S5). Syn S4 (45 
mg, 0.15 mmol, 1.0 equiv.) was taken up in 1,4-dioxane (600 uL) and pyridine (24 uL, 
0.30 mmol, 2.0 equiv.); trifluoroacetic anhydride (23 uL, 0.166 mmol, 1.1 equiv.) was 
then added dropwise. The reaction mixture was stirred for 4h, after which it was diluted 
with ~ 30 mL dichloromethane and washed with 2 x ~ 30 mL water. Dried over Na2SO4 
and concentrated under reduced pressure; purified on a silica column with 20% 
EtOAc:hexanes. Syn S5 obtained as a white solid (28 mg, 67%). 1H NMR (400 MHz, 
CDCl3) δ = 7.58 - 7.47 (m, 3H), 7.45 - 7.37 (m, 4H), 7.23 (dt, J = 1.6, 8.3 Hz, 1H), 6.66 - 
H
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6.60 (m, 1H), 5.71 (q, J = 7.8 Hz, 1H), 4.15 - 4.07 (m, 1H), 3.13 (td, J = 7.7, 13.0 Hz, 
1H), 2.28 (td, J = 8.1, 13.2 Hz, 1H). 
 
 
 
N-((syn)-3-(1H-tetrazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-3-fluorobenzamide (2). A 
vial was charged with syn S5 (28 mg, 0.1 mmol, 1.0 equiv.), sodium azide (13 mg, 0.2 
mmol, 2.0 equiv.), zinc bromide (11.3 mg, 0.05 mmol, 0.5 equiv.), isopropanol (150 uL), 
and water (300 uL). The vial was sealed and heated at 80 °C for 16h. The crude 
reaction mixture was transferred to a sep funnel with excess water, acidified with 3N 
HCl, and extracted with 3 x ~ 30 mL EtOAc. The combined organics were dried over 
MgSO4 and concentrated; purified by reverse phase HPLC (water/MeOH/0.05% formic 
acid) to afford syn 2 (28 mg, 87%) as a white solid. 1H NMR (400 MHz, CD3OD) δ = 
7.75 - 7.70 (m, 1H), 7.66 - 7.61 (m, 1H), 7.54 - 7.47 (m, 1H), 7.42 - 7.38 (m, 1H), 7.36 - 
7.25 (m, 3H), 7.12 (d, J = 7.3 Hz, 1H), 5.79 (t, J = 7.8 Hz, 1H), 4.81 (br d, J = 2.6 Hz, 
1H), 3.16 - 3.07 (m, 1H), 2.45 - 2.36 (m, 1H); LRMS (ESI) calculated for C17H13FN5 [M - 
H]- m/z 322.11, found 322.05. 
 
 
 
methyl 3-(3-(trifluoromethyl)benzamido)-2,3-dihydro-1H-indene-1-carboxylate 
(S6). S2 (1.051 g, 4.18 mmol, 1.0 equiv.) was reacted with commercially available 3-
(trifluoromethyl)benzoyl chloride in dry tetrahydrofuran (40 mL) and acetonitrile (20 mL) 
according to general procedure A. S6 (715.6 mg, 47%) obtained as a white solid (nearly 
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all anti-diastereomer). 1H NMR (400 MHz, CDCl3) δ = 8.15 (s, 1H), 7.99 (d, J = 8.0 Hz, 
1H), 7.74 (br dd, J = 0.7, 7.8 Hz, 2H), 7.62 - 7.53 (m, 2H), 7.44 - 7.39 (m, 1H), 7.34 - 
7.28 (m, 2H), 5.80 (dt, J = 1.9, 8.4 Hz, 1H), 4.14 (dd, J = 2.1, 8.2 Hz, 1H), 3.79 (s, 3H), 
2.74 (td, J = 8.0, 14.1 Hz, 1H), 2.38 (td, J = 2.1, 14.1 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ = 175.79, 164.54, 143.79, 140.29, 135.21, 131.06 (q, J = 32.3 Hz), 130.01, 
129.06, 128.90, 128.79, 127.91 (q, J = 3.7 Hz), 125.85, 124.87, 124.34 (q, J = 3.9 Hz), 
123.75 (d, J = 272.2 Hz), 53.67, 52.71, 48.81, 35.79; 19F NMR (376 MHz, CDCl3) δ = -
62.77 (s, 3F); LRMS (ESI) calculated for C19H16F3NNaO3 [M + Na]+ m/z 386.10, found 
385.91. 
 
 
 
3-(3-(trifluoromethyl)benzamido)-2,3-dihydro-1H-indene-1-carboxylic acid (S7). S6 
(698.1 mg, 1.92 mmol, 1.0 equiv.) was reacted in methanol (25 mL) with 1M lithium 
hydroxide (15 mL, 15 mmol, 7.81 equiv.) according to general procedure B. Semi-crude 
S7 (667.9 mg, 100%) obtained as a white solid (mixture of diastereomers). LRMS (ESI) 
calculated for C18H13F3NO3 [M - H]- m/z 348.09, found 348.01. 
 
 
 
3-(3-(trifluoromethyl)benzamido)-2,3-dihydro-1H-indene-1-carboxamide (S8). 
Semi-crude S7 (200.0 mg, 0.573 mmol, 1.0 equiv.) was taken up in DMF (5 mL) and 
N,N-diisopropylethylamine (100 uL, 0.573 mmol, 1.0 equiv.). HATU (283 mg, 0.744 
mmol, 1.3 equiv.) was then added; after 10m ammonium chloride (153 mg, 2.86 mmol, 
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5.0 equiv) was added, followed by N,N-diisopropylethylamine (600 uL, 3.44 mmol, 6.0 
equiv.). After stirring for 14h, the reaction mixture was transferred to a sep funnel with ~ 
125 mL EtOAc; the organic layer was washed with ~ 3 x 50 mL brine, dried over 
MgSO4, and concentrated under reduced pressure. Purified on a silica column with 50-
100% EtOAc:hexanes. Wet S8 (262.4 mg, 132%, wet with EtOAc) obtained as a white 
semi-solid (mixture of diastereomers). 1H NMR (400 MHz, CD3OD) δ = 8.18 (s, 1H), 
8.13 - 8.07 (m, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.68 - 7.62 (m, 1H), 7.42 - 7.34 (m, 2H), 
7.32 - 7.24 (m, 2H), 5.94 (t, J = 7.4 Hz, 0.5H), 5.68 (dd, J = 5.4, 7.8 Hz, 0.5H), 4.20 (dd, 
J = 3.7, 8.5 Hz, 0.5H), 4.06 (dd, J = 5.5, 7.9 Hz, 0.5H), 2.87 - 2.69 (m, 1H), 2.34 - 2.22 
(m, 1H); 13C NMR (100 MHz, CD3OD) δ = 179.19, 167.28, 145.15, 145.11, 143.35, 
143.14, 136.78, 136.61, 132.32 - 132.12 (m), 131.99 - 131.78 (m), 130.79, 130.68, 
129.66, 129.49, 129.42 - 129.18 (m), 125.77 (t, J = 1.8 Hz), 125.57, 125.53 - 125.32 
(m), 125.46 (q, J = 271.4 Hz), 125.44 (q, J = 271.4 Hz), 56.17, 55.29, 50.66, 50.55, 
38.99, 38.22; 19F NMR (376 MHz, CD3OD) δ = -64.10 (s, 3F), -64.13 (s, 1F); LRMS 
(ESI) calculated for C18H16F3N2O2 [M + H]+ m/z 349.12, found 350.06. 
 
 
 
N-(3-cyano-2,3-dihydro-1H-inden-1-yl)-3-(trifluoromethyl)benzamide (S9). Wet S7 
(262.4 mg, 0.753 mmol, 1.0 equiv.) was suspended with dry 1,4-dioxane (10 mL); 
pyridine (182 uL, 2.26 mmol, 3.0 equiv.) was then added, followed by dropwise addition 
of trifluoroacetic anhydride (314 ul, 2.26 mmol, 3.0 equiv.). After stirring for 14h, the 
crude reaction mixture was transferred to a sep funnel with ~ 120 mL EtOAc and ~ 20 
mL water. The organic layer was washed with 0.1 N HCl, water, and brine. Dried over 
H
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MgSO4, concentrated, and purified on a silica column with EtOAc:hexanes. S9 obtained 
as a white solid (169.0 mg, 68%) (mixture of diastereomers). 1H NMR (400 MHz, 
DMSO-d6) δ = 9.21 (d, J = 8.3 Hz, 0.6H), 9.13 (d, J = 7.8 Hz, 0.4H), 8.31 - 8.17 (m, 2H), 
7.97 - 7.88 (m, 1H), 7.80 - 7.69 (m, 1H), 7.53 - 7.29 (m, 4H), 5.75 - 5.61 (m, 1H), 4.71 
(dd, J = 5.6, 8.5 Hz, 0.4H), 4.52 (dd, J = 8.4, 9.4 Hz, 0.6H), 3.00 (td, J = 7.8, 12.2 Hz, 
0.6H), 2.74 (ddd, J = 5.6, 7.8, 13.4 Hz, 0.4H), 2.54 - 2.44 (m, 0.4H), 2.28 (td, J = 9.8, 
12.2 Hz, 0.6H); 13C NMR (100 MHz, DMSO-d6) δ = 164.79, 164.65, 143.12, 142.96, 
137.73, 137.19, 134.89, 134.84, 131.63, 129.71, 129.66, 128.69 (dd, J = 16.1, 38.9 Hz), 
128.14 - 127.86 (m), 125.19, 124.48, 124.37, 123.98 (q, J = 272.0 Hz), 125.50 - 122.48 
(m), 121.43, 121.20, 53.11, 52.71, 37.45, 37.11, 32.11, 31.22; 19F NMR (376 MHz, 
DMSO-d6) δ = -61.11 (s, 1.9F), -61.13 (s, 3F); LRMS (ESI) calculated for C18H14F3N2O 
[M + H]+ m/z 331.11, found 330.99. 
 
 
 
N-((syn)-3-(1H-tetrazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-3-
(trifluoromethyl)benzamide (3), N-((anti)-3-(1H-tetrazol-5-yl)-2,3-dihydro-1H-inden-
1-yl)-3-(trifluoromethyl)benzamide (4). A sealed tube was charged with S9 (153.6 mg, 
0.465 mmol, 1.0 equiv.), sodium azide (90.7 mg, 1.40 mmol, 3.0 equiv.), ammonium 
chloride (79.6 mg, 1.49 mmol, 3.2 equiv.), and DMF (9 mL). The tube was sealed and 
heated at 120 °C behind a blast shield for 14h. The crude reaction mixture was directly 
purified by reverse phase HPLC (water/MeOH/0.05% formic acid) to afford syn 3 (43.1 
mg, 25%) and anti 4 (77.3 mg, 45%) as white solids. 3: 1H NMR (400 MHz, CD3OD, 
drops CDCl3) δ = 8.15 (s, 1H), 8.05 (br d, J = 7.8 Hz, 1H), 7.74 (br d, J = 7.5 Hz, 1H), 
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7.61 - 7.54 (m, 1H), 7.47 - 7.40 (m, 1H), 7.33 - 7.23 (m, 2H), 7.16 (br d, J = 6.6 Hz, 1H), 
5.87 (br dd, J = 5.4, 7.3 Hz, 1H), 5.06 (br t, J = 7.2 Hz, 1H), 2.88 - 2.78 (m, 1H), 2.63 
(ddd, J = 5.1, 8.3, 13.6 Hz, 1H); 13C NMR (100 MHz, CD3OD, drops CDCl3) δ = 167.58, 
164.36, 143.29, 142.49, 135.53, 131.34, 129.68, 129.42, 129.02, 128.63 (br d, J = 2.9 
Hz), 125.58, 125.31, 125.01 (br s), 124.38 (q, J = 271.4 Hz), 54.76, 39.64, 39.23; 19F 
NMR (376 MHz, CD3OD, drops CDCl3) δ = -63.26 (s, 3F); LRMS (ESI) calculated for 
C18H13F3N5O [M - H]- m/z 372.11, found 372.02. 4: 1H NMR (400 MHz, CD3OD, drops 
CDCl3) δ = 8.22 (s, 1H), 8.13 (br d, J = 7.8 Hz, 1H), 7.76 (br d, J = 7.5 Hz, 1H), 7.61 (br 
t, J = 7.8 Hz, 1H), 7.41 (br d, J = 7.3 Hz, 1H), 7.31 - 7.19 (m, 2H), 7.06 (br d, J = 7.1 Hz, 
1H), 5.82 (br t, J = 6.9 Hz, 1H), 4.78 (br t, J = 7.4 Hz, 1H), 3.11 (td, J = 7.8, 13.4 Hz, 
1H), 2.40 (td, J = 6.8, 13.3 Hz, 1H); 13C NMR (100 MHz, CD3OD, drops CDCl3) δ = 
166.56, 160.44, 142.75, 141.51, 134.91, 130.94 (q, J = 32.3 Hz), 130.53, 129.20, 
128.57, 128.31, 128.20 - 127.92 (m), 124.58, 124.54 - 124.40 (m), 124.36, 123.81 (q, J 
= 272.2 Hz), 53.66, 39.00, 38.27; 19F NMR (376 MHz, CD3OD, drops CDCl3) δ = -63.35 
(s, 3F); LRMS (ESI) calculated for C18H13F3N5O [M - H]- m/z 372.11, found 372.02. 
 
 
 
methyl 3-((3-(trifluoromethyl)phenyl)sulfonamido)-2,3-dihydro-1H-indene-1-
carboxylate (S10). S2 (1.027 g, 4.09 mmol, 1.0 equiv.) was reacted with commercially 
available 3-(trifluoromethyl)benzenesulfonyl chloride in dry tetrahydrofuran (40 mL) and 
acetonitrile (20 mL) according to general procedure A. S10 (502.8 mg, 31%) obtained 
as a white solid (mixture of diastereomers). 1H NMR (400 MHz, CDCl3) δ = 8.25 - 8.09 
(m, 2H), 8.02 (d, J = 8.0 Hz, 0.5H), 7.90 - 7.82 (m, 1H), 7.70 (td, J = 7.6, 15.5 Hz, 1H), 
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7.63 - 7.57 (m, 0.5H), 7.44 (s, 0.3H), 7.40 (s, 0.3H), 7.37 - 7.31 (m, 1H), 7.30 - 7.20 (m, 
2H), 7.18 - 7.13 (m, 0.5H), 5.12 (t, J = 7.2 Hz, 0.5H), 4.97 (s, 0.3H), 4.94 (s, 0.3H), 4.96 
- 4.92 (m, 0.5H), 4.09 (dd, J = 3.4, 8.5 Hz, 0.5H), 3.94 (dd, J = 3.2, 7.8 Hz, 0.5H), 3.73 
(s, 1.5H), 3.67 (s, 1.5H), 2.67 (ddd, J = 3.5, 7.5, 13.5 Hz, 0.5H), 2.42 (td, J = 7.9, 14.1 
Hz, 0.5H), 2.07 - 1.96 (m, 1H); 13C NMR (100 MHz, CDCl3) δ = 174.91, 173.22, 146.69, 
146.03, 142.90, 142.54, 141.72, 139.90, 130.26, 130.18, 129.99, 129.89, 129.51, 
129.30, 129.07, 128.90, 128.70, 128.50, 127.98, 127.94, 125.48, 125.22, 124.79, 
124.54, 124.18 - 124.03 (m), 123.20, 123.16, 58.02, 57.72, 52.64, 52.28, 48.22, 47.89, 
37.61, 35.92; 19F NMR (376 MHz, CDCl3) δ = -62.79 (s, 1.5F), -62.81 (s, 1.5F); LRMS 
(ESI) calculated for C18H15F3NO4S [M - H]- m/z 398.07, found 397.99. 
 
 
 
3-((3-(trifluoromethyl)phenyl)sulfonamido)-2,3-dihydro-1H-indene-1-carboxylic 
acid (S11). S10 (484.7 mg, 1.21 mmol, 1.0 equiv.) was reacted in methanol (15 mL) 
with 1M lithium hydroxide (10 mL, 10 mmol, 8.24 equiv.) according to general procedure 
B. Semi-crude S11 (473.5 mg, 101%) obtained as a white solid (mixture of 
diastereomers). LRMS (ESI) calculated for C17H13F3NO4S [M - H]- m/z 384.05, found 
384.10. 
 
 
 
3-((3-(trifluoromethyl)phenyl)sulfonamido)-2,3-dihydro-1H-indene-1-carboxamide 
(S12). Semi-crude S11 (214.5 mg, 0.557 mmol, 1.0 equiv.) was taken up in DMF (5 mL) 
O
HO
H
N
S
CF3O O
O
H2N
H
N
S
CF3O O
 211 
and N,N-diisopropylethylamine (97 uL, 0.557 mmol, 1.0 equiv.). HATU (275 mg, 0.724 
mmol, 1.3 equiv.) was then added; after 10m ammonium chloride (149 mg, 2.78 mmol, 
5.0 equiv) was added, followed by N,N-diisopropylethylamine (582 uL, 3.34 mmol, 6.0 
equiv.). After stirring for 14h, the reaction mixture was transferred to a sep funnel with ~ 
125 mL EtOAc; the organic layer was washed with ~ 3 x 50 mL brine, dried over 
MgSO4, and concentrated under reduced pressure. Purified on a silica column with 
30% EtOAc:hexanes. S12 (130.4 mg, 61%) obtained as a yellow semi-solid (mixture of 
diastereomers). 1H NMR (400 MHz, CD3OD) δ = 8.28 - 8.23 (m, 2H), 8.02 (br d, J = 7.5 
Hz, 1H), 7.90 - 7.83 (m, 1H), 7.37 - 7.21 (m, 3H), 7.21 - 7.18 (m, 0.5H), 7.12 (d, J = 7.5 
Hz, 0.5H), 5.19 (t, J = 7.2 Hz, 0.5H), 4.93 (t, J = 7.1 Hz, 0.5H), 4.07 (dd, J = 3.5, 8.4 Hz, 
0.5H), 3.88 (t, J = 7.4 Hz, 0.5H), 2.48 (ddd, J = 3.7, 7.8, 13.1 Hz, 0.5H), 2.39 (td, J = 
7.7, 13.0 Hz, 0.5H), 2.07 - 1.96 (m, 0.5H), 1.96 - 1.87 (m, 0.5H); 13C NMR (100 MHz, 
CD3OD) δ = 178.90, 178.44, 145.00, 144.97, 144.19, 143.99, 142.77, 142.43, 132.72 
(q, J = 33.0 Hz), 131.80 (d, J = 2.9 Hz), 130.32 (t, J = 3.3 Hz), 129.71 (d, J = 2.2 Hz), 
129.18, 129.05, 125.76, 125.66 (d, J = 3.7 Hz), 125.38, 124.89 (q, J = 4.2 Hz), 125.02 
(q, J = 273.0 Hz), 59.53, 58.95, 50.22, 49.89, 39.32, 38.28; 19F NMR (376 MHz, 
CD3OD) δ = -64.24 (s, 3F), -64.25 (s, 3F); LRMS (ESI) calculated for C17H16F3N2O3S [M 
+ H]+ m/z 385.08, found 385.01. 
 
 
 
N-(3-cyano-2,3-dihydro-1H-inden-1-yl)-3-(trifluoromethyl)benzamide (S13). S12 
(130.4 mg, 0.339 mmol, 1.0 equiv.) was suspended with dry 1,4-dioxane (8 mL); 
pyridine (82 uL, 1.02 mmol, 3.0 equiv.) was then added, followed by dropwise addition 
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of trifluoroacetic anhydride (141 ul, 1.02 mmol, 3.0 equiv.). After stirring for 14h, the 
crude reaction mixture was transferred to a sep funnel with ~ 120 mL EtOAc and ~ 20 
mL water. The organic layer was washed with ~ 50 mL 0.1 N HCl, water, and brine. 
Dried over MgSO4, concentrated, and purified on a silica column with EtOAc:hexanes. 
S13 (92.7 mg, 75%) obtained as an off-white solid (mixture of diastereomers). 1H NMR 
(400 MHz, DMSO-d6) δ = 8.64 (d, J = 8.5 Hz, 0.5H), 8.55 (d, J = 8.3 Hz, 0.5H), 8.25 - 
8.17 (m, 1.5H), 8.15 - 8.06 (m, 1.5H), 7.95 - 7.87 (m, 1H), 7.45 - 7.32 (m, 2.5H), 7.32 - 
7.26 (m, 0.5H), 7.16 - 7.11 (m, 0.5H), 7.03 (d, J = 7.5 Hz, 0.5H), 4.98 (dt, J = 5.5, 7.9 
Hz, 0.5H), 4.91 - 4.82 (m, 0.5H), 4.55 (dd, J = 5.8, 8.5 Hz, 0.5H), 4.30 (dd, J = 8.3, 9.3 
Hz, 0.5H), 2.58 - 2.51 (m, 0.5H), 2.41 (ddd, J = 5.8, 7.5, 13.4 Hz, 0.5H), 2.15 (ddd, J = 
5.1, 8.4, 13.5 Hz, 0.5H), 1.87 (td, J = 9.6, 12.0 Hz, 0.5H); 13C NMR (100 MHz, DMSO-
d6) δ = 143.37, 142.21, 142.18, 137.67, 137.10, 131.63, 131.55, 131.00, 130.47 (d, J = 
35.9 Hz), 130.05 - 129.75 (m), 129.67, 129.32, 129.29, 129.10, 125.42, 125.08, 124.73, 
124.51, 123.65 - 123.40 (m), 123.93 (q, J = 272.9 Hz), 121.52, 121.29, 57.14, 56.75, 
38.67, 37.94, 32.25, 31.52; 19F NMR (376 MHz, DMSO-d6) δ = -61.38 (s, 3F), -61.41 (s, 
3F); LRMS (ESI) calculated for C17H12F3N2O2S [M - H]- m/z 365.06, found 365.03. 
 
 
 
N-((syn)-3-(1H-tetrazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-3-
(trifluoromethyl)benzenesulfonamide (5), N-((anti)-3-(1H-tetrazol-5-yl)-2,3-dihydro-
1H-inden-1-yl)-3-(trifluoromethyl)benzenesulfonamide (6). A sealed tube was 
charged with S13 (72.0 mg, 0.197 mmol, 1.0 equiv.), sodium azide (38.3 mg, 0.590 
mmol, 3.0 equiv.), ammonium chloride (33.6 mg, 0.629 mmol, 3.2 equiv.), and DMF (5 
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mL). The tube was sealed and heated at 120 °C behind a blast shield for 14h. The 
crude reaction mixture was directly purified by reverse phase HPLC 
(water/MeOH/0.05% formic acid) to afford syn 5 (20.3 mg, 25%) and anti 6 (30.4 mg, 
38%) as white solids. 5: 1H NMR (400 MHz, CD3OD) δ = 8.25 - 8.17 (m, 2H), 7.96 (d, J 
= 7.8 Hz, 1H), 7.84 - 7.78 (m, 1H), 7.25 - 7.14 (m, 2H), 7.11 - 7.03 (m, 2H), 5.17 (dd, J = 
5.4, 7.1 Hz, 1H), 4.91 - 4.86 (m, 1H), 2.56 (ddd, J = 6.1, 7.2, 13.2 Hz, 1H), 2.34 (ddd, J 
= 5.1, 8.3, 13.4 Hz, 1H); 13C NMR (100 MHz, CD3OD) δ = 167.08, 143.50, 142.37, 
141.84, 131.23 (q, J = 33.8 Hz), 130.31, 130.25, 128.77 (d, J = 3.7 Hz), 128.59, 127.73, 
124.59, 124.45, 123.52 - 123.29 (m), 123.53 (d, J = 272.2 Hz), 57.52, 39.87, 38.45; 19F 
NMR (376 MHz, CD3OD) δ = -64.28 (s, 3F); LRMS (ESI) calculated for C17H13F3N5O2S 
[M - H]- m/z 408.07, found 408.04. 6: 1H NMR (400 MHz, CD3OD) δ = 8.24 - 8.18 (m, 
2H), 7.92 (br d, J = 7.8 Hz, 1H), 7.81 - 7.73 (m, 1H), 7.24 - 7.13 (m, 3H), 6.93 (br d, J = 
6.8 Hz, 1H), 4.97 (t, J = 8.0 Hz, 1H), 4.58 (br t, J = 8.5 Hz, 1H), 2.65 (td, J = 7.3, 12.7 
Hz, 1H), 2.01 (td, J = 9.4, 12.4 Hz, 1H); 13C NMR (100 MHz, CD3OD) δ = 163.15, 
143.49, 142.07, 141.01, 131.26 (d, J = 33.0 Hz), 130.32, 128.88 (q, J = 3.7 Hz), 128.24, 
127.64, 123.99, 123.89, 123.42 (q, J = 3.7 Hz), 123.51 (d, J = 272.2 Hz), 57.01, 40.37, 
37.66; 19F NMR (376 MHz, CD3OD) δ = -64.28 (s, 3F); LRMS (ESI) calculated for 
C17H13F3N5O2S [M - H]- m/z 408.07, found 408.04. 
 
 
 
1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylic acid (S14). Commercially 
available indoline-3-carboxylic acid (100 mg, 0.613 mmol, 1.0 equiv.) was suspended 
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with dry dichloromethane (15 mL). N,N-diisopropylethylamine (267 uL, 1.53 mmol, 2.5 
equiv.) was then added, and the resulting solution was cooled to 0 °C. 3-
(trifluoromethyl)benzoyl chloride (111 ul, 0.735 mmol, 1.2 equiv.) was then added 
dropwise at 0 °C. The reaction mixture was allowed to warm to r.t. overnight. The 
solvent was then removed under reduced pressure and the reaction mixture redissolved 
in DMF; directly purified by reverse phase HPLC (water/MeOH/0.05% formic acid) to 
afford S14 (129.7 mg, 63%) as a white solid. 1H NMR (400 MHz, CD3OD) δ = 8.11 (br s, 
1H), 7.87 (br s, 1H), 7.80 (br d, J = 7.5 Hz, 2H), 7.69 - 7.61 (m, 1H), 7.45 (d, J = 7.5 Hz, 
1H), 7.22 (br s, 1H), 7.07 (br s, 1H), 4.33 (br s, 1H), 4.21 - 4.04 (m, 2H); 13C NMR (100 
MHz, CD3OD) δ = 174.46 (br s), 169.27 (br s), 143.60 - 143.03 (m), 139.01 (br s), 
132.29 (q, J = 33.0 Hz), 131.94 (br s), 130.95, 129.66 (br s), 128.34 (br s), 126.58 (br s), 
126.08 (br s), 125.29 (br s), 125.34 (q, J = 272.2 Hz), 119.03, 54.45 (br s), 46.84 (br s); 
19F NMR (376 MHz, CD3OD) δ = -64.08 (s, 3F); LRMS (ESI) calculated for C17H11F3NO3 
[M - H]- m/z 334.07, found 334.03. 
 
 
 
1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxamide (S15). S14 (129.7 mg, 0.387 
mmol, 1.0 equiv.) was dissolved with dry acetone (3.5 mL); ammonium bicarbonate (40 
mg, 0.503, 1.3 equiv.), pyridine (4 uL, 0.05 mmol, 0.13 equiv.), and di-tert-butyl 
dicarbonate (110 mg, 0.503 mmol, 1.3 equiv.) were then added. The reaction was 
stirred for 14h, at which point the acetone was removed under reduced pressure. The 
resulting residue was transferred to a sep funnel with ~ 75 mL EtOAc; washed with 
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dilute citric acid, water, and brine. Dried over MgSO4, concentrated, and purified on a 
silica column with 0-4% dichloromethane:MeOH. S15 (90.9 mg, 70%) obtained as a 
white solid. 1H NMR (400 MHz, CDCl3, drops CD3OD) δ = 8.12 (br s, 1H), 7.82 (br s, 
1H), 7.73 (br d, J = 5.1 Hz, 2H), 7.63 - 7.54 (m, 1H), 7.31 (br d, J = 7.3 Hz, 1H), 7.25 (br 
s, 1H), 7.07 (br s, 1H), 4.35 (br s, 1H), 4.09 (br s, 1H), 3.73 (br s, 1H); 13C NMR (100 
MHz, CDCl3, drops CD3OD) δ = 174.22 (br s), 167.81 (br s), 142.40 (br s), 137.32 (br s), 
131.44 (q, J = 33.7 Hz), 130.64 (br s), 129.64, 129.05 (br s), 127.52 (br s), 125.49 - 
124.01 (m), 53.95 (br s), 46.78 (br s); 19F NMR (376 MHz, CDCl3, drops CD3OD) δ = -
59.08 (s, 3F); LRMS (ESI) calculated for C17H14F3N2O2 [M + H]+ m/z 335.10, found 
335.01.  
 
 
 
1-(3-(trifluoromethyl)benzoyl)indoline-3-carbonitrile (S16). S15 (90.9 mg, 0.272 
mmol, 1.0 equiv.) was dissolved with dry 1,4-dioxane (7 mL); pyridine (66 uL, 0.816 
mmol, 3.0 equiv.) was then added, and the reaction mixture was cooled to 0 °C. 
trifluoroacetic anhydride (114 uL, 0.816 mmol, 3.0 equiv.) was then added dropwise, 
and the reaction mixture was allowed to slowly warm to r.t. After stirring for 14h, the 
crude reaction mixture was transferred to a sep funnel with ~ 120 mL EtOAc and ~ 20 
mL water. The organic layer was washed with ~ 50 mL 0.1 N HCl, water, and brine. 
Dried over MgSO4, concentrated, and purified on a silica column with EtOAc:hexanes. 
S16 (87.3 mg, 102%, wet with EtOAc) obtained as a white solid. 1H NMR (400 MHz, 
CD3OD, drops CDCl3) δ = 7.88 - 7.77 (m, 4H), 7.71 - 7.64 (m, 1H), 7.44 (d, J = 7.5 Hz, 
N
O
CF3
N
 216 
1H), 7.28 (br s, 1H), 7.21 - 7.14 (m, 1H), 4.60 (dd, J = 7.4, 9.1 Hz, 1H), 4.42 (br t, J = 
10.0 Hz, 1H), 4.31 - 4.22 (m, 1H); 13C NMR (100 MHz, CD3OD, drops CDCl3) δ = 
168.19, 142.23 (br s), 137.22 (br s), 131.96 (q, J = 32.8 Hz), 131.25 (br s), 130.34, 
130.25, 128.32 (br s), 127.54 (br s), 126.06 (br s), 125.63 (br s), 124.87 (br s), 124.33 
(q, J = 273.0 Hz), 119.28, 54.63 - 54.00 (m), 31.35 (br s); 19F NMR (376 MHz, CD3OD, 
drops CDCl3) δ = -63.62 (s, 3F); LRMS (ESI) calculated for C17H10F3N2O [M - H]- m/z 
315.08, found 314.96. 
 
 
 
(3-(1H-tetrazol-5-yl)indolin-1-yl)(3-(trifluoromethyl)phenyl)methanone (7). A sealed 
tube was charged with S16 (89.3 mg, 0.282 mmol, 1.0 equiv.), sodium azide (55 mg, 
0.847 mmol, 3.0 equiv.), ammonium chloride (48 mg, 0.904 mmol, 3.2 equiv.), and DMF 
(4 mL). The tube was sealed and heated at 140 °C behind a blast shield for 14h. The 
crude reaction mixture was directly purified by reverse phase HPLC 
(water/MeOH/0.05% formic acid) to afford 7 (56.5 mg, 56%) as a white solid. 1H NMR 
(400 MHz, DMSO-d6) δ = 8.15 (br s, 1H), 8.04 - 7.95 (m, 2H), 7.92 (br d, J = 7.8 Hz, 
1H), 7.81 - 7.73 (m, 1H), 7.29 (br s, 2H), 7.11 (br s, 1H), 5.12 (br dd, J = 6.8, 9.3 Hz, 
1H), 4.57 - 4.48 (m, 1H), 4.37 (br dd, J = 6.7, 10.3 Hz, 1H); 13C NMR (100 MHz, DMSO-
d6) δ = 166.45, 157.59, 142.00 (br s), 137.56 (br s), 131.68 (br s), 131.15 (br s), 129.90, 
129.40 (q, J = 32.0 Hz), 128.42, 127.00 (br s), 125.37 - 125.09 (m), 124.54 (br s), 
123.91 (br s), 123.86 (q, J = 272.4 Hz), 117.11 (br s), 55.09 - 54.49 (m), 36.25 - 35.49 
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(m); 19F NMR (376 MHz, DMSO-d6) δ = -61.18 (s, 3F); LRMS (ESI) calculated for 
C17H11F3N5O [M - H]- m/z 358.09, found 358.12. 
 
 
 
methyl indoline-3-carboxylate sulfate (S17). Commercially available indoline-3-
carboxylic acid (100 mg, 0.613 mmol, 1.0 equiv.) was dissolved in dry methanol (25 
mL). Sulfuric acid (37 uL, 0.674 mmol, 1.1 equiv.) was then added, and the reaction 
mixture was refluxed for 18h. The solvent was then removed under reduced pressure, 
and the residue dried under hivac overnight. Wet S17 (208.5 mg, 124%) obtained as a 
thick, brown oil. (Note: the free base is not stable; will spontaneously oxidize) 1H NMR 
(400 MHz, CD3OD) δ = 7.65 - 7.61 (m, 1H), 7.55 - 7.48 (m, 3H), 4.60 (dd, J = 5.2, 8.9 
Hz, 1H), 4.25 - 4.19 (m, 1H), 4.07 (dd, J = 8.8, 12.2 Hz, 1H), 3.61 (s, 3H); 13C NMR (100 
MHz, CD3OD) δ = 171.85, 137.11, 134.44, 131.53, 131.11, 127.67, 120.94, 55.30, 
53.56, 48.08; LRMS (ESI) calculated for C10H12NO2 [M + H]+ m/z 178.09, found 177.94. 
 
 
 
methyl 1-((3-(trifluoromethyl)phenyl)sulfonyl)indoline-3-carboxylate (S18). S17 
(208.5 mg, 0.757 mmol, 1.0 equiv.) was reacted with commercially available 3-
(trifluoromethyl)benzene sulfonyl chloride (1.5 equiv.) in dry DMF (5 mL) according to 
general procedure A, except 5.0 equiv. of N,N-diisopropylethylamine was used. S18 
(108.0 mg, 37%) obtained as a tan oil. 1H NMR (400 MHz, CDCl3) δ = 8.07 (s, 1H), 8.00 
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(d, J = 8.0 Hz, 1H), 7.81 (dd, J = 0.7, 8.5 Hz, 1H), 7.68 - 7.57 (m, 2H), 7.35 - 7.26 (m, 
2H), 7.05 (dt, J = 1.1, 7.6 Hz, 1H), 4.40 (dd, J = 5.8, 11.2 Hz, 1H), 4.20 - 4.12 (m, 1H), 
4.07 - 4.01 (m, 1H), 3.63 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 170.59, 140.97, 
137.97, 131.56 (q, J = 33.7 Hz), 130.38 (d, J = 1.5 Hz), 129.99 - 129.70 (m), 129.33, 
128.60, 125.89, 124.45 - 124.27 (m), 125.72 (d, J = 273.0 Hz), 121.65, 114.90, 52.55, 
51.71, 44.90; 19F NMR (376 MHz, CDCl3) δ = -62.94 (s, 3F); LRMS (ESI) calculated for 
C17H14F3NNaO4S [M + Na]+ m/z 408.05, found 408.04. 
 
 
 
1-((3-(trifluoromethyl)phenyl)sulfonyl)indoline-3-carboxylic acid (S19). S18 (108.0 
mg, 0.280 mmol, 1.0 equiv.) was reacted in methanol (4 mL) with 1M lithium hydroxide 
(3 mL, 3 mmol, 10.7 equiv.) according to general procedure B. Semi-crude S19 (101.2 
mg, 97%) obtained as a tan powder. 1H NMR (400 MHz, CD3OD, drops CDCl3) δ = 8.03 
- 7.96 (m, 2H), 7.84 (d, J = 7.8 Hz, 1H), 7.68 - 7.57 (m, 2H), 7.36 (d, J = 7.5 Hz, 1H), 
7.27 (t, J = 7.7 Hz, 1H), 7.04 (dt, J = 1.0, 7.5 Hz, 1H), 4.36 (dd, J = 5.8, 11.2 Hz, 1H), 
4.16 - 4.08 (m, 1H), 4.04 - 3.97 (m, 1H); 13C NMR (100 MHz, CD3OD, drops CDCl3) δ = 
173.20, 141.90, 138.75, 132.36 (q, J = 33.7 Hz), 131.52, 131.11, 130.91 (q, J = 3.2 Hz), 
130.59, 129.90, 126.92, 125.38, 125.10 (q, J = 3.9 Hz), 124.14 (q, J = 272.2 Hz), 
115.74, 52.93, 45.94; 19F NMR (376 MHz, CD3OD, drops CDCl3) δ = -63.89 (s, 3F); 
LRMS (ESI) calculated for C16H11F3NO4S [M - H]- m/z 370.04, found 370.04. 
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1-((3-(trifluoromethyl)phenyl)sulfonyl)indoline-3-carboxamide (S20). Semi-crude 
S19 (101.2 mg, 0.273 mmol, 1.0 equiv.) was dissolved with dry acetone (3.5 mL); 
ammonium bicarbonate (28 mg, 0.354, 1.3 equiv.), pyridine (4 uL, 0.05 mmol, 0.18 
equiv.), and di-tert-butyl dicarbonate (77 mg, 0.354 mmol, 1.3 equiv.) were then added. 
The reaction was stirred for 14h, at which point the acetone was removed under 
reduced pressure. The resulting residue was transferred to a sep funnel with ~ 75 mL 
EtOAc; washed with dilute citric acid, water, and brine. Dried over MgSO4, 
concentrated, and run on a silica column with 0-5% dichloromethane:MeOH. Attempts 
to fully clean up the product were unsuccessful; crude S20 (49.3 mg, est. 80% purity) 
obtained as an off-white solid. LRMS (ESI) calculated for C16H14F3N2O3S [M + H]+ m/z 
371.07, found 370.95. 
 
 
 
1-((3-(trifluoromethyl)phenyl)sulfonyl)indoline-3-carbonitrile (S21). Crude S20 (101 
mg, 0.272 mmol, 1.0 equiv.) was suspended with dry 1,4-dioxane (8 mL); pyridine (66 
uL, 0.817 mmol, 3.0 equiv.) was then added, followed by dropwise addition of 
trifluoroacetic anhydride (114 uL, 0.817 mmol, 3.0 equiv.). After stirring for 14h, the 
crude reaction mixture was transferred to a sep funnel with ~ 120 mL EtOAc and ~ 20 
mL water. The organic layer was washed with ~ 50 mL 0.1 N HCl, water, and brine. 
Dried over MgSO4, concentrated, and purified on a silica column with 0-25% 
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EtOAc:hexanes. S21 (37.0 mg, 39% over two steps) obtained as a white solid. 1H NMR 
(400 MHz, CD3OD) δ = 8.07 (d, J = 8.0 Hz, 1H), 8.00 (s, 1H), 7.97 - 7.93 (m, 1H), 7.76 - 
7.68 (m, 2H), 7.45 - 7.39 (m, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.18 (dt, J = 1.0, 7.5 Hz, 1H), 
4.40 - 4.35 (m, 1H), 4.35 - 4.28 (m, 1H), 4.23 - 4.16 (m, 1H); 13C NMR (100 MHz, 
CD3OD) δ = 142.31, 138.84, 132.73 (q, J = 33.8 Hz), 132.00, 131.91, 131.65 (q, J = 3.4 
Hz), 131.22, 128.71, 126.72, 126.66, 125.15 (q, J = 3.9 Hz), 124.51 (q, J = 272.2 Hz), 
119.42, 117.38, 54.37, 31.55; 19F NMR (376 MHz, CD3OD) δ = -64.51 (s, 3F); LRMS 
(ESI) calculated for C16H10F3N2O2S [M - H]+ m/z 351.04, found 350.29.  
 
 
 
3-(1H-tetrazol-5-yl)-1-((3-(trifluoromethyl)phenyl)sulfonyl)indoline (8). A sealed 
tube was charged with S21 (37.0 mg, 0.105 mmol, 1.0 equiv.), sodium azide (20.5 mg, 
0.315 mmol, 3.0 equiv.), ammonium chloride (18 mg, 0.336 mmol, 3.2 equiv.), and DMF 
(4 mL). The tube was sealed and heated at 120 °C behind a blast shield for 14h. The 
crude reaction mixture was directly purified by reverse phase HPLC 
(water/MeOH/0.05% formic acid) to afford 8 (25.1 mg, 61%) as a white solid. 1H NMR 
(400 MHz, DMSO-d6) δ = 8.16 (br d, J = 7.8 Hz, 1H), 8.08 (br d, J = 8.0 Hz, 1H), 8.04 (s, 
1H), 7.82 (t, J = 7.8 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.34 (t, J = 7.7 Hz, 1H), 7.20 (br d, 
J = 7.3 Hz, 1H), 7.11 - 7.04 (m, 1H), 4.96 (br dd, J = 6.8, 9.3 Hz, 1H), 4.52 (t, J = 10.3 
Hz, 1H), 4.34 (dd, J = 6.6, 11.0 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) δ = 161.69, 
140.45, 136.99, 131.41 - 131.09 (m), 130.90, 130.75 (d, J = 2.9 Hz), 130.08 (d, J = 33.0 
Hz), 129.22, 125.94, 124.68, 123.65 (d, J = 3.7 Hz), 123.15 (d, J = 272.9 Hz), 114.46, 
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54.22, 35.30; 19F NMR (376 MHz, DMSO-d6) δ = -61.50 (s, 3F); LRMS (ESI) calculated 
for C16H11F3N5O2S [M - H]- m/z 394.06, found 393.83. 
 
 
 
N-(1H-tetrazol-5-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxamide (9). S14 
(342.3 mg, 1.02 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate in 50 
mL dichloromethane according to general procedure C. 9 (91.2 mg, 22%) obtained as a 
white solid. Note: Unstable long-term at r.t. or in solution; store cold. 1H NMR (400 MHz, 
DMSO-d6) δ = 12.13 (br s, 1H), 8.34 - 7.66 (br m, 5H), 7.61 - 6.98 (br m, 3H), 4.68 - 
4.12 (br m, 3H); 13C NMR (100 MHz, DMSO-d6) δ = 170.40, 166.83, 163.62, 152.17 (br 
s), 142.82 (br s), 138.21, 131.55 (br s), 130.44 (br s), 129.85 (br d, J = 35.2 Hz), 128.98 
(br s), 127.46 (br s), 125.71 (br s), 125.53 (br s), 124.83 (br s), 124.25 (br s), 117.76 (br 
s), 53.45 (br s), 46.49 (br s); 19F NMR (376 MHz, DMSO-d6) δ = -61.16 (s, 3F); LRMS 
(ESI) calculated for C18H12F3N6O2 [M - H]- m/z 401.10, found 400.99. 
 
 
 
N-(1H-tetrazol-5-yl)-1-((3-(trifluoromethyl)phenyl)sulfonyl)indoline-3-carboxamide 
(10). Semi-crude S19 (130 mg, 0.350 mmol, 1.0 equiv.) was reacted with 5-
aminotetrazole monohydrate in 3.5 mL DMF according to general procedure D (20m 
activation). 10 (20.8 mg, 14%) obtained as a white solid. Note: Unstable long-term at r.t. 
or in solution; store cold. 1H NMR (400 MHz, DMSO-d6) δ = 12.48 - 11.87 (br s, 1H), 
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8.19 (br d, J = 7.8 Hz, 1H), 8.10 (br d, J = 7.5 Hz, 1H), 8.04 (s, 1H), 7.86 (br t, J = 7.8 
Hz, 1H), 7.54 (br d, J = 8.0 Hz, 1H), 7.38 - 7.27 (m, 2H), 7.10 - 7.02 (m, 1H), 4.40 - 4.27 
(m, 2H), 4.27 - 4.17 (m, 1H); 13C NMR (100 MHz, DMSO-d6) δ = 169.20, 163.04, 
140.72, 137.04, 131.34, 131.19, 130.71 (br d, J = 3.6 Hz), 130.14 (d, J = 5.3 Hz), 
129.13, 125.57, 124.26, 123.74 - 123.38 (m), 123.17 (d, J = 273.1 Hz), 113.98, 52.22, 
45.40; 19F NMR (376 MHz, DMSO-d6) δ = -61.46 (s, 3F); LRMS (ESI) calculated for 
C17H12F3N6O3S [M - H]- m/z 437.06, found 437.12. 
 
 
 
methyl 1,2,3,4-tetrahydroisoquinoline-4-carboxylate sulfate (S22). Commercially 
available 1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid (200 mg, 1.13 mmol, 1.0 
equiv.) was dissolved in dry methanol (25 mL). Sulfuric acid (69 uL, 1.24 mmol, 1.1 
equiv.) was then added, and the reaction mixture was refluxed for 18h. The solvent was 
then removed under reduced pressure, and the residue dried under hivac overnight. 
Wet S22 (429.5 mg, 132%) obtained as a thick, tan oil. 1H NMR (400 MHz, CD3OD) δ = 
7.48 - 7.42 (m, 1H), 7.33 - 7.27 (m, 2H), 7.26 - 7.20 (m, 1H), 4.39 (s, 2H), 4.20 (t, J = 
4.4 Hz, 1H), 3.88 (dd, J = 3.7, 13.1 Hz, 1H), 3.72 (s, 3H), 3.53 (dd, J = 5.2, 13.0 Hz, 
1H); 13C NMR (100 MHz, CD3OD) δ = 173.23, 130.51, 129.46, 129.34, 129.31, 129.16, 
128.03, 55.09, 45.29, 43.88, 41.33; LRMS (ESI) calculated for C11H14NO2 [M + H]+ m/z 
192.10, found 191.91. 
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methyl 2-(3-(trifluoromethyl)benzoyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxylate 
(S23). S22 (215.2 mg, 0.744 mmol, 1.1 equiv.) was reacted with commercially available 
3-(trifluoromethyl)benzoyl chloride in dry DMF (5 mL) according to general procedure A, 
with slight modification: prior to base addition, the reaction vessel was cooled to 0 °C; 
5.0 equiv of N,N-diisopropylethylamine was used, and allowed to stir at 0 °C for 5m; 
after acyl chloride addition, the reaction mixture was allowed to slowly warm to r.t. S23 
(188.9 mg, 77%) obtained as a colorless oil. Note: Diastereomers from the 
atropisomers of the secondary amide observable by NMR. 1H NMR (400 MHz, CDCl3) δ 
= 7.73 - 7.65 (m, 2H), 7.61 (br d, J = 6.8 Hz, 1H), 7.57 - 7.50 (m, 1H), 7.22 (br s, 3H), 
6.94 (br s, 1H), 5.13 (br s, 1H), 4.62 (br s, 2H), 4.10 (br s, 1H), 3.96 (br s, 1H), 3.84 - 
3.54 (m, 3H); 13C NMR (100 MHz, CDCl3) δ = 171.83 (br s), 169.27 (br s), 136.53 (br s), 
132.27 (br s), 130.74 (q, J = 33.0 Hz), 130.21, 128.91 (d, J = 2.2 Hz), 127.71 (br s), 
126.80 (br s), 126.32 (br s), 123.90 (q, J = 3.9 Hz), 123.51 (q, J = 272.9 Hz), 52.14, 
49.26 (br s), 46.18 (br s), 44.20 (br s), 42.31 (br s); 19F NMR (376 MHz, CDCl3) δ = -
62.71 (s, 3F); LRMS (ESI) calculated for C19H17F3NO3 [M + H]+ m/z 364.12, found 
363.96.  
 
 
 
2-(3-(trifluoromethyl)benzoyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid 
(S24). S23 (98.5 mg, 0.271 mmol, 1.0 equiv.) was reacted in methanol (4 mL) with 1M 
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lithium hydroxide (4 mL, 4 mmol, 14.8 equiv.) according to general procedure B, except 
the reaction was cooled to 0 °C prior to hydroxide addition, and allowed to slowly warm 
to r.t. Semi-crude S24 (89.6 mg, 95%) obtained as a colorless oil. Note: Diastereomers 
from the atropisomers of the secondary amide observable by NMR.  1H NMR (400 MHz, 
CD3OD, CDCl3) δ = 7.84 - 7.60 (m, 4H), 7.34 - 7.18 (m, 3H), 6.98 (br s, 1H), 5.19 (br d, 
J = 17.3 Hz, 0.4H), 4.92 (br s, 0.6H), 4.76 (br d, J = 9.7 Hz, 0.4H), 4.58 (br s, 0.6H), 
4.13 (br s, 0.4H), 3.98 (br s, 0.4H), 3.80 (br s, 0.6H), 3.76 - 3.56 (m, 0.6H); 13C NMR 
(100 MHz, CD3OD, CDCl3) δ = 173.00, 172.53, 169.79 (br s), 165.90, 135.88 (br s), 
132.04, 131.43, 130.76 (br d, J = 30.8 Hz), 129.89 - 129.25 (m), 128.56 - 127.95 (m), 
126.65, 125.91 - 125.25 (m), 125.15 (br d, J = 3.7 Hz), 123.23 - 122.59 (m), 123.01 (d, J 
= 273.0 Hz), 48.46 (br s), 45.68 (br s), 43.44, 41.51 (br s); 19F NMR (376 MHz, CD3OD, 
CDCl3) δ = -63.98 (br s, 3F), -64.04 (br s, 1.7F); LRMS (ESI) calculated for C18H13F3NO3 
[M - H]- m/z 348.09, found 348.23.  
 
 
 
N-(1H-tetrazol-5-yl)-2-(3-(trifluoromethyl)benzoyl)-1,2,3,4-tetrahydroisoquinoline-4-
carboxamide (11). Semi-crude S24 (89.6 mg, 0.257 mmol, 1.0 equiv.) was reacted with 
5-aminotetrazole monohydrate (1.5 equiv.) in 4 mL DMF according to general procedure 
D (10m activation), except 3.0 equiv. N,N-diisopropylethylamine was added initially, with 
no second addition. 11 (29.0 mg, 27%) obtained as a white solid. Note: Diastereomers 
from the atropisomers of the secondary amide observable by NMR. 1H NMR (400 MHz, 
DMF-d7) δ = 7.83 (br s, 4H), 7.67 - 7.06 (br m, 4H), 5.22 (br s, 1H), 4.77 (br s, 1H), 4.59 
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- 4.33 (br m, 1H), 4.15 (br s, 1H), 3.97 (br s, 1H); 19F NMR (376 MHz, DMF-d7) δ = -
62.96 (s, 3F), -63.04 (s, 3F); LRMS (ESI) calculated for C19H14F3N6O2 [M - H]- m/z 
415.11, found 415.26. 
 
 
 
methyl 2-(3-(trifluoromethyl)benzoyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxylate 
(S25). S22 (212.4 mg, 0.734 mmol, 1.1 equiv.) was reacted with commercially available 
3-(trifluoromethyl)benzenesulfonyl chloride in dry DMF (5 mL) according to general 
procedure A, with slight modification: prior to base addition, the reaction vessel was 
cooled to 0 °C; 5.0 equiv of N,N-diisopropylethylamine was added and allowed to stir at 
0 °C for 5m; after acyl chloride addition, the reaction mixture was allowed to slowly 
warm to r.t. S25 (206.6 mg, 78%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) 
δ = 8.09 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 7.8 Hz, 1H), 7.72 - 7.65 (m, 1H), 
7.24 - 7.15 (m, 3H), 7.09 - 7.04 (m, 1H), 4.41 (d, J = 15.1 Hz, 1H), 4.23 (d, J = 15.1 Hz, 
1H), 3.97 (dd, J = 5.2, 12.1 Hz, 1H), 3.92 - 3.88 (m, 1H), 3.69 (s, 3H), 3.41 (dd, J = 4.6, 
11.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ = 171.45, 137.92, 131.58 (q, J = 33.7 Hz), 
131.15, 130.71, 129.95, 129.90, 129.47 (q, J = 3.4 Hz), 129.22, 127.57, 127.01, 126.33, 
124.35 (q, J = 4.2 Hz), 123.00 (q, J = 273.0 Hz), 52.30, 47.13, 45.42, 44.24; 19F NMR 
(376 MHz, CDCl3) δ = -62.75 (s, 3F); LRMS (ESI) calculated for C18H17F3NO4S [M + H]+ 
m/z 400.08, found 399.98. 
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2-((3-(trifluoromethyl)phenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxylic 
acid (S26). S25 (108.5 mg, 0.272 mmol, 1.0 equiv.) was reacted in methanol (4 mL) 
with 1M lithium hydroxide (4 mL, 4 mmol, 14.7 equiv.) according to general procedure 
B, except the reaction was cooled to 0 °C prior to hydroxide addition, and allowed to 
slowly warm to r.t. Semi-crude S26 (91.2 mg, 87%) obtained as a white solid. 1H NMR 
(400 MHz, CD3OD, CDCl3) δ = 8.10 - 8.05 (m, 2H), 7.91 (d, J = 7.8 Hz, 1H), 7.80 - 7.72 
(m, 1H), 7.25 - 7.14 (m, 3H), 7.11 - 7.06 (m, 1H), 4.41 (d, J = 15.3 Hz, 1H), 4.16 (d, J = 
15.3 Hz, 1H), 4.00 (dd, J = 5.0, 12.1 Hz, 1H), 3.86 (t, J = 4.9 Hz, 1H), 3.37 (dd, J = 4.9, 
12.2 Hz, 1H); 13C NMR (100 MHz, CD3OD, CDCl3) δ = 174.94, 139.27, 132.76, 132.83 
(q, J = 33.0 Hz), 132.35, 131.90, 131.69, 130.96 (q, J = 3.4 Hz), 130.74, 128.68, 
128.18, 127.58, 125.56 (q, J = 4.2 Hz), 124.65 (q, J = 272.2 Hz), 48.64, 47.15, 45.62; 
19F NMR (376 MHz, CD3OD, CDCl3) δ = -63.81 (s, 3F); LRMS (ESI) calculated for 
C17H13F3NO4S [M - H]- m/z 384.05, found 384.02. 
 
 
 
N-(1H-tetrazol-5-yl)-2-((3-(trifluoromethyl)phenyl)sulfonyl)-1,2,3,4-
tetrahydroisoquinoline-4-carboxamide (12). Semi-crude S26 (91.2 mg, 0.237 mmol, 
1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.5 equiv.) in 4 mL DMF 
according to general procedure D (10m activation), except 3.0 equiv. N,N-
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diisopropylethylamine was added initially, with no second addition. 12 (16.3 mg, 15%) 
obtained as a white solid. 1H NMR (400 MHz, DMF-d7) δ = 8.52 - 7.69 (m, 4H), 7.28 (br 
s, 4H), 4.78 - 4.19 (m, 3H), 4.11 (br s, 1H), 3.64 (br s, 1H); 19F NMR (376 MHz, DMF-
d7) δ = -62.64 (s, 3F); LRMS (ESI) calculated for C18H14F3N6O3S [M - H]- m/z 451.08, 
found 450.90. 
 
 
 
1-(tert-butyl) 3-methyl indoline-1,3-dicarboxylate (S27). Commercially available 
methyl indole-3-carboxylate (6.500 g, 37.1 mmol, 1.0 equiv.) and sodium hydride (60% 
in mineral oil) (2.226 g, 55.7 mmol, 1.5 equiv.) were placed in a 200 mL round bottom 
flask and cooled to 0 °C with an ice bath. Dry tetrahydrofuran (55 mL) was slowly added 
under Ar with stirring. After 30 minutes of cooling, di-tert-butyl dicarbonate (12.147 g, 
55.7 mmol, 1.5 equiv.) was added in two portions at 0 °C, solidifying the solution. 
Additional dry tetrahydrofuran (100 mL) was subsequently added; stirred at r.t for 1.5h, 
then heated to 65 °C for 14h. The reaction mixture was quenched with a slow addition 
of ~ 20 mL sat. NH4Cl -- the crude reaction slurry was transferred to a sep. funnel with ~ 
500 mL ether, and the organic layer was washed with 3 x 500 mL water. The ether layer 
was dried over MgSO4, filtered, and concentrated; dried under hivac overnight. The 
resulting tan powder was dissolved in methanol (750 mL) and EtOAc (250 mL) and 
hydrogenated for 14d using an “H-Cube” flow hydrogenator with a 10% Pd/C cartridge; 
1 mL/min, 60 bar H2, 50 °C, loop configuration. (Note: During this period the cartridge 
was replaced three times. Slurry hydrogenation sans EtOAc is likely a better option.) 
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After completion of the hydrogenation, the system was purged with methanol and the 
combined mixture concentrated under reduced pressure. Purified directly on a silica 
column with 0-3% dichloromethane:methanol. S27 (7.590 g, 74%) obtained as colorless 
oil. (Note: will slowly oxidize back to indole, store cold) 1H NMR (400 MHz, CDCl3) δ = 
7.89 (br s, 1H), 7.36 (d, J = 7.5 Hz, 1H), 7.24 (t, J = 7.8 Hz, 1H), 6.97 (t, J = 7.4 Hz, 1H), 
4.39 (br dd, J = 5.8, 11.0 Hz, 1H), 4.26 - 4.19 (m, 1H), 4.19 - 4.06 (m, 1H), 3.79 (s, 3H), 
1.58 (br s, 9H); 13C NMR (100 MHz, CDCl3) δ = 171.90, 152.06 (br), 142.00 (br), 
128.95, 127.44 (br), 125.08 (br), 122.25, 114.92, 80.93 (br), 52.57, 49.77, 44.70 (br), 
28.40; LRMS (ESI) calculated for C15H19NNaO4 [M + Na]+ m/z 300.12, found 299.98. 
 
 
 
1-(tert-butyl) 3-methyl indoline-1,3-dicarboxylate (S28). S27 (202.7 mg, 0.731 mmol, 
1.0 equiv.) was dissolved in dry tetrahydrofuran (15 mL) and cooled to -78 °C. n-butyl 
lithium (434 ul, 0.694 mmol, 0.95 equiv.) (1.6M in hexanes) was then added dropwise to 
the solution -- stirred for 60 min at -78 °C. Separately, iodomethane was passed over a 
plug of activated alumina under Ar; iodomethane (137 ul, 2.19 mmol, 3.0 equiv.) was 
then added dropwise at -78 °C. Allowed to slowly warm to r.t. over 14h. Quenched with 
2 mL sat NH4Cl and transferred to a sep. funnel; diluted with sat. NH4Cl and extracted 
with 3 x ~ 30mL EtOAc. Organics were combined, washed with ~ 50 mL sat. NaHCO3 
and brine, dried over MgSO4, and concentrated. Purified on a silica column with 0-5% 
EtOAc:hexanes. S28 (65.1 mg, 31%) obtained as a light tan oil. Note: Atropisomers of 
the secondary carbamate observable by NMR; caused extensive peak broadening.  1H 
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NMR (400 MHz, CDCl3) δ = 7.87 (br s, 0.6H), 7.50 (br s, 0.4H), 7.31 (d, J = 7.5 Hz, 1H), 
7.23 (t, J = 7.7 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 4.58 (br d, J = 11.4 Hz, 1H), 3.72 (br s, 
4H), 1.60 (s, 3H), 1.58 (br s, 9H); 13C NMR (100 MHz, CDCl3) δ = 174.34, 152.11 (br), 
141.96 (br), 134.07 (br), 128.83, 123.95 (br), 122.38, 114.77, 80.86 (br), 57.91 (br), 
52.65, 49.74 (br s), 28.38, 25.58 (br); LRMS (ESI) calculated for C16H21NNaO4 [M + 
Na]+ m/z 314.14, found 313.94. 
 
 
 
methyl 3-methylindoline-3-carboxylate hydrochloride (S29). S28 (65.1 mg, 0.223 
mmol, 1.0 equiv.) was reacted with 4M HCl in dioxanes (4 mL) according to general 
procedure E (20h). Semi-crude S29 (62.4 mg, 123%) obtained as a colorless semi-
solid. 1H NMR (400 MHz, CD3OD) δ = 7.65 - 7.60 (m, 1H), 7.60 - 7.52 (m, 3H), 4.47 (d, 
J = 11.9 Hz, 1H), 3.74 (s, 3H), 3.68 (d, J = 5.1 Hz, 1H), 1.74 (s, 3H); 13C NMR (100 
MHz, CD3OD) δ = 174.12, 139.70, 136.99, 131.88, 131.39, 126.67, 120.93, 56.13, 
53.98, 53.84, 23.41; LRMS (ESI) calculated for C11H14NO2 [M + H]+ m/z 192.10, found 
191.89. 
 
 
 
methyl 3-methyl-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylate (S30). Semi-
crude S29 (62.4 mg, 0.274 mmol, 1.0 equiv.) was reacted with commercially available 
3-(trifluoromethyl)benzoyl chloride in dry dichloromethane (5 mL) according to general 
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procedure A, with slight modification: prior to base addition, the reaction vessel was 
cooled to 0 °C; 2.5 equiv. of N,N-diisopropylethylamine was used, and allowed to stir at 
0 °C for 5m; after acyl chloride addition, the reaction mixture was allowed to slowly 
warm to r.t. S30 (70.3 mg, 71%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) 
δ = 8.19 (br s, 1H), 7.87 (s, 1H), 7.82 - 7.73 (m, 2H), 7.65 - 7.58 (m, 1H), 7.40 (d, J = 
7.8 Hz, 1H), 7.27 (br s, 1H), 7.12 (br s, 1H), 4.70 (br d, J = 9.7 Hz, 1H), 3.76 (br s, 1H), 
3.72 (s, 3H), 1.62 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 173.59, 167.09, 141.49 (br s), 
137.25 (br s), 134.69 (br s), 131.19 (q, J = 33.0 Hz), 130.47 (br s), 129.27, 128.85 (br d, 
J = 2.9 Hz), 127.14 (br s), 124.87 - 124.56 (m), 124.45 - 123.81 (m), 123.59 (q, J = 
272.4 Hz), 117.77 (br s), 60.44 (br s), 52.82, 50.53 (br s), 24.05; LRMS (ESI) calculated 
for C19H17F3NO3 [M + H]+ m/z 364.12, found 363.84. 
 
 
 
3-methyl-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylic acid (S31). S30 (67.0 
mg, 0.193 mmol, 1.0 equiv.) was reacted in methanol (5 mL) with 1M lithium hydroxide 
(5 mL, 5 mmol, 26 equiv.) according to general procedure B, except the reaction was 
cooled to 0 °C prior to hydroxide addition, and allowed to slowly warm to r.t. Semi-crude 
S31 (67.0 mg, 99%) obtained as a white solid. 1H NMR (400 MHz, CD3OD) δ = 8.15 (br 
s, 1H), 8.01 - 7.83 (m, 3H), 7.78 - 7.70 (m, 1H), 7.49 (br d, J = 7.5 Hz, 1H), 7.29 (br s, 
1H), 7.16 (br s, 1H), 4.67 (br s, 1H), 3.82 (br d, J = 9.0 Hz, 1H), 1.59 (br s, 3H); LRMS 
(ESI) calculated for C18H13F3NO3 [M - H]- m/z 348.09, found 347.96. 
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3-methyl-N-(1H-tetrazol-5-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxamide 
(13). Semi-crude S31 (67.0 mg, 0.192 mmol, 1.0 equiv.) was reacted with 5-
aminotetrazole monohydrate (1.1 equiv.) in 4 mL DMF according to general procedure 
D (10m activation). 13 (25.6 mg, 32%) obtained as a white solid. 1H NMR (400 MHz, 
CD3OD) δ = 8.14 (br s, 1H), 8.00 - 7.82 (m, 3H), 7.76 - 7.68 (m, 1H), 7.54 (br d, J = 6.8 
Hz, 1H), 7.31 (br s, 1H), 7.18 (br s, 1H), 4.72 (br d, J = 8.3 Hz, 1H), 3.97 (br d, J = 10.0 
Hz, 1H), 1.73 (br s, 3H); LRMS (ESI) calculated for C19H14F3N6O2 [M - H]- m/z 415.11, 
found 415.04. 
 
 
 
methyl indoline-3-carboxylate hydrochloride (S32). S27 (782.4 mg, 2.82 mmol, 1.0 
equiv.) was reacted with 4M HCl in dioxanes (10 mL) according to general procedure E 
(20h). Semi-crude S32 (595.6 mg, 99%) obtained as a light pink foam. Note: Unstable; 
will spontaneously oxidize. Store cold. 1H NMR (400 MHz, CD3OD) δ = 7.66 - 7.60 (m, 
1H), 7.56 - 7.45 (m, 3H), 4.60 (dd, J = 5.1, 8.8 Hz, 1H), 4.21 (dd, J = 5.4, 12.2 Hz, 1H), 
4.06 (dd, J = 8.8, 12.2 Hz, 1H), 3.76 (s, 3H); 13C NMR (100 MHz, CD3OD) δ = 171.80, 
137.08, 134.46, 131.51, 131.12, 127.71, 121.00, 53.65, 48.11; LRMS (ESI) calculated 
for C10H12NO2 [M + H]+ m/z 178.09, found 177.94. 
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methyl 1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylate (S33). Semi-crude S32 
(595.6 mg, 2.79 mmol, 1.0 equiv.) was reacted with commercially available 3-
(trifluoromethyl)benzoyl chloride in dry dichloromethane (25 mL) according to general 
procedure A, with slight modification: prior to base addition, the reaction vessel was 
cooled to 0 °C; 2.5 equiv. of N,N-diisopropylethylamine was used, and allowed to stir at 
0 °C for 5m; after acyl chloride addition, the reaction mixture was allowed to slowly 
warm to r.t. S33 (889.5 mg, 91%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) 
δ = 8.18 (br s, 1H), 7.84 (s, 1H), 7.73 (br dd, J = 8.3, 11.2 Hz, 2H), 7.60 - 7.52 (m, 1H), 
7.40 (d, J = 7.8 Hz, 1H), 7.20 (br s, 1H), 7.06 (br d, J = 6.3 Hz, 1H), 4.45 (br s, 1H), 4.23 
- 4.15 (m, 1H), 4.08 (br s, 1H), 3.71 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 170.99, 
166.89 (br s), 141.84 (br s), 137.13 (br s), 130.87 (q, J = 33.0 Hz), 130.25 (br s), 129.11, 
128.63 (br s), 126.89 (br s), 125.14 (br s), 124.37 (br s), 123.97 (br s), 123.45 (q, J = 
272.9 Hz), 117.35 (br s), 60.05, 52.39, 45.02 (br s); 19F NMR (376 MHz, CDCl3) δ = -
62.78 (s, 3F); LRMS (ESI) calculated for C18H14F3NNaO3 [M + Na]+ m/z 372.08, found 
371.94.  
 
 
 
methyl 3-phenyl-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylate (S34). S33 
(213.8 mg, 0.612 mmol, 1.0 equiv.) was dissolved in dry tetrahydrofuran (10 mL) and 
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cooled to -78 °C. LHMDS (581 uL, 0.581 mmol, 0.95 equiv.) (1M in tetrahydrofuran) was 
then added dropwise to the solution -- stirred at -78 °C. Separately, diphenyliodonium 
trifluoromethanesulfonate (316 mg, 0.734 mmol, 1.2 equiv.) was suspended in dry 
dichloromethane (6 mL) and cooled to -78 °C. After 90 minutes of enolization, the 
suspension was cannulated over at -78 °C and the reaction was allowed to slowly warm 
to r.t. over 16h. Quenched with 2 mL sat NH4Cl and transferred to a sep. funnel; diluted 
with sat. NH4Cl and extracted with 3 x ~ 30 mL EtOAc. Organics were combined, 
washed with ~ 50 mL sat. NaHCO3 and brine, dried over MgSO4, and concentrated. 
Purified on a silica column with 0-15% EtOAc:hexanes. S34 (26.7 mg, 10%) obtained as 
a waxy white solid. 1H NMR (400 MHz, CDCl3) δ = 8.26 (br s, 1H), 7.81 (s, 1H), 7.77 - 
7.71 (m, 2H), 7.57 (dd, J = 7.9, 17.9 Hz, 2H), 7.37 - 7.29 (m, 4H), 7.21 (br t, J = 7.1 Hz, 
1H), 7.11 (br d, J = 6.6 Hz, 2H), 5.03 (br d, J = 11.2 Hz, 1H), 3.98 (br s, 1H), 3.77 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ = 172.22, 167.10, 142.74 (br s), 141.07, 137.13 (br 
s), 131.21 (q, J = 33.0 Hz, 1C), 130.43 (br s), 129.44 (br s), 129.22, 128.95, 127.87, 
127.18 (br s), 126.51, 124.80 (br s), 124.37 (br s), 123.58 (q, J = 274.1 Hz), 117.69 (br 
s), 62.19 (br s), 60.36 (br s), 53.13; 19F NMR (376 MHz, CDCl3) δ = -62.78 (s, 3F); 
LRMS (ESI) calculated for C24H19F3NO3 [M + H]+ m/z 426.13, found 425.97. 
 
 
 
3-phenyl-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylic acid (S35). S34 (26.7 
mg, 0.063 mmol, 1.0 equiv.) was reacted in methanol (4 mL) with 1M lithium hydroxide 
(3 mL, 3 mmol, 48 equiv.) according to general procedure B. Semi-crude S35 (25.3 mg, 
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98%) obtained as a white solid. 1H NMR (400 MHz, CD3OD) δ = 8.18 (br s, 1H), 7.82 (br 
d, J = 5.6 Hz, 2H), 7.78 (br d, J = 7.8 Hz, 1H), 7.71 - 7.63 (m, 1H), 7.57 (dd, J = 0.7, 7.8 
Hz, 1H), 7.37 - 7.20 (m, 5H), 7.16 (br d, J = 7.1 Hz, 2H), 4.99 - 4.91 (m, 1H), 4.03 - 3.93 
(m, 1H); 13C NMR (100 MHz, CD3OD) δ = 173.30, 167.58, 142.40 (br s), 141.32, 137.20 
(br s), 132.88, 130.82 (br q, J = 32.7 Hz), 130.48 (br s), 129.46, 129.25, 128.76 (br s), 
128.51, 128.11, 127.41, 127.01 (br s), 126.42, 126.37, 124.94 - 124.60 (m), 123.83 (br 
d, J = 5.1 Hz), 123.78 (q, J = 271.7 Hz), 117.51 (br s), 62.28 (br s), 60.45 (br s); 19F 
NMR (376 MHz, CD3OD) δ = -64.23 (s, 3F); LRMS (ESI) calculated for C23H17F3NO3 [M 
+ H]+ m/z 412.12, found 411.99. 
 
 
 
3-phenyl-N-(1H-tetrazol-5-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxamide 
(14). Semi-crude S35 (25.3 mg, 0.062 mmol, 1.0 equiv.) was reacted with 5-
aminotetrazole monohydrate (1.1 equiv.) in 3 mL DMF according to general procedure 
D (10m activation). 14 (6.9 mg, 24%) obtained as a white solid. 1H NMR (400 MHz, 
CD3OD) δ = 7.96 - 7.85 (m, 3H), 7.81 (br d, J = 7.5 Hz, 1H), 7.76 - 7.68 (m, 1H), 7.56 - 
7.16 (m, 8H), 5.12 (br d, J = 9.5 Hz, 1H), 4.08 (br d, J = 10.2 Hz, 1H); 19F NMR (376 
MHz, CD3OD) δ = -64.25 (br s, 3F); LRMS (ESI) calculated for C24H16F3N6O2 [M - H]- 
m/z 477.13, found 477.05. 
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methyl 3-benzyl-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylate (S36). S33 
(49.1 mg, 0.141 mmol, 1.0 equiv.) was dissolved in dry tetrahydrofuran (3.3 mL) and 
cooled to -78 °C. LHMDS (134 uL, 0.134 mmol, 0.95 equiv.) (1M in tetrahydrofuran) was 
then added dropwise to the solution -- stirred at -78 °C for 45m. Benzyl bromide (20 uL, 
0.169 mmol, 1.2 equiv.) was then added dropwise, and the reaction was allowed to 
slowly warm to r.t. over 16h. Quenched with 2 mL sat NH4Cl and transferred to a sep. 
funnel; diluted with sat. NH4Cl and extracted with 3 x ~ 30 mL EtOAc. Organics were 
combined, washed with ~ 50 mL sat. NaHCO3 and brine, dried over MgSO4, and 
concentrated. Purified on a silica column with 0-20% EtOAc:hexanes. S36 (60.0 mg, 
97%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.47 - 7.84 (m, 1H), 
7.73 (br d, J = 7.3 Hz, 1H), 7.66 - 7.48 (m, 4H), 7.26 - 7.09 (m, 5H), 6.84 (br s, 2H), 4.51 
(br d, J = 4.6 Hz, 1H), 3.96 (br s, 1H), 3.81 (s, 3H), 3.35 (br d, J = 13.6 Hz, 1H), 3.18 (br 
d, J = 12.7 Hz, 1H); 19F NMR (376 MHz, CDCl3) δ = -62.70 (s, 3F); LRMS (ESI) 
calculated for C25H21F3NO3 [M + H]+ m/z 440.15, found 440.11. 
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3-benzyl-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylic acid (S37). S36 (60.0 
mg, 0.137 mmol, 1.0 equiv.) was reacted in methanol (6 mL) with 1M lithium hydroxide 
(5 mL, 5 mmol, 37 equiv.) according to general procedure B. Semi-crude S37 (64.6 mg, 
111%) obtained as a white solid. 1H NMR (400 MHz, CD3OD, drops CDCl3) δ = 8.01 (br 
s, 1H), 7.84 - 7.75 (m, 1H), 7.74 - 7.50 (m, 3H), 7.46 - 7.04 (m, 6H), 6.86 (br s, 2H), 4.56 
- 4.37 (m, 1H), 3.90 (br s, 1H), 3.36 (d, J = 13.4 Hz, 1H), 3.14 (br s, 1H); 19F NMR (376 
MHz, CD3OD, drops CDCl3) δ = -64.04 (br s, 3F); LRMS (ESI) calculated for 
C24H17F3NO3 [M - H]- m/z 424.12, found 424.15. 
 
 
 
3-benzyl-N-(1H-tetrazol-5-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxamide 
(15). Semi-crude S37 (64.6 mg, 0.152 mmol, 1.0 equiv.) was reacted with 5-
aminotetrazole monohydrate (1.1 equiv.) in 3 mL DMF according to general procedure 
D (10m activation). 15 (18.6 mg, 25%) obtained as a white solid. 1H NMR (400 MHz, 
DMSO-d6) δ = 7.99 (br s, 1H), 7.90 (br d, J = 7.3 Hz, 1H), 7.85 - 7.66 (m, 3H), 7.35 (br 
s, 1H), 7.30 - 7.00 (m, 5H), 6.91 (br s, 2H), 4.41 (br d, J = 9.5 Hz, 1H), 4.21 (br s, 1H), 
3.66 (br d, J = 13.6 Hz, 1H), 3.27 - 3.13 (m, 1H); 13C NMR (100 MHz, DMSO-d6) δ = 
170.71 (br s), 165.81 (br s), 152.19 (br s), 142.28 (br s), 137.50 (br s), 135.90 (br s), 
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133.53 (br s), 130.90 (br s), 129.86, 129.50 (br s), 129.24 (d, J = 31.8 Hz), 128.93 - 
128.55 (m), 128.00, 126.84 (br s), 125.73 - 125.28 (m), 124.64 - 124.11 (m), 123.76 - 
123.48 (m), 123.84 (d, J = 272.4 Hz), 116.89 (br s), 56.91 (br s), 56.28 (br s), 41.72; 19F 
NMR (376 MHz, DMSO-d6) δ = -61.18 (s, 3F); LRMS (ESI) calculated for C25H18F3N6O2 
[M - H]- m/z 491.15, found 491.15.  
 
 
 
methyl 3-azido-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylate (S38). S33 
(255.6 mg, 0.732 mmol, 1.0 equiv.) was reacted in 15 mL tetrahydrofuran according to 
general procedure F. S38 (210.4 mg, 74%) obtained as a white solid. 1H NMR (400 
MHz, CDCl3) δ = 8.22 (br s, 1H), 7.88 (s, 1H), 7.78 (br dd, J = 3.7, 6.8 Hz, 2H), 7.65 - 
7.59 (m, 1H), 7.50 (d, J = 7.5 Hz, 1H), 7.43 (br s, 1H), 7.20 (br t, J = 7.2 Hz, 1H), 4.67 
(d, J = 12.2 Hz, 1H), 3.97 (br s, 1H), 3.90 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 
168.86, 167.01, 142.30 (br s), 136.50, 131.41 (br s), 131.32 (q, J = 33.0 Hz), 130.47 (br 
s), 129.36, 127.53 (br d, J = 2.9 Hz), 124.73 (br s), 124.35 (br s), 123.93 (br s), 123.47 
(q, J = 272.9 Hz), 117.84 (br s), 69.68 (br s), 59.16 (br s), 53.71; 19F NMR (376 MHz, 
CDCl3) δ = -62.79 (s, 3F); LRMS (ESI) calculated for C18H14F3N4O3 [M + H]+ m/z 
391.10, found 390.81. 
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methyl 3-((tert-butoxycarbonyl)amino)-1-(3-(trifluoromethyl)benzoyl)indoline-3-
carboxylate (S39). A round bottom flask was charged with S38 (150.8 mg, 0.386 mmol, 
1.0 equiv.) and dry methanol (3.5 mL), then cooled to 0 °C. Anhydrous tin(II) chloride 
(147 mg, 0.773 mmol, 2.0 equiv.) was then added; stirred at 0 °C for 5m, then r.t. for 2h. 
The methanol was then removed under reduced pressure. 1,4-dioxane (3 mL) was then 
added, followed by di-tert-butyl dicarbonate (126 mg, 0.580 mmol, 1.5 equiv.) in 700 uL 
1,4-dioxane. Finally, a slurry of sodium bicarbonate (130 mg, 1.55 mmol, 4.0 equiv.) in 
water (700 uL) was added, and the resulting slurry was allowed to stir for 22h. The 
reaction mixture was then transferred to a sep. funnel with excess EtOAc and water and 
adjusted to pH 1 with 2N NaHSO4. The layers were separated, and the aqueous layer 
was further extracted with ~ 50 mL EtOAc. The organic layers were combined, washed 
with sat. NaHCO3, dried over MgSO4, and concentrated under reduced pressure. 
Purified on a silica column with 15% EtOAc:hexanes. S39 (157.0 mg, 88%) obtained as 
a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.24 (br s, 1H), 7.84 (br s, 1H), 7.75 (br t, 
J = 6.5 Hz, 2H), 7.63 - 7.54 (m, 1H), 7.36 (d, J = 7.5 Hz, 1H), 7.27 (br s, 1H), 7.10 (br t, 
J = 6.7 Hz, 1H), 4.91 (br d, J = 11.2 Hz, 1H), 4.09 (br s, 1H), 3.75 (s, 3H), 1.39 (br s, 
9H); 13C NMR (100 MHz, CDCl3) δ = 171.02, 167.31 (br s), 154.72 (br s), 142.51 (br s), 
136.96, 131.32, 130.83 (d, J = 33.0 Hz), 130.76 (br s), 130.28 (br s), 129.45 (br s), 
127.18 (br d, J = 2.9 Hz), 125.09 - 124.66 (m), 124.20 (br s), 123.35 (br s), 123.51 (q, J 
= 272.2 Hz), 117.86 (br s), 80.89 (br s), 64.55 (br s), 60.64 (br s), 53.25, 28.00 (br s); 
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19F NMR (376 MHz, CDCl3) δ = -62.83 (s, 3F); LRMS (ESI) calculated for C23H24F3N2O5 
[M + H]+ m/z 465.16, found 465.04.  
 
 
 
3-((tert-butoxycarbonyl)amino)-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylic 
acid (S40). S39 (157.0 mg, 0.338 mmol, 1.0 equiv.) was reacted in methanol (7 mL) 
with 1M lithium hydroxide (700 uL, 0.700 mmol, 2.1 equiv.) according to general 
procedure B, except the reaction was cooled to 0 °C prior to hydroxide addition, and 
allowed to slowly warm to r.t. for 3h. Semi-crude S40 (134.6 mg, 88%) obtained as a 
white solid. 1H NMR (400 MHz, CD3OD, drops CDCl3) δ = 8.20 (br s, 1H), 7.85 (br s, 
1H), 7.80 (br s, 2H), 7.72 - 7.62 (m, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.38 (br s, 1H), 7.16 
(br s, 1H), 4.88 (br s, 1H), 4.10 (br s, 1H), 1.40 (br s, 9H); 13C NMR (100 MHz, CD3OD, 
drops CDCl3) δ = 173.34 (br s), 169.04 (br s), 156.90 (br s), 143.33 (br s), 138.24 (br s), 
132.24 (br d, J = 33.0 Hz), 131.39, 130.66, 128.31 (br s), 126.75 - 125.88 (m), 125.12 
(br s), 124.78 (q, J = 271.9 Hz), 119.10 (br s), 82.70 (br s), 65.61 (br s), 62.31 (br s), 
28.86 (br s); 19F NMR (376 MHz, CD3OD, drops CDCl3) δ = -63.58 (s, 3F); LRMS (ESI) 
calculated for C22H20F3N2O5 [M - H]- m/z 449.13, found 449.08.  
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tert-butyl (3-((1H-tetrazol-5-yl)carbamoyl)-1-(3-(trifluoromethyl)benzoyl)indolin-3-
yl)carbamate (16). Semi-crude S40 (68.0 mg, 0.151 mmol, 1.0 equiv.) was reacted with 
5-aminotetrazole monohydrate (1.1 equiv.) in 4 mL DMF according to general procedure 
D (10m activation). 16 (36.0 mg, 46%) obtained as a white solid. 1H NMR (400 MHz, 
CD3OD, drops CDCl3) δ = 8.20 (br s, 1H), 7.92 (br s, 2H), 7.84 (br d, J = 7.8 Hz, 1H), 
7.75 - 7.67 (m, 1H), 7.62 (d, J = 7.5 Hz, 1H), 7.39 (br s, 1H), 7.18 (br s, 1H), 5.16 (br s, 
1H), 4.06 (br d, J = 9.7 Hz, 1H), 1.37 (br s, 9H); 19F NMR (376 MHz, CD3OD, drops 
CDCl3) δ = -63.82 (s, 3F); LRMS (ESI) calculated for C23H21F3N7O4 [M - H]- m/z 516.16, 
found 516.27. 
 
 
 
3-amino-N-(1H-tetrazol-5-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxamide 
formate (17). 16 (22.0 mg, 0.043 mmol, 1.0 equiv.) was reacted with 4M HCl in 
dioxanes (4 mL) according to general procedure E (42h), except the resulting residue 
was taken up in DMF and purified by reverse phase HPLC (water/MeOH/0.05% formic 
acid) to afford 17 (19.0 mg, 96%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 
8.27 (br s, 1H), 8.01 - 7.89 (m, 3H), 7.86 - 7.77 (m, 1H), 7.58 (br s, 1H), 7.43 (d, J = 7.8 
Hz, 1H), 7.23 (br s, 1H), 4.74 (d, J = 13.1 Hz, 1H), 4.17 (br s, 1H); 19F NMR (376 MHz, 
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DMSO-d6) δ = -61.26 (s, 3F); LRMS (ESI) calculated for C18H15F3N7O2 [M + H]+ m/z 
418.12, found 417.77. 
 
 
 
methyl 3-amino-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylate (S41). S38 
(946.9 mg, 2.43 mmol, 1.0 equiv.) was suspended in dry methanol (44 mL) and cooled 
to 0 °C. Anhydrous tin(II) chloride (920 mg, 4.85 mmol, 2.0 equiv.) was then added, and 
the reaction was stirred at 0 °C for 10m, then allowed to warm to r.t. for an additional 3h. 
The methanol was removed under reduced pressure; the resulting foam was transferred 
to a sep. funnel with ~ 75 mL EtOAc and partitioned with ~ 75 mL sat. NaHCO3. The 
aqueous layer was further extracted with 2 x 50 mL EtOAc; the organics were 
combined, dried over MgSO4, and concentrated to give semi-crude S41 (913.5 mg, 
103%) as a light yellow oil. LRMS (ESI) calculated for C18H16F3N2O3 [M + H]+ m/z 
365.11, found 364.95. 
 
 
 
methyl 3-(((benzyloxy)carbonyl)amino)-1-(3-(trifluoromethyl)benzoyl)indoline-3-
carboxylate (S42). Semi-crude S41 (295.4 mg, 0.811 mmol, 1.0 equiv.) was reacted 
with commercially available benzyl chloroformate in dry dichloromethane (7.5 mL) 
according to general procedure A, with slight modification: prior to base addition, the 
N
O
O
O
CF3
NH2
N
O
O
O
CF3
NHCbz
 242 
reaction vessel was cooled to 0 °C; 2.5 equiv. of N,N-diisopropylethylamine was used, 
and allowed to stir at 0 °C for 5m; after chloroformate addition, the reaction mixture was 
allowed to slowly warm to r.t. S42 (314.0 mg, 78%) obtained as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ = 8.27 (br s, 1H), 7.87 (br s, 1H), 7.77 (br d, J = 7.8 Hz, 2H), 7.66 - 
7.55 (m, 1H), 7.39 - 7.29 (m, 7H), 7.14 (br t, J = 6.7 Hz, 1H), 5.15 - 5.02 (m, 2H), 4.93 
(br d, J = 11.9 Hz, 1H), 4.21 (br s, 1H), 3.77 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 
171.10, 167.28 (br s), 155.07, 142.66 (br s), 136.89, 135.68, 131.29 (d, J = 32.3 Hz), 
131.30 - 130.59 (m), 130.34 (br s), 129.32, 128.52, 128.35, 128.11, 127.33 (br d, J = 3.7 
Hz), 124.97 (br d, J = 3.7 Hz), 124.35 (br s), 123.20 (br s), 123.56 (d, J = 272.0 Hz), 
116.27 (br s), 67.31, 64.77 (br s), 60.36 (br s), 53.57; 19F NMR (376 MHz, CDCl3) δ = -
62.76 (s, 3F). 
 
 
 
3-(((benzyloxy)carbonyl)amino)-1-(3-(trifluoromethyl)benzoyl)indoline-3-
carboxylic acid (S43). S42 (37.4 mg, 0.075 mmol, 1.0 equiv.) was reacted in methanol 
(3 mL) with 1M lithium hydroxide (3 mL, 3 mmol, 40 equiv.) according to general 
procedure B. Semi-crude S43 (33.1 mg, 91%) obtained as a white solid. LRMS (ESI) 
calculated for C25H18F3N2O5 [M - H]- m/z 483.12, found 483.05. 
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benzyl (3-((1H-tetrazol-5-yl)carbamoyl)-1-(3-(trifluoromethyl)benzoyl)indolin-3-
yl)carbamate (18). Semi-crude S43 (33.1 mg, 0.068 mmol, 1.0 equiv.) was reacted with 
5-aminotetrazole monohydrate (1.1 equiv.) in 2 mL DMF according to general procedure 
D (10m activation). 18 (8.7 mg, 23%) obtained as a white solid. 1H NMR (400 MHz, 
DMSO-d6) δ = 8.13 (br s, 1H), 8.06 - 7.87 (m, 3H), 7.79 (br d, J = 6.8 Hz, 2H), 7.31 (br 
s, 6H), 7.16 (br s, 1H), 5.04 (br s, 2H), 4.90 (br d, J = 6.6 Hz, 1H), 4.11 (br d, J = 10.7 
Hz, 1H); 13C NMR (100 MHz, DMSO-d6) δ = 168.26, 166.36 (br s), 156.82 (br s), 155.50 
(br s), 142.09 (br s), 137.65, 136.46 (br s), 131.05 (br s), 129.87 (br s), 129.40 (br d, J = 
32.2 Hz), 128.29, 127.76, 127.52 (br s), 127.01 (br s), 125.56 - 125.08 (m), 124.29 (br 
s), 123.88 (br s), 123.85 (d, J = 272.5 Hz), 117.04 (br s), 65.84 (br s), 60.41 (br s); 19F 
NMR (376 MHz, DMSO-d6) δ = -61.13 (br s, 3F); LRMS (ESI) calculated for 
C26H19F3N7O4 [M - H]- m/z 550.15, found 550.39. 
 
 
 
2-methyl-N-(2-nitrobenzyl)propan-2-amine (S44). A 20 mL vial was charged with 2-
nitrobenzaldehyde (108 mg, 0.714 mmol, 1.0 equiv.), fitted with a septa, and purged 
with Ar. tert-butylamine (75 uL, 0.714 mmol, 1.0 equiv.) was then added, followed by dry 
methanol (3 mL). The vial was foiled; stirred overnight. Sodium borohydride (30 mg, 
0.785 mmol, 1.1 equiv.) was then added in one portion. After 2h of stirring, the reaction 
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mixture was quenched with ~ 30 mL water and transferred to a sep. funnel with 
additional water, then extracted with 3 x 40 mL DCM. The organic layers were 
combined, dried over MgSO4, and concentrated. Purified on a silica column with 0-
100% EtOAc:hexanes. S44 (136.3 mg, 92%) obtained as a yellow oil. Note: Fairly 
photo stable, but avoid direct sunlight. 1H NMR (400 MHz, CDCl3) δ = 7.88 (dd, J = 1.1, 
8.2 Hz, 1H), 7.65 (d, J = 7.5 Hz, 1H), 7.55 (dt, J = 1.2, 7.5 Hz, 1H), 7.40 - 7.32 (m, 1H), 
3.93 (s, 2H), 1.16 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 149.22, 136.63, 133.09, 
131.65, 127.60, 124.35, 50.79, 44.13, 28.95; LRMS (ESI) calculated for C11H17N2O2 [M 
+ H]+ m/z 209.13, found 209.06. 
 
 
 
methyl 3-(3-(tert-butyl)-3-(2-nitrobenzyl)ureido)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxylate (S45). Semi-crude S41 (53.1 mg, 
0.146 mmol, 1.0 equiv.) was reacted with partner amine S44 (1.1 equiv.) according to 
general procedure G. The reaction vessel was foiled. S45 (83.6 mg, 96%) obtained as a 
white solid. 1H NMR (400 MHz, CDCl3) δ = 8.11 (d, J = 8.3 Hz, 1H), 8.19 (br s, 1H), 7.84 
- 7.77 (m, 3H), 7.77 - 7.71 (m, 2H), 7.63 - 7.56 (m, 1H), 7.54 - 7.48 (m, 1H), 7.29 (br s, 
1H), 6.99 - 6.88 (m, 2H), 5.06 - 4.94 (m, 3H), 4.76 (d, J = 19.7 Hz, 1H), 3.75 (s, 3H), 
1.40 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 171.05, 167.43 (br s), 158.09, 147.18, 
142.72 (br s), 137.01, 134.84, 134.14, 131.20 (q, J = 32.9 Hz), 130.74 (br s), 130.26 (br 
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s), 129.57 - 129.35 (m), 129.30, 128.43, 127.95, 127.20 (br d, J = 2.9 Hz), 125.73, 
125.07 - 124.63 (m), 124.25 (br d, J = 3.9 Hz), 122.57 (br s), 123.56 (q, J = 272.6 Hz), 
118.33 (br s), 65.28 (br s), 61.46 (br s), 57.17, 53.15, 46.87, 28.80; 19F NMR (376 MHz, 
CDCl3) δ = -62.75 (s, 3F); LRMS (ESI) calculated for C30H30F3N4O6 [M + H]+ m/z 
599.21, found 599.16. 
 
 
 
3-(3-(tert-butyl)-3-(2-nitrobenzyl)ureido)-1-(3-(trifluoromethyl)benzoyl)indoline-3-
carboxylic acid (S46). S45 (83.6 mg, 0.140 mmol, 1.0 equiv.) was reacted in methanol 
(5 mL) with 1M lithium hydroxide (196 uL, 0.196 mmol, 1.4 equiv.) according to general 
procedure B, except a second addition of 1M lithium hydroxide (75 uL) was required. 
The reaction vessel was foiled. Semi-crude S46 (70.5 mg, 86%) obtained as a white 
solid. LRMS (ESI) calculated for C29H26F3N4O6 [M - H]- m/z 583.18, found 583.20. 
 
 
 
3-(3-(tert-butyl)-3-(2-nitrobenzyl)ureido)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (S47). Semi-crude S46 (70.5 mg, 
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0.121 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 
3.5 mL DMF according to general procedure D (1h activation; 48h), except the product 
was unstable to purification/concentration. Crude S47 (13.0 mg, 17%) obtained as a 
white solid (~ 70% pure). LRMS (ESI) calculated for C30H27F3N9O5 [M - H]- m/z 650.21, 
found 650.33. 
 
 
 
3-(3-(tert-butyl)ureido)-N-(1H-tetrazol-5-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-
3-carboxamide (19). Crude S47 (13.0 mg, 0.020 mmol, 1.0 equiv.) was taken up in 
methanol (2.5 mL) and irradiated with 365 nm hv (TLC lamp, 4 watt) for 90m. The 
reaction mixture was concentrated and purified by reverse phase HPLC 
(water/MeOH/0.05% formic acid) to afford 19 (3.3 mg, 4% over 3 steps) as a white solid. 
1H NMR (400 MHz, DMSO-d6) δ = 12.10 (br s, 1H), 8.13 (br s, 1H), 8.06 - 7.91 (m, 3H), 
7.87 - 7.77 (m, 2H), 7.44 (br s, 1H), 7.22 (br t, J = 6.8 Hz, 1H), 6.93 (s, 1H), 6.52 (s, 
0.5H), 6.13 (s, 1H), 4.97 - 4.83 (m, 1H), 4.14 (br dd, J = 3.4, 5.6 Hz, 1H), 1.17 (s, 9H); 
19F NMR (376 MHz, DMSO-d6) δ = -61.17 (s, 3F); LRMS (ESI) calculated for 
C23H22F3N8O3 [M - H]- m/z 515.18, found 515.24. 
 
 
 
N-benzyl-1-(4-methoxyphenyl)methanamine (S48). A 20 mL vial was charged with 4-
anisaldehyde (111 uL, 0.916 mmol, 1.0 equiv.), fitted with a septa, and purged with Ar. 
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Benzylamine (100 uL, 0.916 mmol, 1.0 equiv.) was then added, followed by dry 
methanol (3 mL); stirred overnight. Sodium borohydride (38.1 mg, 1.01 mmol, 1.1 
equiv.) was then added in one portion. After 2h of stirring, the reaction mixture was 
quenched with ~ 30 mL water and transferred to a sep. funnel with additional water, 
then extracted with 3 x 40 mL DCM. The organic layers were combined, dried over 
MgSO4, and concentrated. Purified on a silica column with 0-55% EtOAc:hexanes. S48 
(183.9 mg, 88%) obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.43 - 7.37 (m, 
4H), 7.35 - 7.30 (m, 3H), 6.96 - 6.95 (m, 1H), 6.94 - 6.92 (m, 1H), 3.86 (s, 2H), 3.84 (s, 
3H), 3.81 (s, 2H); 13C NMR (100 MHz, CDCl3) δ = 158.46, 140.13, 132.17, 129.17, 
128.21, 127.99, 126.75, 113.60, 55.02, 52.83, 52.33; LRMS (ESI) calculated for 
C15H18NO [M + H]+ m/z 228.14, found 228.02. 
 
 
 
methyl 3-(3-benzyl-3-(4-methoxybenzyl)ureido)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxylate (S49). Semi-crude S41 (72.8 mg, 
0.200 mmol, 1.0 equiv.) was reacted with partner amine S48 (1.1 equiv.) according to 
general procedure G. S49 (108.0 mg, 88%) obtained as a white solid. 1H NMR (400 
MHz, CDCl3) δ = 8.22 (br s, 1H), 7.85 (s, 1H), 7.76 (br d, J = 7.1 Hz, 2H), 7.63 - 7.56 (m, 
1H), 7.38 - 7.28 (m, 4H), 7.21 (br d, J = 6.8 Hz, 2H), 7.13 (d, J = 8.5 Hz, 2H), 7.00 (br t, 
J = 7.4 Hz, 1H), 6.90 - 6.83 (m, 3H), 5.28 (s, 1H), 5.07 (br d, J = 11.9 Hz, 1H), 4.44 (br 
s, 2H), 4.40 (br s, 2H), 3.80 (s, 3H), 3.74 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 
170.69, 167.41 (br s), 159.16, 157.47, 142.57 (br s), 137.04, 136.86 (br s), 131.13 (q, J 
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= 33.0 Hz), 130.65 (br s), 130.20 (br s), 129.52 (br s), 129.26, 128.73, 128.63 (br s), 
127.65, 127.25 (br s), 127.17 - 127.02 (m), 124.69 (br s), 124.16 (br d, J = 2.2 Hz), 
122.84 (br s), 123.55 (q, J = 272.2 Hz), 118.14 (br s), 114.10, 65.05 (br s), 61.33 (br s), 
55.15, 53.03, 50.35, 50.00; 19F NMR (376 MHz, CDCl3) δ = -62.68 (s, 3F); LRMS (ESI) 
calculated for C34H31F3N3O5 [M + H]+ m/z 618.22, found 618.10. 
 
 
 
3-(3-benzyl-3-(4-methoxybenzyl)ureido)-1-(3-(trifluoromethyl)benzoyl)indoline-3-
carboxylic acid (S50). S49 (108.0 mg, 0.175 mmol, 1.0 equiv.) was reacted in 
methanol (5.5 mL) with 1M lithium hydroxide (245 uL, 0.245 mmol, 1.4 equiv.) according 
to general procedure B, except a second addition of 1M lithium hydroxide (50 uL) was 
required. Semi-crude S50 (99.5 mg, 94%) obtained as a white solid. LRMS (ESI) 
calculated for C33H27F3N3O5 [M - H]- m/z 602.19, found 602.13. 
 
 
 
3-(3-benzyl-3-(4-methoxybenzyl)ureido)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (S51). Semi-crude S50 (99.5 mg, 
0.165 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 
2.5 mL DMF according to general procedure D (1h activation). S51 (52.3 mg, 45% over 
2 steps) obtained as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.33 (br s, 1H), 
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8.13 (br s, 1H), 8.09 - 7.88 (m, 4H), 7.89 - 7.74 (m, 2H), 7.44 (br s, 1H), 7.33 - 7.00 (m, 
8H), 6.82 (br s, 2H), 5.07 (br s, 1H), 4.77 (br s, 2H), 4.10 (br d, J = 9.0 Hz, 1H), 3.95 (br 
s, 2H), 3.71 (br s, 3H); 19F NMR (376 MHz, DMSO-d6) δ = -61.13 (br s, 3F); LRMS (ESI) 
calculated for C34H28F3N8O4 [M - H]- m/z 669.22, found 670.11. 
 
 
 
3-(3-benzylureido)-N-(1H-tetrazol-5-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-3-
carboxamide (20). S51 (44.9 mg, 0.067 mmol, 1.0 equiv.) was suspended in 
acetonitrile (2.4 mL) and water (600 uL). Ammonium cerium(IV) nitrate (165 mg, 0.301 
mmol, 4.5 equiv.) was then added in 0.5 equiv. portions over 3h. The crude reaction 
mixture was transferred to a sep. funnel with EtOAc and water; the layers were 
separated, and the aqueous layer was further extracted with 3 x 50 mL EtOAc. The 
organics were combined, dried over MgSO4, and concentrated. Purified by reverse 
phase HPLC (water/MeOH/0.05% formic acid) to afford 20 (10.7 mg, 29%) as a white 
solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.25 (br s, 1H), 8.15 (br s, 1H), 8.01 (br s, 
2H), 7.95 (br d, J = 7.8 Hz, 1H), 7.88 (br d, J = 7.8 Hz, 1H), 7.84 - 7.77 (m, 1H), 7.53 - 
7.39 (m, 1H), 7.32 - 7.18 (m, 6H), 6.75 (t, J = 5.8 Hz, 0.5H), 4.94 (br d, J = 9.5 Hz, 1H), 
4.28 - 4.13 (m, 2H), 4.09 (d, J = 11.2 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) δ = 
170.69, 166.31, 157.25, 157.20, 150.16 (br s), 142.02 (br s), 139.93, 137.37, 131.06, 
130.45 (br s), 130.33 - 130.09 (m), 130.00, 129.48 (d, J = 32.0 Hz), 128.19, 127.34 - 
127.12 (m), 126.84, 126.66, 124.89 - 124.65 (m), 124.61 - 124.42 (m), 123.81 (br d, J = 
3.3 Hz), 123.83 (q, J = 272.0 Hz), 117.68 (br s), 65.32 (br s), 61.41 (br s), 42.79; 19F 
N
N
H
O
CF3
HN O
HN
O
NN
N
N
H
 250 
NMR (376 MHz, DMSO-d6) δ = -61.11 (s, 3F); LRMS (ESI) calculated for C26H20F3N8O3 
[M - H]- m/z 549.16, found 549.14. 
 
 
 
N-(2-nitrobenzyl)-2-phenylpropan-2-amine (S52). A 20 mL vial was charged with 2-
nitrobenzaldehyde (105 mg, 0.695 mmol, 1.0 equiv.), fitted with a septa, and purged 
with Ar. cumylamine (100 uL, 0.695 mmol, 1.0 equiv.) was then added, followed by dry 
methanol (3 mL). The vial was foiled; stirred overnight. Sodium borohydride (29 mg, 
0.765 mmol, 1.1 equiv.) was then added in one portion. After 2h of stirring, the reaction 
mixture was quenched with ~ 30 mL water and transferred to a sep. funnel with 
additional water, then extracted with 3 x 40 mL DCM. The organic layers were 
combined, dried over MgSO4, and concentrated. Purified on a silica column with 0-25% 
EtOAc:hexanes. S52 (150.0 mg, 80%) obtained as a yellow oil. Note: Fairly photo-
stable, but avoid direct sunlight. 1H NMR (400 MHz, CDCl3) δ = 7.93 - 7.88 (m, 1H), 
7.62 - 7.53 (m, 4H), 7.42 - 7.36 (m, 3H), 7.30 - 7.24 (m, 1H), 3.72 (s, 2H), 1.57 (s, 6H); 
13C NMR (100 MHz, CDCl3) δ = 149.20, 147.30, 136.53, 133.15, 131.67, 128.22, 
127.65, 126.41, 125.91, 124.39, 56.29, 44.71, 29.61; LRMS (ESI) calculated for 
C16H19N2O2 [M + H]+ m/z 271.14, found 271.04. 
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methyl 3-(3-(2-nitrobenzyl)-3-(2-phenylpropan-2-yl)ureido)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxylate (S53). Semi-crude S41 (80.2 mg, 
0.220 mmol, 1.0 equiv.) was reacted with partner amine S52 (1.1 equiv.) according to 
general procedure G. The reaction vessel was foiled. S53 (126.0 mg, 87%) obtained as 
a white solid. 1H NMR (400 MHz, CDCl3) δ = 8.16 (br s, 1H), 7.98 (dd, J = 1.1, 8.2 Hz, 
1H), 7.80 (s, 1H), 7.75 - 7.64 (m, 4H), 7.59 - 7.52 (m, 1H), 7.46 - 7.34 (m, 6H), 7.28 (br 
s, 1H), 6.92 (br t, J = 7.3 Hz, 1H), 6.31 (d, J = 7.5 Hz, 1H), 5.31 - 5.21 (m, 1H), 5.18 (s, 
1H), 5.14 - 5.06 (m, 1H), 4.93 (br d, J = 11.7 Hz, 1H), 3.66 (s, 3H), 1.66 (s, 3H), 1.50 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ = 170.48, 167.26 (br s), 158.19, 147.49, 146.34, 
142.25 (br s), 137.01, 135.83, 133.32, 131.06 (q, J = 32.8 Hz), 130.70 - 130.40 (m), 
130.13 (br s), 129.41, 129.23, 128.96, 127.92, 127.50, 127.18 - 126.95 (m), 125.22, 
124.72, 124.46 (br s), 124.19 - 123.92 (m), 122.56 (br s), 123.51 (q, J = 272.6 Hz), 
118.08 (br s), 65.07 (br s), 61.68 (br s), 61.06, 52.85, 45.16, 30.89, 26.52 (br s); 19F 
NMR (376 MHz, CDCl3) δ = -62.74 (s, 3F); LRMS (ESI) calculated for C35H32F3N4O6 [M 
+ H]+ m/z 661.23, found 661.13. 
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3-(3-(2-nitrobenzyl)-3-(2-phenylpropan-2-yl)ureido)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxylic acid (S54). S53 (126.0 mg, 0.191 
mmol, 1.0 equiv.) was reacted in methanol (6 mL) with 1M lithium hydroxide (267 uL, 
0.267 mmol, 1.4 equiv.) according to general procedure B, except a second addition of 
1M lithium hydroxide (50 uL) was required. The reaction vessel was foiled. Semi-crude 
S54 (124.2 mg, 101%) obtained as a white solid. LRMS (ESI) calculated for 
C34H28F3N4O6 [M - H]- m/z 645.20, found 645.09. 
 
 
 
3-(3-(2-nitrobenzyl)-3-(2-phenylpropan-2-yl)ureido)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (S55). Semi-crude S54 (124.2 mg, 
0.192 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 
3 mL DMF according to general procedure D (1h activation), except the product was 
unstable to purification/concentration. Crude S55 (31.2 mg, 23%) obtained as a white 
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solid (~ 56% pure). LRMS (ESI) calculated for C35H29F3N9O5 [M - H]- m/z 712.22, found 
712.31. 
 
 
 
3-(3-(2-phenylpropan-2-yl)ureido)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (21). Crude S55 (31.2 mg, 0.044 
mmol, 1.0 equiv.) was taken up in methanol (3 mL) and irradiated with 365 nm hv (TLC 
lamp, 4 watt) for 3h. The reaction mixture was concentrated and purified by reverse 
phase HPLC (water/MeOH/0.05% formic acid) to afford 21 (7.5 mg, 7% over 3 steps) as 
a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.27 (br s, 1H), 8.15 (br s, 1H), 7.99 
(br s, 2H), 7.92 (br t, J = 7.2 Hz, 2H), 7.81 - 7.74 (m, 1H), 7.46 (br s, 1H), 7.31 (br d, J = 
7.5 Hz, 2H), 7.28 - 7.21 (m, 1H), 7.19 - 7.11 (m, 2H), 7.10 - 7.04 (m, 1H), 6.74 (d, J = 
1.5 Hz, 0.6H), 4.88 - 4.78 (m, 1H), 3.99 (d, J = 11.2 Hz, 1H), 1.48 (br s, 6H); 13C NMR 
(100 MHz, DMSO-d6) δ = 171.20, 166.80 (br s), 156.60, 156.56, 150.42 (br s), 148.56, 
142.48 (br s), 137.85, 131.48, 130.96 (br s), 130.79 - 130.54 (m), 130.44, 129.94 (br d, 
J = 32.3 Hz), 128.21, 127.79 - 127.49 (m), 126.12, 125.25 (br s), 124.87 (br s), 124.38 - 
124.05 (m), 124.28 (d, J = 272.9 Hz), 118.10 (br s), 65.49 (br s), 61.98 (br s), 55.14, 
30.57 (br s), 30.46; 19F NMR (376 MHz, DMSO-d6) δ = -61.15 (s, 3F); LRMS (ESI) 
calculated for C28H24F3N8O3 [M - H]- m/z 577.19, found 577.27.  
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2-(1H-pyrazol-5-yl)propan-2-ol (S56). A round bottom was charged with 
tetrahydrofuran (5 mL) and methylmagnesium bromide (1.427 mL, 4.28 mmol, 3.0 
equiv.) (3.0M in diethyl ether), then cooled to 0 °C. Ethyl 2H-pyrazole-3-carboxylate 
(200 mg, 1.43 mmol, 1.0 equiv.) was then added, followed by a 1.5 mL tetrahydrofuran 
rinse. After the addition was complete, the vessel was immediately warmed to r.t. and 
allowed to stir for 3h. The reaction mixture was quenched with 0.1N HCl until bubbling 
ceased, and transferred to a sep. funnel with EtOAc and brine. The aqueous pH was 
adjusted to 6 with 12M HCl; extracted with 3 x 50 mL 20% isopropanol:chloroform. The 
organics were combined, dried over MgSO4, and concentrated to give S56 (161.8 mg, 
90%) as a white solid. 1H NMR (400 MHz, CDCl3, CD3OD) δ = 7.35 (br d, J = 7.8 Hz, 
1H), 6.07 (br d, J = 7.8 Hz, 1H), 1.51 (s, 3H), 1.48 (d, J = 1.2 Hz, 3H); 13C NMR (100 
MHz, CDCl3, CD3OD) δ = 154.83, 134.32, 100.91, 68.56, 30.20; LRMS (ESI) calculated 
for C6H11N2O [M + H]+ m/z 127.09, found 127.27. 
 
 
 
N-(2-nitrobenzyl)-2-(1H-pyrazol-5-yl)propan-2-amine (S57). A flask was charged with 
S56 (161.8 mg, 1.28 mmol, 1.0 equiv.), sodium azide (183 mg, 2.82 mmol, 2.2 equiv.), 
and dry dichloromethane (3 mL), then cooled to 0 °C. A solution of trifluoroacetic acid 
(491 uL, 6.41 mmol, 5.0 equiv.) in dichloromethane (1 mL) was then added; the reaction 
mixture was allowed to warm to r.t. overnight. The reaction was then pushed to 
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completion by the addition of 4.4 equiv. sodium azide and 25 equiv. trifluoroacetic acid 
over 3d (r.t.), and heating at 40 °C for 5h (behind a blast shield). After complete SM 
consumption by LCMS, the crude reaction mixture was transferred to a sep. funnel with 
dichloromethane and sat. NaHCO3. The layers were separated, and the aqueous layer 
was further extracted with 3 x 50 mL 20% isopropanol:chloroform. The organics were 
combined, dried over MgSO4, and concentrated; dried under hivac for 5m. The resulting 
oil was taken up in dry methanol (13 mL) and cooled to 0 °C. Anhydrous tin(II) chloride 
(486 mg, 2.67 mmol, 2.0 equiv.) was then added, and after 10m the reaction was 
immediately warmed to r.t. and stirred for 14h. The methanol was then removed under 
reduced pressure, and the residue transferred to a sep. funnel with 20% 
isopropanol:chloroform. 1M NaHCO3 was added, the layers separated, and the 
aqueous layer further extracted with 3 x 50 mL 20% isopropanol:chloroform. The 
combined organic layers were dried over MgSO4 and concentrated to dryness in a 20 
mL vial. The vial was purged with Ar, foiled, and charged with 2-nitrobenzaldehyde (426 
mg, 2.82 mmol, 2.20 equiv.) and dry tetrahydrofuran (12 mL). After stirring for 12h, 
sodium borohydride (107 mg, 2.82 mmol, 2.20 equiv.) was added, and the reaction was 
stirred for an additional 12h. The crude reaction mixture was transferred to a sep. funnel 
with EtOAc and sat. NaHCO3; the layers were separated, and the aqueous layer was 
further extracted with 2 x 50 mL EtOAc. The organics were combined, dried over 
MgSO4, and concentrated; the resulting residue was purified on a silica column with 40-
100% EtOAc:hexanes to yield S57 (24.7 mg, 7%) as a yellow film. 1H NMR (400 MHz, 
CDCl3) δ = 7.90 - 7.86 (m, 1H), 7.55 - 7.46 (m, 3H), 7.37 (ddd, J = 2.2, 6.4, 8.2 Hz, 1H), 
6.21 (d, J = 1.9 Hz, 1H), 3.77 (s, 2H), 1.55 (s, 6H); 13C NMR (100 MHz, CDCl3) δ = 
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152.99 (br), 149.16, 135.81, 135.23 (br), 133.25, 131.82, 127.90, 124.47, 102.62, 53.23, 
44.96, 28.52; LRMS (ESI) calculated for C13H17N4O2 [M + H]+ m/z 261.13, found 261.10. 
 
 
 
N-(2-nitrobenzyl)-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)propan-2-
amine (S58). A 20 mL vial was charged with S57 (24.7 mg, 0.095 mmol, 1.0 equiv.), 
N,N-diisopropylethylamine (33 uL, 0.190 mmol, 2.0 equiv.), and dry dichloromethane 
(1.5 mL); 2-(trimethylsilyl)ethoxymethyl chloride (17 uL, 0.095 mmol, 1.0 equiv.) was 
then added dropwise. The reaction vial was foiled as stirred for 14h, at which point 
additional 2-(trimethylsilyl)ethoxymethyl chloride (8 uL) and dichloromethane (500 uL) 
were added. After an additional 5h, the reaction mixture was directly loaded onto a silica 
column and purified with 0-50% EtOAc:hexanes. S58 (28.2 mg, 76%) was obtained as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.86 (dd, J = 1.2, 8.0 Hz, 1H), 7.64 - 7.59 (m, 
1H), 7.53 (dt, J = 1.3, 7.5 Hz, 1H), 7.49 (d, J = 2.4 Hz, 1H), 7.38 - 7.32 (m, 1H), 6.29 (d, 
J = 2.4 Hz, 1H), 5.39 (s, 2H), 3.79 (s, 2H), 3.56 (dd, J = 7.7, 8.6 Hz, 2H), 1.52 (s, 6H), 
0.92 - 0.87 (m, 2H), -0.05 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 159.15, 149.20, 
136.65, 132.99, 131.57, 130.22, 127.52, 124.31, 104.13, 79.87, 66.37, 53.68, 44.79, 
28.34, 17.64, -1.53; LRMS (ESI) calculated for C19H31N4O3Si [M + H]+ m/z 391.22, 
found 391.15. 
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methyl 3-(3-(2-nitrobenzyl)-3-(2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-
yl)propan-2-yl)ureido)-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylate (S59). 
Semi-crude S41 (27.6 mg, 0.076 mmol, 1.0 equiv.) was reacted with partner amine S58 
(0.95 equiv.) according to general procedure G. The reaction vessel was foiled. S59 
(47.2 mg, 80%) obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ = 8.23 (br s, 
1H), 8.03 - 7.99 (m, 1H), 7.81 (s, 1H), 7.73 (d, J = 7.8 Hz, 2H), 7.64 - 7.52 (m, 4H), 7.39 
(dt, J = 2.1, 7.4 Hz, 1H), 7.40 (br s, 1H), 7.24 - 7.19 (m, 1H), 7.19 - 7.13 (m, 1H), 6.39 
(s, 1H), 6.23 (d, J = 2.2 Hz, 1H), 5.12 - 5.06 (m, 3H), 4.98 (d, J = 11.0 Hz, 1H), 4.94 (br 
d, J = 11.9 Hz, 1H), 3.71 (s, 3H), 3.42 (dd, J = 7.5, 8.5 Hz, 2H), 1.76 (s, 3H), 1.58 (s, 
3H), 0.82 (dt, J = 1.8, 8.1 Hz, 2H), -0.05 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 
170.58, 167.45 (br s), 158.39, 157.82, 147.32, 142.57 (br s), 137.01, 136.38, 133.31, 
131.83, 131.23 (d, J = 33.0 Hz), 130.85 - 130.53 (m), 130.31 - 130.10 (m), 129.69, 
129.33, 128.79, 127.41, 127.23 (br d, J = 3.3 Hz), 124.82, 124.70 (br s), 124.35 - 
124.06 (m), 123.44 (br s), 123.58 (d, J = 272.5 Hz), 118.45 (br s), 104.40, 79.79, 66.66, 
65.09 (br s), 61.68 (br s), 56.66, 53.08, 45.45, 28.13, 27.21 (br s), 17.49, -1.53; 19F 
NMR (376 MHz, CDCl3) δ = -62.73 (s, 3F); LRMS (ESI) calculated for C38H44F3N6O7Si 
[M + H]+ m/z 781.30, found 781.28. 
 
N
O
O
CF3
HN O
N
O
O2N
N NSEM
 258 
 
 
3-(3-(2-nitrobenzyl)-3-(2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-
yl)propan-2-yl)ureido)-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylic acid 
(S60). S59 (47.2 mg, 0.060 mmol, 1.0 equiv.) was reacted in methanol (2.5 mL) with 1M 
lithium hydroxide (85 uL, 0.085 mmol, 1.4 equiv.) according to general procedure B 
(48h), except a second addition of 1M lithium hydroxide (20 uL) was required for 
completion. The reaction vessel was foiled. Semi-crude S60 (45.1 mg, 97%) obtained 
as a brown oil. LRMS (ESI) calculated for C37H40F3N6O7Si [M - H]- m/z 765.29, found 
765.39. 
 
 
 
3-(3-(2-nitrobenzyl)-3-(2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-
yl)propan-2-yl)ureido)-N-(1H-tetrazol-5-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-3-
carboxamide (S61). Semi-crude S60 (45.1 mg, 0.059 mmol, 1.0 equiv.) was reacted 
with 5-aminotetrazole monohydrate (1.1 equiv.) in 2.5 mL DMF according to general 
procedure D (1h activation), except the product was unstable to 
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purification/concentration. Crude S61 (15.3 mg, 31%) obtained as a white solid (~ 26% 
pure). LRMS (ESI) calculated for C38H41F3N11O6Si [M - H]- m/z 832.30, found 832.54. 
 
 
 
3-(3-(2-(1H-pyrazol-3-yl)propan-2-yl)ureido)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (22). Crude S61 (15.3 mg, 0.018 
mmol, 1.0 equiv.) was taken up in methanol (5 mL) and irradiated with 365 nm hv (TLC 
lamp, 4 watt) for 2h. The methanol was then removed under reduced pressure; the 
residue was dissolved in dry tetrahydrofuran (3 mL). Tetrabutylammonium fluoride (3 
mL, 3.0 mmol, 163 equiv.) (1M solution in tetrahydrofuran) was then added, and the 
reaction was heated at 40 °C for 26h. The crude reaction mixture was transferred to a 
sep. funnel with EtOAc and water, and the aqueous layer was adjusted to pH 2.5 with 
0.1N HCl. The layers were separated, and the aqueous layer was further extracted with 
2 x 50 mL EtOAc. The organics were combined, dried over MgSO4, and concentrated. 
The resulting residue was purified by reverse phase HPLC (water/MeOH/0.05% formic 
acid) to afford 22 (1.6 mg, 5% over 3 steps) as a white solid. 1H NMR (400 MHz, 
DMSO-d6) δ = 12.70 (br s, 1H), 12.23 (br s, 1H), 8.21 (br s, 1H), 8.05 - 7.91 (m, 3H), 
7.87 - 7.74 (m, 2H), 7.44 (br s, 2H), 7.34 (br s, 1H), 7.28 - 7.16 (m, 1H), 6.60 (s, 1H), 
6.52 (s, 0.5H), 6.11 (s, 1H), 5.01 - 4.74 (m, 1H), 4.01 (d, J = 11.2 Hz, 1H), 1.51 (br s, 
3H), 1.50 (br s, 3H); 19F NMR (376 MHz, DMSO-d6) δ = -61.14 (br s, 3F); LRMS (ESI) 
calculated for C25H22F3N10O3 [M - H]- m/z 567.18, found 567.16. 
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methyl 3-(3,3-dimethylbutanamido)-1-(3-(trifluoromethyl)benzoyl)indoline-3-
carboxylate (S62). Semi-crude S41 (41.9 mg, 0.115 mmol, 1.0 equiv.) was reacted with 
commercially available 3,3-dimethylbutyryl chloride in dry dichloromethane (2 mL) 
according to general procedure A, with slight modification: prior to base addition, the 
reaction vessel was cooled to 0 °C; 2.2 equiv. of N,N-diisopropylethylamine was used; 
after acyl chloride addition, the reaction mixture was allowed to slowly warm to r.t. S62 
(32.1 mg, 60%) obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ = 8.22 (br s, 
1H), 7.83 (s, 1H), 7.79 - 7.71 (m, 2H), 7.64 - 7.56 (m, 1H), 7.39 (d, J = 7.5 Hz, 1H), 7.40 
(br s, 1H), 7.16 (br t, J = 7.4 Hz, 1H), 6.26 (s, 1H), 5.04 (d, J = 11.9 Hz, 1H), 4.04 (br d, 
J = 9.3 Hz, 1H), 3.77 (s, 3H), 2.04 (s, 2H), 1.01 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 
171.74, 169.74, 167.49 (br s), 142.76, 136.85, 131.06 (br s), 131.34 (q, J = 33.0 Hz), 
130.22 (br s), 129.36, 127.53 - 127.14 (m), 125.22 - 124.95 (m), 124.41 - 124.06 (m), 
123.42 (br s), 123.54 (q, J = 272.6 Hz), 118.50 (br s), 64.27 (br s), 60.51 (br s), 53.30, 
49.35, 31.14, 29.59; 19F NMR (376 MHz, CDCl3) δ = -62.81 (s, 3F); LRMS (ESI) 
calculated for C24H26F3N2O4 [M + H]+ m/z 463.18, found 463.03. 
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3-(3,3-dimethylbutanamido)-1-(3-(trifluoromethyl)benzoyl)indoline-3-carboxylic 
acid (S63). S62 (32.1 mg, 0.069 mmol, 1.0 equiv.) was reacted in methanol (3 mL) with 
1M lithium hydroxide (416 uL, 0.416 mmol, 6.0 equiv.) according to general procedure 
B. Semi-crude S63 (32.0 mg, 103%) obtained as a white solid. 1H NMR (400 MHz, 
CDCl3, CD3OD) δ = 8.11 (br s, 1H), 7.73 (br s, 1H), 7.67 (br d, J = 7.5 Hz, 2H), 7.56 - 
7.49 (m, 1H), 7.38 (br d, J = 7.3 Hz, 1H), 7.29 (br s, 1H), 7.06 (br s, 1H), 4.89 (br d, J = 
11.9 Hz, 1H), 3.92 (br s, 1H), 1.95 (br s, 2H), 0.88 (s, 9H); 13C NMR (100 MHz, CDCl3, 
CD3OD) δ = 172.62, 171.13, 167.65 (br s), 142.25 (br s), 136.67 (br s), 131.05 (q, J = 
33.3 Hz), 130.50 - 130.23 (m), 130.21 - 129.95 (m), 129.24, 127.32 - 126.99 (m), 
125.22 - 124.80 (m), 123.88 (br s), 123.36 (q, J = 272.5 Hz), 117.97 (br s), 63.95 (br s), 
60.41 (br s), 48.70 (br s), 30.87, 29.28; 19F NMR (376 MHz, CHLOROFORM-d) δ = -
59.14 (s, 3F); LRMS (ESI) calculated for C23H22F3N2O4 [M - H]- m/z 447.15, found 
447.22. 
 
 
 
3-(3,3-dimethylbutanamido)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (23). Semi-crude S63 (32.0 mg, 
0.071 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 
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1.5 mL DMF according to general procedure D (20m activation). 23 (5.2 mg, 14% over 2 
steps) obtained as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 10.69 (br s, 1H), 
8.82 (br s, 1H), 8.39 (br s, 1H), 8.13 (br s, 1H), 8.05 - 7.96 (m, 1H), 7.96 - 7.90 (m, 2H), 
7.83 - 7.72 (m, 2H), 7.41 (br s, 1H), 7.24 - 7.09 (m, 1H), 5.00 (br d, J = 11.4 Hz, 1H), 
4.02 - 3.92 (m, 1H), 2.12 (br d, J = 13.4 Hz, 1H), 1.97 - 1.90 (m, 1H), 0.85 (s, 9H); 19F 
NMR (376 MHz, DMSO-d6) δ = -61.23 (s, 3F); LRMS (ESI) calculated for C24H23F3N7O3 
[M - H]- m/z 514.18, found 514.33. 
 
 
 
methyl 3-((N-(tert-butyl)-N-(2-nitrobenzyl)sulfamoyl)amino)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxylate (S64). Semi-crude S41 (50.2 mg, 
0.138 mmol, 1.0 equiv.) was reacted with partner amine S44 (1.1 equiv.) according to 
general procedure G, except sulfuryl chloride (1.1 equiv.) was used instead of p-
nitrophenyl chloroformate. The reaction vessel was foiled. S64 (17.9 mg, 21%) obtained 
as a light yellow oil. 1H NMR (400 MHz, CDCl3) δ = 8.24 (br s, 1H), 8.04 (dd, J = 1.2, 8.3 
Hz, 1H), 7.88 - 7.81 (m, 2H), 7.76 (br d, J = 7.8 Hz, 2H), 7.66 - 7.56 (m, 2H), 7.45 - 7.31 
(m, 3H), 7.19 - 7.10 (m, 1H), 5.06 (br s, 1H), 4.90 - 4.71 (m, 3H), 4.50 (br d, J = 10.5 Hz, 
1H), 3.78 (s, 3H), 1.42 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 169.96, 167.40 (br s), 
147.15, 142.47, 136.75, 135.72, 133.66, 131.25 (br s), 131.32 (d, J = 32.7 Hz), 130.31 
(br s), 129.32, 129.12, 127.75, 127.56 - 127.29 (m), 125.13 - 124.93 (m), 124.87, 
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124.45 (br s), 124.25 - 123.92 (m), 123.55 (d, J = 272.3 Hz), 118.19 (br s), 67.36 (br s), 
60.65, 59.11 (br s), 53.79, 47.77, 29.54; 19F NMR (376 MHz, CDCl3) δ = -62.82 (s, 3F); 
LRMS (ESI) calculated for C29H29F3N4NaO7S [M + H]+ m/z 657.16, found 657.18. 
 
 
 
3-((N-(tert-butyl)-N-(2-nitrobenzyl)sulfamoyl)amino)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxylic acid (S65). S64 (17.9 mg, 0.028 
mmol, 1.0 equiv.) was reacted in methanol (2 mL) with 1M lithium hydroxide (40 uL, 
0.040 mmol, 1.4 equiv.) according to general procedure B, except a second addition of 
1M lithium hydroxide (15 uL) was required. The reaction vessel was foiled. Semi-crude 
S65 (18.8 mg, 107%) obtained as a brown oil. LRMS (ESI) calculated for 
C28H28F3N4O7S [M + H]+ m/z 621.16, found 621.14. 
 
 
 
3-((N-(tert-butyl)-N-(2-nitrobenzyl)sulfamoyl)amino)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (S66). Semi-crude S65 (17.5 mg, 
0.028 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 
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2 mL DMF according to general procedure D (1h activation; 72h), except the product 
was unstable to purification/concentration. Crude S66 (3.7 mg, 19%) obtained as a 
white solid (~ 80% pure). LRMS (ESI) calculated for C29H28F3N9NaO6S [M + Na]+ m/z 
710.17, found 710.18. 
 
 
 
3-((N-(tert-butyl)sulfamoyl)amino)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (24). Crude S66 (3.7 mg, 0.005 
mmol, 1.0 equiv.) was taken up in methanol (3 mL) and irradiated with 365 nm hv (TLC 
lamp, 4 watt) for 3h. The reaction mixture was concentrated and purified by reverse 
phase HPLC (water/MeOH/0.05% formic acid) to afford 24 (1.1 mg, 7% over 3 steps) as 
a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.01 (br s, 1H), 8.02 - 7.93 (m, 3H), 
8.06 (br s, 1H), 7.85 - 7.76 (m, 2H), 7.43 (br s, 1H), 7.19 (br s, 1H), 6.88 (br s, 1H), 6.52 
(s, 1H), 4.77 (br d, J = 11.2 Hz, 1H), 4.59 (br d, J = 11.2 Hz, 1H), 1.13 (s, 9H); 19F NMR 
(376 MHz, DMSO-d6) δ = -61.14 (br s, 3F); LRMS (ESI) calculated for C22H22F3N8O4S 
[M - H]- m/z 551.14, found 551.19. 
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ethyl 3-((2-hydroxy-2-methylpropyl)amino)-1-(3-(trifluoromethyl)benzoyl)indoline-
3-carboxylate (S67). Semi-crude S41 (53.8 mg, 0.148 mmol, 1.05 equiv.) was 
dissolved in absolute ethanol (2 mL); isobutylene oxide (12.5 uL, 0.141 mmol, 1.0 
equiv.) was then added, followed by N,N-diisopropylethylamine (25.8 uL, 0.148 mmol, 
1.05 equiv.). The reaction vial was sealed and heated at 80 °C overnight. The reaction 
was pushed to completion by adding 3 equiv. isobutylene oxide every day for an 
additional 5d (80 °C). The crude reaction mixture was transferred to a sep funnel with ~ 
75 mL EtOAc and partitioned with ~ 75 mL sat. NaHCO3. The aqueous layer was 
washed with an additional 2 x 50 mL EtOAc; the organics were combined, dried over 
MgSO4, and concentrated. Purified on a silica column with 0-50% EtOAc:hexanes. S67 
(50.1 mg, 79%) obtained as a colorless oil. Note: Atropisomers of the secondary amide 
observable by NMR; split peaks reported by integration values in 1H. 1H NMR (400 
MHz, CDCl3) δ = 8.24 (br s, 1H), 7.90 - 7.83 (m, 1H), 7.77 (br d, J = 7.5 Hz, 2H), 7.66 - 
7.58 (m, 1H), 7.44 - 7.24 (m, 2H), 7.13 (br s, 1H), 4.69 (d, J = 11.2 Hz, 0.2H), 4.59 (br d, 
J = 10.0 Hz, 0.8H), 4.28 - 4.17 (m, 2H), 3.97 (br s, 0.8H), 3.12 (d, J = 13.4 Hz, 0.2H), 
2.47 - 2.26 (m, 2H), 1.59 (s, 0.6H), 1.48 (s, 0.6H), 1.26 (t, J = 7.1 Hz, 3H), 1.14 (s, 
4.8H); 13C NMR (100 MHz, CDCl3) δ = 171.54, 169.92, 167.32 (br s), 167.04, 142.45 (br 
s), 141.74, 137.14 (br s), 131.75 (br s), 131.27 (q, J = 33.0 Hz), 130.48 - 130.20 (m), 
130.17 - 129.80 (m), 129.35, 129.28, 127.53 - 127.35 (m), 127.32 - 127.09 (m), 124.85 - 
124.43 (m), 124.39 - 124.01 (m), 123.99 - 123.34 (m), 123.55 (q, J = 272.2 Hz), 118.19 
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(br s), 83.69, 69.28, 68.64 (br s), 62.26, 58.07 (br s), 54.33, 27.20, 27.07, 26.67, 26.46, 
14.00; 19F NMR (376 MHz, CDCl3) δ = -62.75 (s, 0.9F), -62.79 (s, 3F); LRMS (ESI) 
calculated for C23H26F3N2O4 [M + H]+ m/z 451.18, found 451.21. 
 
 
 
ethyl 3-(5,5-dimethyl-2-oxooxazolidin-3-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-
3-carboxylate (S68). S67 (50.1 mg, 0.111 mmol, 1.0 equiv.) was dissolved in dry 
dichloromethane (4.44 mL). N,N-diisopropylethylamine (39 uL, 0.222 mmol, 2.0 equiv.), 
1,1’-carbonyldiimidazole (19 mg, 0.117 mmol, 1.05 equiv.), and 4-
dimethylaminopyridine (14 mg, 0.111 mmol, 1.0 equiv.) were then added, and the 
reaction vial was firmly sealed and heated at 50 °C overnight. The reaction was pushed 
to completion by adding 1.05 equiv. 1,1’-carbonyldiimidazole every day for an additional 
4d (70 °C). The crude reaction mixture was transferred to a sep. funnel with ~ 80 mL 
dichloromethane; the organic layer was washed with ~ 50 mL sat. NaHCO3, 0.1N HCl, 
and brine. Dried over MgSO4, concentrated, and purified on a silica column with 0-40% 
EtOAc:hexanes. S68 (36.9 mg, 70%) obtained as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ = 8.19 (br s, 1H), 7.86 (s, 1H), 7.77 (d, J = 8.0 Hz, 2H), 7.66 - 7.58 (m, 1H), 
7.51 - 7.41 (m, 1H), 7.38 (d, J = 7.1 Hz, 1H), 7.21 - 7.15 (m, 1H), 5.01 (d, J = 12.2 Hz, 
1H), 4.35 (br d, J = 11.0 Hz, 1H), 4.30 (q, J = 7.1 Hz, 2H), 3.45 (d, J = 8.3 Hz, 1H), 2.86 
(d, J = 8.0 Hz, 1H), 1.48 (s, 3H), 1.35 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ = 168.90, 167.39, 157.02, 143.22, 136.48, 131.33, 131.43 (q, J = 33.0 
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Hz), 130.23, 129.41, 127.63 (d, J = 3.7 Hz), 127.28, 125.04, 124.70, 124.42 (q, J = 4.2 
Hz,), 123.49 (br q, J = 272.2 Hz), 118.55 (br s), 79.11, 66.92 (br s), 62.86, 59.52 (br s), 
56.35, 27.13, 26.65, 14.01; 19F NMR (376 MHz, CDCl3) δ = -62.81 (s, 3F); LRMS (ESI) 
calculated for C24H24F3N2O5 [M + H]+ m/z 477.16, found 477.12. 
 
 
 
3-(5,5-dimethyl-2-oxooxazolidin-3-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-3-
carboxylic acid (S69). S68 (36.9 mg, 0.077 mmol, 1.0 equiv.) was reacted in methanol 
(3 mL) with 1M lithium hydroxide (93 uL, 0.093 mmol, 1.2 equiv.) according to general 
procedure B, except three additions of 1M lithium hydroxide (155 uL, 0.155 mmol, 2.0 
equiv.) were required (2d). The resulting residue was purified on a silica column with 0-
15% dichloromethane:methanol. Semi-crude S69 (17.0 mg, 49%) obtained as a white 
solid. LRMS (ESI) calculated for C22H18F3N2O5 [M - H]- m/z 447.12, found 447.21. 
 
 
 
3-(5,5-dimethyl-2-oxooxazolidin-3-yl)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (25). Semi-crude S69 (17.0 mg, 
0.038 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 
1 mL DMF according to general procedure D (20m activation). 25 (10.4 mg, 53%) 
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obtained as a white solid. 1H NMR (400 MHz, CD3OD, drops CDCl3) δ = 8.18 - 7.91 (m, 
3H), 7.88 (br d, J = 8.0 Hz, 1H), 7.79 - 7.71 (m, 1H), 7.57 (br d, J = 7.5 Hz, 1H), 7.46 (br 
s, 1H), 7.25 (br t, J = 7.3 Hz, 1H), 5.03 (br d, J = 12.2 Hz, 1H), 4.37 (br d, J = 11.7 Hz, 
1H), 3.57 (br d, J = 8.5 Hz, 1H), 3.10 (br d, J = 8.5 Hz, 1H), 1.57 (s, 3H), 1.40 (s, 3H); 
19F NMR (376 MHz, CD3OD, drops CDCl3) δ = -64.16 (s, 3F); LRMS (ESI) calculated for 
C23H19F3N7O4 [M - H]- m/z 514.15, found 514.33.  
 
 
 
ethyl 3-(((R)-2-hydroxy-2-phenylethyl)amino)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxylate (S70). Semi-crude S41 (53.3 mg, 
0.146 mmol, 1.0 equiv.) was dissolved in absolute ethanol (2 mL); (R)-styrene oxide (17 
uL, 0.146 mmol, 1.0 equiv.) was then added, followed by N,N-diisopropylethylamine (27 
uL, 0.154 mmol, 1.05 equiv.). The reaction vial was sealed and heated at 80 °C 
overnight. The reaction was pushed to completion by adding 5.0 equiv. (R)-styrene 
oxide over 7d (80 °C). The crude reaction mixture was transferred to a sep funnel with ~ 
75 mL EtOAc and partitioned with ~ 75 mL sat. NaHCO3. The aqueous layer was 
washed with an additional 2 x 50 mL EtOAc; the organics were combined, dried over 
MgSO4, and concentrated. Purified on a silica column with 0-50% EtOAc:hexanes. S70 
(45.5 mg, 62%) (mixture of diastereomers) obtained as an orange oil. Note: 
Diastereomers combined with the atropisomers of the secondary amide resulted in a 
multitude of split peaks. 1H NMR (400 MHz, CDCl3) δ = 8.25 (br s, 0.5H), 7.86 (br s, 
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0.5H), 7.82 - 7.74 (m, 1H), 7.73 - 7.59 (m, 1H), 7.48 - 7.40 (m, 1H), 7.40 - 7.25 (m, 7H), 
7.23 - 7.04 (m, 2H), 4.79 (dd, J = 3.4, 8.3 Hz, 0.5H), 4.73 - 4.52 (m, 1H), 4.31 - 4.18 (m, 
1H), 4.17 - 3.93 (m, 1H), 3.77 - 3.70 (m, 0.5H), 3.70 - 3.55 (m, 1H), 3.53 - 3.43 (m, 
0.5H), 2.87 - 2.67 (m, 1H), 2.68 - 2.43 (m, 1H), 1.31 - 1.15 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δ = 171.45 (br s), 167.27 (br s), 167.03 (br s), 141.98 (br s), 141.70, 141.64, 
140.94, 140.90, 140.56, 131.40 (br s), 131.01 (br s), 130.76 (br s), 130.56 - 130.21 (m), 
130.20 - 129.82 (m), 129.63, 129.36, 128.97 - 128.75 (m), 128.63, 128.62, 128.44, 
128.42, 127.85, 127.95 - 127.75 (m), 127.26 (br s), 126.84, 125.99, 125.71, 125.65, 
124.79 (br s), 124.22 (br s), 123.55 (q, J = 272.9 Hz), 118.04 (br s), 74.57, 72.75, 72.54, 
68.02, 67.09, 62.47, 62.37, 62.33, 62.28, 59.41 (br s), 58.31 (br s), 51.49, 51.38, 13.98, 
13.79; 19F NMR (376 MHz, CDCl3) δ = -62.62 (br s, 1F), -62.68 (br s, 1F), -62.75 (br s, 
3F); LRMS (ESI) calculated for C27H26F3N2O4 [M + H]+ m/z 499.18, found 499.08. 
 
 
 
ethyl 3-((R)-2-oxo-5-phenyloxazolidin-3-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-
3-carboxylate (S71). S70 (45.5 mg, 0.091 mmol, 1.0 equiv.) was dissolved in dry 
dichloromethane (3.5 mL). N,N-diisopropylethylamine (32 uL, 0.183 mmol, 2.0 equiv.), 
1,1’-carbonyldiimidazole (16 mg, 0.096 mmol, 1.05 equiv.), and 4-
dimethylaminopyridine (11 mg, 0.091 mmol, 1.0 equiv.) were then added, and the 
reaction vial was firmly sealed and heated at 70 °C overnight. Additional 1,1’-
carbonyldiimidazole (7.4 mg, 0.046 mmol, 0.5 equiv.) was then added; heated at 70 °C 
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for two days. 1.0 equiv. 4-dimethylaminopyridine was then added every day for an 
additional 3d (80 °C). The crude reaction mixture was transferred to a sep. funnel with ~ 
80 mL dichloromethane; the organic layer was washed with ~ 50 mL sat. NaHCO3, 0.5M 
KHSO4, and brine. Dried over MgSO4, concentrated, and purified on a silica column with 
0-40% EtOAc:hexanes. S71 (18.7 mg, 39%) (mixture of diastereomers) obtained as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.28 (br s, 0.6H), 7.92 (s, 0.4H), 7.84 - 7.76 
(m, 2H), 7.72 - 7.59 (m, 2H), 7.51 - 7.33 (m, 5H), 7.32 - 7.10 (m, 3H), 5.57 (dd, J = 5.8, 
8.5 Hz, 0.6H), 5.39 (dd, J = 8.2, 9.4 Hz, 0.4H), 5.03 (dd, J = 2.6, 12.3 Hz, 0.9H), 4.90 (d, 
J = 12.2 Hz, 0.1H), 4.55 - 4.47 (m, 0.5H), 4.41 - 4.23 (m, 2.5H), 4.02 (t, J = 8.5 Hz, 
0.6H), 3.80 - 3.75 (m, 0.1H), 3.70 (dd, J = 8.5, 9.5 Hz, 0.4H), 3.66 - 3.61 (m, 0.1H), 3.41 
(t, J = 8.2 Hz, 0.4H), 3.05 (dd, J = 5.8, 8.5 Hz, 0.6H), 1.41 - 1.23 (m, 3H); 13C NMR (100 
MHz, CDCl3) δ = 169.02, 168.50, 167.42, 167.32, 157.59, 157.19, 143.38 (br s), 143.04 
(br s), 137.90, 137.20, 136.49, 136.43, 131.66, 131.49 (br s), 131.42 (br s), 131.32, 
130.35, 130.17 (br s), 129.44, 129.39, 129.26, 129.10, 128.98, 128.93, 128.68, 127.83 - 
127.57 (m), 127.18, 126.72, 126.12, 125.16, 125.05 (br s), 124.98 - 124.80 (m), 124.75 
- 124.55 (m), 124.48 - 124.25 (m), 123.54 (d, J = 272.4 Hz), 123.51 (d, J = 272.3 Hz), 
118.54 (br s), 76.47, 75.41, 67.16 (br s), 63.07, 63.02, 59.65 (br s), 59.05 (br s), 53.00, 
51.54, 14.14, 14.07; 19F NMR (376 MHz, CDCl3) δ = -62.77 (br s, 3F), -62.78 (s, 2.5F); 
LRMS (ESI) calculated for C28H24F3N2O5 [M + H]+ m/z 525.16, found 525.08. 
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3-((R)-2-oxo-5-phenyloxazolidin-3-yl)-1-(3-(trifluoromethyl)benzoyl)indoline-3-
carboxylic acid (S72). S71 (18.7 mg, 0.036 mmol, 1.0 equiv.) was reacted in methanol 
(3 mL) with 1M lithium hydroxide (43 uL, 0.043 mmol, 1.2 equiv.) according to general 
procedure B, except three additions of 1M lithium hydroxide (71 uL, 0.071 mmol, 2.0 
equiv.) were required (2d). The resulting residue was purified on a silica column with 0-
10% dichloromethane:methanol with 0.1% formic acid. Semi-crude S72 (7.6 mg, 43%) 
(mixture of diastereomers) obtained as a white solid. LRMS (ESI) calculated for 
C26H18F3N2O5 [M - H]- m/z 495.12, found 495.02. 
 
 
 
3-((R)-2-oxo-5-phenyloxazolidin-3-yl)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (26). Semi-crude S72 (7.6 mg, 
0.015 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 
1 mL DMF according to general procedure D (20m activation). 26 (2.3 mg, 27%) 
(mixture of diastereomers) obtained as a white solid. 1H NMR (400 MHz, CD3OD) δ = 
7.98 - 7.88 (m, 3H), 7.76 (t, J = 7.7 Hz, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.52 - 7.34 (m, 
7H), 7.32 - 7.20 (m, 2H), 5.79 (t, J = 8.6 Hz, 1H), 5.12 (br d, J = 11.9 Hz, 1H), 4.33 (br d, 
J = 11.7 Hz, 1H), 4.07 (t, J = 8.3 Hz, 1H); 19F NMR (376 MHz, CD3OD) δ = -64.19 (s, 
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1F), -64.22 (s, 3F); LRMS (ESI) calculated for C27H21F3N7O4 [M + H]+ m/z 564.16, found 
564.12. 
 
 
 
ethyl 3-(((S)-3-(benzyloxy)-2-hydroxypropyl)amino)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxylate (S73). Semi-crude S41 (156.8 mg, 
0.430 mmol, 1.0 equiv.) was dissolved in absolute ethanol (6 mL); benzyl (s)-(+)-glycidyl 
ether (66 uL, 0.430 mmol, 1.0 equiv.) was then added, followed by N,N-
diisopropylethylamine (79 uL, 0.452 mmol, 1.05 equiv.). The reaction vial was sealed 
and heated at 80 °C overnight. The reaction was pushed to completion by adding 2.0 
equiv. benzyl (s)-(+)-glycidyl ether over 3d (80 °C). The crude reaction mixture was 
transferred to a sep funnel with ~ 75 mL EtOAc and partitioned with ~ 75 mL sat. 
NaHCO3. The aqueous layer was washed with an additional 2 x 50 mL EtOAc; the 
organics were combined, dried over MgSO4, and concentrated. Purified on a silica 
column with 0-50% EtOAc:hexanes. S73 (143.8 mg, 62%) (mixture of diastereomers) 
obtained as a light yellow oil. Note: Diastereomers combined with the atropisomers of 
the secondary amide resulted in a multitude of split peaks. 1H NMR (400 MHz, CDCl3) δ 
= 8.26 (br s, 1H), 7.91 - 7.83 (m, 1H), 7.76 (m, 2H), 7.63 - 7.50 (m, 1H), 7.42 - 7.25 (m, 
6.5H), 7.24 - 7.19 (m, 0.5H), 7.12 (br s, 1H), 4.69 - 4.54 (m, 1H), 4.50 (s, 1.6H), 4.42 (br 
d, J = 1.5 Hz, 0.4H), 4.27 - 4.16 (m, 2H), 3.98 (br s, 1H), 3.87 - 3.77 (m, 1H), 3.52 - 3.31 
(m, 2H), 2.65 - 2.41 (m, 2H), 1.30 - 1.21 (m, 3H); 13C NMR (100 MHz, CDCl3) δ = 
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171.38, 171.32, 170.02, 169.84, 167.09 (br s), 142.30 (br s), 137.70, 137.46, 137.16, 
137.08 (br s), 131.09 (q, J = 33.0 Hz), 130.28 (br s), 129.83 (br s), 129.23, 128.42, 
128.34, 128.28, 127.92, 127.71, 127.69, 127.63, 127.58, 127.56, 127.55, 127.29 - 
126.94 (m), 124.60 (br s), 124.30 - 123.58 (m), 123.49 (q, J = 272.4 Hz), 123.44 (d, J = 
272.9 Hz), 118.00 (br s), 73.83, 73.68, 73.28, 73.25, 72.45, 72.34, 69.71, 69.64, 69.24, 
69.21, 68.43 (br s), 62.09, 62.06, 57.98 (br s), 46.41, 46.17, 13.88, 13.86; 19F NMR (376 
MHz, CDCl3) δ = -62.67 (br s, 0.7F), -62.71 (s, 3F), -62.74 (br s, 0.3F); LRMS (ESI) 
calculated for C29H30F3N2O5 [M + H]+ m/z 543.21, found 543.09. 
 
 
 
ethyl 3-((S)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxylate (S74). S73 (143.8 mg, 0.265 mmol, 
1.0 equiv.) was dissolved in dry dichloromethane (10.5 mL). N,N-diisopropylethylamine 
(92 uL, 0.530 mmol, 2.0 equiv.), 1,1’-carbonyldiimidazole (45 mg, 0.278 mmol, 1.05 
equiv.), and 4-dimethylaminopyridine (32 mg, 0.265 mmol, 1.0 equiv.) were then added, 
and the reaction vial was firmly sealed and heated at 70 °C overnight. Additional 1,1’-
carbonyldiimidazole (21.5 mg, 0.133 mmol, 0.5 equiv.) was then added; heated at 70 °C 
for 4d. 1.0 equiv. 4-dimethylaminopyridine was then added every day for an additional 
2d (80 °C). The crude reaction mixture was transferred to a sep. funnel with ~ 80 mL 
dichloromethane; the organic layer was washed with ~ 50 mL sat. NaHCO3, 0.5M 
KHSO4, and brine. Dried over MgSO4, concentrated, and purified on a silica column with 
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0-30% EtOAc:hexanes. S74 (110.9 mg, 74%) (mixture of diastereomers) obtained as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.25 (br s, 0.5H), 7.88 (s, 0.5H), 7.82 - 7.71 
(m, 2H), 7.67 - 7.57 (m, 1H), 7.56 - 7.50 (m, 0.6H), 7.43 (br d, J = 7.5 Hz, 1.4H), 7.39 - 
7.24 (m, 5H), 7.22 - 7.13 (m, 2H), 4.98 (dd, J = 10.1, 12.1 Hz, 1H), 4.67 (qd, J = 4.2, 8.7 
Hz, 0.5H), 4.62 - 4.54 (m, 1.5H), 4.53 - 4.43 (m, 1H), 4.39 (br d, J = 11.4 Hz, 0.5H), 4.33 
- 4.21 (m, 2.5H), 3.73 (t, J = 8.6 Hz, 0.5H), 3.70 - 3.59 (m, 1.5H), 3.56 (dd, J = 4.1, 10.7 
Hz, 0.5H), 3.45 (dd, J = 3.8, 10.6 Hz, 0.5H), 3.16 - 3.03 (m, 1H), 1.31 - 1.20 (m, 3H); 13C 
NMR (100 MHz, CDCl3) δ = 168.73, 168.59, 167.22 (br s), 157.17, 157.06, 143.16 (br 
s), 137.32, 137.03, 136.50, 136.40, 131.29 (br d, J = 3.7 Hz), 131.28 (q, J = 33.0 Hz), 
131.23 (q, J = 33.0 Hz), 130.25 (br s), 130.12 (br s), 129.28, 129.25, 128.42, 128.37, 
127.88, 127.85, 127.67, 127.55 (br s), 127.51, 127.40 (br s), 127.36 (br s), 127.03 (br 
s), 125.08 (br s), 124.61 (br ), 124.49 (br s), 124.45 (br s), 124.31 (br s), 124.27 (br s), 
123.46 (d, J = 272.9 Hz), 123.44 (d, J = 272.9 Hz), 118.39 (br s), 73.54, 73.47, 73.39, 
72.88, 69.67, 69.45, 66.96 (br s), 62.79, 59.33 (br s), 58.94 (br s), 46.68, 45.94, 13.91; 
19F NMR (376 MHz, CHLOROFORM-d) δ = -62.73 (s, 2.8F), -62.74 (br s, 3F); LRMS 
(ESI) calculated for C30H28F3N2O6 [M + H]+ m/z 569.19, found 569.09. 
 
 
 
3-((S)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxylic acid (S75). S74 (49.5 mg, 0.087 
mmol, 1.0 equiv.) was reacted in methanol (3.5 mL) with 1M lithium hydroxide (218 uL, 
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0.218 mmol, 2.5 equiv.) according to general procedure B. The resulting residue was 
purified on a silica column with 0-15% dichloromethane:methanol. Semi-crude S75 
(25.2 mg, 54%) (mixture of diastereomers) obtained as a white solid. LRMS (ESI) 
calculated for C28H22F3N2O6 [M - H]- m/z 539.14, found 539.29. 
 
 
 
3-((S)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (28). Semi-crude S75 (25.2 mg, 
0.047 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 
2 mL DMF according to general procedure D (20m activation). 28 (21.6 mg, 76%) 
(mixture of diastereomers)  obtained as a white solid. 1H NMR (400 MHz, CD3OD, drops 
CDCl3) δ = 8.24 (br s, 0.5H), 7.97 - 7.88 (m, 1H), 7.87 - 7.79 (m, 2H), 7.73 - 7.68 (m, 
1H), 7.66 - 7.56 (m, 1.5H), 7.52 - 7.40 (m, 1.3H), 7.40 - 7.18 (m, 5.7H), 5.05 (br dd, J = 
11.9, 17.8 Hz, 1H), 4.79 - 4.71 (m, 1H), 4.56 - 4.41 (m, 2H), 4.17 (br d, J = 11.4 Hz, 
0.6H), 3.85 (t, J = 8.6 Hz, 0.6H), 3.79 - 3.66 (m, 2H), 3.58 - 3.51 (m, 1H), 3.51 - 3.36 (m, 
0.6H), 3.26 (dd, J = 7.1, 8.0 Hz, 0.7H); 13C NMR (100 MHz, CD3OD, drops CDCl3) δ = 
169.78, 169.48, 169.04 (br s), 160.08, 159.58, 151.63 (br s), 151.45 (br s), 144.26 (br 
s), 144.09 (br s), 139.24, 139.21 (br s), 138.79, 138.44, 138.18 (br s), 138.05, 132.54 
(br s), 132.50 (br s), 132.21 (br s), 132.17, 131.84 (br s), 131.71 (br s), 130.85 (br s), 
130.82 (br s), 129.63, 129.58, 129.46, 129.37, 129.33, 129.24, 129.04, 128.83 (br s), 
128.82 (br s), 128.79, 128.68 (br s), 126.57 (br s), 126.47 - 126.22 (m), 125.53 - 125.18 
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(m), 123.69 (br s), 123.65, 119.49 (br s), 75.87, 75.48, 74.69, 74.50, 73.48, 73.11, 
71.66, 70.87, 62.25, 61.59, 59.16 (br s), 58.84 (br s), 46.67, 46.29; 19F NMR (376 MHz, 
CD3OD, drops CDCl3) δ = -63.89 (br s, 0.5F), -63.91 (br s, 0.5F), -63.94 (s, 3F), -63.98 
(s, 1.6F); LRMS (ESI) calculated for C29H23F3N7O5 [M - H]- m/z 606.17, found 606.31. 
 
 
 
3-((S)-5-(hydroxymethyl)-2-oxooxazolidin-3-yl)-N-(1H-tetrazol-5-yl)-1-(3-
(trifluoromethyl)benzoyl)indoline-3-carboxamide (27). 28 (18.3 mg, 0.030 mmol, 1.0 
equiv.) was dissolved in ethanol (10 mL) and hydrogenated for 3h using an “H-Cube” 
flow hydrogenator with a 10% Pd/C cartridge; 1 mL/min, 10 bar H2, 25 °C, loop 
configuration. The reaction mixture was concentrated and purified by reverse phase 
HPLC (water/MeOH/0.05% formic acid) to afford 27 (7.2 mg, 46%) (mixture of 
diastereomers) as a white solid. Note: Diastereomers combined with the atropisomers 
of the secondary amide resulted in a multitude of split peaks. 1H NMR (400 MHz, 
CD3OD, drops CDCl3) δ = 8.23 (br s, 1H), 8.03 - 7.92 (m, 2H), 7.91 - 7.84 (m, 1H), 7.78 
- 7.69 (m, 1H), 7.61 (m, 0.5H), 7.55 - 7.40 (m, 1.5H), 7.26 (b q, J = 7.1 Hz, 1H), 5.14 - 
5.03 (m, 0.4H), 4.95 - 4.87 (m, 1H), 4.81 - 4.68 (m, 0.8H), 4.56 (d, J = 12.7 Hz, 0.25H), 
4.51 (br d, J = 12.4 Hz, 0.25H), 4.44 (br d, J = 11.4 Hz, 0.05H), 4.26 (br d, J = 11.7 Hz, 
0.3H), 4.22 (br dd, J = 2.1, 5.7 Hz, 0.1H), 3.98 - 3.84 (m, 0.4H), 3.81 (dd, J = 2.4, 12.7 
Hz, 0.3H), 3.75 (t, J = 8.5 Hz, 0.4H), 3.72 - 3.39 (m, 2.5H), 3.23 (t, J = 7.7 Hz, 0.3H); 13C 
NMR (100 MHz, CD3OD, drops CDCl3) δ = 170.24, 169.59 (br s), 160.60, 160.22, 
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154.80 (br s), 152.08 (br s), 145.58 (br s), 144.64 (br s), 138.77 (br s), 138.69 (br s), 
133.05 - 132.90 (m), 132.90 - 132.76 (m), 132.62 - 132.38 (m), 132.28 - 132.08 (m), 
131.26, 131.23, 131.16 (br s), 130.20, 129.59, 129.31 - 129.05 (m), 129.03 - 128.85 
(m), 127.37 - 127.07 (m), 126.78 - 126.55 (m), 125.98 - 125.73 (m), 125.72 - 125.52 
(m), 125.53 (q, J = 271.9 Hz), 119.77 (br s), 77.64, 77.09, 73.09 (br s), 71.19, 70.64, 
69.46, 65.66, 64.79, 64.49, 63.03, 61.88, 59.11 (br s), 47.12, 46.09, 45.99; 19F NMR 
(376 MHz, CD3OD, drops CDCl3) δ = -64.15 (s, 3F), -64.19 (s, 2.2F); LRMS (ESI) 
calculated for C22H17F3N7O5 [M - H]- m/z 516.12, found 516.07. 
 
 
 
tert-butyl (1-((1H-tetrazol-5-yl)carbamoyl)cyclopropyl)carbamate (29). 
Commercially available 1-((tert-Butoxycarbonyl)amino)cyclopropanecarboxylic acid (100 
mg, 0.497 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.5 
equiv.) in 4 mL DMF according to general procedure D (10m activation), except 3.0 
equiv. N,N-diisopropylethylamine was added initially, with no second addition. 29 (106.5 
mg, 80%) obtained as a white solid. Note: Atropisomers resulted in some split peaks. 
1H NMR (400 MHz, DMSO-d6) δ = 11.88 (br s, 0.2H), 11.73 (br s, 0.8H), 7.41 (br s, 
0.8H), 7.11 (br s, 0.2H), 1.54 - 1.23 (m, 11H), 1.10 (br s, 2H); 13C NMR (100 MHz, 
DMSO-d6) δ = 172.45, 155.84 (br), 150.20 (br), 78.67, 35.40 (br), 28.21, 17.87; LRMS 
(ESI) calculated for C10H15N6O3 [M - H]- m/z 267.12, found 267.10. 
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tert-butyl (1-((1H-tetrazol-5-yl)carbamoyl)cyclobutyl)carbamate (30). Commercially 
available boc-1-amino-1-cyclobutanecarboxylic acid (100 mg, 0.465 mmol, 1.0 equiv.) 
was reacted with 5-aminotetrazole monohydrate (1.5 equiv.) in 4 mL DMF according to 
general procedure D (10m activation), except 3.0 equiv. N,N-diisopropylethylamine was 
added initially, with no second addition. 30 (101.1 mg, 77%) obtained as a white solid. 
Note: Atropisomers gave many split peaks in 1H and 13C. 1H NMR (400 MHz, DMSO-
d6) δ = 11.71 (br s, 0.3H), 11.59 (br s, 0.7H), 7.46 (br s, 0.7H), 7.10 (br s, 0.3H), 2.62 - 
2.46 (m, 2H), 2.12 (q, J = 9.3 Hz, 2H), 1.88 (br s, 1H), 1.81 - 1.67 (m, 1H), 1.33 (br s, 
6H), 1.18 (br s, 3H); 13C NMR (100 MHz, DMSO-d6) δ = 173.37 (br), 173.01, 154.57, 
153.53 (br), 150.35 (br), 78.77, 58.69 (br), 30.92 (br), 30.32, 28.16 (br), 14.65, 14.32 
(br); LRMS (ESI) calculated for C11H17N6O3 [M - H]- m/z 281.14, found 281.06. 
 
 
 
tert-butyl (1-((1H-tetrazol-5-yl)carbamoyl)cyclopentyl)carbamate (31). Commercially 
available 1-N-Boc-Aminocyclopentanecarboxylic acid (100 mg, 0.436 mmol, 1.0 equiv.) 
was reacted with 5-aminotetrazole monohydrate (1.5 equiv.) in 4 mL DMF according to 
general procedure D (10m activation), except 3.0 equiv. N,N-diisopropylethylamine was 
added initially, with no second addition. 31 (99.2 mg, 77%) obtained as a white solid. 
Note: Atropisomers resulted in some split peaks. 1H NMR (400 MHz, DMSO-d6) δ = 
11.83 (br s, 0.3H), 11.69 (br s, 0.7H), 7.08 (br s, 0.7H), 6.79 (br s, 0.3H), 2.20 - 2.04 (m, 
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2H), 1.86 (br s, 2H), 1.75 - 1.51 (m, 4H), 1.32 (br s, 9H); 13C NMR (100 MHz, DMSO-d6) 
δ = 173.95 (br), 154.93 (br), 150.34 (br), 78.61 (br), 66.47 (br), 35.91 (br), 28.14 (br), 
23.91; LRMS (ESI) calculated for C12H19N6O3 [M - H]- m/z 295.15, found 295.10.  
 
 
 
tert-butyl (2-((1H-tetrazol-5-yl)amino)-2-oxo-1-phenylethyl)carbamate (32). 
Commercially available tert-butoxycarbonylamino-phenyl-acetic acid (100 mg, 0.398 
mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.5 equiv.) in 4 mL 
DMF according to general procedure D (10m activation), except 3.0 equiv. N,N-
diisopropylethylamine was added initially, with no second addition. 32 (50.3 mg, 40%) 
obtained as a white solid. Note: Slight atropisomerism observed by 1H NMR. 1H NMR 
(400 MHz, DMSO-d6) δ = 12.34 (br s, 1H), 7.78 (br d, J = 7.3 Hz, 0.85H), 7.49 (br d, J = 
7.1 Hz, 2.15H), 7.42 - 7.22 (m, 3H), 5.41 (br d, J = 7.3 Hz, 0.85H), 5.27 (br s, 0.15H), 
1.39 (s, 7.6H), 1.30 (br s, 1.4H); 13C NMR (100 MHz, DMSO-d6) δ = 170.08, 155.25, 
149.53 (br), 136.13, 128.54, 128.30, 127.90, 78.67, 58.13, 28.17; LRMS (ESI) 
calculated for C14H17N6O3 [M - H]- m/z 317.14, found 317.16. 
 
 
 
tert-butyl (1-((1H-tetrazol-5-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (33). 
Commercially available boc-DL-Phe-OH (100 mg, 0.377 mmol, 1.0 equiv.) was reacted 
with 5-aminotetrazole monohydrate (1.5 equiv.) in 4 mL DMF according to general 
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procedure D (10m activation), except 3.0 equiv. N,N-diisopropylethylamine was added 
initially, with no second addition. 33 (33.3 mg, 27%) obtained as a white solid. Note: 
Slight atropisomerism observed by 1H NMR. 1H NMR (400 MHz, DMSO-d6) δ = 12.27 
(br s, 1H), 7.42 - 7.24 (m, 5H), 7.24 - 7.15 (m, 1H), 6.96 (br s, 0.2H), 4.41 (br s, 1H), 
3.10 - 2.93 (m, 1H), 2.91 - 2.74 (m, 1H), 1.31 (s, 7.6H), 1.20 (br s, 1.4H); 13C NMR (100 
MHz, DMSO-d6) δ = 171.73, 155.46, 149.53 (br), 137.52, 129.27, 128.11, 126.46, 
78.36, 56.20, 36.58, 28.12; LRMS (ESI) calculated for C15H19N6O3 [M - H]- m/z 331.15, 
found 331.14. 
 
 
 
tert-butyl (2-((1H-tetrazol-5-yl)carbamoyl)-2,3-dihydro-1H-inden-2-yl)carbamate 
(34). Commercially available boc-2-aminoindane-2-carboxylic acid (100 mg, 0.361 
mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.5 equiv.) in 3 mL 
DMF according to general procedure D (10m activation), except 3.0 equiv. N,N-
diisopropylethylamine was added initially, with no second addition. 34 (84.6 mg, 68%) 
obtained as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.14 (br s, 0.25H), 12.00 
(br s, 0.75H), 7.50 (br s, 0.7H), 7.25 - 7.18 (m, 2H), 7.18 - 7.12 (m, 2H), 3.60 (br d, J = 
16.6 Hz, 2H), 3.22 (br d, J = 16.6 Hz, 2H), 1.35 (br s, 9H); 13C NMR (100 MHz, DMSO-
d6) δ = 173.45 (br), 155.45 (br), 150.80, 140.42, 127.08, 124.89, 79.29 (br), 66.87 (br), 
42.78 (br), 28.55 (br); LRMS (ESI) calculated for C16H19N6O3 [M - H]- m/z 343.15, found 
343.16. 
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methyl 4-azido-2-(3-(trifluoromethyl)benzoyl)-1,2,3,4-tetrahydroisoquinoline-4-
carboxylate (S76). S23 (87.1 mg, 0.240 mmol, 1.0 equiv.) was reacted in 8 mL 
tetrahydrofuran according to general procedure F. S76 (90.8 mg, 94%) obtained as a 
colorless oil. Note: Atropisomerism observed by NMR. 1H NMR (400 MHz, CDCl3) δ = 
7.93 - 7.68 (m, 3H), 7.67 - 7.53 (m, 1.5H), 7.48 - 7.20 (m, 3.5H), 5.54 (br s, 0.5H), 4.55 
(br s, 2H), 3.95 (br s, 1H), 3.80 (br s, 3H), 3.70 (br s, 0.5H); 13C NMR (100 MHz, CDCl3) 
δ = 170.07 (br s), 169.71 (br s), 135.74, 132.42 (br s), 131.14 (br s), 130.99 - 130.64 
(m), 130.49 (br s), 130.31, 130.30, 129.80 (br s), 129.09, 129.01, 128.99, 127.83 (br s), 
127.75 - 127.20 (m), 127.01 (br s), 126.86 - 126.57 (m), 126.57 - 125.99 (m), 124.79 - 
124.18 (m), 124.03, 124.00, 123.59 (q, J = 272.7 Hz), 123.55 (q, J = 272.4 Hz), 66.59 
(br s), 53.36, 50.84 (br s), 44.12 (br s); 19F NMR (376 MHz, CDCl3) δ = -62.75 (s, 3F); 
LRMS (ESI) calculated for C19H16F3N4O3 [M + H]+ m/z 405.12, found 405.07. 
 
 
 
methyl 4-((tert-butoxycarbonyl)amino)-2-(3-(trifluoromethyl)benzoyl)-1,2,3,4-
tetrahydroisoquinoline-4-carboxylate (S77). A round bottom flask was charged with 
S76 (90.8 mg, 0.225 mmol, 1.0 equiv.) and dry methanol (4 mL), then cooled to 0 °C. 
Anhydrous tin(II) chloride (85.2 mg, 0.449 mmol, 2.0 equiv.) was then added; stirred at 0 
°C for 5m, then r.t. for 3.5h. The methanol was then removed under reduced pressure. 
N
O
O
O
CF3
N3
N
O
O
O
CF3
NHBoc
 282 
1,4-dioxane (3 mL) was then added, followed by di-tert-butyl dicarbonate (74 mg, 0.337 
mmol, 1.5 equiv.) in 500 uL 1,4-dioxane. Finally, a slurry of sodium bicarbonate (75 mg, 
0.898 mmol, 4.0 equiv.) in water (1 mL) was added, and the resulting slurry was allowed 
to stir for 22h. 2.0 equiv. di-tert-butyl dicarbonate and 1 mL water were then added; 
stirred for 24h. Additional 2.0 equiv. di-tert-butyl dicarbonate and 1 mL water were 
added; stirred for 32h. The reaction mixture was then transferred to a sep. funnel with 
excess EtOAc and water and adjusted to pH 1 with 2N NaHSO4. The layers were 
separated, and the aqueous layer was further extracted with ~ 50 mL EtOAc. The 
organic layers were combined, washed with sat. NaHCO3, dried over MgSO4, and 
concentrated under reduced pressure. Purified on a silica column with 15-30% 
EtOAc:hexanes. S77 (70.6 mg, 66%) obtained as a colorless oil. Note: Atropisomerism 
observed by NMR. 1H NMR (400 MHz, CDCl3) δ = 7.80 - 7.64 (m, 2H), 7.64 - 7.48 (m, 
2H), 7.41 (br d, J = 6.8 Hz, 1H), 7.37 - 7.18 (m, 2.6H), 6.97 (br s, 0.4H), 5.27 (br s, 
0.5H), 5.15 (br s, 0.6H), 5.01 (br s, 0.4H), 4.84 - 4.53 (m, 2H), 4.41 (br s, 0.5H), 3.70 (s, 
3H), 1.32 (br s, 7.5H), 1.06 (br s, 1.5H); 13C NMR (100 MHz, CDCl3) δ = 170.86 (br s), 
169.89 (br s), 154.08 (br s), 153.39 (br s), 136.44 - 135.89 (m), 133.59 (br s), 131.78 (br 
s), 131.15 (br s), 130.85 (br s), 130.73 - 129.80 (m), 129.37 - 128.70 (m), 128.64 - 
128.11 (m), 127.70 (br s), 127.36 - 126.82 (m), 126.58 (br s), 126.04 (br s), 124.86 - 
124.33 (m), 124.25 - 123.67 (m), 123.60 (q, J = 272.2 Hz), 80.29 (br s), 59.86 (br s), 
53.48 (br s), 52.99 (br s), 49.61 (br s), 45.27 (br s), 44.32 (br s), 28.08 (br s); 19F NMR 
(376 MHz, CDCl3) δ = -62.71 (br s, 3F), -62.82 (br s, 1.6F); LRMS (ESI) calculated for 
C24H26F3N2O5 [M + H]+ m/z 479.18, found 479.10. 
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4-((tert-butoxycarbonyl)amino)-2-(3-(trifluoromethyl)benzoyl)-1,2,3,4-
tetrahydroisoquinoline-4-carboxylic acid (S78). S77 (70.6 mg, 0.148 mmol, 1.0 
equiv.) was reacted in methanol (3.5 mL) with 1M lithium hydroxide (370 uL, 0.370 
mmol, 2.5 equiv.) according to general procedure B, except the reaction was cooled to 0 
°C prior to hydroxide addition, and allowed to slowly warm to r.t.; three additions of 1M 
lithium hydroxide (370 uL, 0.370 mmol, 2.5 equiv.) were added over the following 8h. 
Semi-crude S78 (64.7 mg, 94%) obtained as a colorless oil. LRMS (ESI) calculated for 
C23H22F3N2O5 [M - H]- m/z 463.15, found 463.14. 
 
 
 
tert-butyl (4-((1H-tetrazol-5-yl)carbamoyl)-2-(3-(trifluoromethyl)benzoyl)-1,2,3,4-
tetrahydroisoquinolin-4-yl)carbamate (35). Semi-crude S78 (64.7 mg, 0.139 mmol, 
1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 3.5 mL DMF 
according to general procedure D (10m activation). 35 (30.0 mg, 41%) obtained as a 
white solid. Note: Atropisomerism observed by NMR. 1H NMR (400 MHz, DMSO-d6) δ = 
12.30 (br s, 0.25H), 12.18 (br s, 0.25H), 12.02 (br s, 0.25H), 7.94 - 7.45 (m, 5.5H), 7.38 
(br s, 1.5H), 7.33 - 7.22 (m, 1.5H), 7.12 (br s, 0.5H), 5.15 - 5.01 (m, 0.25H), 4.98 - 4.43 
(m, 2.25H), 4.34 (br d, J = 12.4 Hz, 1H), 4.25 - 4.09 (m, 0.25H), 3.86 - 3.70 (m, 0.25H), 
1.51 - 1.20 (m, 7H), 0.85 (br s, 2H); 13C NMR (100 MHz, DMSO-d6) δ = 170.30 (br s), 
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168.79 (br s), 155.30 (br s), 150.44 (br s), 137.34 (br s), 134.22, 132.55 - 131.03 (m), 
130.24 - 129.64 (m), 129.43, 128.94 (br s), 127.91 - 127.47 (m), 127.44 - 127.01 (m), 
126.88 - 126.49 (m), 124.59 - 124.20 (m), 124.38 (d, J = 272.2 Hz), 80.17 (br s), 79.42 
(br s), 61.14 (br s), 50.15 (br s), 49.41 (br s), 44.94 (br s), 28.54 (br s), 27.64 (br s); 19F 
NMR (376 MHz, DMSO-d6) δ = -61.17 (br s, 1.5F), -61.24 (br s, 3F); LRMS (ESI) 
calculated for C24H23F3N7O4 [M - H]- m/z 530.18, found 530.17. 
 
 
 
methyl 4-azido-2-((3-(trifluoromethyl)phenyl)sulfonyl)-1,2,3,4-
tetrahydroisoquinoline-4-carboxylate (S79). S25 (96.3 mg, 0.241 mmol, 1.0 equiv.) 
was reacted in 8 mL tetrahydrofuran according to general procedure F. S79 (105.0 mg, 
99%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.16 (s, 1H), 8.13 - 
8.04 (m, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.73 (t, J = 7.9 Hz, 1H), 7.41 - 7.33 (m, 1H), 7.33 
- 7.27 (m, 2H), 7.24 - 7.18 (m, 1H), 4.67 (d, J = 15.6 Hz, 1H), 4.23 (d, J = 15.3 Hz, 1H), 
3.97 (dd, J = 1.2, 12.7 Hz, 1H), 3.82 (s, 3H), 3.70 (d, J = 15.8 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ = 169.43, 138.37, 131.43, 131.79 (q, J = 33.5 Hz), 130.71 (br s), 130.07, 
129.96, 129.72 (q, J = 3.7 Hz), 129.61, 129.36, 129.26, 127.80, 127.65, 127.09, 127.01 
(d, J = 1.5 Hz), 126.41, 124.47 (q, J = 3.9 Hz), 123.02 (q, J = 272.9 Hz), 66.45, 53.44, 
50.31, 46.98; 19F NMR (376 MHz, CDCl3) δ = -62.79 (s, 3F); LRMS (ESI) calculated for 
C18H15F3N4NaO4S [M + Na]+ m/z 463.07, found 462.99. 
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methyl 4-((tert-butoxycarbonyl)amino)-2-((3-(trifluoromethyl)phenyl)sulfonyl)-
1,2,3,4-tetrahydroisoquinoline-4-carboxylate (S80). A round bottom flask was 
charged with S79 (105.0 mg, 0.238 mmol, 1.0 equiv.) and dry methanol (4.4 mL), then 
cooled to 0 °C. Anhydrous tin(II) chloride (90.4 mg, 0.477 mmol, 2.0 equiv.) was added; 
stirred at 0 °C for 5m, then r.t. for 4.5h. The methanol was then removed under reduced 
pressure. 1,4-dioxane (3.2 mL) was added, followed by di-tert-butyl dicarbonate (78 mg, 
0.358 mmol, 1.5 equiv.) in 500 uL 1,4-dioxane. Finally, a slurry of sodium bicarbonate 
(80 mg, 0.954 mmol, 4.0 equiv.) in water (1 mL) was added, and the resulting slurry was 
allowed to stir for 14h. 2.0 equiv. di-tert-butyl dicarbonate and 1 mL water were then 
added; stirred for 24h. Additional 2.0 equiv. di-tert-butyl dicarbonate and 1 mL water 
were added; stirred for 28h. The reaction mixture was then transferred to a sep. funnel 
with excess EtOAc and water and adjusted to pH 1 with 2N NaHSO4. The layers were 
separated, and the aqueous layer was further extracted with ~ 50 mL EtOAc. The 
organic layers were combined, washed with sat. NaHCO3, dried over MgSO4, and 
concentrated under reduced pressure. Purified on a silica column with 10-25% 
EtOAc:hexanes. S80 (84.5 mg, 69%) obtained as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ = 8.11 (s, 1H), 8.06 (br d, J = 7.8 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.75 - 7.69 
(m, 1H), 7.53 (br d, J = 7.5 Hz, 1H), 7.33 - 7.23 (m, 2H), 7.13 (dd, J = 0.7, 7.3 Hz, 1H), 
4.61 (br d, J = 14.9 Hz, 1H), 4.51 (br d, J = 12.7 Hz, 1H), 4.10 (br d, J = 14.3 Hz, 1H), 
3.77 (s, 3H), 3.53 (br d, J = 12.7 Hz, 1H), 1.45 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 
170.70, 153.87, 138.60, 132.32, 131.89 (q, J = 33.8 Hz), 131.63, 130.66, 130.09, 
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129.53 (q, J = 3.7 Hz), 129.03, 127.99, 126.98, 126.80, 124.29 (q, J = 3.9 Hz), 123.11 
(q, J = 273.6 Hz), 80.53, 59.85, 53.03, 48.19, 47.60, 28.18; 19F NMR (376 MHz, CDCl3) 
δ = -62.73 (s, 3F); LRMS (ESI) calculated for C23H26F3N2O6S [M + H]+ m/z 515.15, 
found 515.05.  
 
 
 
4-((tert-butoxycarbonyl)amino)-2-((3-(trifluoromethyl)phenyl)sulfonyl)-1,2,3,4-
tetrahydroisoquinoline-4-carboxylic acid (S81). S80 (84.5 mg, 0.164 mmol, 1.0 
equiv.) was reacted in 1,4-dioxane (3 mL) with 1M lithium hydroxide (3 mL, 3.0 mmol, 
18.3 equiv.) according to general procedure B. Semi-crude S81 (88.2 mg, 107%) 
obtained as a white solid. LRMS (ESI) calculated for C22H22F3N2O6S [M - H]- m/z 
499.12, found 499.09. 
 
 
 
tert-butyl (4-((1H-tetrazol-5-yl)carbamoyl)-2-((3-(trifluoromethyl)phenyl)sulfonyl)-
1,2,3,4-tetrahydroisoquinolin-4-yl)carbamate (36). Semi-crude S81 (88.2 mg, 0.176 
mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 4.4 mL 
DMF according to general procedure D (10m activation). 36 (26.6 mg, 27%) obtained as 
a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.01 (br s, 1H), 8.14 (d, J = 7.3 Hz, 
2H), 8.04 (s, 1H), 7.97 - 7.89 (m, 1H), 7.69 (br s, 1H), 7.44 (br d, J = 7.1 Hz, 1H), 7.36 - 
7.22 (m, 3H), 6.54 (br s, 0.1H), 4.44 (br d, J = 15.3 Hz, 1H), 4.23 (br d, J = 15.3 Hz, 1H), 
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4.09 (br d, J = 11.9 Hz, 1H), 3.84 (br d, J = 12.2 Hz, 1H), 1.40 (br s, 9H); 13C NMR (100 
MHz, DMSO-d6) δ = 169.89, 155.11 (br s), 150.81, 137.68, 133.12, 132.92, 131.90 (br 
d, J = 3.8 Hz), 130.70 (br d, J = 4.5 Hz), 130.64 (br d, J = 32.9 Hz), 128.90, 127.81, 
127.66, 127.05, 124.11 (d, J = 4.0 Hz), 123.81 (d, J = 273.0 Hz), 79.48, 61.61, 48.21 (br 
s), 48.02, 28.64 (br s); 19F NMR (376 MHz, DMSO-d6) δ = -61.33 (br s, 3F); LRMS (ESI) 
calculated for C23H23F3N7O5S [M - H]- m/z 566.14, found 566.21.  
 
 
 
1-benzyl 3-methyl indoline-1,3-dicarboxylate (S82). Semi-crude S32 (149.8 mg, 
0.701 mmol, 1.0 equiv.) was reacted with commercially available benzyl chloroformate 
in dry dichloromethane (6.2 mL) according to general procedure A, with slight 
modification: prior to base addition, the reaction vessel was cooled to 0 °C; 2.5 equiv. of 
N,N-diisopropylethylamine was used, and allowed to stir at 0 °C for 5m; after acyl 
chloride addition, the reaction mixture was allowed to slowly warm to r.t. S82 (178.3 mg, 
82%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 7.96 (br s, 1H), 7.51 - 
7.33 (m, 6H), 7.32 - 7.19 (m, 1H), 7.02 (br t, J = 7.3 Hz, 1H), 5.40 - 5.21 (m, 2H), 4.51 
(dd, J = 5.0, 10.6 Hz, 1H), 4.28 - 4.13 (m, 2H), 3.78 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ = 171.49, 152.31 (br), 142.16 (br), 136.06 (br), 128.95, 128.45, 128.09, 127.91 (br), 
127.41 (br), 124.98 (br), 122.66, 114.91 (br), 66.97 (br), 52.47, 49.44 (br), 44.72 (br); 
LRMS (ESI) calculated for C18H17NNaO4 [M + Na]+ m/z 334.11, found 333.97. 
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1-benzyl 3-methyl 3-azidoindoline-1,3-dicarboxylate (S83). S82 (178.3 mg, 0.573 
mmol, 1.0 equiv.) was reacted in 12 mL tetrahydrofuran according to general procedure 
F. S83 (103.3 mg, 51%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.05 
(br s, 1H), 7.53 - 7.33 (m, 7H), 7.11 (br t, J = 7.4 Hz, 1H), 5.30 (br s, 2H), 4.60 (d, J = 
12.4 Hz, 1H), 4.09 (br d, J = 11.7 Hz, 1H), 3.89 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 
169.17, 152.02 (br), 142.57 (br), 135.67 (br), 131.59, 128.57, 128.34, 128.13 (br), 
126.06 (br), 123.84 (br), 122.97, 115.70, 69.64 (br), 67.45 (br), 56.78 (br), 53.57; LRMS 
(ESI) calculated for C18H16N4NaO4 [M + Na]+ m/z 375.10, found 375.00. 
 
 
 
methyl 4-((tert-butoxycarbonyl)amino)-2-((3-(trifluoromethyl)phenyl)sulfonyl)-
1,2,3,4-tetrahydroisoquinoline-4-carboxylate (S84). A round bottom flask was 
charged with S83 (103.3 mg, 0.293 mmol, 1.0 equiv.) and dry methanol (6 mL), then 
cooled to 0 °C. Anhydrous tin(II) chloride (111 mg, 0.586 mmol, 2.0 equiv.) was added; 
stirred at 0 °C for 5m, then r.t. for 4 h. The methanol was then removed under reduced 
pressure. 1,4-dioxane (5.5 mL) was added, followed by di-tert-butyl dicarbonate (96 mg, 
0.440 mmol, 1.5 equiv.) in 700 uL 1,4-dioxane. Finally, a slurry of sodium bicarbonate 
(99 mg, 1.17 mmol, 4.0 equiv.) in water (1.4 mL) was added, and the resulting slurry 
was allowed to stir for 14h. The reaction mixture was then transferred to a sep. funnel 
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with excess EtOAc and water and adjusted to pH 1 with 1M KHSO4. The layers were 
separated, and the aqueous layer was further extracted with ~ 50 mL EtOAc. The 
organic layers were combined, washed with sat. NaHCO3, dried over MgSO4, and 
concentrated under reduced pressure. Purified on a silica column with 0-15% 
EtOAc:hexanes. S84 (88.9 mg, 71%) obtained as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ = 7.96 (br d, J = 6.6 Hz, 1H), 7.48 - 7.28 (m, 7H), 7.01 (br t, J = 7.4 Hz, 1H), 
5.28 (br s, 2H), 4.95 (br d, J = 10.7 Hz, 1H), 4.22 (br d, J = 10.2 Hz, 1H), 3.76 (s, 3H), 
1.45 (br s, 9H); 13C NMR (100 MHz, CDCl3) δ = 170.74 (br), 154.76 (br), 152.39 (br), 
142.81 (br), 135.95 (br), 130.98 (br), 128.52, 128.19 (br), 128.07 (br), 123.25 (br), 
123.03 (br), 115.48 (br), 80.70 (br), 67.16 (br), 64.28 (br), 58.26 (br), 53.23; LRMS (ESI) 
calculated for C23H26N2NaO6 [M + Na]+ m/z 449.17, found 449.00. 
 
 
 
methyl 3-((tert-butoxycarbonyl)amino)indoline-3-carboxylate (S85). S84 (810.9 mg, 
1.90 mmol, 1.0 equiv.) was dissolved in methanol (100 mL) and hydrogenated for 6h 
using an “H-Cube” flow hydrogenator with a 10% Pd/C cartridge; 2 mL/min, 1 atm H2, 
40 °C, loop configuration. The reaction mixture was concentrated and transferred to a 
sep. funnel with ~ 75 mL EtOAc and partitioned with ~ 75 mL sat. NaHCO3. The organic 
layer was separated, and the aqueous layer was further extracted with 2 x 50 mL 
EtOAc. The organic layers were combined, dried over MgSO4, and concentrated. S85 
(548.4 mg, 99%) obtained as a waxy white solid; used without further purification. LRMS 
(ESI) calculated for C15H21N2O4 [M + H]+ m/z 293.15, found 293.03. 
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methyl 3-((tert-butoxycarbonyl)amino)-1-(3-(trifluoromethyl)benzyl)indoline-3-
carboxylate (S86). In a 20 mL vial, S85 (40.0 mg, 0.137 mmol, 1.0 equiv.) was reacted 
with commercially available 3-(trifluoromethyl)benzyl bromide in dry dichloromethane (2 
mL) according to general procedure A, with slight modification: prior to base addition, 
the reaction vessel was cooled to 0 °C; 2.0 equiv. of N,N-diisopropylethylamine was 
used; after halide addition, the reaction mixture was allowed to slowly warm to r.t. 
overnight. Since reaction progress was slow, the vial was firmly sealed and heated at 80 
°C for 48h. S86 (38.8 mg, 63%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) 
δ = 7.63 (s, 1H), 7.58 - 7.52 (m, 2H), 7.51 - 7.43 (m, 1H), 7.26 (dd, J = 1.0, 7.8 Hz, 1H), 
7.20 (dt, J = 1.2, 7.8 Hz, 1H), 6.75 - 6.68 (m, 1H), 6.51 (br d, J = 7.8 Hz, 1H), 4.52 - 4.38 
(m, 2H), 4.34 (d, J = 10.5 Hz, 1H), 3.79 (s, 3H), 3.66 (br d, J = 10.2 Hz, 1H), 1.43 (br s, 
9H); 13C NMR (100 MHz, CDCl3) δ = 171.19 (br s), 154.86 (br s), 151.43 (br s), 138.87, 
130.98, 130.71 (br s), 130.96 (br q, J = 32.3 Hz), 129.08, 126.21, 124.27 - 123.97 (m), 
123.83, 124.08 (q, J = 272.2 Hz), 117.92, 107.42, 80.42 (br s), 65.09 (br s), 62.52 (br s), 
52.96, 51.65, 28.17; 19F NMR (376 MHz, CDCl3) δ = -62.56 (s, 3F); LRMS (ESI) 
calculated for C23H26F3N2O4 [M + H]+ m/z 451.18, found 451.06. 
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3-((tert-butoxycarbonyl)amino)-1-(3-(trifluoromethyl)benzyl)indoline-3-carboxylic 
acid (S87). S86 (38.8 mg, 0.086 mmol, 1.0 equiv.) was reacted in methanol (3.5 mL) 
with 1M lithium hydroxide (172 uL, 0.172 mmol, 2.0 equiv.) according to general 
procedure B, except the reaction was cooled to 0 °C prior to hydroxide addition, and 
allowed to slowly warm to r.t. overnight. Since conversion was slow, an additional 2.0 
equiv. 1M lithium hydroxide and methanol (500 uL) were added; stirred at 35 °C for 22h. 
An additional aliquot of 2.0 equiv. 1M lithium hydroxide was subsequently added; 
heated at 50 °C for 23h. Semi-crude S87 (38.8 mg, 103%) obtained as a white solid. 
LRMS (ESI) calculated for C22H22F3N2O4 [M - H]- m/z 435.15, found 435.17. 
 
 
 
tert-butyl (3-((1H-tetrazol-5-yl)carbamoyl)-1-(3-(trifluoromethyl)benzyl)indolin-3-
yl)carbamate (37). Semi-crude S87 (38.8 mg, 0.089 mmol, 1.0 equiv.) was reacted with 
5-aminotetrazole monohydrate (1.1 equiv.) in 3 mL DMF according to general procedure 
D (20m activation, 48h). 37 (20.1 mg, 45%) obtained as a tan solid. Note: 
Atropisomerism observed by NMR. 1H NMR (400 MHz, DMSO-d6) δ = 12.29 (br s, 
0.3H), 12.15 (br s, 0.7H), 7.82 (br s, 1H), 7.74 (s, 1H), 7.72 - 7.42 (m, 4H), 7.19 - 7.10 
(m, 1H), 6.73 - 6.58 (m, 2H), 4.65 - 4.53 (m, 1H), 4.52 - 4.33 (m, 2H), 3.41 - 3.35 (m, 
1H), 1.36 (br s, 6H), 1.21 (br s, 3H); 13C NMR (100 MHz, DMSO-d6) δ = 170.34, 155.25, 
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151.18, 150.30 (br s), 139.65, 131.67 (br s), 130.43, 129.53, 129.21 (q, J = 31.5 Hz), 
125.54 (br s), 125.30, 124.24 (q, J = 3.9 Hz), 123.96 - 123.77 (m), 124.28 (q, J = 272.4 
Hz), 117.25, 107.40, 79.23 (br s), 65.96, 62.18 (br s), 50.81, 28.04 (br s); 19F NMR (376 
MHz, DMSO-d6) δ = -60.96 (s, 3F); LRMS (ESI) calculated for C23H23F3N7O3 [M - H]- 
m/z 502.18, found 502.09. 
 
 
 
methyl 1-benzoyl-3-((tert-butoxycarbonyl)amino)indoline-3-carboxylate (S88). S85 
(40.0 mg, 0.137 mmol, 1.0 equiv.) was reacted with commercially available benzoyl 
chloride in dry dichloromethane (2 mL) according to general procedure A, with slight 
modification: prior to base addition, the reaction vessel was cooled to 0 °C; 2.0 equiv. of 
N,N-diisopropylethylamine was used; after acyl chloride addition, the reaction mixture 
was allowed to slowly warm to r.t. S88 (50.1 mg, 92%) obtained as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ = 8.19 (br s, 1H), 7.61 - 7.53 (m, 2H), 7.52 - 7.41 (m, 3H), 
7.39 - 7.21 (m, 2H), 7.08 (br t, J = 6.8 Hz, 1H), 5.46 (br s, 1H), 4.97 (br d, J = 11.4 Hz, 
1H), 4.18 (br s, 1H), 3.76 (s, 3H), 1.40 (br s, 9H); 13C NMR (100 MHz, CDCl3) δ = 
170.58 (br), 169.03 (br), 154.66 (br), 142.94 (br), 136.18, 130.71 (br), 130.58, 129.43 
(br), 128.61, 127.11, 124.40 (br), 123.25 (br), 118.17 (br s), 80.81 (br), 64.52 (br), 60.73 
(br), 53.25, 28.09 (br); LRMS (ESI) calculated for C22H25N2O5 [M + H]+ m/z 397.18, 
found 397.03. 
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1-benzoyl-3-((tert-butoxycarbonyl)amino)indoline-3-carboxylic acid (S89). S88 
(50.1 mg, 0.126 mmol, 1.0 equiv.) was reacted in methanol (3 mL) with 1M lithium 
hydroxide (379 uL, 0.379 mmol, 3.0 equiv.) according to general procedure B, except 
the reaction was cooled to 0 °C prior to hydroxide addition, and allowed to slowly warm 
to r.t. Semi-crude S89 (50.1 mg, 104%) obtained as a white solid. LRMS (ESI) 
calculated for C21H21N2O5 [M - H]- m/z 381.15, found 381.23. 
 
 
 
tert-butyl (3-((1H-tetrazol-5-yl)carbamoyl)-1-benzoylindolin-3-yl)carbamate (38). 
Semi-crude S89 (50.1 mg, 0.131 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole 
monohydrate (1.1 equiv.) in 3 mL DMF according to general procedure D (20m 
activation, 48h). 38 (26.6 mg, 45%) obtained as a white solid. Note: Atropisomerism 
observed by NMR. 1H NMR (400 MHz, DMSO-d6) δ = 12.47 (br s, 0.3H), 12.32 (br s, 
0.7H), 8.25 (br s, 1H), 8.08 (br s, 1H), 7.83 (br d, J = 6.8 Hz, 1H), 7.65 (br s, 2H), 7.61 - 
7.48 (m, 3H), 7.37 (br s, 1H), 7.15 (br s, 1H), 4.90 (br d, J = 10.5 Hz, 1H), 4.15 - 3.95 
(m, 1H), 1.36 (br s, 6H), 1.15 (br s, 3H); 13C NMR (100 MHz, DMSO-d6) δ = 170.10 (br), 
167.86 (br), 155.50, 150.03 (br), 142.21 (br), 136.39 (br), 130.60, 130.14 (br), 129.46 
(br), 128.63 (br), 127.10, 125.53 (br), 124.17 (br), 117.06 (br), 79.69 (br), 65.61 (br), 
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60.66 (br), 28.05 (br); LRMS (ESI) calculated for C22H22N7O4 [M - H]- m/z 448.17, found 
448.06. 
 
 
 
methyl 3-((tert-butoxycarbonyl)amino)-1-picolinoylindoline-3-carboxylate (S90). 
S85 (40.0 mg, 0.137 mmol, 1.0 equiv.) was reacted with commercially available 
pyridine-2-carbonyl chloride hydrochloride in dry dichloromethane (2 mL) according to 
general procedure A, with slight modification: prior to base addition, the reaction vessel 
was cooled to 0 °C; 3.0 equiv. of N,N-diisopropylethylamine was used; after acyl 
chloride addition, the reaction mixture was allowed to slowly warm to r.t. S90 (42.8 mg, 
79%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.64 (d, J = 4.9 Hz, 
1H), 8.35 (br d, J = 6.6 Hz, 1H), 7.89 (br s, 1H), 7.88 - 7.80 (m, 1H), 7.47 - 7.32 (m, 3H), 
7.13 (br t, J = 7.4 Hz, 1H), 5.42 (br s, 1H), 5.21 (br d, J = 11.4 Hz, 1H), 4.57 (br d, J = 
11.9 Hz, 1H), 3.74 (s, 3H), 1.41 (br s, 9H); 13C NMR (100 MHz, CDCl3) δ = 170.66 (br), 
166.11 (br), 154.78 (br), 153.58, 148.28 (br), 143.50 (br), 137.04, 130.84 (br), 129.25 
(br), 125.29, 124.72, 124.22 (br), 123.14 (br), 118.56 (br), 80.71 (br), 64.97 (br), 60.93 
(br), 53.21, 28.11 (br); LRMS (ESI) calculated for C21H24N3O5 [M + H]+ m/z 398.17, 
found 398.09. 
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3-((tert-butoxycarbonyl)amino)-1-picolinoylindoline-3-carboxylic acid (S91). S90 
(42.8 mg, 0.108 mmol, 1.0 equiv.) was reacted in methanol (3.5 mL) with 1M lithium 
hydroxide (323 uL, 0.323 mmol, 3.0 equiv.) according to general procedure B, except 
the reaction was cooled to 0 °C prior to hydroxide addition, and allowed to slowly warm 
to r.t. Semi-crude S91 (41.3 mg, 100%) obtained as a white solid. LRMS (ESI) 
calculated for C20H20N3O5 [M - H]- m/z 382.14, found 382.44. 
 
 
 
tert-butyl (3-((1H-tetrazol-5-yl)carbamoyl)-1-picolinoylindolin-3-yl)carbamate (39). 
Semi-crude S91 (41.3 mg, 0.108 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole 
monohydrate (1.1 equiv.) in 3 mL DMF according to general procedure D (20m 
activation, 48h). 39 (23.3 mg, 48%) obtained as a white solid. Note: Slight 
atropisomerism observed by NMR. 1H NMR (400 MHz, DMSO-d6) δ = 12.31 (br s, 1H), 
8.70 (br d, J = 4.4 Hz, 1H), 8.29 - 8.12 (m, 2H), 8.05 (dt, J = 1.6, 7.7 Hz, 1H), 7.95 - 7.75 
(m, 2H), 7.61 (dd, J = 5.1, 7.1 Hz, 1H), 7.44 (br t, J = 7.7 Hz, 1H), 7.19 (br t, J = 7.4 Hz, 
1H), 5.11 (br d, J = 11.7 Hz, 1H), 4.22 (br d, J = 10.5 Hz, 1H), 1.36 (br s, 6H), 1.18 (br s, 
3H); 13C NMR (100 MHz, DMSO-d6) δ = 170.11 (br), 165.41 (br), 155.45 (br), 153.34, 
150.28 (br), 148.35 (br), 142.51, 137.78, 130.32 (br), 129.34 (br), 125.87, 125.47 (br), 
N
O
NHBoc
HO
O
N
N
O
NHBoc
NH
O
NN
N NH
N
 296 
124.54 (br), 123.96 (br), 117.26, 79.66 (br), 65.78 (br), 60.56 (br), 28.03 (br); LRMS 
(ESI) calculated for C21H21N8O4 [M - H]- m/z 449.17, found 449.05. 
 
 
 
methyl 3-((tert-butoxycarbonyl)amino)-1-(pyrimidine-2-carbonyl)indoline-3-
carboxylate (S92). Pyrimidine-2-carboxylic acid (17 mg, 0.137 mmol, 1.0 equiv.) was 
reacted with S85 (40.0 mg, 0.137 mmol, 1.0 equiv.) in 2 mL DMF according to general 
procedure D (10m activation), except the resulting mixture was transferred to a sep. 
funnel with ~ 75 mL EtOAc. The organic layer was washed with ~ 50 mL sat. NaHCO3, 
water, and 0.1N HCl; dried over MgSO4 and concentrated. Purified on a silica column 
with 0-40% EtOAc:hexanes. S92 (29.7 mg, 55%) obtained as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ = 8.88 (d, J = 4.9 Hz, 2H), 8.41 (br d, J = 8.3 Hz, 1H), 7.47 - 7.34 
(m, 3H), 7.19 - 7.11 (m, 1H), 5.36 (br s, 1H), 5.10 (br d, J = 11.9 Hz, 1H), 4.34 (br d, J = 
12.2 Hz, 1H), 3.75 (s, 3H), 1.40 (br s, 9H); 13C NMR (100 MHz, CDCl3) δ = 170.36 (br), 
163.31 (br), 161.12, 157.43, 154.79 (br), 142.88, 131.11 (br), 129.06 (br), 125.07, 
123.18 (br), 121.79, 118.58 (br), 80.83 (br), 64.85 (br), 59.96 (br), 53.28 (br), 28.11 (br); 
LRMS (ESI) calculated for C20H23N4O5 [M + H]+ m/z 399.17, found 399.01. 
 
 
 
3-((tert-butoxycarbonyl)amino)-1-(pyrimidine-2-carbonyl)indoline-3-carboxylic 
acid (S93). S92 (29.7 mg, 0.075 mmol, 1.0 equiv.) was reacted in methanol (3 mL) with 
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1M lithium hydroxide (224 uL, 0.224 mmol, 3.0 equiv.) according to general procedure 
B, except the reaction was cooled to 0 °C prior to hydroxide addition, and allowed to 
slowly warm to r.t. Semi-crude S93 (25.1 mg, 88%) obtained as a white solid. LRMS 
(ESI) calculated for C19H19N4O5 [M - H]- m/z 383.14, found 383.35. 
 
 
 
tert-butyl (3-((1H-tetrazol-5-yl)carbamoyl)-1-(pyrimidine-2-carbonyl)indolin-3-
yl)carbamate (40). Semi-crude S93 (25.1 mg, 0.065 mmol, 1.0 equiv.) was reacted with 
5-aminotetrazole monohydrate (1.1 equiv.) in 2 mL DMF according to general procedure 
D (20m activation). 40 (16.2 mg, 55%) obtained as a white solid. Note: Slight 
atropisomerism observed by NMR. 1H NMR (400 MHz, DMSO-d6) δ = 12.36 (br s, 1H), 
9.03 (d, J = 4.9 Hz, 2H), 8.25 (br s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.85 (br d, J = 7.5 Hz, 
1H), 7.72 (t, J = 4.9 Hz, 1H), 7.51 - 7.42 (m, 1H), 7.22 (t, J = 7.5 Hz, 1H), 4.90 (br d, J = 
11.0 Hz, 1H), 3.95 (br d, J = 11.4 Hz, 1H), 1.35 (br s, 6H), 1.12 (br s, 3H); 13C NMR 
(100 MHz, DMSO-d6) δ = 169.99 (br), 162.89, 160.75, 157.97, 155.55 (br), 150.21 (br), 
141.71, 130.62, 129.09 (br), 125.56 (br), 124.94, 122.65, 116.91, 79.75 (br), 65.74 (br), 
59.55 (br), 27.98 (br); LRMS (ESI) calculated for C20H20N9O4 [M - H]- m/z 450.16, found 
450.11. 
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methyl 3-((tert-butoxycarbonyl)amino)-1-(thiophene-2-carbonyl)indoline-3-
carboxylate (S94). S85 (40.0 mg, 0.137 mmol, 1.0 equiv.) was reacted with 
commercially available 2-thiophenecarbonyl chloride in dry dichloromethane (2 mL) 
according to general procedure A, with slight modification: prior to base addition, the 
reaction vessel was cooled to 0 °C; 2.0 equiv. of N,N-diisopropylethylamine was used; 
after acyl chloride addition, the reaction mixture was allowed to slowly warm to r.t. S94 
(53.0 mg, 96%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.20 (br d, J 
= 7.1 Hz, 1H), 7.64 (d, J = 3.4 Hz, 1H), 7.57 (br d, J = 4.9 Hz, 1H), 7.42 - 7.31 (m, 2H), 
7.16 - 7.05 (m, 2H), 5.45 (br s, 1H), 5.30 (br d, J = 11.2 Hz, 1H), 4.52 (br d, J = 11.4 Hz, 
1H), 3.78 (s, 3H), 1.43 (br s, 9H); 13C NMR (100 MHz, CDCl3) δ = 170.53 (br), 161.47 
(br), 154.81 (br), 143.40, 138.80 (br), 130.96, 130.77, 130.28 (br), 128.81 (br), 127.49 
(br), 124.60, 123.13, 118.50 (br), 80.94 (br), 65.02 (br), 60.64 (br), 53.36, 28.13; LRMS 
(ESI) calculated for C20H23N2O5S [M + H]+ m/z 403.13, found 403.03. 
 
 
 
3-((tert-butoxycarbonyl)amino)-1-(thiophene-2-carbonyl)indoline-3-carboxylic acid 
(S95). S94 (53.0 mg, 0.132 mmol, 1.0 equiv.) was reacted in methanol (3 mL) with 1M 
lithium hydroxide (395 uL, 0.395 mmol, 3.0 equiv.) according to general procedure B, 
except the reaction was cooled to 0 °C prior to hydroxide addition, and allowed to slowly 
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warm to r.t. Semi-crude S95 (52.5 mg, 103%) obtained as a white solid. LRMS (ESI) 
calculated for C19H19N2O5S [M - H]- m/z 387.10, found 387.08. 
 
 
 
tert-butyl (3-((1H-tetrazol-5-yl)carbamoyl)-1-(thiophene-2-carbonyl)indolin-3-
yl)carbamate (41). Semi-crude S95 (52.5 mg, 0.135 mmol, 1.0 equiv.) was reacted with 
5-aminotetrazole monohydrate (1.1 equiv.) in 3 mL DMF according to general procedure 
D (20m activation, 48h). 41 (24.4 mg, 40%) obtained as a white solid. Note: Slight 
atropisomerism observed by NMR. 1H NMR (400 MHz, DMSO-d6) δ = 12.52 (br s, 
0.4H), 12.36 (br s, 0.6H), 8.31 (br s, 1H), 8.01 (br d, J = 7.3 Hz, 1H), 7.92 (d, J = 4.9 Hz, 
1H), 7.88 - 7.75 (m, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.30 - 7.23 (m, 1H), 7.21 - 7.12 (m, 
1H), 5.28 (br d, J = 10.5 Hz, 1H), 4.40 (br d, J = 10.2 Hz, 1H), 1.39 (br s, 6H), 1.25 (br s, 
3H); 13C NMR (100 MHz, DMSO-d6) δ = 172.04, 160.73 (br), 155.53 (br), 150.16 (br), 
142.48, 138.64, 131.64 (br), 130.57 (br), 130.21 (br), 129.35 (br), 127.92, 125.52 (br), 
124.35 (br), 117.42, 79.67 (br), 65.95 (br), 60.75 (br), 28.09 (br); LRMS (ESI) calculated 
for C20H20N7O4S [M - H]- m/z 454.13, found 454.06. 
 
 
 
methyl 3-((tert-butoxycarbonyl)amino)-1-(1H-pyrrole-2-carbonyl)indoline-3-
carboxylate (S96). Pyrrole-2-carboxylic acid (15.2 mg, 0.137 mmol, 1.0 equiv.) was 
reacted with S85 (40.0 mg, 0.137 mmol, 1.0 equiv.) in 2 mL DMF according to general 
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procedure D (10m activation). After 24h, the reaction was heated at 80 °C; 1.0 equiv. 
acid and 1.0 equiv HATU were added every day for 4d. The resulting mixture was 
transferred to a sep. funnel with ~ 75 mL EtOAc. The organic layer was washed with ~ 
50 mL sat. NaHCO3, water, and 0.1N HCl; dried over MgSO4 and concentrated. Purified 
on a silica column with 0-50% EtOAc:hexanes. S96 (11.1 mg, 21%) obtained as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.33 (d, J = 7.8 Hz, 1H), 7.43 - 7.35 (m, 
2H), 7.09 (dt, J = 1.0, 7.5 Hz, 1H), 7.05 (br s, 1H), 6.86 (br s, 1H), 6.35 (br d, J = 2.9 Hz, 
1H), 5.63 (br s, 0.2H), 5.43 (br s, 0.8H), 5.32 (br d, J = 10.7 Hz, 1H), 4.60 (br d, J = 11.2 
Hz, 1H), 3.79 (s, 3H), 1.45 (br s, 9H); LRMS (ESI) calculated for C20H24N3O5 [M + H]+ 
m/z 386.17, found 386.09. 
 
 
 
3-((tert-butoxycarbonyl)amino)-1-(1H-pyrrole-2-carbonyl)indoline-3-carboxylic 
acid (S97). S96 (11.1 mg, 0.029 mmol, 1.0 equiv.) was reacted in methanol (3 mL) with 
1M lithium hydroxide (58 uL, 0.058 mmol, 2.0 equiv.) according to general procedure B, 
except the reaction was cooled to 0 °C prior to hydroxide addition, and allowed to slowly 
warm to r.t. After 18h, additional 1M lithium hydroxide (2.0 equiv) and methanol (500 uL) 
were added; allowed to stir for 30h. Semi-crude S96 (10.7 mg, 100%) obtained as a 
white solid. LRMS (ESI) calculated for C19H20N3O5 [M - H]- m/z 370.14, found 370.14. 
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tert-butyl (3-((1H-tetrazol-5-yl)carbamoyl)-1-(1H-pyrrole-2-carbonyl)indolin-3-
yl)carbamate (42). Semi-crude S97 (10.7 mg, 0.029 mmol, 1.0 equiv.) was reacted with 
5-aminotetrazole monohydrate (1.1 equiv.) in 2 mL DMF according to general procedure 
D (20m activation, 48h). 42 (2.7 mg, 21%) obtained as a tan solid. 1H NMR (400 MHz, 
CD3OD, CDCl3) δ = 8.19 (br d, J = 8.0 Hz, 1H), 7.58 (br d, J = 7.5 Hz, 1H), 7.37 (br t, J 
= 7.8 Hz, 1H), 7.11 (br t, J = 7.4 Hz, 1H), 7.06 (br s, 1H), 6.84 (br s, 1H), 6.33 - 6.29 (m, 
1H), 5.56 (br d, J = 11.2 Hz, 1H), 4.39 (br d, J = 11.2 Hz, 1H), 3.70 - 3.66 (m, 1H), 3.58 - 
3.54 (m, 1H), 1.43 (br s, 9H); LRMS (ESI) calculated for C20H21N8O4 [M - H]- m/z 
437.17, found 436.92. 
 
 
 
1-((benzyloxy)carbonyl)-3-((tert-butoxycarbonyl)amino)indoline-3-carboxylic acid 
(S98). S84 (88.9 mg, 0.208 mmol, 1.0 equiv.) was reacted in methanol (4 mL) with 1M 
lithium hydroxide (625 uL, 0.625 mmol, 3.0 equiv.) according to general procedure B, 
except the reaction was cooled to 0 °C prior to hydroxide addition, and allowed to slowly 
warm to r.t. Semi-crude S98 (89.3 mg, 104%) obtained as a colorless oil. LRMS (ESI) 
calculated for C22H23N2O6 [M - H]- m/z 411.16, found 411.16. 
 
N
O
NHBoc
NH
O
NN
N NH NH
NCbz
HO
O
NHBoc
 302 
 
 
benzyl 3-((1H-tetrazol-5-yl)carbamoyl)-3-((tert-butoxycarbonyl)amino)indoline-1-
carboxylate (43). Semi-crude S98 (89.3 mg, 0.217 mmol, 1.0 equiv.) was reacted with 
5-aminotetrazole monohydrate (1.1 equiv.) in 4 mL DMF according to general procedure 
D (10m activation). 43 (53.0 mg, 51%) obtained as a white solid. Note: Extreme peak 
broadening in the 1H NMR; presumably atropisomerism. 1H NMR (400 MHz, CD3OD, 
drops CDCl3) δ = 7.89 (br s, 1H), 7.58 - 7.17 (m, 7H), 6.95 (br s, 1H), 5.25 (br s, 3H), 
4.12 - 3.87 (m, 2H), 1.26 (br s, 9H); 13C NMR (100 MHz, CD3OD, drops CDCl3) δ = 
170.11, 155.08 (br), 152.41 (br), 150.16, 142.18 (br), 135.42 (br), 131.07, 128.30 (br), 
128.07 (br), 127.83 (br), 126.74 (br), 123.58 (br), 123.11 (br), 115.29 (br), 80.98, 67.20 
(br), 65.12 (br), 57.74, 27.64; LRMS (ESI) calculated for C23H24N7O5 [M - H]- m/z 
478.18, found 478.19. 
 
 
 
methyl 1-acetylindoline-3-carboxylate (S99). Semi-crude S32 (145.0 mg, 0.679 
mmol, 1.0 equiv.) was reacted with commercially available acetyl chloride in dry 
dichloromethane (6 mL) according to general procedure A, with slight modification: prior 
to base addition, the reaction vessel was cooled to 0 °C; 2.5 equiv. of N,N-
diisopropylethylamine was used, and allowed to stir at 0 °C for 5m; after acyl chloride 
addition, the reaction mixture was allowed to slowly warm to r.t. S99 (119.2 mg, 80%) 
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obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.19 (d, J = 8.0 Hz, 1H), 7.37 
(br d, J = 7.3 Hz, 1H), 7.23 (t, J = 7.7 Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H), 4.46 (dd, J = 5.6, 
10.5 Hz, 1H), 4.25 (br dd, J = 5.5, 9.9 Hz, 1H), 4.14 - 4.07 (m, 1H), 3.76 (s, 3H), 2.41 (br 
s, 0.3H), 2.22 (s, 2.6H); 13C NMR (100 MHz, CDCl3) δ = 171.29, 168.34, 142.40, 
128.90, 127.62, 124.82, 123.53, 116.90, 52.58, 50.57, 45.05, 24.02; LRMS (ESI) 
calculated for C12H14NO3 [M + H]+ m/z 220.10, found 219.91. 
 
 
 
methyl 1-acetyl-3-azidoindoline-3-carboxylate (S100). S99 (119.2 mg, 0.554 mmol, 
1.0 equiv.) was reacted in 11.3 mL tetrahydrofuran according to general procedure F. 
S100 (77.7 mg, 55%) obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.29 
(d, J = 8.3 Hz, 1H), 7.48 - 7.39 (m, 2H), 7.12 (dt, J = 1.0, 7.5 Hz, 1H), 4.64 (d, J = 11.4 
Hz, 1H), 3.95 (d, J = 11.4 Hz, 1H), 3.89 (s, 3H), 2.46 (br s, 0.4H), 2.25 (s, 2.6H); 13C 
NMR (100 MHz, CDCl3) δ = 169.01, 168.27, 142.79, 131.65, 126.12, 123.80, 123.58, 
117.69, 69.87, 57.80, 53.67, 24.00; LRMS (ESI) calculated for C12H13N4O3 [M + H]+ m/z 
261.10, found 261.06. 
 
 
 
methyl 1-acetyl-3-((tert-butoxycarbonyl)amino)indoline-3-carboxylate (S101). A 
round bottom flask was charged with S100 (77.7 mg, 0.299 mmol, 1.0 equiv.) and dry 
methanol (6 mL), then cooled to 0 °C. Anhydrous tin(II) chloride (113 mg, 0.597 mmol, 
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2.0 equiv.) was added; stirred at 0 °C for 5m, then r.t. for 4 h. The methanol was then 
removed under reduced pressure. 1,4-dioxane (5.5 mL) was added, followed by di-tert-
butyl dicarbonate (97 mg, 0.448 mmol, 1.5 equiv.) in 700 uL 1,4-dioxane. Finally, a 
slurry of sodium bicarbonate (100 mg, 1.19 mmol, 4.0 equiv.) in water (1.4 mL) was 
added, and the resulting slurry was allowed to stir for 18h. The reaction mixture was 
then transferred to a sep. funnel with excess EtOAc and water and adjusted to pH 1 
with 1M KHSO4. The layers were separated, and the aqueous layer was further 
extracted with ~ 50 mL EtOAc. The organic layers were combined, washed with sat. 
NaHCO3, dried over MgSO4, and concentrated under reduced pressure. Purified on a 
silica column with 0-45% EtOAc:hexanes. S101 (70.7 mg, 71%) obtained as a colorless 
oil. 1H NMR (400 MHz, CDCl3) δ = 8.21 (d, J = 8.3 Hz, 1H), 7.36 - 7.29 (m, 2H), 7.03 (t, 
J = 7.5 Hz, 1H), 5.57 (s, 1H), 4.97 (br d, J = 11.2 Hz, 1H), 4.14 (br d, J = 11.4 Hz, 1H), 
3.76 (s, 3H), 2.21 (s, 3H), 1.44 (br s, 9H); 13C NMR (100 MHz, CDCl3) δ = 170.56 (br), 
168.66 (br), 154.96 (br), 142.92, 130.98, 128.07 (br), 123.89, 123.16, 117.50, 80.86 
(br), 64.56 (br), 59.42 (br), 53.26, 28.13, 24.09; LRMS (ESI) calculated for C17H23N2O5 
[M + H]+ m/z 335.16, found 335.04. 
 
 
 
1-acetyl-3-((tert-butoxycarbonyl)amino)indoline-3-carboxylic acid (S102). S101 
(70.7 mg, 0.211 mmol, 1.0 equiv.) was reacted in methanol (4 mL) with 1M lithium 
hydroxide (634 uL, 0.634 mmol, 3.0 equiv.) according to general procedure B, except 
the reaction was cooled to 0 °C prior to hydroxide addition, and allowed to slowly warm 
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to r.t. Semi-crude S102 (65.2 mg, 96%) obtained as a white solid. LRMS (ESI) 
calculated for C16H19N2O5 [M - H]- m/z 319.13, found 319.16. 
 
 
 
tert-butyl (3-((1H-tetrazol-5-yl)carbamoyl)-1-acetylindolin-3-yl)carbamate (44). 
Semi-crude S102 (65.2 mg, 0.204 mmol, 1.0 equiv.) was reacted with 5-aminotetrazole 
monohydrate (1.1 equiv.) in 4 mL DMF according to general procedure D (10m 
activation). 44 (58.3 mg, 74%) obtained as a white solid. Note: Slight atropisomerism 
observed by NMR. 1H NMR (400 MHz, DMSO-d6) δ = 12.49 (br s, 0.3H), 12.35 (br s, 
0.7H), 8.19 (br s, 1H), 8.09 (br d, J = 7.8 Hz, 1H), 7.77 (br s, 1H), 7.33 (br t, J = 6.9 Hz, 
1H), 7.08 (br s, 1H), 5.01 (br d, J = 10.7 Hz, 1H), 4.06 (br d, J = 11.2 Hz, 1H), 2.24 (br s, 
3H), 1.40 (br s, 6H), 1.29 (br s, 3H); 13C NMR (100 MHz, DMSO-d6) δ = 170.28 (br), 
168.35, 155.49 (br), 150.22 (br), 142.46, 130.36 (br), 128.41 (br), 125.42 (br), 123.43 
(br), 116.17, 79.64 (br), 65.52 (br), 58.94 (br), 28.13 (br), 24.09 (br); LRMS (ESI) 
calculated for C17H20N7O4 [M - H]- m/z 386.16, found 386.07. 
 
 
 
tert-butyl (3-((1H-tetrazol-5-yl)carbamoyl)indolin-3-yl)carbamate, bis-
triethylammonium salt (45). 43 (23.0 mg, 0.048 mmol, 1.0 equiv.) was dissolved 
in ethanol (40 mL) and DMF (300 uL) and hydrogenated for 5h using an “H-Cube” flow 
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hydrogenator with a 10% Pd/C cartridge; 1 mL/min, 1 atm H2, 40 °C, loop configuration. 
The crude reaction mixture was concentrated and directly purified by reverse phase 
HPLC (water/MeOH/0.1% TEA:AcOH) to afford the desired product as a 
triethylammonium salt. Note: Crude reaction mixture unstable; store cold or purify 
immediately. 45 (3.9 mg, 18%) obtained as a tan film. 1H NMR (400 MHz, CD3OD) δ = 
7.41 (br d, J = 7.5 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 6.77 - 6.70 (m, 2H), 4.52 (br d, J = 
10.5 Hz, 1H), 3.67 - 3.62 (m, 1H), 3.13 (q, J = 7.3 Hz, 12H), 1.44 (br s, 9H), 1.26 (t, J = 
7.2 Hz, 18H); LRMS (ESI) calculated for C15H18N7O3 [M - H]- m/z 344.15, found 344.14. 
 
 
 
methyl (tert-butoxycarbonyl)tryptophanate (S103). Commercially available DL-
tryptophan methyl ester hydrochloride (100 mg, 0.393 mmol, 1.0 equiv.) was reacted 
with di-tert-butyl dicarbonate in dry dichloromethane (4 mL) according to general 
procedure A, except 1.1 equiv. of N,N-diisopropylethylamine was used, and the reaction 
mixture was concentrated and directly purified, sans workup. S103 (125.2 mg, 100%) 
obtained as a white solid. Note: Atropisomerism observed by NMR. 1H NMR (400 MHz, 
DMSO-d6) δ = 10.85 (br s, 0.3H), 7.49 (d, J = 7.8 Hz, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.20 
(br d, J = 8.0 Hz, 0.4H), 7.16 (s, 1H), 7.11 - 7.04 (m, 1H), 7.03 - 6.94 (m, 1H), 4.25 - 
4.16 (m, 0.84H), 4.12 (br s, 0.16H), 3.60 (s, 3H), 3.16 - 3.06 (m, 1H), 3.05 - 2.94 (m, 
1H), 1.33 (s, 7.5H), 1.22 (br s, 1.5H); 13C NMR (100 MHz, DMSO-d6) δ = 172.93, 
155.31, 136.09, 135.93, 127.02, 123.73, 123.57, 120.94, 118.39, 117.99, 111.38, 
O
NHBoc
O
NH
 307 
109.70, 78.23, 54.67, 54.58, 51.73, 28.13, 27.75 (br), 26.76; LRMS (ESI) calculated for 
C17H22N2NaO4 [M + Na]+ m/z 341.15, found 341.03. 
 
 
 
(tert-butoxycarbonyl)tryptophan (S104). S103 (105.2 mg, 0.330 mmol, 1.0 equiv.) 
was reacted in methanol (5 mL) with 1M lithium hydroxide (661 uL, 0.661 mmol, 2.0 
equiv.) according to general procedure B, except after 7h additional 1M lithium 
hydroxide (2.0 equiv.) and methanol (2 mL) were added. Semi-crude S104 (99.1 mg, 
99%) obtained as a white solid. LRMS (ESI) calculated for C16H19N2O4 [M - H]- m/z 
303.14, found 303.3. 
 
 
 
tert-butyl (1-((1H-tetrazol-5-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-
yl)carbamate (46). Semi-crude S104 (99.1 mg, 0.326 mmol, 1.0 equiv.) was reacted 
with 5-aminotetrazole monohydrate (1.1 equiv.) in 2 mL DMF according to general 
procedure H. 46 (32.2 mg, 28%) obtained as a light tan solid. Note: Product is prone to 
oxidation (N-oxide) on the benchtop; store cold under Ar. Note: Slight atropisomerism 
observed by 1H NMR. 1H NMR (400 MHz, DMSO-d6) δ = 12.28 (br s, 1H), 10.84 (br s, 
1H), 7.71 (br d, J = 7.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.21 (br s, 1H), 7.17 (br d, J = 
7.3 Hz, 1H), 7.05 (t, J = 7.4 Hz, 1H), 7.00 - 6.91 (m, 1H), 4.52 - 4.36 (m, 1H), 3.21 - 3.09 
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(m, 1H), 3.01 (br dd, J = 9.4, 14.2 Hz, 1H), 1.32 (s, 7.4H), 1.17 (br d, J = 2.9 Hz, 1.6H); 
13C NMR (100 MHz, DMSO-d6) δ = 172.19, 155.36, 149.64 (br), 136.03, 127.11, 124.25, 
120.91, 118.64, 118.20, 111.29, 109.30, 78.35, 55.33, 28.14, 27.21; LRMS (ESI) 
calculated for C17H20N7O3 [M - H]- m/z 370.16, found 370.19. 
 
 
 
2‐(bis((tert‐butoxy)carbonyl)amino)prop‐2‐enoate (S105). A dried 50 mL RB was 
charged with commercially available methyl (tert-butoxycarbonyl)serinate (1.500 ml, 
7.40 mmol, 1.0 equiv.) and dry acetonitrile (14.8 mL). Di-tert-butyl dicarbonate (4.039 g, 
18.5 mmol, 2.5 equiv.) was then added, followed by dropwise addition of N,N-
diisopropylethylamine (2.579 ml, 14.8 mmol, 2.0 equiv.). After 3h, 4-
dimethylaminopyridine (452 mg, 3.70 mmol, 0.5 equiv.) was added. Another 0.5 equiv. 
4-dimethylaminopyridine was added at 5h, followed by 1.0 equiv. 4-
dimethylaminopyridine at 7h. After 24h, 0.5 equiv. 4-dimethylaminopyridine was added, 
and the reaction was heated at 45 °C for 4h. The crude reaction mixture was transferred 
to a sep. funnel with ~ 125 mL EtOAc and washed with sat. NH4Cl, sat. NaHCO3, and 
brine. The organic layer was further washed with 3 x 50 mL sat. NH4Cl, dried over 
MgSO4, and concentrated. The resulting oil was dried under hivac overnight. S105 
(2.440 g, 109%, wet with EtOAc) obtained as a yellow solid. 1H NMR (400 MHz, CDCl3) 
δ = 6.33 (s, 1H), 5.63 (s, 1H), 3.78 (s, 3H), 1.45 (s, 18H); 13C NMR (100 MHz, CDCl3) δ 
= 163.93, 150.58, 136.02, 124.61, 83.10, 52.32, 27.81; LRMS (ESI) calculated for 
C14H23NNaO6 [M + Na]+ m/z 324.14, found 324.10. 
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methyl 2‐(bis((tert‐butoxy)carbonyl)amino)‐3‐(2‐oxo‐2,3‐dihydro‐1,3‐
benzoxazol‐3‐yl)propanoate (S106). A 3 mL vial was charged with S105 (200.0 mg, 
0.664, 1.0 equiv.), benzo[d]oxazol-2(3H)-one (92 mg, 0.682 mmol, 1.0 equiv.), and dry 
acetonitrile (2 mL). Cesium carbonate (22 mg, 0.066 mmol, 0.1 equiv.) was then added, 
and the vial was sealed and heated at 80 °C overnight. The crude reaction mixture was 
transferred to a sep. funnel with ~ 100 mL EtOAc and washed with ~ 50 mL water and 
brine; the organic layer was dried over MgSO4, concentrated, and purified on a silica 
column with 0-40% EtOAc:hexanes. S106 (256.9 mg, 89%) obtained as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 7.10 - 7.02 (m, 2H), 7.02 - 6.95 (m, 1H), 6.87 (d, J = 7.8 
Hz, 1H), 5.31 (dd, J = 5.4, 8.8 Hz, 1H), 4.45 - 4.32 (m, 2H), 3.68 (s, 3H), 1.27 (s, 18H); 
13C NMR (100 MHz, CDCl3) δ = 168.40, 153.88, 151.27, 142.35, 130.99, 123.53, 
122.13, 109.62, 107.91, 83.46, 55.82, 52.19, 41.56, 27.36; LRMS (ESI) calculated for 
C21H28N2NaO8 [M + Na]+ m/z 459.17, found 459.08. 
 
 
 
methyl 2-((tert-butoxycarbonyl)amino)-3-(2-oxobenzo[d]oxazol-3(2H)-
yl)propanoate (S107). A 20 mL vial was charged with S106 (257 mg, 0.589, 1.0 equiv.) 
and dry acetonitrile (5.9 mL). Lithium bromide (153 mg, 1.77 mmol, 3.0 equiv.) was then 
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added, and the vial was sealed and heated at 65 °C overnight. The crude reaction 
mixture was transferred to a sep. funnel with EtOAc and partitioned with water; the 
layers were separated, and the aqueous layer was further extracted with 2 x 50 mL 
EtOAc. The organics were combined, dried over MgSO4, and concentrated. Crude S107 
(211.0 mg, 107%) obtained as a colorless oil. LRMS (ESI) calculated for C16H20N2NaO6 
[M + Na]+ m/z 359.12, found 359.03. 
 
 
 
2-((tert-butoxycarbonyl)amino)-3-(2-oxobenzo[d]oxazol-3(2H)-yl)propanoic acid 
(S108). Crude S107 (198.0 mg, 0.589 mmol, 1.0 equiv.) was reacted in methanol (10 
mL) with 1M lithium hydroxide (1.177 mL, 1.18 mmol, 2.0 equiv.) according to general 
procedure B. Semi-crude S108 (165.0 mg, 87%) obtained as a tan solid. LRMS (ESI) 
calculated for C15H17N2O6 [M - H]- m/z 321.11, found 321.21. 
 
 
 
tert-butyl (1-((1H-tetrazol-5-yl)amino)-1-oxo-3-(2-oxobenzo[d]oxazol-3(2H)-
yl)propan-2-yl)carbamate (47). Semi-crude S108 (165.0 mg, 0.512 mmol, 1.0 equiv.) 
was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 3.5 mL DMF according 
to general procedure D (20m activation). 47 (64.9 mg, 28% over 3 steps) obtained as an 
off-white solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.34 (br s, 0.25H), 7.42 - 7.21 (m, 
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2.5H), 7.21 - 7.04 (m, 2H), 4.64 (br s, 1H), 4.28 - 4.13 (m, 1H), 4.14 - 4.00 (m, 1H), 1.23 
(s, 9H); 13C NMR (100 MHz, DMSO-d6) δ = 169.20 (br), 154.99, 154.94, 153.75, 149.40 
(br), 142.00, 131.25, 123.67, 122.19, 109.53, 109.19, 78.72, 52.24 (br), 52.16, 43.02 
(br), 27.86; LRMS (ESI) calculated for C16H18N7O5 [M - H]- m/z 388.14, found 388.12.  
 
 
 
methyl N-(tert-butoxycarbonyl)-O-(methylsulfonyl)serinate (S109). A dried 100 mL 
RB was charged with commercially available methyl (tert-butoxycarbonyl)serinate 
(1.200 ml, 5.92 mmol, 1.0 equiv.) and dry dichloromethane (36 mL), then cooled to 0 °C. 
Methanesulfonyl chloride (550 uL, 7.11 mmol, 1.2 equiv.) was then added, followed by 
dropwise addition of N,N-diisopropylethylamine (1.238 mL, 7.11 mmol, 1.2 equiv.). After 
addition was complete, the reaction mixture was immediately warmed to r.t. and allowed 
to stir for 1h. The crude reaction mixture was then transferred to a sep. funnel with 
dichloromethane and water, the layers separated, and the organic layer was washed 
with 2 x ~ 60 mL brine. Dried over MgSO4 and concentrated; dried under hivac for 2h. 
Note: This product is unstable at r.t., and rapidly begins to decompose. Crude S109 
(1.760 g, 100%) obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 5.48 (br d, J = 
7.3 Hz, 1H), 4.59 - 4.49 (m, 1H), 4.48 - 4.41 (m, 1H), 3.77 - 3.72 (m, 3H), 2.98 (s, 3H), 
1.40 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 168.98, 154.91, 80.38, 68.87, 52.83, 
52.39, 37.14, 28.03; LRMS (ESI) calculated for C10H19NNaO7S [M + Na]+ m/z 320.08, 
found 320.07. 
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methyl 2-((tert-butoxycarbonyl)amino)-3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-
1-yl)propanoate (S110). A 3 mL vial was charged with crude S109 (326.4 mg, 1.10 
mmol, 1.0 equiv.), 2-hydroxybenzimidazole (147 mg, 1.10 mmol, 1.0 equiv.), cesium 
carbonate (715 mg, 2.20 mmol, 2.0 equiv.), and dry DMF (2 mL). The vial was sealed 
and heated at 60 °C overnight. The crude reaction mixture was transferred to a sep. 
funnel with ~ 100 mL EtOAc and sat. NH4Cl, the layers separated, and the organic layer 
further extracted with brine. Dried over MgSO4, concentrated, and purified on a silica 
column with 30-60% EtOAc:hexanes. S110 (74.4 mg, 20%) obtained as a white solid. 
1H NMR (400 MHz, CD3OD, drops CDCl3) δ = 7.08 - 6.89 (m, 5H), 4.54 (br t, J = 5.5 Hz, 
1H), 4.20 (br d, J = 5.8 Hz, 2H), 3.65 (s, 3H), 1.32 (s, 9H); 13C NMR (100 MHz, CD3OD, 
drops CDCl3) δ = 171.05, 156.02, 155.79, 130.43, 128.30, 122.19, 121.72, 109.90, 
108.22, 80.48, 53.31, 52.90, 42.42, 28.30; LRMS (ESI) calculated for C16H22N3O5 [M + 
H]+ m/z 336.16, found 336.09. 
 
 
 
2-((tert-butoxycarbonyl)amino)-3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)propanoic acid (S111). S110 (74.4 mg, 0.222 mmol, 1.0 equiv.) was reacted in 
methanol (5 mL) with 1M lithium hydroxide (444 uL, 0.444 mmol, 2.0 equiv.) according 
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to general procedure B. Semi-crude S111 (70.2 mg, 99%) obtained as a white solid. 
LRMS (ESI) calculated for C15H18N3O5 [M - H]- m/z 320.13, found 320.15. 
 
 
 
tert-butyl (1-((1H-tetrazol-5-yl)amino)-1-oxo-3-(2-oxo-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)propan-2-yl)carbamate (48). Semi-crude S111 (70.2 mg, 0.218 
mmol, 1.0 equiv.) was reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 2.5 mL 
DMF according to general procedure D (10m activation). 48 (8.4 mg, 10% over two 
steps) obtained as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.27 (br s, 1H), 
10.91 (br s, 1H), 7.23 - 7.04 (m, 2H), 6.94 (br s, 3H), 4.54 (br d, J = 6.1 Hz, 1H), 4.25 - 
4.03 (m, 2H), 1.28 (s, 9H); 13C NMR (100 MHz, DMSO-d6) δ = 169.68 (br), 154.88, 
154.57, 149.60 (br), 130.30, 128.27, 120.99, 120.40 (br), 108.77, 107.72, 78.74, 53.68 
(br), 41.47, 27.94; LRMS (ESI) calculated for C16H19N8O4 [M - H]- m/z 387.15, found 
387.13. 
 
 
 
spiro[indoline-3,2'-[1,3]dithiolan]-2-one (S112). A dried 25 mL RB was charged with 
indoline-2,3-dione (200 mg, 1.36 mmol, 1.0 equiv.), then purged with Ar. Dry 
dichloromethane (6.5 mL) was then added, followed by 1,2-ethanedithiol (125 ul, 1.50 
mmol, 1.1 equiv.). Boron trifluoride diethyl etherate (218 uL, 1.77 mmol, 1.3 equiv.) was 
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then added dropwise. The reaction mixture was allowed to stir at r.t. overnight. The 
crude reaction mixture was then directly purified on a silica column with 0-35% 
EtOAc:hexanes. S112 (288.2 mg, 95%) obtained as a white solid. 1H NMR (400 MHz, 
DMSO-d6) δ = 10.62 (br s, 1H), 7.41 (dd, J = 0.7, 7.5 Hz, 1H), 7.25 (dt, J = 1.3, 7.7 Hz, 
1H), 7.02 (dt, J = 1.0, 7.5 Hz, 1H), 6.85 (d, J = 7.8 Hz, 1H), 3.80 - 3.65 (m, 4H); 13C 
NMR (100 MHz, DMSO-d6) δ = 178.32, 141.57, 129.98, 126.62, 125.17, 122.37, 
110.00, 61.98, 40.10; LRMS (ESI) calculated for C10H10NOS2 [M - H]- m/z 224.02, found 
224.00. 
 
 
 
methyl 2-((tert-butoxycarbonyl)amino)-3-(2-oxospiro[indoline-3,2'-[1,3]dithiolan]-1-
yl)propanoate (S113). A 20 mL vial was charged with crude S109 (361.4 mg, 1.22 
mmol, 1.0 equiv.), S112 (271.4 mg, 1.22 mmol, 1.0 equiv.), cesium carbonate (792 mg, 
2.43 mmol, 2.0 equiv.), and dry DMF (6 mL). The vial was sealed and stirred overnight. 
The crude reaction mixture was transferred to a sep. funnel with ~ 100 mL EtOAc and 
water, the layers separated, and the organic layer further extracted with 2 x 60 mL 
brine, dried over MgSO4, concentrated, and purified on a silica column with 0-35% 
EtOAc:hexanes. Semi-crude S113 (335.8 mg, 65%) obtained as a yellow oil; 
contaminated with ~ 15% S112 (1H NMR). 1H NMR (400 MHz, CDCl3) δ = 7.49 (d, J = 
7.3 Hz, 1H), 7.31 - 7.25 (m, 1H), 7.10 - 7.05 (m, 1H), 7.06 - 7.00 (m, 1H), 5.51 (br d, J = 
7.3 Hz, 1H), 4.55 (q, J = 6.7 Hz, 1H), 4.08 - 4.03 (m, 1H), 4.02 - 3.94 (m, 1H), 3.88 - 
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3.81 (m, 2H), 3.70 (s, 3H), 3.65 - 3.59 (m, 2H), 1.39 (s, 9H); 13C NMR (100 MHz, CDCl3) 
δ = 178.13, 170.43, 154.82, 142.06, 129.90, 125.91, 125.33, 123.22, 108.74, 79.97, 
61.87, 52.87, 51.23, 41.69, 40.29, 40.18, 28.05; LRMS (ESI) calculated for 
C19H25N2O5S2 [M + H]+ m/z 425.12, found 425.04. 
 
 
 
methyl 2-((tert-butoxycarbonyl)amino)-3-(2-oxoindolin-1-yl)propanoate (S114). 
Semi-crude S113 (335.8 mg, 0.791 mmol, 1.0 equiv.) was taken up in dry methanol (20 
mL). Nickel(II) bromide ethylene glycol dimethyl ether complex (488 mg, 1.58 mmol, 2.0 
equiv.) was then added; sodium borohydride (126 mg, 3.32 mmol, 4.2 equiv.) was then 
added portionwise (12 mg per) over 2h30m. NOTE: Sodium borohydride addition is very 
exothermic – do not add in bulk without sufficient thermal control. Once addition was 
complete, the crude reaction mixture was diluted with EtOAc and filtered through Celite. 
The organic washings were transferred to a sep. funnel and diluted with water; adjusted 
to pH 1 with 0.1N HCl. The layers were separated, and the organic layer was further 
washed with 2 x 60 mL brine. Dried over MgSO4, concentrated, and purified on a silica 
column with 0-15% acetone:dichloromethane. S114 (116.4 mg, 29% over two steps) 
obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ = 7.26 - 7.17 (m, 2H), 7.05 - 
6.98 (m, 1H), 6.95 (br d, J = 7.8 Hz, 1H), 5.53 (br d, J = 6.8 Hz, 1H), 4.54 (q, J = 5.8 Hz, 
1H), 4.05 (br d, J = 5.6 Hz, 2H), 3.71 (s, 3H), 3.48 (s, 2H), 1.37 (s, 9H); 13C NMR (100 
MHz, CDCl3) δ = 175.67, 170.55, 155.01, 144.11, 127.81, 124.32, 124.18, 122.40, 
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108.33, 79.96, 52.69, 52.22, 41.58, 35.32; LRMS (ESI) calculated for C17H23N2O5 [M + 
H]+ m/z 335.16, found 335.03. 
 
 
 
2-((tert-butoxycarbonyl)amino)-3-(2-oxoindolin-1-yl)propanoic acid (S115). S114 
(116.4 mg, 0.348 mmol, 1.0 equiv.) was reacted in methanol (5 mL) with 1M lithium 
hydroxide (696 uL, 0.696 mmol, 2.0 equiv.) according to general procedure B. Semi-
crude S115 (107.6 mg, 97%) obtained as a tan solid. LRMS (ESI) calculated for 
C16H19N2O5 [M - H]- m/z 319.13, found 319.39. 
 
 
 
tert-butyl (1-((1H-tetrazol-5-yl)amino)-1-oxo-3-(2-oxoindolin-1-yl)propan-2-
yl)carbamate (49). Semi-crude S115 (50.0 mg, 0.156 mmol, 1.0 equiv.) was reacted 
with 5-aminotetrazole monohydrate (1.1 equiv.) in 2 mL DMF according to general 
procedure D (10m activation). 49 (16.9 mg, 13% over two steps) obtained as a light tan 
solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.25 (br s, 0.5H), 7.30 - 7.11 (m, 2H), 7.06 - 
6.90 (m, 2H), 4.50 (br s, 1H), 4.11 - 3.88 (m, 2H), 3.49 (br s, 2H), 1.28 (br s, 9H); 13C 
NMR (100 MHz, DMSO-d6) δ = 175.01, 169.79 (br), 154.94 (br), 149.51 (br), 144.22, 
127.30, 124.61, 124.21, 121.82, 108.35, 78.75, 52.58 (br), 40.80 (br), 34.98, 27.95; 
LRMS (ESI) calculated for C17H20N7O4 [M - H]- m/z 386.16, found 386.29.  
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methyl 2-((tert-butoxycarbonyl)amino)-3-(2-oxopyridin-1(2H)-yl)propanoate (S116). 
A 3 mL vial was charged with crude S109 (328.3 mg, 1.10 mmol, 1.0 equiv.), 2-
hydroxypyridine (105 mg, 1.10 mmol, 1.0 equiv.), cesium carbonate (720 mg, 2.21 
mmol, 2.0 equiv.), and dry DMF (2 mL). The vial was sealed and heated at 100 °C 
overnight. The crude reaction mixture was transferred to a sep. funnel with ~ 100 mL 
EtOAc and water, and the aqueous pH was adjusted to 7 with 0.1N HCl. The layers 
were separated, and the organic layer was further washed with 2 x 50 mL brine, dried 
over MgSO4, concentrated, and purified on a silica column with 0-70% EtOAc:hexanes. 
S116 (24.6 mg, 8%) obtained as a gray film. 1H NMR (400 MHz, CDCl3) δ = 7.33 (br t, J 
= 7.3 Hz, 1H), 7.22 (br d, J = 6.6 Hz, 1H), 6.54 (br d, J = 9.0 Hz, 1H), 6.15 (t, J = 6.6 Hz, 
1H), 5.77 (br d, J = 5.8 Hz, 1H), 4.64 - 4.48 (m, 1H), 4.34 (br d, J = 2.4 Hz, 2H), 3.76 (s, 
3H), 1.39 (s, 9H); 13C NMR (100 MHz, CDCl3) δ = 170.38, 163.14, 155.30, 139.98, 
138.26, 120.83, 106.11, 80.13, 53.33, 52.73, 50.33, 28.17; LRMS (ESI) calculated for 
C14H21N2O5 [M + H]+ m/z 297.14, found 297.15. 
 
 
 
2-((tert-butoxycarbonyl)amino)-3-(2-oxopyridin-1(2H)-yl)propanoic acid (S117). 
S116 (42.6 mg, 0.144 mmol, 1.0 equiv.) was reacted in methanol (3 mL) with 1M lithium 
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hydroxide (288 uL, 0.288 mmol, 2.0 equiv.) according to general procedure B (5h). 
Semi-crude S117 (29.7 mg, 73%) obtained as a brown film. LRMS (ESI) calculated for 
C13H17N2O5 [M - H]- m/z 281.11, found 281.29. 
 
 
 
tert-butyl (1-((1H-tetrazol-5-yl)amino)-1-oxo-3-(2-oxopyridin-1(2H)-yl)propan-2-
yl)carbamate (50). Semi-crude S117 (29.7 mg, 0.105 mmol, 1.0 equiv.) was reacted 
with 5-aminotetrazole monohydrate (1.1 equiv.) in 2 mL DMF according to general 
procedure D (20m activation). 50 (12.9 mg, 26% over two steps) obtained as a tan solid. 
1H NMR (400 MHz, CD3OD) δ = 7.53 (br s, 2H), 6.56 (br d, J = 8.5 Hz, 1H), 6.38 (br d, J 
= 5.6 Hz, 1H), 4.83 (br s, 1H), 4.71 - 4.56 (m, 1H), 4.19 - 3.96 (m, 1H), 1.37 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ = 170.77 (br), 165.27 (br), 157.54 (br), 151.49 (br), 142.68, 
140.75 (br), 120.97 (br), 108.75, 81.40, 54.47 (br), 52.18 (br), 28.72; LRMS (ESI) 
calculated for C14H18N7O4 [M - H]- m/z 348.14, found 348.24. 
 
 
 
methyl 2‐(bis((tert‐butoxy)carbonyl)amino)‐3‐(2‐oxo‐1,2‐dihydroquinolin‐1‐
yl)propanoate (S118). A 3 mL vial was charged with S105 (200.0 mg, 0.664, 1.0 
equiv.), 2-hydroxyquinolone (99 mg, 0.684 mmol, 1.03 equiv.), and dry acetonitrile (2 
mL). Cesium carbonate (22 mg, 0.066 mmol, 0.1 equiv.) was then added, and the vial 
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was sealed and heated at 80 °C overnight. The crude reaction mixture was transferred 
to a sep. funnel with ~ 100 mL EtOAc and washed with ~ 50 mL water and brine; the 
organic layer was dried over MgSO4, concentrated, and purified on a silica column with 
30-80% EtOAc:hexanes. S118 (108.9 mg, 3789%) obtained as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ = 7.64 - 7.58 (m, 1H), 7.52 - 7.47 (m, 1H), 7.46 - 7.37 (m, 2H), 7.19 
- 7.12 (m, 1H), 6.64 - 6.58 (m, 1H), 5.53 - 5.46 (m, 1H), 5.11 - 4.99 (m, 1H), 4.83 (br dd, 
J = 3.0, 14.5 Hz, 1H), 3.75 (br s, 3H), 1.27 (s, 18H); 13C NMR (100 MHz, CDCl3) δ = 
169.24, 162.17, 151.36, 139.74, 139.24, 130.47, 128.89, 121.97, 121.35, 120.70, 
113.58, 83.07, 56.00, 52.24, 42.06, 27.51; LRMS (ESI) calculated for C23H31N2O7 [M + 
H]+ m/z 447.21, found 447.07. 
 
 
 
methyl 2-((tert-butoxycarbonyl)amino)-3-(2-oxoquinolin-1(2H)-yl)propanoate 
(S119). A 20 mL vial was charged with S118 (108.9 mg, 0.244, 1.0 equiv.) and dry 
acetonitrile (2.45 mL). Lithium bromide (64 mg, 0.732 mmol, 3.0 equiv.) was then 
added, and the vial was sealed and heated at 65 °C overnight. The crude reaction 
mixture was transferred to a sep. funnel with EtOAc and partitioned with water; the 
layers were separated, and the aqueous layer was further extracted with 2 x 50 mL 
EtOAc. The organics were combined, dried over MgSO4, and concentrated. Crude S119 
(82.8 mg, 98%) obtained as a colorless oil. LRMS (ESI) calculated for C18H23N2O5 [M + 
H]+ m/z 347.16, found 347.10. 
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2-((tert-butoxycarbonyl)amino)-3-(2-oxoquinolin-1(2H)-yl)propanoic acid (S120). 
Crude S119 (82.8 mg, 0.239 mmol, 1.0 equiv.) was reacted in methanol (5 mL) with 1M 
lithium hydroxide (478 uL, 0.478 mmol, 2.0 equiv.) according to general procedure B. 
Semi-crude S120 (69.9 mg, 88%) obtained as a tan solid. LRMS (ESI) calculated for 
C17H19N2O5 [M - H]- m/z 331.13, found 331.01. 
 
 
 
tert-butyl (1-((1H-tetrazol-5-yl)amino)-1-oxo-3-(2-oxoquinolin-1(2H)-yl)propan-2-
yl)carbamate (51). Semi-crude S120 (69.9 mg, 0.210 mmol, 1.0 equiv.) was reacted 
with 5-aminotetrazole monohydrate (1.1 equiv.) in 2.5 mL DMF according to general 
procedure D (20m activation). 51 (29.0 mg, 30% over 3 steps) obtained as a white solid. 
Note: Slight atropisomerism observed by NMR. 1H NMR (400 MHz, DMSO-d6) δ = 
12.32 (br s, 0.3H), 12.22 (br s, 0.7H), 7.92 (d, J = 9.5 Hz, 1H), 7.71 (br d, J = 7.5 Hz, 
1H), 7.64 - 7.54 (m, 2H), 7.25 (br t, J = 6.8 Hz, 1H), 7.16 (br d, J = 6.6 Hz, 0.7H), 6.60 
(d, J = 9.5 Hz, 1H), 4.68 - 4.48 (m, 3H), 1.25 (s, 7.5H), 1.09 (br s, 1.5H); 13C NMR (100 
MHz, DMSO-d6) δ = 169.94, 161.84, 154.96, 149.61 (br), 140.05, 139.36, 130.69, 
HO
NHBoc
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O
HN
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129.05, 122.08, 120.78, 120.48, 114.36, 78.76, 52.78, 42.75, 27.93; LRMS (ESI) 
calculated for C18H20N7O4 [M - H]- m/z 398.16, found 398.14. 
 
 
 
8-bromo-2-((4-methoxybenzyl)oxy)quinolone (S121). A dried 25 mL RB was charged 
with commercially available 8-bromoquinolin-2(1H)-one (200 mg, 0.893 mmol, 1.0 
equiv.) and dry DMF (8 mL). The reaction mixture was cooled to 0 °C, and 60.0% 
sodium hydride (43 mg, 1.07 mmol, 1.2 equiv.) was added, followed by a 1 mL rinse of 
dry DMF. The bubbling suspension was immediately warmed to r.t. and allowed to stir 
for 30m, at which point 4-methoxybenzylchloride (157 uL, 1.16 mmol, 1.3 equiv.) was 
added dropwise. The reaction mixture was stirred at 60 °C overnight. Note: Heating 
NaH/DMF is unsafe, especially at larger scales – take appropriate care. The crude 
reaction mixture was transferred to a sep. funnel with ~ 100 mL EtOAc and diluted with 
sat. NH4Cl. The layers were separated, and the organic layer was washed with 
additional 2 x 50 mL brine, dried over MgSO4, and concentrated. Purified on a silica 
column with 0-25% EtOAc:hexanes. S121 (241.6 mg, 79%) obtained as a light pink 
solid. 1H NMR (400 MHz, CDCl3) δ = 8.00 - 7.90 (m, 2H), 7.67 - 7.60 (m, 3H), 7.22 (t, J 
= 7.8 Hz, 1H), 6.96 (d, J = 8.5 Hz, 3H), 5.63 (s, 2H), 3.83 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ = 162.15, 159.40, 143.49, 139.10, 132.95, 130.63, 129.12, 127.01, 126.12, 
124.28, 122.40, 113.99, 113.70, 67.69, 55.13; LRMS (ESI) calculated for 
C17H14BrNNaO2 [M + Na]+ m/z 366.01, found 365.94. 
 
N
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(2-methoxy-2-oxoethyl)zinc(II) bromide (S122). A dried 25 mL pear-shaped RB was 
charged with zinc powder (415 mg, 6.35 mmol, 2.0 equiv.), then purged with Ar. Dry 
tetrahydrofuran (12.7 mL) was then added, followed by dropwise addition of 
chlorotrimethylsilane (40 ul, 0.318 mmol, 0.1 equiv.). The suspension was allowed to stir 
at r.t. for 20m, then heated to 45 °C. Methyl bromoacetate (300 ul, 3.17 mmol, 1.0 
equiv.) was then added dropwise, and the reaction was allowed to stir at 45 °C for 45 
minutes, then cooled to r.t. The remaining Zn was allowed to settle. The resulting yellow 
solution was used as a 250 mM stock for couplings. Note: The solution was made fresh 
for couplings; begins to lose coloration ~ 12h at r.t/Ar. 
 
 
 
methyl 2-(2-((4-methoxybenzyl)oxy)quinolin-8-yl)acetate (S123). A 20 mL vial was 
charged with S121 (266 mg, 0.773 mmol, 1.0 equiv.), 
tris(dibenzylideneacetone)dipalladium (35.4 mg, 0.039 mmol, 0.05 equiv.), and QPhos 
(27.5 mg, 0.039 mmol, 0.05 equiv.). The vial was fitted with a septa, purged with Ar, and 
dry tetrahydrofuran (3 mL) was added, followed by a 0.25M solution of S122 (3.712 ml, 
0.928 mmol, 1.2 equiv.) in THF. The septa was replaced with a teflon cap and the vial 
was heated at 70 °C overnight. The crude reaction mixture was transferred to a sep. 
funnel with ~ 100 mL EtOAc and washed with sat. NaHCO3 and brine, dried over 
MgSO4, and concentrated. Purified on a silica column with 0-25% EtOAc:hexanes. 
O
O
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O
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S123 (247.4 mg, 95%) obtained as a light pink solid. 1H NMR (400 MHz, CDCl3) δ = 
7.96 (d, J = 9.0 Hz, 1H), 7.66 (dd, J = 1.2, 8.0 Hz, 1H), 7.60 (d, J = 7.1 Hz, 1H), 7.57 - 
7.52 (m, 2H), 7.37 (dd, J = 7.3, 8.0 Hz, 1H), 7.02 - 6.95 (m, 3H), 5.53 (s, 2H), 4.22 (s, 
2H), 3.82 (s, 3H), 3.75 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 172.42, 160.92, 159.16, 
144.48, 138.83, 131.23, 130.25, 129.70, 129.25, 126.68, 124.74, 123.40, 113.61, 
112.90, 67.13, 54.90, 51.48, 37.33; LRMS (ESI) calculated for C20H19NNaO4 [M + Na]+ 
m/z 360.12, found 360.01. 
 
 
 
methyl 2-azido-2-(2-((4-methoxybenzyl)oxy)quinolin-8-yl)acetate (S124). S123 
(180.1 mg, 0.534 mmol, 1.0 equiv.) was reacted in 15 mL tetrahydrofuran according to 
general procedure F. Note: The generated enolate was not soluble in THF; rapid stirring 
of a thick suspension required. S124 (66.5 mg, 33%) obtained as a white solid. 1H NMR 
(400 MHz, CDCl3) δ = 8.03 (d, J = 9.0 Hz, 1H), 7.78 (dd, J = 1.2, 8.0 Hz, 1H), 7.68 (dd, 
J = 1.2, 7.3 Hz, 1H), 7.47 (d, J = 8.5 Hz, 2H), 7.45 - 7.40 (m, 1H), 7.00 (d, J = 8.8 Hz, 
1H), 6.97 - 6.92 (m, 2H), 5.98 (s, 1H), 5.53 - 5.40 (m, 2H), 3.83 (s, 3H), 3.76 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ = 170.25, 161.74, 159.46, 143.71, 139.16, 130.82, 129.90, 
129.09, 129.04, 128.85, 125.30, 123.73, 113.96, 113.90, 68.00, 61.47, 55.26, 52.68; 
LRMS (ESI) calculated for C20H18N4NaO4 [M + Na]+ m/z 401.12, found 400.95. 
 
N O
O
O
O
N3
 324 
 
 
methyl 2-((tert-butoxycarbonyl)amino)-2-(2-((4-methoxybenzyl)oxy)quinolin-8-
yl)acetate (S125). A round bottom flask was charged with S124 (66.5 mg, 0.176 mmol, 
1.0 equiv.) and dry methanol (6 mL). Anhydrous tin(II) chloride (67 mg, 0.351 mmol, 2.0 
equiv.) was then added; stirred at r.t. for 68h. The crude reaction mixture was 
transferred to a sep. funnel with ~ 75 mL EtOAc and partitioned with 75 mL sat. 
NaHCO3. The aqueous layer was extracted with an additional 2 x 50 mL EtOAc; the 
organics were combined, dried over MgSO4, and concentrated. The resulting residue 
was taken up tetrahydrofuran (2.5 mL); solid di-tert-butyl dicarbonate (46 mg, 0.211 
mmol, 1.2 equiv.) was then added, followed by dropwise addition of N,N-
diisopropylethylamine (37 ul, 0.211 mmol, 1.2 equiv.). The reaction mixture was stirred 
for 14h, at which point it was transferred to a sep. funnel with ~75 mL EtOAc and 
washed with ~50 mL sat. NaHCO3 and brine. The EtOAc layer was dried over MgSO4 
and concentrated -- purified on a silica column with 0-30% EtOAc:hexanes. S125 (47.2 
mg, 59%) obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ = 8.01 (d, J = 8.8 Hz, 
1H), 7.76 - 7.61 (m, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.38 (dd, J = 7.3, 8.0 Hz, 1H), 7.01 - 
6.91 (m, 3H), 6.20 (br d, J = 9.3 Hz, 1H), 5.81 (d, J = 9.5 Hz, 1H), 5.49 (d, J = 12.4 Hz, 
1H), 5.34 (d, J = 12.4 Hz, 1H), 3.82 (s, 3H), 3.65 (s, 3H), 1.45 (s, 9H); 13C NMR (100 
MHz, CDCl3) δ = 172.07, 161.47, 159.35, 155.49, 143.64, 139.37, 133.66, 130.80, 
129.47, 129.14, 127.86, 125.29, 123.96, 113.95, 113.44, 79.72, 67.80, 56.39, 55.20, 
52.44, 28.34; LRMS (ESI) calculated for C25H29N2O6 [M + H]+ m/z 453.20, found 453.15. 
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2-((tert-butoxycarbonyl)amino)-2-(2-((4-methoxybenzyl)oxy)quinolin-8-yl)acetic 
acid (S126). S125 (47.2 mg, 0.104 mmol, 1.0 equiv.) was reacted in methanol (4 mL) 
with 1M sodium hydroxide (146 uL, 0.146 mmol, 1.4 equiv.) according to general 
procedure B, except three additional aliquots of 1M sodium hydroxide (146 uL, 0.146 
mmol, 1.4 equiv.) were added over 3d. Semi-crude S126 (47.2 mg, 103%) obtained as 
a white solid. LRMS (ESI) calculated for C24H25N2O6 [M - H]- m/z 437.17, found 437.04. 
 
 
 
tert-butyl (2-((1H-tetrazol-5-yl)amino)-1-(2-((4-methoxybenzyl)oxy)quinolin-8-yl)-2-
oxoethyl)carbamate (S127). Semi-crude S126 (45.7 mg, 0.104 mmol, 1.0 equiv.) was 
reacted with 5-aminotetrazole monohydrate (1.1 equiv.) in 3 mL DMF according to 
general procedure D (1h activation). S127 (23.0 mg, 43% over two steps) obtained as a 
white solid. 1H NMR (400 MHz, DMF-d7) δ = 12.46 (br s, 1H), 8.35 (d, J = 9.0 Hz, 1H), 
7.95 (d, J = 7.8 Hz, 1H), 7.85 (d, J = 7.1 Hz, 1H), 7.61 (br d, J = 8.5 Hz, 1H), 7.55 - 7.42 
(m, 3H), 7.10 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.5 Hz, 2H), 6.53 (d, J = 8.5 Hz, 1H), 5.55 
- 5.38 (m, 2H), 3.83 (s, 3H), 1.44 (s, 9H); 13C NMR (100 MHz, DMF-d7) δ = 172.01, 
162.59, 160.65, 156.75, 151.74, 144.94, 141.09, 134.51, 131.14, 130.66, 130.31, 
129.26, 126.38, 124.95, 114.87, 114.35, 79.79, 68.77, 56.89, 55.98, 28.87; LRMS (ESI) 
calculated for C25H26N7O5 [M - H]- m/z 504.20, found 504.22. 
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tert-butyl (2-((1H-tetrazol-5-yl)amino)-2-oxo-1-(2-oxo-1,2-dihydroquinolin-8-
yl)ethyl)carbamate (52). S127 (23.0 mg, 0.045 mmol, 1.0 equiv.) was suspended in 
acetonitrile (4 mL) and water (1 mL). Ammonium cerium(IV) nitrate (224 mg, 0.409 
mmol, 9.0 equiv.) was then added in 1.0 equiv. aliquots (25 mg) over 5h. After complete 
conversion, the crude reaction mixture was transferred to a sep. funnel with EtOAc and 
water. The layers were separated, and the aqueous layer was further extracted with 2 x 
50 mL EtOAc. The organics were combined, dried over MgSO4, and concentrated. 
Purified by reverse phase HPLC (water/MeOH/0.05% formic acid) to afford 52 (11.3 mg, 
64%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ = 12.42 (br s, 1H), 10.79 (br s, 
1H), 8.04 (br s, 1H), 7.96 (d, J = 9.5 Hz, 1H), 7.68 (d, J = 7.3 Hz, 1H), 7.55 (br d, J = 6.8 
Hz, 1H), 7.21 (t, J = 7.7 Hz, 1H), 6.57 (d, J = 9.5 Hz, 1H), 5.83 (br s, 1H), 1.39 (br s, 
9H); 13C NMR (100 MHz, DMSO-d6) δ = 169.41 (br), 161.75, 155.55 (br), 149.72 (br), 
141.01, 136.96 (br), 130.84 (br), 128.90 (br), 121.98 (br), 121.74, 121.62 (br), 119.93 
(br), 79.16, 54.55 (br), 28.10 (br); LRMS (ESI) calculated for C17H18N7O4 [M - H]- m/z 
384.14, found 384.09. 
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Chapter 5 
Fragment Discovery for Diverse β-lactamases 
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Fragment Screening: 
Our previous synthetic efforts to inhibit new β-lactamases were primarily structure-
guided migrations from the original CTX-M series, as discussed in Chapters 1 and 4. 
Despite the homology between KPC-2 and CTX-M, these efforts failed to generate an 
inhibitor scaffold that could target both enzymes. While the resulting scaffold from 
Chapter 4 could likely be modified to do so, inhibiting more diverse β-lactamases, such 
as the metallo-lactamase NDM-1 or the Class D OXA-48, proves to be quite challenging 
due to the lack of tractable knowledge around non-covalent affinity with these enzymes. 
Computational screening against CTX-M resulted in chemotypes with cross-class 
activity (Chapter 2), but these molecules were already quite large with poor ligand 
efficiency (LE), representing a suboptimal approach to gain insight into molecular 
recognition. To this end, we felt comparative fragment screening offered the best 
approach, as fragment hits would have higher LE, representing discrete molecular 
interactions, and cross-class hits would likely bind within a shared substrate envelope, 
making further optimization tractable. Importantly, these efforts are also backed by 
robust crystallography, allowing us to view the binding orientation for hits and any 
subsequent fragment enumeration. 
We opted to use surface plasmon resonance (SPR) as our primary screen due to 
the throughput and material requirements; SPR also allows for subsequent “pair-wise” 
binding and competition experiments for confirmed hits. In order to validate the 
approach, various N-terminal tagged His-Avi(Biotin) proteins were immobilized onto a 
Neutravidin conjugated GE CM5 chip and tested with putative positive controls, which 
are necessary to adjust for surface degradation throughout the screening run. CTX-M-
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14 immobilized well; the positive control was our previously reported compound 1,1 
which displayed a Kd of 160 nM, in line with our observed Ki of 90 nM (Figure 5-1). 
Importantly, compound 1 binding could be ablated by preincubation with avibactam prior 
to immobilization, combined with 5 µM avibactam in the running buffer (CTX-M t1/2: ~ 40 
m),2 suggesting the binding of 1 accurately represents the state of the active site. While 
carbapenemase KPC-2 immobilized well, we could not bind inhibitor 1, which has a 
weaker affinity for KPC-2,3 as well as β-lactam substrates meropenem or nitrocefin. 
Attempts to alter the buffer composition or temperature did not restore substrate 
binding; non-specific immobilization with EDC/NHS also failed to produce substrate-
active KPC-2. Given these results, we decided that any fragment hit would be assessed 
for KPC-2 activity at the biochemical validation stage. Metallo-lactamase NDM-1 has 
been previously used in SPR experiments,4 and we confirmed that when immobilized, it 
recognizes substrate meropenem (not shown). Meropenem has aqueous stability issues 
making it ill suited for a screening control,5 so captopril was tested. Notably, purchased 
captopril required TCEP in the running buffer, and displayed a two-site binding curve, 
consistent with the presence of an L and D form (Figure 5-2). The observed Kd values 
were close to the previously reported IC50 values,6 suggesting captopril would be a 
reasonable proxy for protein state. OXA-48 has also been used in SPR experiments,7 
and when immobilized, recognized substrate meropenem (not shown). Substrate 
binding could be ablated by preincubation with avibactam prior to immobilization (OXA-
48 t1/2: 17h),2  suggesting functional enzyme (not shown). Given the stability of 
meropenem, we sought to use compound 2 as a control, which was discovered from a 
previously reported fragment screen.7  In our hands compound 2 showed a two-site 
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binding curve, with a Kd1: 28 µM/ Stoichiometry: 1 for “site one”, in line with the reported 
Kd; “site two” was a weaker, non-specific binding element with some reference channel 
binding (Figure 5-3). Like other positive controls, “site-one” binding could be ablated by 
preincubation with avibactam prior to immobilization, leaving only the nonspecific 
binding elements. While imperfect as a control, we felt that sufficiently low 
concentrations of 2 should approximate active site availability in OXA-48. 
 
 
Figure 5-1. Compound 1 binding to CTX-M-14. a Compound 1 binding could be 
ablated by preincubation with avibactam prior to immobilization, combined with 5 µM 
avibactam in the running buffer. 
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Figure 5-2. Captopril binding to NDM-1. Captopril showed a two-site binding curve, 
consistent with the presence of an L and D form. Removing TCEP ablated most activity. 
a Reported in reference 6. 
 
 
Figure 5-3. Compound 2 binding to OXA-48. Compound 2 showed a two-site binding 
curve, the weaker of which seemed to be non-specific binding unaffected by avibactam. 
a Reported in reference 7. b The tighter binding site of compound 2 could be ablated by 
preincubation with avibactam prior to immobilization. 
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With controls in hand, we screened CTX-M, NDM-1, and OXA-48 against two 
fragment libraries totaling ~ 4300 fragments. Our internal library was assembled from 
commercial fragments available from Maybridge, Life Chemicals, and Asinex; the Drug 
Discovery Unit (DDU) at University of Dundee also provided a bespoke library, which is 
structurally distinct and complementary to ours, and in particular possesses a higher 
proportion of fragments with saturated (sp3) hybridized carbon atoms (Figure 5-4). We 
anticipate that this second library will help reveal distinct consensus binding 
interactions, especially when considering the types of scaffolds preferred in Chapter 4. 
Once complete, the primary screening data was loess normalized for surface 
degradation and inter-assay variability using RALPH.8 The resulting scatterplots are 
shown below with initial hits denoted in red, as defined per boxplot cutoff (75th percentile 
+ 3xIQR) (Figure 5-5). 
 
 
Figure 5-4. Histogram analysis of both fragment libraries. Fraction of sp3 atoms 
(0.1-1; x-axis) and molecular weight (color) distribution of fragments in the SMDC and 
DDU libraries. 
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Figure 5-5. Primary screening scatterplots for CTX-M-14, NDM-1, and OXA-48. 
Solvent corrected data was loess normalized for surface degradation and variability per 
flow cell. Initial hits denoted in red, as defined per boxplot cutoff (75th percentile + 
3xIQR). The DDU fragment collection still needs to be screened against OXA-48. 
 
Fragment Validation: 
Screening hit rates were roughly equivalent between libraries and enzymes, 
averaging to about 5% (Table 5-1). One of the drawbacks of an unbiased SPR screen 
is false-positives; fragments are more promiscuous binders by virtue, and can bind 
allosterically or non-specifically elsewhere in the protein, incorrectly reporting as a hit. In 
order to weed out non-functional molecules, hits were pooled and tested for biochemical 
activity in single point response against all enzymes. While this work is still in progress, 
early results from our internal library are encouraging (Table 5-2). Though few of the 
tested compounds possess tri-class activity, many inhibit two classes, suggesting 
conserved binding hotspots. Some of the fragments even possess mid-µM activity, 
especially against OXA-48, which has been challenging to link with Class A active 
scaffolds. Perhaps unsurprisingly, many of the biochemically active hits are carboxylic 
acids, which are recognized by the acid-binding motif. The DDU library should nicely 
compliment these flatter and more rigid fragments, especially during later growing and 
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merging efforts. Once the initial hits have been profiled for single point biochemical 
activity, select fragments will be characterized in dose response for biochemical and 
SPR activity, and subsequently crystallized with the appropriate proteins. We anticipate 
that this fragment-based approach will nicely compliment our previous structure-based 
efforts, helping to create a more discrete rule set for building non-covalent affinity 
across diverse β-lactamases. 
 
Table 5-1. Hit rate by enzyme and library.  
 
 
 
 
 
 
 
  
CTX-M-14 NDM-1 OXA-48
UCSF 158 (5.9%) 148 (5.5%) 108 (4.0%)
DDU 63 (4.0%) 82 (5.2%)
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Table 5-2. Single point inhibition for selected hits (2.4 mM). 
 
CTX-M-14 
Initial Hit
NDM-1 
Initial Hit
OXA-48 
Initial Hit Total Hits CTX-M-14 NDM-1 OXA-48
Y Y Y 3 No Inhibition No Inhibition 51% Inhib
Y Y Y 3 No Inhibition Insoluble 17% Inhib
Y Y Y 3 No Inhibition 52% Inhib      (Ki: 568 μM)
74% Inhib    
(Ki = 650 μM)
Y N Y 2 38% Inhib No Inhibition No Inhibition
Y N Y 2 24% Inhib No Inhibition 12% Inhib
Y N Y 2 21% Inhib No Inhibition No Inhibition
Y N Y 2 No Inhibition No Inhibition 21% Inhib
Y N Y 2 No Inhibition No Inhibition 15% Inhib
Y N Y 2 No Inhibition No Inhibition 18% Inhib
Y N Y 2 14% Inhib No Inhibition No Inhibition
Y N Y 2 Insoluble No Inhibition No Inhibition
Y N Y 2 24% Inhib 25% Inhib 16% Inhib
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CTX-M-14 
Initial Hit
NDM-1 
Initial Hit
OXA-48 
Initial Hit Total Hits CTX-M-14 NDM-1 OXA-48
Y N Y 2 19% Inhib No Inhibition No Inhibition
Y N Y 2 19% Inhib No Inhibition 32% Inhib
Y N Y 2 17% Inhib No Inhibition No Inhibition
Y N Y 2 41% Inhib No Inhibition 25% Inhib
Y N Y 2 16% Inhib No Inhibition 25% Inhib
Y N Y 2 21% Inhib No Inhibition No Inhibition
Y N Y 2 12% Inhib No Inhibition No Inhibition
Y N Y 2 16% Inhib No Inhibition No Inhibition
Y N Y 2 14% Inhib No Inhibition 
Y N Y 2 16% Inhib No Inhibition No Inhibition
Y N Y 2 18% Inhib No Inhibition No Inhibition
Y N Y 2 28% Inhib No Inhibition 12% Inhib
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CTX-M-14 
Initial Hit
NDM-1 
Initial Hit
OXA-48 
Initial Hit Total Hits CTX-M-14 NDM-1 OXA-48
Y N Y 2 16% Inhib No Inhibition No Inhibition
Y N Y 2 14% Inhib No Inhibition No Inhibition
Y N Y 2 25% Inhib No Inhibition 22% Inhib
Y N Y 2 18% Inhib No Inhibition 64% Inhib
Y N Y 2 12% Inhib No Inhibition 15% Inhib
Y N N 1 No Inhibition No Inhibition No Inhibition
Y N N 1 17% Inhib No Inhibition No Inhibition
N Y N 1 12% Inhib No Inhibition No Inhibition
Y N N 1 No Inhibition No Inhibition 37% Inhib
Y N N 1 16% Inhib No Inhibition No Inhibition
Y N N 1 No Inhibition 32% Inhib No Inhibition
Y N N 1 30% Inhib No Inhibition 
90% Inhib   
(Ki = 178 
μM) 
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CTX-M-14 
Initial Hit
NDM-1 
Initial Hit
OXA-48 
Initial Hit Total Hits CTX-M-14 NDM-1 OXA-48
Y N N 1 No Inhibition No Inhibition 57% Inhib
Y N N 1 No Inhibition No Inhibition 20% Inhib
Y N N 1 No Inhibition No Inhibition No Inhibition
Y N N 1 No Inhibition 19% Inhib 27% Inhib
Y N N 1 No Inhibition No Inhibition No Inhibition
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Methods: 
Fragment Screens 
Screening experiments were run on a GE Biacore 4000, which has four flow cells 
with five hydrodynamically addressable spots per flow cell. N-terminal His-Avi(Biotin) 
proteins were captured on a Neutravidin conjugated CM5 chip, where the Neutravidin 
was first conjugated using EDC/NHS and quenched with 1M ethanolamine. Proteins 
were immobilized to 7-10000 RU using an immobilization buffer consisting of 10 mM 
HEPES pH 7.5, 150 mM NaCl, 0.05% Tween 20, and 250 µM TCEP. Unbound 
Neutravidin was blocked with NH2-PEG2-Biotin, including the reference spot, which was 
also Neutravidin conjugated. Running buffer varied per enzyme, and consisted of the 
following: CTX-M-14: 10 mM HEPES pH 7.5, 150 mM NaCl, 0.05% Tween 20, 250 µM 
TCEP, and 5% DMSO; NDM-1: 100 mM HEPES pH 7.5, 150 mM NaCl, 200 µM ZnCl2, 
100 µM TCEP, 0.05% Tween 20, and 5% DMSO; OXA-48: 100 mM Tris-H2SO4 pH 7.0, 
50 mM NaHCO3, 0.01% Triton X-100, 250 µM TCEP, and 5% DMSO. The fragment 
libraries were split between flow cells and run in parallel. Positive and negative (DMSO 
blank) controls were run every 10 cycles, and consisted of the following: CTX-M-14: 1 at 
150 nM; NDM-1: captopril at 100 µM; OXA-48: 27 at 50 µM. All data was reference and 
blank subtracted per flow cell, and solvent corrected for bulk refractive index shift using 
a correction curve from 3.75-6.25% DMSO. The corrected data was subsequently 
normalized per flow cell using RALPH,8 which loess normalizes the positive control 
regression and baseline drift throughout the run. Each scatterplot shown is from a single 
flow cell. Hits were defined per boxplot cutoff (75th percentile + 3xIQR). 
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